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Abstract
The work presented in this thesis aimed to investigate the consequences and causes of 
ketamine abuse and compare them with the acute effects of the drug. Seven 
experimental chapters report the findings of a total of 9 studies: 5 with ketamine users, 
3 administering ketamine to healthy volunteers and 1 with psychosis-prone individuals. 
Acute studies with volunteers demonstrated ketamine-induced impairments to item 
recognition, source memory, controlled semantic processing, working memory and 
procedural learning. There was also a suggestion of a disruption in self-monitoring but 
perceptual priming and executive functioning were largely preserved. Ketamine was 
subjectively reinforcing in healthy volunteers. Suggested chronic effects of ketamine in 
drug users included deficits in source memory and controlled semantic processing 
indicative of a degraded semantic store. Following substantial reduction in ketamine 
use, semantic function appeared to recover whilst episodic and attentional impairments 
appeared persistent. Overall, this thesis suggested that ketamine, both acutely and 
chronically, produces selective cognitive impairments, particularly to those functions 
that require integration of contextual information. The implications of this thesis are 
drawn out for an acute versus ‘chronic’ model of psychosis. Chronic deficits in 
ketamine users may reflect neurological changes associated with repeated NMDA- 
receptor antagonism and hence may be more similar to changes observed in the later 
stages of schizophrenia, whereas acute ketamine may better model the acute phase. 
Persisting cognitive impairments are of concern in light of the burgeoning population of 
ketamine users.
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Chapter 1: Introduction
“Words are, o f course, the most powerful drug used by mankind?'
Rudyard Kipling
This chapter is structured in two parts. Following a brief historical consideration of the 
use and abuse of ketamine and related compounds, a summary is presented of their 
chemical mechanism and neuropharmacology. This background section then leads on to 
a review of the literature on the cognitive and psychotomimetic properties of N-methyl- 
D-aspartate receptor antagonists.
1.1. History of the use of ketamine and related compounds in anaesthesia
Ketamine is a member of a class of compounds known as arylcyclohexylamines, with 
others being phencyclidine (PCP) and MK-801. PCP was the first compound of this 
group to be synthesised. Originally, it was designed for use as an anaesthetic and was 
given to humans in the late 1950s (Greifenstein et al., 1958). Whilst PCP did have 
profound analgesic and anaesthetic effects, in approximately 50% of patients the drug 
also induced severe reactions characterised by agitation, paranoia, depersonalisation, 
concreteness of thought, bizarre behaviour and hallucinations (Johnstone et al., 1958) 
which persisted for up to 6 hours and could produce a psychotic phase lasting several 
weeks (Aniline & Pitts, 1982). These undesirable post-operative psychotomimetic 
effects, combined with its duration of action, led to the drug being withdrawn from 
anaesthetic use in humans (Grinspoon & Bakalar, 1997). It did however continue to be 
used as a tranquilliser for animals marketed under the name Semylan.
Impressed by the analgesic and anaesthetic properties of PCP, Parke Davis developed a 
congener of PCP in 1962 for use in human anaesthesia: 2-orthochlorophenyl, 2- 
methylamino cyclohexanone hydrochloride or Cl 581. Later called ketamine 
hydrochloride, this compound was purported to offer the same benefits as PCP but with 
fewer psychotomimetic side-effects. Ketamine was described as producing:
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“ ... profound analgesia and short lasting anaesthesia...Respiratory 
depression is transient and not a serious problem... Many protective 
reflexes such as laryngeal, pharyngeal, eyelid and corneal are present 
during the patients' unresponsiveness. No liver, kidney, or blood 
abnormalities or venous irritation were noted in the subjects tested... ”
Domino, Chodoff & Corssen, (1965, pp.279)
The unique cataleptic-like state associated with ketamine, and indeed other 
arylcyclohexamines, where patients were fully awake but “..not there..” led Edward 
Domino (1965) to coin the term ‘dissociative anaesthetic’ to describe this class of 
drugs. However, with increasing experience of ketamine, clinicians noticed 
complications associated with the use of the drug similar to, although more transient 
than, those observed with PCP. Post-operatively patients experienced confiisional 
states, vivid dreaming and hallucinations (Siegel, 1978). These side effects limited the 
routine use of ketamine in anaesthesia (Goodman & Gilman, 2001). Nevertheless, the 
unique effects of ketamine mean that it continues to be used as an anaesthetic within 
veterinary and paediatric anaesthesia and for anaesthetising patients at risk of 
hypotension and bronchiospasm. The highly effective analgesia is also considered 
useful for treating bums victims and in emergency field work. Indeed, the drug was the 
most popular anaesthetic used in the Vietnam War (Siegel, 1978). Ketamine is also 
used in intensive treatment units and palliative care for its profound analgesic effects. 
More recently ketamine has enjoyed some success in the treatment of chronic pain 
patients (Enarson et al., 1999) although it is still not licensed for this use (Joint 
Formulary Committee, 2005).
1.2 History the abuse of ketamine and PCP by recreational users
Precisely the effects that limited the clinical use of ketamine and PCP were those that 
made the drug popular with recreational users. Reports first spread of PCP abuse in the 
late sixties where it appeared on the streets under a variety of names; ‘angel dust’, ‘hog’ 
and ‘super weed’ (Feldman et al., 1997). In the early seventies it was placed on the 
schedule of controlled drugs in the United States. Use of PCP rose throughout the 
1970s but has steadily declined since 1979 (Johnston et al., 1987). PCP also became
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controlled under the Misuse of Drugs Act (1971) as a Class A drug in the U.K, 
although is nowadays very rarely found in this country (DrugScope, 2001).
Street use of ketamine was first noted in 1971 in the U.S. (Siegel, 1978) where it was 
primarily sold in solution but by 1974 there were reports of its sale in powder and tablet 
form. By the mid 1970’s the recreational use of ketamine had spread to countries such 
as England, Sweden and Russia (Kelly, 1999). Despite worldwide reports of use of the 
drug, at this stage the numbers of recreational users were still relatively small.
The last two decades have seen a rapid increase in the use of ketamine with the advent 
of dance music culture. Ketamine first appeared on the ‘rave’ scene as a contaminant in 
±3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) tablets (Dalgamo &
Shewan, 1996) but then became available in its pure form where it is referred to as 
‘Special K’, ‘K’ , ‘K50’, ‘Gold-top’, ‘Vitamin K’ and ‘Super K’ (Curran & Morgan,
2000). Reports of increasing recreational ketamine use appeared in the medical 
literature (e.g. Dalgamo & Shewan, 1996) and in the popular media (McDermott, 1992) 
in the late 1990’s. A survey of London night-clubs found that 40% of the 200 
respondents had experimented with ketamine and intended to use it the same evening 
(Release, 1997; McDermott, 1992). A more recent survey suggested there may be 
approximately 90 000 regular, and 500 000 occasional ketamine users in the UK 
(Independent Drug Monitoring Unit: IDMU, 2005). The increase in ketamine abuse in 
the U.S was such that ketamine became a Schedule III drug at the federal level. 
(F.D.A., 1999). In the U.K. ketamine is not controlled under the Misuse of Drugs Act 
(1971). It is controlled under the Medicines Act (1968) however this status is currently 
under review (Advisory Council on the Misuse of Drugs - ACMD 2004).
Debate over the long-term effects of ketamine has raged since the very beginning of its 
recreational use when a ketamine user, wrote of the drug:
“ ...Ifcaptains o f  industry, leaders o f  nations could partake o f  this love medicine 
then the whole planet might be converted into the Garden o f Eden . . . ”
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Marcia Moore, Journeys into the Bright World (Moore & Altounian, 1978)
Her husband, Howard Altounian, an anaesthetist, expressed a different view:
th“Marcia became addicted to ketamine and committed suicide (January 14 , 1979). 
Ketamine is dangerous. Its use should not be encouraged. ..”
Howard Altounian (1998) c.f. Jansen (2001)
For the growing population of recreational users there is a clear need to investigate the 
dependence forming potential of ketamine and to characterise the side effects 
associated with long term use of this drug.
1.3 Basic pharmacology of ketamine, PCP and dizocilipine
The chemical structure of ketamine is shown in Figure 1.1. Ketamine, PCP and 
dizocilipine are lipid soluble molecules that readily cross the blood-brain barrier 
following peripheral administration. Preclinical work has demonstrated that ketamine 
and PCP are stored in adipose tissue and then slowly released back into the plasma 
compartment (Martin & Lodge, 1985). The alpha phase of ketamine distribution lasts 
about 45 minutes, with a half-life of 10 to 15 minutes. This first phase corresponds 
clinically to the anaesthetic effect of the drug. When administered intravenously for 
anaesthesia, a sensation of dissociation occurs within 15 seconds and anaesthesia 
occurs within 30 seconds (in 3-4 minutes for intra-muscular (IM) route). The 
anaesthetic effects are terminated by a combination of redistribution and hepatic 
biotransformation to an active metabolite, norketamine (Goodman & Gilman, 2001). 
Norketamine has itself been suggested to have some psychotomimetic effects 
(Lindefors et al., 1997). The terminal half life of ketamine is about 2-3 hours.
Ketamine and PCP are available in solutions for injection for anaesthetic use (either IM 
or IV). Recreational ketamine and PCP users use a variety of routes of administration. 
PCP can be injected, taken intranasally or orally, or smoked. Ketamine is generally 
self-administered intranasally but some users inject the drug or take it orally. After
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intranasal administration of ketamine onset of effects is between 5 - 1 5  min, duration 
approximately 45 - 60 min and after about 2 - 4  hours users are back to baseline 
(Jansen, 2000). Nasal doses are highly nonlinear compared with oral and IM doses 
however Erowid (2002), an internet based drug user resource, suggests that a dose of 
lOOmg - 200mg is enough for users to achieve what is referred to as “The K-hole”. This 
is a highly dissociated catatonic state where the user experiences dramatic 
hallucinations and minimal self-awareness.
1.4 The chemical mechanism of the arylcyclohexylamines
Early studies of the pharmacology of PCP and ketamine suggested a variety of 
candidates for the neurochemical induction of their psychotomimetic and cognitive 
effects. Initial suggestions regarding the mechanism of PCP-induced effects included: 
increased dopamine release and blockade of dopamine reuptake; elevated 5-HT levels; 
potentiation of acetylcholine release; and various effects at a-noradrenergic receptors, 
sigma receptors and Gamma-aminobutyric acid (GABA) receptors (Domino et al., 
1965). But whilst PCP was found to interact with these targets, the majority of these 
interactions occurred at concentrations unlikely to be reached in clinical situations. 
Zukin and Zukin (1979) reasoned that the PCP receptor site within the N-methyl-D- 
aspartate receptor complex (NMDA-R) at which the neurotransmitter glutamate 
functions - a site with submicromolar affinity for PCP, ketamine and MK-801 - was the 
best candidate receptor in mediating the behavioural effects of these compounds.
NH
Figure 1.1: Ketamine molecule
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1.5 Glutamate, the NMDA -receptor complex and Long-Term Potentiation
Glutamate is an amino acid that can be readily synthesised in the brain and thus is not 
required in the diet. The excitatory properties of glutamate were first described by 
Hayashi (1954) and but it was not until the last two decades (Watkins & Evams, 1981) 
that glutamate was recognised as the major excitatory neurotransmitter in the brain 
(Javitt & Zukin, 1991) . The glutamate system is composed of widely spread 
projections to most brain regions. Glutamate is implicated in both the rapid transfer of 
information between cortical and sub-cortical structures and in longer term changes 
related to the adaptation of the central nervous system (CNS) over time (Feldman et al. 
1996). The NMDA-R is one type of glutamate receptor, others include other iontropic 
receptors e.g. a-amino-3-hydroxy-5-methyl-4-isoxazolepropanoic acid (AMPA) and 
kainate receptors and metabotropic glutamate receptors. The functioning of the NMDA- 
R has been extensively investigated leading to a thorough understanding of the 
mechanism by which it operates.
The NMDA-R controls a calcium channel (Javitt & Zukin, 1991) and the receptor 
functioning is dependent upon the potential of the neuronal membrane. At the 
physiological resting membrane potential, magnesium ions (Mg2+) effectively block ion 
fluxes through the NMDA-receptor gated ion channel. When the membrane is 
depolarised, the Mg2+ block is displaced and the binding of glutamate and glycine to 
their sites on the NMDA-R allows the channel to open and calcium ions (Ca 2+) to enter 
the channel, the calcium is excitatory and the potential passes between the presynaptic 
and post-synaptic cells. However, if there is prolonged and excessive influx of Ca 2+ 
into the neuron toxicity can occur. This is a simplified explanation of a phenomena 
known as excitotoxicity which is the putative mechanism underlying neuronal 
degeneration arising from cerebral ischaemia (disruption of blood flow to the brain), 
hypoxia (reduction of oxygen blood flow) (Olney et al., 1989), epilepsy (Choi, 1990) 
and other neurological disorders.
Another important mechanism which the NMDA-R is proposed to mediate is long-term 
potentiation (LTP). LTP is the putative mechanism of neuronal learning and was first 
conceived by Donald Hebb in 1949 (Hebb, 1949). He proposed that learning occurs 
when the strength of synaptic connections rises among neurons that are active at the
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same time i.e. neurons that fire together, wire together. Briefly, the mechanism of LTP 
is proposed to begin with glutamatergic signalling at AMPA and kainate receptors, 
reflecting pre-synaptic depolarisation of a certain critical frequency. Prolonged 
activation then facilitates functioning of the post-synaptic NMDA-R (Kandel, 1991). 
NMDA-R activation raises intracellular Ca 2+ and has downstream effects on calcium 
dependent protein kinases leading to a cascade of events altering cellular function and 
gene transcription (See Figure 1.2). The postsynaptic cell also releases retrograde 
signalling molecules (possibly nitrous oxide) effecting intracellular machinery of the 
pre-synaptic cell (Thomas, 1995). In this way both the capacity of the pre-synaptic cell 
to release glutamate and the post-synaptic cell to detect it are altered (See Figure 1.2). 
More recently other forms of synaptic plasticity involving NMDA-R and non-NMDA 
glutamate receptors have been documented including long-term depression (LTD) and 
short-term potentiation (STP) (Thomas, 1995). Much of the evidence for the role of the 
NMDA-R in LTP and other forms of synaptic plasticity comes from pre-clinical work 
with NMDA-R antagonists which will be reviewed later in this chapter.
1.6. Effects on other neurotransmitter systems
As discussed above, the behavioural effects of the aryclcylohexamines are thought to be 
largely mediated by glutamatergic neurotransmission at the NMDA-receptor. However, 
the arycyclohexamines are also recognised as having downstream actions on other 
neurotransmitters systems in the brain.
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There has been considerable debate about the dopaminergic effects of ketamine and 
PCP. Low concentrations have been shown to antagonise NMDA-evoked DA release in 
the striatum (Moghaddam et al., 1997) . However, many of the behavioural effects of 
ketamine and PCP resemble those of a DA agonist (e.g. psychotomimetic properties 
and stereotypy in rats). At sub-anaesthetic doses NMDA-receptor antagonists increase 
extracellular DA concentrations in the rat pre-frontal cortex (Lindefors et al., 1997; 
Moghaddam et al., 1997). This increase in DA is associated with poorer performance 
on a working memory task (Verma & Moghaddam, 1997). Some positron emission 
tomography (PET) studies have demonstrated that ketamine stimulates the release of 
dopamine from striatal terminals (Smith et al., 1998) although more recent studies cast 
some doubt over these findings (Aalto et al., 2002; Kegeles et al., 2002).
PCP and ketamine have also been shown to inhibit NMDA-stimulated ACh release 
from rat cerebral cortical and striatal slices at very low concentrations (nanomolar to 
micromolar) (Kegeles et al. 2002; Lodge & Johnston, 1985). However, more recent 
animal studies also suggest an increase in cortical acetylcholine release with 
administration of acute and repeated doses of ketamine (Nelson et al., 2002). MK-801 
and PCP have been shown to inhibit NMDA-induced cortical GAB A release (Drejer & 
Honore, 1987). Ketamine also interacts with p-opiod receptors and with the non-opiod 
o receptor site, although the affinities of the drug for these receptors is at least one 
order of magnitude lower than for the PCP site (Oye et al., 1992). Effects of these drugs 
on other neurotransmitter systems will be given further consideration in Section 1.3.7 
when interactive effects of the arylcyclohexamines and other drugs will be discussed.
1.7 PET and BOLD fMRI studies with ketamine and PCP
Given that the main behavioural effects of ketamine and related compounds have been 
attributed to NMDA-R antagonism, the areas of brain activation associated with the 
administration of NMDA-R antagonists might be hypothesised to those with a high 
concentration of NMDA-Rs. Although NMDA-Rs are located throughout the 
mammalian brain, the highest densities are in the cerebral cortex, the limbic system and 
striatum (Monaghan et al., 1985). Preliminary work with rodents using
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autoradiographic techniques supported the view that NMDA-R antagonist-mediated 
brain activation occurs where NMDA-R populations are located. Studies demonstrated 
increased activation in cortical and limbic regions after ketamine and PCP 
administration (Crosby et al., 1982; Meibach et al., 1979). Further animal research has 
used ,4C-2-deoxyglucose (2DG) techniques and immunocyctochemical staining for 
Fos-like proteins (Fos-Li) to examine the effects of ketamine on brain metabolic 
activity (Duncan et al., 1998). At a sub-anaesthetic dose of 35 mg kg 1 ketamine 
increased metabolic activity in limbic and cortical regions including the medial 
prefrontal, ventrolateral orbital, cingulate and retrosplenial cortices. Ketamine also 
increased metabolism in areas of the hippocampal formation and in select thalamic 
nuclei and the basolateral amygdala. Human studies using positron emission 
tomography (PET) methodology have shown marked increases in frontal cortex activity 
after ketamine administration (Vollenweider et al., 1997) in addition to increased 
activity in the anterior cingulate cortex. The frontal cortex is also more stimulated by 
ketamine than the occipital cortex, despite nearly equal NMDA-R densities (Breier et 
al., 1997) and it has been suggested that reduction of the inhibitory influence of 
GABAergic activity may result in some of the hyperfrontality observed following 
ketamine administration. In a further study using FDG-PET, ketamine was associated 
with an increase in activation in the prefrontal cortex but no other region (Hartvig et al.,
1995).
Blood oxygen level dependent (BOLD) changes observed with functional magnetic 
resonance imaging (fMRI) has provided a new perspective on brain activity associated 
with ketamine. Abel et al.(2003b) suggested that ketamine’s effects are not either a 
global increase or decrease in activation but represent increases in activity relative to 
task specific demands, and demonstrated these effects on a gender discrimination task. 
This assertion has been supported by subsequent work (Honey et al., 2005; Honey et 
al., 2004). These results will be discussed further in the section concerning acute effects 
of ketamine in humans (Section 1.9).
Studies in schizophrenic populations have also examined changes in brain 
haemodynamics following ketamine. Ketamine induced an increase in blood flow to 
the anterior cingulate and a decrease in blood flow to the hippocampus and primary
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visual cortex in five schizophrenic patients examined with [150]H20 PET (Lahti et al., 
1995a). Medoff et al. (2001) used a similar PET technique and found that a low dose of 
ketamine reduced blood flow in the hippocampus of a schizophrenic group but did not 
affect blood flow in healthy volunteers. This may be due to underlying differences in 
NMDA-R antagonist sensitivity in normal and schizophrenic volunteers (Medoff et al.,
2001). Two studies have examined the effect of chronic NMDA-R antagonist 
administration in humans. They both found a reduction in frontal blood flow in drug- 
free PCP users compared to poly-drug taking controls (Hertzman et al., 2002) and 
healthy volunteers (Wu et al., 1991).
1.8 Summary
The principal mode of action of ketamine, PCP and MK-801 is at the PCP-receptor site 
of the NMDA-R complex. The magnitude of the behavioural effects of each drug is 
thought to be associated with their relative affinity for the NMDA-R; of which 
ketamine has the lowest affinity. These drugs are also reported to have effects at other 
receptors (e.g. DA, GABA and opiate receptors). The degree to which these effects on 
different systems may be responsible for some of the cognitive and psychotomimetic 
effects of ketamine and related compounds is not yet clear. Some research has begun to 
investigate this and is described in Section 1.9.7.
Hyperfrontality after ketamine has been found in two PET studies investigating brain 
activation changes along with increased activation of the anterior cingulate cortex. Task 
dependent increases in activation have been found in similar areas on fMRI studies. 
Acute ketamine challenge in schizophrenic patients has been associated with decreased 
activation of the hippocampus and increased anterior cingulate function but not 
increased frontal functioning. This may reflect some underlying differences in 
sensitivity to NMDA-R antagonists as a result of endogenous psychosis or 
neurodegenerative changes.
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LITERATURE REVIEW
From the background given above it is apparent that ketamine and other NMDA- 
receptor antagonists provide unique tools to investigate the link between human, animal 
and neuronal models of learning and memory. The drug also induces a state resembling 
both the positive and negative symptoms of schizophrenia, thus the psychotomimetic 
properties of ketamine have been investigated to gain insight into the pathophysiology 
of schizophrenia. In addition, ketamine is increasingly being abused by recreational 
drug users in dance venues and ‘raves’ and some research has examined the effects of 
chronic abuse of this drug. It is in these three contexts that literature surrounding 
NMDA-receptor antagonists will be discussed in this review.
Part I: Acute and sub-acute studies of the cognitive effects of NMDA-R antagonists 
will outline studies of the acute and sub-acute effects of NMDA-R antagonists 
discussed in the framework of Tulving’s (1985) memory systems model. This section 
will mention pre-clinical research but focus mainly on the effects of NMDA-R 
antagonists in humans.
Part II: Acute and sub-acute studies of the psychotomimetic effects of NMDA-R 
antagonists will provide a general background to schizophrenia and cognitive 
dysfunction associated with it. Then studies of the acute and sub-acute 
psychotomimetic effects of NMDA-R antagonists in animals and humans will be 
reviewed. Symptom exacerbation studies will also be reviewed in addition to studies 
looking at the interactive effects of ketamine and antipsychotic and sedative 
compounds.
Part III: Chronic Effects of NMDA-R antagonists will examine the literature 
concerning the chronic effects of NMDA-receptor antagonists. Preclinical studies will 
be covered, reviewing evidence for neurotoxicity and then clinical research on chronic 
effects of ketamine and PCP- which is at this stage is confined to recreational drug 
users- will be considered
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PART I: ACUTE EFFECTS OF NMDA-R ANTAGONISM ON 
COGNITIVE FUNCTION
1.9.1 Animal studies of cognitive function after acute administration of NMDA-R 
antagonists
There has been an abundance of research concerning learning and memory in animals 
following NMDA-antagonist administration (See Morris & Davis, 1984 for a review). 
This will be only briefly addressed as a background to the human research, which is the 
focus of this review. The rationale for much of this work has been to investigate the 
link between LTP and the behavioural correlates of learning and memory in animals. 
Whilst much of the preclinical research has been conducted with the selective NMDA- 
R antagonist AP5, work has also been carried out with ketamine, PCP and MK-801. 
These drugs were considered ideal tools with which to block hippocampal LTP in vivo 
and so investigate the effect of this antagonism on synaptic plasticity (Morris & Davis, 
1994). The finding that NMDA-R antagonists can block learning at concentrations 
similar to those that block LTP in vitro (Davis et al., 1992) was considered further 
evidence for the link between hippocampal LTP and learning in animals.
It has been well established that spatial learning in paradigms such as the Morris Water 
Maze is disrupted after competitive and non-competitive NMDA-R antagonist 
administration in rats and cats (Balster & Chait, 1976; Davis et al. 1992; Handelman et 
al., 1987; Morris et al., 1990; Spangler et al., 1991). Spatial learning tasks are 
dependent on the integrity of the hippocampus (O'Keefe & Nadel, 1978) in which LTP 
was first discovered and investigated (Bliss & Lomo, 1973). Thus, this work further 
supports the idea that hippocampal LTP may be involved in learning and memory. In 
rodents, the deficit in memory function induced by NMDA antagonists appears to 
involve an impairment in the acquisition or encoding of new information rather than its 
retrieval (Spangler et al. 1991). In non-human primates similar impairments have been 
reported (Frederick et al., 1995; Thompson et al., 1987) again suggesting impairments 
of encoding rather than retrieval of new information (Buffalo et al., 2002).
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Research has further demonstrated deficits in performance on the delayed non­
matching to sample task designed to tap working memory, after administration of an 
NMDA receptor antagonist in rats (Lyford et al., 1993). In non-human primates, acute 
PCP administration impairs performance in a similar delayed non-matching to sample 
task of working memory task, but in a delay independent fashion (Boyce et al., 1991).
Administration of ketamine, PCP and MK-801 has also been shown to impair 
performance on amygdalar and simple associative learning tasks such as acquisition of 
a conditioned emotional response (Hoehn-Saric et al., 1991), flavour aversion (Aguado 
et al., 1994), an operant response (Pallares et al., 1995) or conditioned cue preference 
(Stevens et al., 1997). Deficits in conditional discrimination tasks (Moerschbaecher & 
Thompson, 1980) and tasks that measure motivation (Frederick et al. 1995) have also 
been observed. In summary, NMDA-R antagonists produce wide-ranging deficits in 
pre-clinical models of cognition, most notably in paradigms thought to depend upon 
the integrity of the hippocampus and amygdala.
1.9.2 Memory Systems and NMDA-R Hypofunotion
In 1994, Schacter and Tulving published an influential essay on memory systems. This 
summarised the main proposed systems of memory up to that time Tulving defined a 
memory system in general as “a set of correlated processes” (Tulving, 1985 p.386, c.f. 
Schacter, 1999). Differing memory systems have been identified by their representation 
of different kinds of information, in addition to distinct neurobiological underpinnings. 
Separate memory systems were suggested to have different laws and principles 
characterising their operation and differences in their ontogenetic and phylogenetic 
development (Schacter, 1999). The memory systems model was developed from the 
findings of cognitive, neuropsychological, psychopharmacological and more recently 
neuroimaging research. The five proposed memory systems are: episodic memory, 
working memory, semantic memory, procedural memory and the perceptual 
representation system. This framework, including Baddeley’s (2000) conceptualisation 
of working memory, will be used in this review for examining the evidence concerning 
the mnemonic consequences of NMDA-receptor antagonism.
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An important caveat to consider before examining research into ketamine’s effects on 
memory systems, is that no one task can tap a single memory system or process. The 
five systems to be discussed below are interactive and one task may involve two or 
three memory systems. For example in immediate prose recall, the recency effect 
(better memory for most recently presented material) involves aspects of working 
memory and yet the primacy effect (better memory for material presented first) 
probably involves episodic memory, whereas understanding the meaning of the prose is 
a function of semantic memory. With this caveat in mind, the findings of studies 
reviewed below are summarised in Table 1.1. in terms of the principal system thought 
to be tapped by the task employed. Other factors that complicate comparisons between 
the studies reviewed below include I) the wide variety of tasks used across the different 
studies II) the wide variety of doses, routes of administration and populations III) the 
variation in test times post-ketamine that have been used. Further differences have also 
been observed that are not accounted for by the above explanations (see Honey et al., 
2003). These may be related to individual differences in drug response (e.g. Malhotra et 
al., 1998) or the use of different strategies to meet task demands that may vary from 
subject to subject (Honey et al., 2003). Despite this however there is sufficient 
commonality in the studies to allow comparison, and the memory systems framework is 
useful conceptually in the examination of these studies.
1.9.3 Episodic Memory
Episodic memory makes possible what Tulving (1998) terms ‘mental time travel’ back 
into a person’s past. It facilitates the acquisition and retrieval of information about 
specific personal experiences that occur at a particular time and place (Tulving, 1985b; 
Tulving & Markowitsch, 1998). A large number of studies have consistently found 
ketamine-induced decrements across tasks which principally tap episodic memory at a 
range of doses (Hetem et al., 2000; Ghoneim et al., 1985; Krystal et al., 1994; Malhotra 
et al., 1997a; Newcomer et al., 1999). In addition, these effects have been found across 
diverse measures, including recognition tasks (Hetem et al., 2000; Ghoneim et al., 
1985; Honey et al., 2003), recall of passages of prose (Newcomer et al., 1999), recall of 
high and low frequency word lists (Hetem et al., 2000; Ghoneim et al., 1985; Malhotra
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et al., 1996), spatial learning paradigms (Rowland et al., 2005) and, of particular 
relevance to episodic memory, source memory tasks (Honey et al., submitted).
Other studies have investigated the relative contributions of encoding and retrieval to 
these verbal episodic memory deficits. Ghoneim et al. (1985) reported that acute 
ketamine (0.25mg/kg and 0.5mg/kg) produces significant dose dependent impairments 
in delayed recall of word lists learnt both pre and post drug administration in healthy 
volunteers; they concluded that ketamine impairs retrieval and not encoding. However, 
this study did not maintain a steady state infusion, and participants were tested on the 
pre-drug words shortly after a bolus when they were highly dissociated. In addition, 
practice effects and differing duration and nature of retention intervals between each 
testing complicates interpretation of these data. Further work appears to contradict 
these findings. Hetem et al. (2000) looked at recall of words learnt before and after drug 
administration and found that recall was only significantly impaired for words 
presented post-drug. A similar impairment in memory of information learnt post­
infusion has been noted on recognition memory tasks (Hetem et al., 2000; Honey et al., 
submitted) and a virtual Morris water maze (Rowland et al., 2005). Pre-clinical support 
for ketamine-induced encoding impairment (discussed in section 1.9.1.) is provided by 
studies describing NMDA antagonist-induced deficits in acquisition (i.e. encoding) but 
not performance (i.e. retrieval) in spatial learning tasks (Ohno et al., 1994). Indirect 
evidence from another study (Malhotra et al., 1996) suggests that ketamine 
preferentially impairs encoding processes. Ketamine produces decrements in both free 
recall and recognition. Impaired recognition implies impaired encoding. The reasoning 
behind this being that recall, but not recognition, performance requires retrieval 
processes in searching for information in memory. The latter findings may also be 
interpreted in terms of the recollection / familiarity distinction discussed below.
Another facet of verbal episodic memory, the conscious state associated with 
remembering, also appears to be affected by ketamine. Memory research has promoted 
the view that episodic memory may be characterised by the subjective awareness of 
recreating events and experiences and reliving these events and experiences mentally. 
Tulving (1985) termed this type of awareness ‘autonoetic’ awareness and contrasted it
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with ‘noetic’ awareness, that is feelings of familiarity with an event or experience 
without conscious recollection. This can also be thought of as the difference between 
‘remembering’ and ‘knowing’. Ketamine has been found to decrease remember and 
know responses, but not to selectively affect any particular state of awareness in 
recognition compared to controls (Hetem et al., 2000). This is an interesting finding in 
that several clinical populations, e.g. schizophrenic patients (Huron et al., 1995), 
amnesics (Knowlton & Squire, 1995), Alzheimers patients (Schacter et al., 1997) and 
psychopharmacological studies with amnestic agents such as lorazepam (Curran et al., 
1993) and alcohol (Curran & Hildebrandt, 1999) have demonstrated preserved ‘know’ 
responses but reduced remember responses. The original theory relating to autonoetic 
awareness proposed by Tulving (1985) was that remembering responses are best 
accounted for by episodic memory and know responses by semantic memory. The 
results of Hetem et al.’s study could be explained by the preliminary evidence of 
semantic memory deficits found with ketamine which are discussed further below, in 
section 1.2.5. However, a complication in the design of the task in the Hetem et al. 
study was that the recognition test did not include lures, or new items, therefore the 
post-drug differences could be explained in a change in bias of responding (Honey et 
al., submitted). A subsequent study, however, found evidence suggesting impaired 
recollective (‘remember’) processes in the face of preserved familiarity (‘know’) 
suggested by preserved memory for shallowly and deeply encoded words but impaired 
memory for words encoded at an intermediate level (Honey et al., submitted) which 
casts doubt over Hetem et al.’s findings.
Recent neuroimaging data have also shed light on processes involved in episodic 
memory following ketamine. Compared to placebo at encoding of subsequently 
successfully remembered words, a dose of ketamine produced an increase in left frontal 
activity on a deep encoding task, as estimated by the BOLD signal (Honey et al., 2005). 
The authors interpreted this finding as difficulties in selecting semantic attributes 
relevant to the semantic judgement that constituted the deep encoding task. In addition, 
they observed increased right lateral prefrontal cortex activation which may reflect 
incidental non-verbal processing (Honey et al., 2005). At retrieval, ketamine affected 
hippocampal and frontal activity. Decreased left prefrontal response was observed, 
which the authors suggest may indicate a failure to retrieve contextual detail associated
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with stimuli. Increased BOLD response in the bilateral PFC and right hippocampus was 
also observed. This may indicate the more demanding nature of retrieval on ketamine 
and reduced access to contextual details. ACC activation was also greater to incorrect 
responses, on placebo this was reduced in relation to correct trials. The ACC is thought 
to be involved in error monitoring, thus this may indicate deficient error monitoring on 
ketamine. It is worth noting that these changes were observed in the absence of any 
behavioural impairment. This highlights how imaging may be useful in demonstrating 
subtle differences which are not apparent on behavioural tasks. Making the 
presupposition that BOLD signal changes reflect changes in underlying neural activity, 
the authors also note however that without performance differences it is difficult to 
ascertain whether greater activation reflects increased glutamatergic activity at non- 
NMDA receptors, and possibly enhanced function or whether this reflects a 
compensatory mechanism for inefficient processing.
1.9.4 Working Memory, Attention and Executive functioning
Working memory is proposed to facilitate the maintenance and manipulation of internal 
representations such that these representations can be used to guide future behaviour 
(Baddeley, 1998). The most recent form of the model is comprised of four components: 
the phonological loop, the visual-spatial scratchpad, the central executive and the 
episodic buffer (Baddeley, 2001). Baddeley suggests that the phonological loop is 
involved in rehearsal and temporary storage of auditory verbal information and that the 
visual-spatial scratchpad serves an analogous function for visual and spatial properties 
of a stimulus (these two are termed ‘slave systems’). The central executive is thought to 
be a limited capacity supervisory attentional mechanism (Shallice, 1982) and the 
episodic buffer, the newest component of the model, is proposed to facilitate the 
integration of information from all of the above sources and long-term memory.
Forwards digit span, which involves repeating back a sequence of numbers, may be 
seen as an index of the phonological loop. Performance on this task is intact following 
ketamine adminstration (Ghonheim et al., 1985; Honey et al., 2003; Rowland et al., 
2005; Abel et al., 2003). From the limited evidence available - one study examining 
forwards spatial span (Rowland et al., 2005) and a spatial delayed response task
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Principal memory 
system tapped
Task Study
Episodic Memory Immediate verbal recall Ghoneim et al. (1985), X
Krystal et al. (1994) V
Harbome et al. (1996) X
Malhotra et al. (1996) X
Newcomer et al. (1999) X
Hetem et al. (2000) X
Delayed verbal recall Ghoneim et al.(1985) X
Krystal et al. (1994) X
Verbal recognition Ghoneim et al. (1985) X
Malhotra et al. (1996) X
Hetem et al. (2000) X
Honey et al. submitted X
Source Memory Honey et al. submitted X
Spatial Memory Rowland et al. (2005) X
Associative Memory Harris et al. (1975) X
Harbome et al. (1996) X
Category Fluency Ghoneim et al. (1985), “V '
Adler etal. (1998) X
Semantic memory Digit span Harris et al.(1975) V
(forwards / backwards) Ghoneim et al. (1985) V V
Honey et al. (2003) V x
Abel et al. (2003) V x
Rowland et al. (2005) V V
Working Memory Spatial Span Rowland et al. (2005) V
N-back -  1-back, 2 back Newcomer et al. (1999) X
Spatial working memory Newcomer et al. (1999) V
(SDR)
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Principal memory 
system tapped
Task Study
Attention CPT Krystal et al. (1994) X
Harbome et al. (1996) V
Malhotra et al. (1996) X
Adler etal. (1998) V
Newcomer et al. (1999) V
Umbricht et al. (2001) X
N-back -  0-back Newcomer et al. (1999) V
Stroop Harbome et al. (1996) V
Newcomer et al. (1999) V
DSST/ SCT Hetem et al. (2000) X
Executive Verbal fluency Krystal et al. (1994), X
Functioning Krystal et al.(1997) X
Adler et al. (1998), X
Newcomer et al. (1999) V
Krystal et al.(1999) V
Abel et al. (2003) V
Rowland et al. (2005) V
Trailmaking Harbome et al. (1996) A-B V
WCST Krystal et al. (1994) X
Tower of London Honey et al. (2003) V
Procedural No studies ??
Memory
PRS No studies ??
Table 1.1. Findings of studies administering an acute dose of ketamine to healthy 
volunteers, summarised in terms of the ‘memory systems’ model.
40
(Newcomer et al., 1999)- the operations of the visual-spatial scratchpad also seem to be 
unaffected by ketamine.
Ketamine’s effects on integration and manipulation within working memory, i.e. the 
central executive, have also been investigated although findings are less consistent than 
those relating to the slave systems. Preserved backwards digit span has been observed 
in some (Rowland et al., 2005; Ghonheim et al., 185; Harris et al., 1975), but not all 
(Honey et al., 2003; Abel et al., 2003) studies. Neuroimaging work has demonstrated 
augmented BOLD response on ketamine in frontal-parietal regions for manipulation but 
not maintenance of information (Honey et al., 2004). This suggests that in the former 
studies, even when no behavioural differences are present, manipulation of information 
in working memory by the central executive is affected by ketamine, although again it 
is unclear what exactly this may reflect i.e. augmented or decreased glutamatergic 
activity and/or performance.
Adler et al. (1998) used the n-back to tap working memory. This involves an attentional 
component (0-back) where participants are required simply to respond to a particular 
number/ letter and then two further components with increasing working memory load. 
In the 1-back, participants are required to respond if the letter/number is the same as the 
one previously presented; in the 2- back they must respond if the letter/number is the 
same as the one two before. Ketamine was associated with decreased scores on the one- 
back and two-back, but not the zero back, components. Conversely, spatial working 
memory was preserved after ketamine administration (Honey et al., 2003). However 
this finding was complicated by the presence of only one version of the spatial working 
memory task within the CANTAB, thus this finding may have been confounded by 
more complicated order x drug interactions in this repeated measures design. On the 
serial seven’s task, which may also tap the episodic buffer, impaired performance after 
PCP administration has been observed (Cohen et al., 1962; Luby et al., 1959).
Results from investigations into ketamine’s effects on sustained attention are again 
relatively equivocal. Some studies report ketamine-induced deficits in sustained 
attention on the continuous performance task (CPT: Krystal et al., 1994; Malhotra et al., 
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1996) but others report no deficits (Krystal et al., 1999; Newcomer et al., 1999). 
Intriguingly, relatively specific deficits have been found on the ‘AX’- version of the 
CPT. This task assesses both sustained attention and the successful processing of task 
relevant cues. Subjects are required to respond to the letter ‘X’ only when it is preceded 
by an ‘A’. Distractor trials in the task include an ‘A’ followed by a ‘Y’ or ‘B’ followed 
by an ‘X’ or a ‘Y \ Ketamine decreased hit rates (on ‘A-X’ trials) and also increased the 
number of ‘B-X errors on this task (Umbricht et al., 2000). The specificity of these 
errors may reflect an inability to use contextual cues appropriately, rather than an 
indiscriminate increase in errors, as other types of errors (AY and BY) were similar 
across groups. In contrast to the work on sustained attention, studies that have 
examined selective attention using the Stroop paradigm have, in general, found it to be 
unimpaired (Harbome et al., 1996; Newcomer et al. 1999; Oranje et al., 2000; Rowland 
et al. 2005) . In light of the attentional difficulties observed it is plausible that these 
may underpin some of the other cognitive deficits observed following ketamine. 
Malhotra et al. (1996) covaried for attentional effects and found ketamine’s effects on 
memory (free recall and recognition) were still significant.
Working memory is also conceptualised under the umbrella term of ‘executive 
functions’. Executive functioning can be conceptualised as the selection, monitoring 
and integration of cognitive and behavioural processes and is served by the frontal 
lobes. After ketamine administration participants made more perseverative errors on the 
Wisconsin Card Sorting task (WCST; Krystal et al., 1994) which is thought to tap 
executive functioning. Krystal et al. (2000) re-examined performance on the WCST by 
repeating the task following ketamine and placebo in a crossover design. Participants 
who had acquired the rules of the WCST whilst on ketamine performed worse in the 
task whereas those who acquired the rules on placebo were relatively unimpaired. The 
authors suggested that general NMDA-receptor mediated impairments to learning do 
not affect the cognitive functions necessary to carry out the WCST such as mental set- 
shifting and that impairments on this task may reflect more general deficits in rule 
learning (Krystal et al., 2000). This may be of relevance for findings of the effects of 
ketamine on the Tower of London task, where no impairment was observed following 
ketamine (Honey et al., 2003). Again, this task is not intended to be repeated as 
strategies can be acquired and in repeated measures designs complex order by drug 
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interactions may occur. Executive functioning has been further examined with a simple 
trailmaking task by Harbome et al. (1996) who found preserved frontal functioning 
(Trails B), once psychomotor slowing (Trails A) had been controlled for. Fluency is 
also considered to be a task tapping executive functions, and may involve the putative 
‘episodic buffer’, but will be discussed below as a semantic memory task as this is how 
it has been classified in the majority of the ketamine studies that have employed it.
1.9.5. Semantic Memory
Semantic memory refers to a person’s general knowledge about the world (Tulving, 
1972). It differs from episodic memory in that semantic information is not associated 
with a specific learning context. Semantic knowledge covers a range of organised 
information including concepts, vocabulary and facts. Prior to some of the studies in 
this thesis, effects of ketamine on semantic memory had been explained only with 
fluency tasks and findings were inconsistent. Whilst some studies showed ketamine- 
induced impairments in category (Abel et al., 2003a; Adler et al., 1998) and phonemic 
fluency (Adler et al. 1998; Krystal et al., 1994; Krystal et al., 1999b) tasks, others have 
found fluency to be intact (Abel et al. 2003a; Newcomer et al. 1999; Rowland et al. 
2005; Krystal et al. 1999b). Overall the existence of semantic memory deficits 
following ketamine administration would appear to still be in debate.
1.9.6 Procedural Memory and Perceptual Representation System (PRS)
Procedural memory and the PRS are non-declarative memory systems where retention 
is assessed indirectly or implicitly. Procedural memory pertains to the learning of motor 
and cognitive skills; ‘real-world’ examples may be learning to ride a bike or learning to 
read. Procedural memory is likely comprised of numerous subsystems with the 
commonality between them being that they all consist of learning a new skill. No 
research prior to this thesis had investigated the effect of NMDA-R antagonism on 
procedural memory. Ketamine was administered on a repeated version of WCST 
(Section 1.9.4) and findings implied an impairment in acquisition but not expression of 
the rules necessary to conduct the task. These data may relate to procedural memory
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impairments but as the WCST is not a procedural task per se, it is difficult to draw any 
conclusions.
The perceptual representation system can be viewed as operating on perceptual 
information about the form and structure of words and objects. In memory research the 
main interest in the PRS relates to its role in perceptual priming. Perceptual priming 
refers to an increased likelihood of identifying or remembering an object as a result of 
previous exposure to it. This relates additionally to implicit memory, or memory when 
stimuli are presented and recalled without awareness. No studies had investigated 
perceptual priming with NMDA-R antagonists.
1.9.7.Summary of acute cognitive effects
NMDA-R antagonists produce impairments in episodic-like memory. These deficits 
appear to be a result of encoding rather than retrieval failures. The central executive 
component of working memory may be impaired by ketamine, whilst slave systems are 
left intact. There is some evidence of semantic impairments following ketamine. 
Priming and procedural memory have not been investigated with NMDA-receptor 
antagonists. Cognitive impairments following NMDA-R antagonist administration have 
been found to be wide-ranging and yet there are still many gaps in our knowledge. As 
cognitive impairments have been used to support the NMDA-R hypofunction / 
glutamatergic hyperfunction model of schizophrenia discussed below it is also 
important to fully characterise these impairments to assess the degree to which 
ketamine and related compounds provide a good model of the cognitive deficits 
associated with schizophrenia.
PART II: SCHIZOPHRENIC SYMPTOMS AND NMDA-R
ANTAGONISTS
First described by Kraeplin (1893) as ‘dementia praecox’, schizophrenia is a
widespread and disabling disorder prevalent in about 1% of the population worldwide
(NICE, 2002). Gaining a thorough understanding of the symptoms and aetiology of the 
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disease remains one of the greatest challenges in psychiatric research. Symptoms of 
schizophrenia can be divided broadly into three groups: 4positive ’ symptoms such as 
delusions, disorganised thinking and speech, hallucinations, altered perceptions and 
inappropriate affect; negative or deficit symptoms such as poverty of speech, blunted 
and flat affect, loss of volition and social withdrawal; cognitive symptoms including 
thought disorder, incoherence, looseness of associations and neologisms.
I.10.1 Background to theories of cognitive dysfunction in schizophrenia
Along with the symptoms described above, patients with schizophrenia exhibit a 
variety of cognitive deficits including impairments in executive functioning, attention, 
working, episodic and semantic memory (Heinrichs & Zakzanis, 1998). These deficits 
are relatively resistant to anti-psychotic medication (Calev et al., 1983; McKenna et al., 
1990), are observed in the unaffected twins of monozygotic pairs (Goldberg et al., 
1993), and can precede the onset of schizophrenia and predict the development of 
symptoms in people who score highly on schizotypy (or psychosis proneness) scales 
(Friedman & Chapman, 1973). Some memory functions are relatively well preserved in 
schizophrenia however, with a crucial determinant appearing to be conscious awareness 
at retrieval (Danion et al., 1999; Danion et al., 2001; Gras-Vicendon et al., 1994; Huron 
et al. 1995). Patients with schizophrenia exhibit impaired retrieval on explicit memory 
tasks such as recall and recognition of word lists but, in general, have intact implicit 
memory or learning (Huron et al., 1995; Danion et al., 2001).
Several theories have suggested that cognitive deficits in schizophrenia may underlie 
symptomatology, in particular, negative symptoms. Neuropsychological theories of 
schizophrenic symptoms include an impairment in working memory and prefrontal 
lobe functioning (Goldman-Rakic, 1988) and a weakening of the influences of stored 
memories on current perception (Hemsley, 1987) with links proposed between this 
abnormality and latent inhibition (Lubow et al., 1982). Frith (1987) proposed that the 
two syndromes of schizophrenia are due to different impairments in the initiation of 
action. Type I, or acute schizophrenia with positive symptoms is thought to be a 
product of inappropriate monitoring of the source of willed intentions and actions. Type
II, or chronic schizophrenia with negative symptoms is hypothesised to be a deficit in 
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forming willed intentions. Frith (2002) extended his monitoring theory to suggest that 
the inability to monitor willed intentions can lead to hallucinations, delusions of control 
and thought insertion, as a result of attributing internal thought and action to external 
sources. Paranoid delusions and ideas of reference are also conceptualised as deficits in 
monitoring of beliefs and intentions of others. However, it seems at best ambitious to 
suppose that a single theory could account for the heterogeneity of symptoms in 
schizophrenia.
Research has been largely unsuccessful in demonstrating a correlation between positive 
symptoms and neuropsychological impairments. This could be a result of the lack of 
sensitivity of cognitive tests which often tap a variety of cognitive functions, or the 
suggestions that cognitive symptoms often persist after the remission of acute positive 
symptoms in schizophrenia. The case for a relationship with negative symptoms is 
stronger but there is danger of circularity with these symptoms e.g. verbal fluency 
impairments are correlated with poverty of speech (Phillips & David, 2000). Given the 
ability of NMDA-R antagonists to induce schizophrenia-like symptoms and the role of 
the NMDA-R in learning, it is tempting to speculate that a common process may 
mediate some of the cognitive dysfunction of schizophrenia and that induced by 
NMDA-R antagonists.
1.10.2 Schizophrenia and NMDA-R Antagonists
Within psychiatric neurobiological research, several methods of inducing psychotic 
symptoms in animals and humans have been used. These include in animals, chronic 
social isolation or stress (Jones et al., 1990) and perinatal insults (Lipska et al., 1993; 
Moore & Grace, 1997) and in both humans and animals, sleep deprivation ( Patat et al.,
1999) and the administration of psychotomimetic drugs (Javitt & Zukin, 1991; Snyder, 
1988). Due to the transience of symptoms and cross-species applicability, one of the 
most popular methods of inducing psychosis in animals and humans is the latter.
Recently, interest in the potential use of non-competitive NMDA-receptor antagonists 
as models of the symptoms, and possibly the aetiology, of schizophrenia has grown. 
During the 1950’s many researchers considered lysergic acid diethylamide (LSD) to be 
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a good pharmacological induction of psychosis (Vollenweider et al., 1998). However, 
this came to be viewed a superficial model that a well-trained observer could easily 
discriminate from true psychosis (Hollister, 1962). A further popular drug model was 
stimulant psychosis, precipitated by chronic amphetamine or cocaine use. Long-term 
amphetamine use induces a form of paranoid psychosis with positive symptoms. In 
addition, high-dose repeated administration of amphetamine to healthy volunteers can 
induce paranoid symptoms that mimic the symptoms of paranoid schizophrenia (van 
Kammen et al., 1982). Indeed, the amphetamine model, along with evidence from 
Parkinson’s patients (Bunney, 1970), contributed to the dopamine hypothesis of 
schizophrenia which led to the development of phenothiazines and other D2 receptor 
antagonists as drug treatments for the disorder. However, while the LSD and chronic 
stimulant models can induce some of the positive symptoms of schizophrenia, evidence 
of any true ‘deficit’ state in either model is conflicting (Angrist & Gershon, 1970). In 
contrast, non-competitive NMDA-R antagonists like ketamine and PCP appear to be 
able to induce both the positive and negative symptoms of schizophrenia (Bakker & 
Amini, 1961; Malhotra et al., 1996).
The ability of PCP to produce a psychosis ‘indistinguishable’ from acute schizophrenia 
was first observed in the late 1950’s (Luby et al., 1959) and then replicated in the early 
1960’s (Bakker & Amini, 1961; Cohen et al., 1962; Davies & Beech, 1960). Due to the 
duration of effects and neurotoxicity of PCP, controlled studies of PCP in humans are 
now prohibited, however animal research with PCP and its stronger congener 
dizocilipine have continued. In addition, several preclinical and clinical studies have 
used ketamine to elicit a ‘model psychosis’.
A clear and insurmountable problem for animal ‘models’ of schizophrenia, is the 
inability to produce certain symptoms associated with the disorder such as those 
associated with verbal behaviour (for example auditory hallucinations). In their review 
of the area, Geyer and Markou (1994) highlight the difficulties of achieving even face 
validity, let alone construct validity in an animal model of schizophrenia. With this 
caveat in mind, the animal literature that has measured behaviours thought to resemble 
the symptoms of schizophrenia with NMDA-R antagonists will be briefly reviewed, 
before moving on to more extensive coverage of the human literature.
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1.10.3 Animal models of other psychotic symptoms
Ketamine, PCP and MK801 administration have been reliably shown to induce 
hyperlocomotion in rats (Boyce et al., 1983; Moghaddam & Adams, 1998). PCP has 
also been shown to inhibit dopamine reuptake which, it has been suggested, may in part 
be responsible for stereotypies and locomotor stimulation in rats (Johnson, 1983). 
However hyperlocomotion has been criticised for not being a reliable indicator of any 
specific schizophrenic symptomatology (Jentsch & Roth, 1999). At higher doses, PCP 
and related compounds have been shown to induce profound tranquillisation, similar to 
dissociative anaesthesia in humans. This tranquillisation resembles a catatonic state 
which invokes parallels with schizophrenic catatonia. In monkeys, PCP tranquillisation 
is so profound that experimenters are able to put their fingers in the monkey’s mouth 
while its eyes are open (Chen & Weston, 1960). PCP has been shown to reduce social 
interaction in rats, however this could be secondary to more general motor and arousal 
deficits. Much effort has been devoted to characterising the ‘cognitive’ impairments 
associated with PCP, MK-801 or ketamine administration in animals often focussing on 
spatial and working memory deficits as described in section 1.2 . 1., which could be 
tenuously linked to the cognitive dysfunction observed in schizophrenia.
One of the broad spectrum of symptoms experienced by people with schizophrenia is 
an inability to filter or ‘gate-out’ irrelevant thoughts and sensory stimuli from conscious 
awareness. A paradigm used to investigate these gating difficulties is prepulse 
inhibition (PPI). PPI refers to a decreased startle response to an intense stimulus when 
it is preceded by a weaker stimulus (or prepulse). PPI has been extensively investigated 
in schizophrenics where deficits in PPI have been found when compared to normal or 
psychiatric controls (see Braff et al., 2001 for a review). Moreover PPI can be readily 
modelled in animals as it is a cross-species phenomenon.
As interest in the NMDA-R hypofunction model of schizophrenia has grown, 
increasing numbers of studies have investigated PPI following ketamine, PCP and MK- 
801 administration in animals. Mansbach and Geyer (1989) first demonstrated that PCP 
and dizocilipine decrease PPI in rats. These findings have since been replicated in many 
studies (Zhang et al., 1997; Bakshi & Geyer, 1995; Depoortere et al., 1999). The effects 
48
on PPI were obtained at doses lower than those required to affect locomotor activity, 
indicating a robust and potent PPI effect. However in the first study (Mansbach & 
Geyer, 1989), ketamine was not observed to disrupt PPL Despite this, every subsequent 
study has demonstrated a decrease in PPI in rats following the administration of 
ketamine (e.g. Mansbach & Geyer, 1991; Swerdlow, 1998; Johansson et al., 1995). 
Factors that may account for the discrepancy between these initial findings and all 
following studies could be wider ranges of stimulus intervals, doses and injection to test 
intervals (Geyer et al., 2005).
1.10.4. Human studies of psychotic symptoms following NMDA-R antagonism
Human research examining the psychotomimetic properties of non-competitive 
NMDA-R antagonists is confined to ketamine, with the exception of the few early PCP 
studies mentioned in Section 1.1. above. The first study to fully characterise psychotic 
symptoms associated with ketamine administration, with the Brief Psychiatric Rating 
Scale (BPRS- Overall and Gorham, 1962), was conducted by Krystal et al. (1994). 
Four key items were chosen to index positive symptoms: conceptual disorganisation, 
hallucinatory behaviour, suspiciousness and unusual thought content. They additionally 
used 3 key items to examine negative symptoms: blunted affect, emotional withdrawal 
and motor retardation and extracted 2 other factors of hostility-suspiciousness and 
activation from the BPRS overall score. Krystal et al. (1994) found an increase 
following ketamine (0.5 mg kg _1) on all four positive symptoms, but no change at a 
lower dose (0.1 mg kg '). However, the hallucinatory behaviour recorded was only 
illusory experiences, mainly confined to the visual domain, which are not classified as 
hallucinations in the BPRS. Ketamine was also reported to dose dependently increase 
all three key negative symptoms in this study. However despite high clinician ratings, 
the paper also states that in several subjects “ ...ketamine evoked intense emotional 
responses...” (pp.204; Krystal et al., 1994). It is not clear the degree to which general 
psychomotor retardation and sedation may have been confounded with the clinician 
rating of emotional withdrawal, motivational deficits and blunted affect. Ketamine was 
also reported to increase behavioural activation and hostility-suspiciousness but only in 
the 0.5 mg/kg group. Perceptual distortions on both the Clinician Administered 
Dissociative Scale (CADSS) and the Perceptual Aberration Sub-scale of the Wisconsin 
Psychosis Proneness scale (WPP) were dose dependently increased. Interestingly, the 
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self-rated PAS and the clinician rated items of the CADSS which both measure 
perceptual distortions were not correlated on the test day, perhaps indicating a 
discrepancy between the clinician ratings and subjective ratings. A problem with the 
BPRS may be that it may not be sensitive to some subtle psychotomimetic drug effects 
as it focuses on only some of the range of psychotic symptoms. It is also difficult to 
administer to patients who are very withdrawn or mute, as participants on ketamine 
may become.
Several other studies have since replicated the findings of elevated total BPRS scores 
following ketamine challenge (Adler et al., 1998; Duncan et al., 2001; Hetem et al., 
2000; Malhotra et al., 1996; Newcomer et al., 1999; Oranje et al., 2000; Umbricht et al., 
2000; Umbricht et al., 2002; van Berckel et al., 1998). However, some have shown 
slight departures from the original findings. Malhotra et al., (1996) found significant 
increases in the factors of withdrawal-retardation and thought disorder but not anxiety- 
depression and hostility-suspiciousness. In a study of healthy volunteers, ketamine 
produced increases in the Assessment of Thought, Language and Communication 
(TLC) total score and on the verbal productivity and disconnection factors of the TLC 
(Adler et al., 1998). In this study, ketamine produced significantly a higher total score 
on the BPRS but the only factor where a significant difference was detected after 
ketamine was thought disorder. The same research group (Adler et al., 1999) validated 
the NMDA-R antagonist model by comparing thought disorder in schizophrenic 
patients to that induced by ketamine. They found no significant differences thus 
providing support for the NMDA-R hypofunction model of thought disorder.
The link between cognition and ketamine-induced schizophrenic-like symptoms has 
also been investigated. Malhotra et al. (1996) further attempted to correlate the 
psychiatric symptoms with cognitive effects but found no relationship of either thought 
disorder or withdrawal-retardation with free recall or recognition memory scores. 
However, a subsequent study did find a relationship between elevated positive 
symptoms following ketamine and recognition memory impairment (Hetem et al.,
2000) although problems with the recognition memory design of this study (discussed 
previously) complicate interpretation of this correlation. In addition, scores on the TLC 
were found to correlate with the 1-back test of working memory (Section 1.9.4.) but not 
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the 2-back test or fluency scores (Adler et al., 1998). The authors interpreted this as 
tentative support for the relationship between working memory and thought disorder 
and evidence against the putative involvement of semantic memory in thought disorder. 
This interpretation is, however, complicated by no correlation on the 2-back task. This 
is the most difficult component of this working memory task and thus the lack of 
correlation may be attributable to floor effects in the ketamine group. However, a 
subsequent study found evidence of elevated thought disorder in the absence of 
working memory impairment, which casts doubt over the putative link between the two 
(Newcomer et al., 1999). LaPorte et al. (1996) also found no impairment to either 
semantic or phonemic fluency performance in schizophrenic patients following 
ketamine challenge; however, these findings are hard to interpret given schizophrenia is 
associated with semantic memory deficits. It is possible that elevated baseline semantic 
memory impairments meant that the verbal fluency and category generation tasks were 
not sensitive enough to pick up ketamine induced changes. Furthermore participants 
were tested 45 min after administration of a ketamine bolus. Previous research suggests 
that the cognitive effects of ketamine in schizophrenic patients remit about 30 min after 
bolus drug administration (Malhotra et al., 1996).
The effects of non-competitive NMDA-R antagonists on PPI in humans have been 
examined in parallel to the preclinical work reviewed above. In contrast to pre-clinical 
observations, findings from ketamine challenge in humans have been largely 
inconsistent. The first study to examine the effects of NMDA-R antagonism on PPI in 
humans (van Berckel et al., 1998) used a low dose of ketamine (0.3mg/kg) and a 
pseudo steady-state infusion. This dose was chosen to minimise p-opiate receptor 
effects and resulted in increases in blood pressure, cortisol levels and heart rate, 
consistent with ketamine effects. Although this dose of ketamine induced a small 
increase in total scores on the BPRS, it did not significantly alter PPI. This may be a 
function of the low dose used (van Berckel et al., 1998). Subsequent studies using 
higher dose of ketamine have found no effect on PPI (Duncan et al., 2001) or in some 
cases slight increases (Abel et al., 2003). Possible reasons for differences between these 
studies and the animal work are the higher doses used in preclinical studies and 
differences in drug metabolism between humans and animals. Moreover, drug-induced 
psychosis in humans is a more efficient model of the acute phase of schizophrenia than 
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chronic stages (Gouzoulis-Mayfrank et al., 1998a) and yet all studies of PPI in 
schizophrenia have focused on chronic patients (Geyer et al., 2005). Furthermore, PPI 
is not a model of schizophrenia merely of the sensorimotor gating deficits associated 
with it.
1.10.5. Administration of NMDA-R antagonists to schizophrenic patients
Further support for the involvement of glutamate in the pathophysiology of 
schizophrenia derives from symptom provocation studies involving NMDA-R 
antagonists. PCP induces a prolonged exacerbation of psychotic symptoms in patients 
which resembles the acute phase of their illnesses (Luby et al., 1959; Ban et al., 1961). 
Studies have also shown increases in positive symptoms in schizophrenics following 
ketamine challenge, both with patients on haloperidol (a DA antagonist) (Lahti et al., 
1995b; Lahti et al., 2001) and neuroleptic-free patients (Lahti et al., 1995; Malhotra et 
al., 1997; Lahti et al., 2001). Neuroleptic free patients in the latter studies reported a 
recurrence of auditory hallucinations during the ketamine infusion and high levels of 
paranoia whereas none of the healthy volunteers reported auditory hallucinations and 
only one healthy volunteer reported feelings of suspiciousness. In the haloperidol group 
(Lahti et al., 1995), many of the positive symptoms induced by ketamine were similar 
the patient’s own acute symptoms. It has been suggested that other drug models of 
psychotic symptoms are more prone to stereotyped responses that do not vary from 
patient to patient (Pennes, 1954). The ability of ketamine to induce symptoms that 
resemble the patient’s original illness, and can vary from patient to patient, suggests a 
close link between glutamatergic transmission and schizophrenia. BPRS change scores 
were not significant between neuroleptic free patients and healthy volunteers, however 
this may be due to inherent difficulties in equating a change in rating of none to mild 
symptoms with a change of moderate to severe symptoms on the BPRS (Malhotra et 
al., 1997b). It is noteworthy only one study observed increases in negative symptoms in 
schizophrenic patients after ketamine challenge (Malhotra et al., 1997). The absence of 
negative symptoms in other studies (Lahti et al., 2001; Lahti et al., 1996) could be due 
to different drug administration i.e. bolus versus continuous infusion. The authors also 
speculate that this could be due to desensitisation of ketamine’s effects on mental state
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in the presence of endogenous psychosis. As noted above, differences in medicated and 
unmedicated schizophrenic patients have been observed. Further studies have explored 
the interactive effects of ketamine with other drugs as a way of elucidating the 
influences of different neurotransmitter systems in the psychotomimetic effects 
ketamine or with the eventual aim of developing antipsychotic medication.
1.10.6. Interactive effects of ketamine with other drugs
Several drugs have been reported to reduce the emergence phenomena associated with 
ketamine anaesthesia. The benzodiazepines (BDZs) modulate the actions of the 
inhibitory neurotransmitter y-aminobutyric acid (GABA) and some lines of evidence 
would suggest an interactive effect with NMDA-R antagonists. Studies have 
demonstrated that abnormal GABA transmission may have a role to play in the 
pathophysiology of schizophrenia. For example, studies of schizophrenics have 
demonstrated lower GABA uptake and release in the frontal cortex (Simpson et al., 
2005). Furthermore, preclinical studies have demonstrated that NMDA-antagonists 
reduce GABAergic inhibition in the cortex (Dingledine et al., 1986) and BDZs reduce 
NMDA-R antagonist stimulation of frontal cortical DA turnover (Bower & Morton, 
1992). BDZs have also been shown to have a weak preventative effect on NMDA-R 
antagonist neurotoxicity (discussed below) (Olney et al., 1991).
Pre-medication with diazepam (Kothary & Zsigmond, 1977; Tucker et al., 1984), 
flunitrazepam (Freuchen et al., 1976), lorazepam (Dundee & Lilbum, 1978) or 
midazolam (White et al., 1982; Renstall, 1988) is effective in preventing dysphoria and 
psychotic symptoms upon emergence from ketamine anesthesia (Zsigmond & Domino, 
1980). Conversely, administration of the BDZ inverse agonist flumazenil has been 
reported to increase emergence reactions in patients treated with midazolam and 
ketamine (Restall et al., 1990). However, these reported effects of the two drugs 
combined were not formally investigated using double blind, placebo-controlled 
methods until Krystal et al. (1998c) examined the interactive effects of lorazepam and 
ketamine. In this study concomitant administration of lorazepam and ketamine 
reduced anxiety and depression ratings on the BPRS. It did not, however, antagonise 
any of ketamine’s other psychotomimetic or cognitive effects. In fact, lorazepam 
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potentiated the amnestic and sedative actions of ketamine consistent with the 
anaesthesia literature (Freuchen et al., 1976). It is likely that this potentiation is at least 
partially responsible for the capacity of BDZs to increase the clinical tolerability of 
ketamine.
Ketamine is also thought to have small, yet significant effects at the DA transporter at 
sub-anaesthetic doses (Iruflne et al., 1991). A [14C]2-deoxyglucose (2-DG) uptake 
study in rodents demonstrated that haloperidol potentiated the uptake of 2-DG in 
specific brain regions associated with administration of sub-anaesthetic doses of 
ketamine including the medial prefrontal cortex, retrosplenial cortex, hippocampus, 
nucleus accumbens, basolateral amygdala and anterior ventral thalamic nucleus 
(Duncan et al., 2003). This finding could relate to the work of Lahti et al. (1995; 2001) 
discussed above, where haloperidol-treated schizophrenic patients showed greater 
increases in psychotic symptomatology after ketamine administration than neuroleptic 
free patients. Krystal et al. (1999b) also examined the interactive effects of haloperidol 
and ketamine in healthy volunteers. Their main finding was that haloperidol reduced 
ketamine-induced impairments on tasks tapping frontal functioning such as the WCST 
and Gorham’s proverb test but did not attenuate impairments on any other tasks.
The failure of typical antipsychotic treatments to block ketamine-induced psychotic 
symptoms provoked an investigation into the effectiveness of novel antipsychotic 
treatments in altering NMDA-R induced psychotomimetic effects. Clozapine is one 
such ‘atypical’ antipsychotic treatment that has proved effective even in patients 
resistant to typical antipsychotic treatment such as haloperidol. The neurochemical 
action of clozapine is not entirely clear but it is known to have some affinity for 
dopamine receptors (Di, D2, D 3 , D 4 ), serotonin receptors (5 -HT2, 5 -HT3, 5-HT6, 5-
H T 7 ) ,  muscarinic cholinergic and adrenergic receptors (Oli , (X2). Clozapine, but not
drugs such as haloperidol, has also been shown to affect glutamatergic 
neurotransmission. Preclinically clozapine increases glutamate levels in the PFC (Daly 
& Moghaddam, 1993)and stimulates glutamate release from the nucleus accumbens 
(Yamamoto & Cooperman, 1994) . Clozapine is also reported to be the most effective 
antipsychotic in combating the cerebrocortical neurotoxicity caused by NMDA-R
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antagonists (Olney & Farber, 1994). In rodent models clozapine, unlike typical 
antipsychotic drugs or D2, Di, and 5-HT2 antagonists, has been shown to prevent the 
effects of NMDA-antagonists on PPI (Bakshi et al., 1994).
The ability of clozapine to blunt ketamine-induced psychosis in a population of 
schizophrenic patients was reported by Malhotra et al. (1997a). Patients were 
antipsychotic drug free and then underwent a single challenge with one ketamine dose 
and a placebo. They were then treated with clozapine and participated in another 
ketamine challenge (except one patient who was tested on clozapine first). Ketamine 
challenge alone increased rating of thought disturbance and withdrawal-retardation. 
Clozapine treatment significantly blocked the ketamine-induced thought disturbance, 
however these results are complicated by the lack of randomisation of treatment order.
Much of the research described in this section has been concerned with formally testing
drugs with a known clinical efficacy for the treatment of schizophrenia or ketamine
induced phenomena. However, an eventual aim of developing a model of the symptoms
of schizophrenia is to suggest new potential antipsychotic drugs. No licensed
antipsychotic drug to date has been developed with the aim of modulating NMDA-R or
glutamatergic function. Considerable debate in the field has centred around whether a
hypo- or hyper-glutamatergic model of schizophrenia is indicated by the literature. As
previously mentioned, preclinical microdialysis research would now suggest that the
effects of NMDA-R antagonists are mediated by increased glutamate release in the PFC
(Adams & Moghaddam, 1998; Moghaddam et al., 1997). This would suggest that the
neuropsychiatric effects of ketamine are mediated not by attenuation of glutamate
activity at the NMDA-receptor but by increased glutamate activity at non-NMDA
glutamate receptors. This concurs with mounting evidence from post-mortem studies
related to hyperglutamatergic functioning in schizophrenic brains, including an
overabundance of glutamatergic synapses in the frontal cortex (Deakin & Simpson,
1997). The hyperfunction hypothesis was tested in a study using the metabotropic type
II glutamate agonist LY3540740. The compound decreased the cognitive and motor
effects of PCP in rats (Moghaddam et al., 1997). Moreover, the same compound
attenuated ketamine-induced working memory deficits in humans (Krystal et al., 2005).
In addition, a study with healthy volunteers investigated the interactive effects of 
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ketamine and lamotrigine (Anand et al., 2000). In this study lamotrigine was found to 
decrease the ketamine-induced positive and negative symptoms of schizophrenia as 
indexed by the BPRS, as well as attenuating ketamine induced perceptual distortions 
and impairments on the Hopkins verbal learning test. Taken together, the above 
evidence would seem to suggest a role for hyperglutamatergic functioning in the 
neuropsychiatric effects of ketamine and other NMDA-R anatgonists and possibly in 
some of the symptoms of schizophrenia.
1.10.7. Summary of acute psychotomimetic effects
Studies that have used NMDA-R antagonists to induce schizophrenic symptoms in 
healthy volunteers have consistently found increases in ratings on the BPRS and other 
scales of psychotic symptoms e.g. the Scale for the Assessment of Negative Symptoms 
(SANS) and the Scale for the Assessment of Thought, Language and Communication 
(TLC). The exact pattern of symptoms has varied. The only consistent symptoms that 
have been induced across healthy volunteers are conceptual disorganisation and thought 
disorder. These differences probably reflect an insensitivity of the BPRS in measuring 
drug-induced symptoms and differences in dose. There may be difficulties 
administering the BPRS to very withdrawn ketamine participants. Studies that have 
attempted to relate cognitive symptoms to psychotic symptoms have yielded no clear 
results to date.
Symptom provocation studies that have administered ketamine to patients have again 
only reliably yielded changes on the thought disorder factor and conceptual 
disorganisation item of the BPRS. However, the common thread from the patient 
research is that ketamine, when administered to people with schizophrenia, induces 
symptoms similar to their own acute-phase symptoms, e.g. delusions of the same 
nature, auditory hallucinations of the same voice. This is certainly encouraging for the 
NMDA-R hypofunction model of schizophrenia in that other pharmacological models 
of schizophrenia (e.g. d-amphetamine), induce homogenous symptoms (Lieberman et 
al., 1987). The ability of ketamine to induce negative symptoms in schizophrenic 
populations appears to still be in dispute, which may be a function of the different 
populations and drug regimes used or may reflect underlying neurobiological 
differences in glutamatergic function.
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Studies have varied as a function of the particular anti-psychotic drugs patients were 
administered. In an attempt to resolve this issue and elucidate the effects of ketamine on 
the various neurotransmitter systems, the interactive effects of NMDA-R antagonists 
and several pharmacological agents have begun to be investigated. Findings have been 
complicated by several issues. Firstly, the sedative effects of these drugs (e.g. 
haloperidol, lorazepam) make it difficult to measure their effects on reducing ketamine- 
induced symptoms. It is possible that drugs such as lorazepam and haloperidol may be 
effective at attenuating ketamine-induced psychosis in higher doses that are unfeasible 
due to sedative effects. Order effects in the patient studies, given the tachyphylaxis 
(rapid tolerance) associated with ketamine have also complicated interpretation of 
results. The interactive effects of ketamine and other drugs would seem to suggest a DA 
modulation of executive frontal impairments induced by ketamine and a role of 
hyperglutamatergic activity in the psychotomimetic and episodic memory effects of 
ketamine. The exact mechanism of these effects and the precise alleviation of 
impairment needs to be investigated further as does ketamine’s impact on other NT 
systems (e.g. NA and opiod).
Often, psychopharmacological models have yielded important insights into the 
pathophysiology of schizophrenia. For instance the discovery of stimulant psychoses 
was one of the key factors in developing the influential DA model of schizophrenia. 
The weight of evidence that has emerged from the investigation of NMDA-R 
antagonism behaviourally and neurologically indicates a role of hyperglutamatergic 
functioning in schizophrenia. In order for the model to persist it should inform 
knowledge about the neurobiology of schizophrenia. Whilst this is beyond the scope of 
this review, recent post-mortem data has begun to demonstrate NMDA-R abnormalities 
in the schizophrenic brain (Krystal et al., 2000a) and this further contributes to the 
validity of NMDA-R hypofimction as a model of some of the symptoms of 
schizophrenia.
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PART IU: CHRONIC EFFECTS OF NMDA-R ANTAGONISTS
1.11.1 NMDA-R antagonist associated neurotoxicity studies
It is now widely accepted that high synaptic glutamate concentrations are neurotoxic 
and that in conditions such as ischaemia, hippocampal glutamate levels increase 
markedly. This ‘excitotoxicity’ as discussed in Section 1.4 can be attenuated with 
NMDA-R antagonists. However, several animal studies have demonstrated that 
NMDA-R antagonists can themselves induce neurotoxicity after very high acute doses 
or chronic exposure (Olney et al., 1989; Olney et al., 1991) . Olney et al. (1989) 
demonstrated that ketamine, PCP and MK-801 can all induce neurotoxic effects in rats. 
The degree of potency of neurotoxic effects (MK-801 > PCP> ketamine) suggested that 
non-competitive NMDA-R antagonism was responsible. They observed a vacuolisation 
of neuronal cytoplasm in the posterior cingulate cortex (retrosplenial cortex). Whilst 
this vacuolisation gradually disappeared 12-18 hours after the drug was administered, 
later research demonstrated that a higher dose of MK-801 resulted in cell death could 
still be observed 48 hours after drug administration (Allen & Iverson, 1990) and 
irreversible vacuolisation after PCP in the pyramidal cells of the hippocampus has also 
been observed (Gao et al., 1993).
Furthermore, repeated administration of PCP or MK-801 generates neurotoxicity in the 
dentate gyrus and olfactory regions, parahippocampal and hippocampal regions and the 
retrosplenial, cingulate and entorhinal cortices (Corso et al., 1997; Ellison & Switzer, 
1993; Ellison, 1995; Horvath & Buzsaki, 1993), predictably these are areas with dense 
populations of NMDA-Rs. More recently, research into the effects of repeated ketamine 
administration has suggested that its chronic effects are observable however less 
profound. Repeated ketamine leads to increased neurogenesis in the sub-granular region 
of the hippocampus (Keilhoff et al., 2004b) but also decreased immunoreactivity of 
parvalbumin in GABA-ergic intemeurons in the hippocampus. In addition, decrease c- 
Fos binding in the dentate gyrus of rats has been observed following repeated ketamine 
application compared to controls (Keilhoff et al., 2004a). This may reflect a reduced 
ability of the hippocampus to cope with novelty and complexity in stimuli. Other 
effects observed in rats following repeated ketamine were increased D2 binding in the
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hippocampus and decreased Glu binding in the frontal cortex (Bernstein et al., 2003). 
Collectively these findings are interesting in that they are fairly consistent with 
neurological differences observed in schizophrenia in post-mortem studies (Tsai et al., 
1995; Reynolds & Beaseley, 2001).
Several studies have examined the reversibility of NMDA-R antagonist-induced 
neurotoxicity. Olney et al. (1991) found that the vacuolisation produced by MK-801 
was blocked by GABA-ergic drugs (diazepam and barbiturates) and anticholinergic 
drugs (scopolamine, benzotropine, trihexylphenidyl). Olney et al. (1991) suggested that 
the effectiveness of these drugs was attributable to a circuit in which cholinergic input 
to these neurons was normally modulated by inhibitory GABA cells, which were 
normally excited by NMDA-R mediated glutamate input. Other research has also 
demonstrated compounds to be effective in preventing ketamine induced neurotoxicity 
in animals. These include haloperidol (Nakki et al., 1996), clozapine and olanzapine 
(Farber et al., 1996) , halothane (Nakao et al., 1996) and agonists of the 5-HT2A 
receptor (Farber et al., 1998). Olney et al. (1999) have suggested that the neurotoxic 
properties of the NMDA-R antagonists may be analogous to processes operating in 
schizophrenia. Unfortunately for this theory, many of the drugs that prevent 
neurotoxicity in animals do not diminish the psychotomimetic effects of ketamine in 
humans. Moreover some of these drugs e.g. 5-HT2A agonists such as the indoleamines, 
LSD and psylocibin, are in fact themselves psychotomimetic.
The neuronal vacuolisation described in some of the above studies has interesting age 
and sex dependent profiles. Following MK-801 or PCP, female rats were more 
vulnerable to neuronal vacuolisation in the retrosplenial cortex than adult male rats 
(Olney et al., 1989). Whilst these results have been replicated in mice (Akinci & 
Johnston, 1993), it is not clear the extent to which these changes hold for higher 
species. MK-801 additionally induces no vacuolisation in female rats aged 1 month, 
weak vacuolisation in rats aged 2-months but clear vacuolisation in 3 month-old rats 
(Fix et al., 1994; Farber et al., 1995; Fix et al., 1993). Heat-shock protein 70 gene 
induction following ketamine, PCP and MK-801 administration was also found to have 
a similar age dependent profile (Sharp et al., 1992). Whilst the density of NMDA-Rs 
changes with age, the age-dependent neurotoxic effects do not fit this pattern. However 
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these studies have only been conducted in female rats and thus these effects could 
conceivably be due to hormonal effects linked with sexual maturation (Ellison, 1995). 
It is tempting to draw parallels between the age-related onset of NMDA-R antagonist 
effects, which is also manifest in human emergence reactions, and the age related onset 
of schizophrenia. However, the human evidence for an age-dependent profile of 
emergence phenomena is scant and indeed anecdotal evidence suggests recurrent 
hallucinations in children administered ketamine as an anaesthetic (Perel & Davidson, 
1976).
1.11.2. Studies of the behavioural and cognitive effects of chronic NMDA-R 
antagonists in animals
Although such studies are few, initial evidence suggests chronic administration of 
NMDA-R antagonists results in a different, more selective profile of deficits than acute 
exposure. Both chronic PCP (Sams-Dodd, 1995, 1996; Steinpreis et al., 1994) and 
ketamine (Bernstein et al., 2003; Keilhoff et al., 2004b) leads to decreased social 
interaction in rats. Jentsch et al. (1997b) investigated the effects of subchronic 
administration of PCP on a spatial delayed alternation task in rats. Impairments were 
seen at long delays but not after no delay, implying a working memory deficit. Chronic 
PCP exposure in monkeys also produced deficits on a response inhibition task (Jenstch 
et al., 2000). The executive functions investigated in these two studies have been linked 
to PFC. Thus the preliminary results in this field suggest that this region may mediate 
the deficits induced by chronic PCP (the dorsolateral PFC in monkeys and the medial 
PFC in rats). Chronic PCP exposure has also been reported to reduce frontal lobe 
glucose utilisation in humans as discussed in section 1.1.3. (Wu et al., 1991). On the 
basis of the selectivity of these deficits and evidence from PCP users, it has been 
suggested that chronic administration of NMDA-R antagonists may provide a better 
model of schizophrenia than acute antagonism (Jentsch & Roth, 1999).
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1.113 Chronic behavioural and cognitive effects of NMDA-R antagonists in 
humans
Evidence for the chronic effects of ketamine and PCP in humans comes solely from 
abusing populations and is hence subject to the many limitations of naturalistic drug 
research (e.g. poly-drug use, pre-existing population differences). In one of the few 
published studies of the cognitive effects of chronic PCP, Carlin et al. (1979) 
administered the Halstead-Reitan neuropsychological battery to 12 PCP abusers, 12 
poly-drug users and 12 non-drug controls. This study found the poly-drug group and 
the PCP group could not be differentiated from each other and both were impaired 
relative to controls on this scale. Ware (1979) compared 8 hospitalised PCP users to 8 
poly-drug users on the WAIS-R and the Halstead Reitan. Differences were observed on 
the WAIS-R but not the Halstead- Reitan. Cognitive impairments were found in a more 
recent study (Cosgrove & Newell, 1991) in a group of 15 chronic PCP drug users. They 
found an overall impairment on a range of cognitive tasks (verbal fluency, trailmaking, 
verbal memory, digit symbol substitution, block design). In this study the PCP abusers 
ceased use of the drug for 4 weeks and then were retested. Verbal memory scores were 
found to improve on cessation of PCP use along with trailmaking and digit symbol 
substitution.
Surveys of PCP users contain numerous reports of persistent problems with memory, 
speech and thinking (Fauman & Fauman, 1978). An early survey of ketamine users 
also indicated the perceived cognitive effects of long-term use to be attentional 
dysfunction and decreased sociability (Siegel, 1978). Feldman et al. (1980) described 
the chronic effects of PCP as leading to significant cognitive impairment characterised 
by confusion, thought disorder and severe memory loss referred to as ‘burnout’ by 
users. A single case report in the literature also indicates chronic memory impairments 
as a result of ketamine use (Jansen, 1990).
Repeated doses of PCP in abusing populations have also been found to induce 
persistent schizophrenia-like symptoms such as psychosis, auditory hallucinations, 
blunted affect, cognitive dysfunction and social withdrawal (Allen & Young, 1978; 
Javitt & Zukin, 1991; Rainey & Crowder, 1974). Unfortunately, the majority of these 
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reports are based on case studies or small sample case-control studies. Anecdotal 
reports of psychosis following ketamine abuse also exist (Lilly, 1978; Moore & 
Altounian, 1978). One large study of 1000 patients presenting with acute PCP 
intoxication found that 25% developed catatonic or psychotic reactions following 
resolution of the acute brain state (Allen & Young, 1978).
Recently, two studies examined the acute and residual behavioural and cognitive effects 
of ketamine in recreational users. Curran & Morgan (2000) compared ketamine abusers 
with polydrug using controls. Participants were assessed on the night of their drug use 
and then 3 days later on tests tapping a several memory functions, attention, mood 
dissociation, and schizoptypal symptomatology. Acutely, the drug users were impaired 
in a similar pattern to laboratory studies of sub-acute effects discussed above (e.g. 
Krystal et al., 1994). Three days later the recreational users were still significantly 
impaired on tests tapping semantic and episodic memory and had elevated scores 
compared to controls on schizotypal and dissociative symptoms scales. A similar 
procedure was used by Curran & Monaghan (2001) who compared frequent ketamine 
users with infrequent ketamine users to explore whether the residual memory effects 
were as a result of chronic ketamine use or pre-existing differences in people attracted 
to ketamine abuse. The acute effects were similar between the frequent and infrequent 
users, despite higher doses taken in the frequent users, indicating some degree of 
tolerance to the cognitive impairments associated with ketamine administration. Three 
days after use of the drug the frequent users still exhibited impairments in tasks tapping 
episodic and semantic memory, whereas the infrequent users did not. These memory 
impairments were not as profound in the infrequent users, suggesting they were not a 
result of residual impairments following a single dose. Rather they appear to be 
cumulative, and a function of degree of ketamine abuse. The profile of cognitive 
impairments observed with these recreational users, especially in episodic and semantic 
memory, is akin to aspects of the profile of impairment in schizophrenia. Naturalistic 
studies such as these are difficult to relate to models of schizophrenia, as it is not clear 
whether the cognitive impairments observed here, and brain activation differences, 
reflect a predisposition to psychosis in this population. Furthermore, ketamine is 
frequently abused with a variety of other drugs such that the effects that are attributable 
to ketamine are difficult to tease apart. However using samples that compare within 
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populations of ketamine users, or that use poly-drug using controls, can help address 
some of these potential difficulties.
1,11.4 PCP, ketamine and dependence
“ I ’d estimate that more than half o f those who have tried and liked K have become 
involved in the trap o f  repeated use...in most cases this syndrome in some way de­
structures, disorganises and even threatens their lives. . ”
Rameses Sputz, High Times 
(1989)
PCP self-administration has been demonstrated across several species including rodents 
(Marquis et al., 1989), dogs (Risner, 1982) and non-human primates (Carroll, 1990). 
Ketamine and PCP have been shown to be equally effective as reinforcers, and are both 
much stronger reinforcers than dizocilpine (Winger et al., 2002). Ketamine was found 
to have the fastest onset of action of the arylcylohexamines (Winger et al., 1989), which 
is proposed to play a role in the reinforcing properties of drugs. Primates have been 
shown to self-administer PCP at doses that are behaviourally toxic to the animal 
(Balster & Woolverston, 1980) although this is not an uncommon finding amongst 
drugs of abuse. Many of the reinforcing properties of drugs are generally attributed to 
DAergic effects (Koob & Nestler, 1997) and ketamine, as discussed in section 1.1.6, 
has effects on this neurotransmitter system. However, it has been suggested that 
glutamate and the NMDA-R have also be involved in processes mediating dependence 
and withdrawal symptoms (Noda & Nabeshima, 2004; Weiss & Koob, 2001). From the 
perspective of addiction research an interesting finding observed by Krystal et al.
(1997) was the failure of haloperidol to block the ketamine induced ‘high’ as rated on 
visual analogue scales. Concordant with this finding is preclinical research suggesting 
that the reinforcing properties of NMDA-R antagonists are not blocked by D2 receptor 
antagonists (Carlezon & Wise, 1996) and that glutamate may have a role to play in the 
neurobiobehavioural problem of drug abuse (Cornish et al., 1993).
Tolerance to, and dependence on, PCP and ketamine have been observed in animal 
studies of chronic drug treatment and withdrawal (Balster & Chait, 1976). Dependence 
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is inferred following withdrawal from chronically administered PCP, in the reduction of 
food intake in monkeys (Carroll & Carmona, 1991) and rodents (Wessinger & Owens, 
1991), in a similar manner to that observed in stimulant dependent humans. In these 
studies however few physical symptoms of drug withdrawal were evident and patterns 
of responding suggest that the above effect may be related instead to motivational 
processes (Carrol & Carmona, 1991).
Very few studies have investigated the dependence forming potential of PCP or 
ketamine in humans. Whether ketamine and PCP are associated with physical or 
psychological dependence is unclear. One study of PCP users found cessation of use of 
the drug produced restlessness, depression and feelings of drug craving (Tenant et al., 
1981). In the previously cited study of the chronic cognitive effects of PCP, Cosgrove 
& Newell (1991) found that of 33 patients wishing to stop their use of PCP only 15 
were able over a one month period, which indicates some form of dependence.
In the ketamine literature, many anecdotal reports exist of ketamine dependence 
(Ahmed & Petchovsky, 1980; Hurt & Ritchie, 1994a; Jansen, 2000; Kamaya & 
Krishna, 1987a; Siegel, 1978) but no controlled studies have as yet been conducted. 
Ketamine has also been shown to alleviate withdrawal symptoms in opiate addicts 
(Herman et al., 1995) and part of this effect may be mediated by its own opioid effects. 
The degree of dependence and withdrawal caused by abuse of ketamine has still yet to 
be investigated.
1.11.5. Summary of Chronic Effects
Neurotoxicity research has demonstrated some evidence for lasting neuronal damage in 
rats following chronic, high doses of highly potent NMDA-R antagonists and more 
subtle, yet enduring, changes following ketamine. The generalisability of this data to 
human-abusing populations is limited again by doses, drugs used (e.g. primarily MK- 
801) but also by metabolic and structural differences in rodent and human brains. 
Interesting age and sex-dependent profiles of NMDA-R antagonist neurotoxic effects 
have been observed, with young rats showing insensitivity to NMDA-R antagonist 
induced neurotoxic effects and females being more sensitive than males. The age-
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dependent profile invokes parallels with age dependency in schizophrenia and with 
onset of psychotomimetic effects of ketamine and PCP.
Preclinical research into the cognitive effects of chronic ketamine is relatively scant. 
The studies that have been conducted indicate persisting deficits in social interaction, 
working memory and response inhibition. Human research is also limited. Studies have 
demonstrated persisting cognitive impairments in both ketamine and PCP users, when 
not under the acute effects of the drug and there is some evidence of persisting 
psychotic effects with both drugs. In ketamine users where effects were characterised 
by a range of cognitive tests, the most marked cognitive impairments, when drug free, 
were in tasks tapping semantic and episodic memory. It is not clear from the literature 
whether these deficits reflect some form of neurotoxicity, outlined at the beginning of 
the section, or are more transient, reversible changes in receptor functioning. Despite 
anecdotal reports, it also unclear from the literature the extent to which tolerance of and 
dependence on ketamine may form. Given the increasing use of ketamine recreationally 
further investigation of these questions is clearly important.
1.12 Overview and Research Questions
The work presented in this chapter has reviewed studies examining the effects of 
NMDA-R antagonists, in particular ketamine, in humans and animals. These drugs 
have been investigated principally in relation to their capacity to transiently induce 
psychosis as they appear to produce the most convincing model of schizophrenia of any 
pharmacological compound. In addition, interest in these compounds has stemmed 
from their action as an NMDA-R antagonist, as it is at this receptor that some of the 
synaptic plasticity important in learning and memory has been demonstrated to occur. 
Research has accordingly examined the cognitive consequences of NMDA-R 
antagonism. A further important area of research, which has been thus far relatively 
neglected, is the effect of ketamine on the growing number of people who abuse this 
drug.
Broadly, the human research so far has demonstrated that an acute dose of ketamine 
produces a consistent increase in schizophrenia-like effects, both in healthy volunteers 
and stabilised schizophrenics. Following ketamine challenge, impairments to memory 
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and cognition occur but there have been some inconsistencies in the literature and a 
lack of through mapping of cognitive effects. Recent work has suggested the existence 
of chronic effects of ketamine in humans who repeatedly take the drug for the ketamine 
’high’. Additionally there have been suggestions in the animal literature that chronic 
administration of NMDA-R antagonists may provide a better model of schizophrenia 
than the acute effects.
A primary aim of this research was to investigate the causes and consequences of 
ketamine use in drug users who repeatedly self-administer this compound. As ketamine 
cannot be given to healthy individuals chronically in the laboratory for ethical reasons, 
this population are particularly interesting in that they provide a naturalistic window 
onto ketamine’s chronic effects. In the work presented in this thesis, I also aimed to 
characterise further some of the hitherto neglected or under-explored cognitive effects 
of an acute dose of ketamine in healthy volunteers. This was to serve two functions: it 
was both interesting, in its own right, to further delineate the effects of an acute dose of 
ketamine on specific cognitive processes, but it also was hoped it would allow for a 
comparison between the acute and ‘chronic’ effects of the drug, where possible, on the 
same tasks. In addition, as work suggesting chronic effects of ketamine in drug users 
has found deficits 3 days after use of the drug, a consequent objective was to 
investigate whether there were any residual (sub-acute) effects in healthy volunteers. If 
not, then this would suggest that any deficits observed may be chronic effects of the 
drug. Further, and perhaps most clinically relevant to this population of drug users, if 
chronic effects were observed, I intended to explore whether these were reversible on 
reduction or cessation of use of ketamine.
In order to examine some of the causes of repeated ketamine use, I aimed to 
characterise the effects of ketamine on processes that have been hypothesised to be 
involved in drug abuse, such as impaired response inhibition, both in ketamine users 
and following an acute dose of ketamine. I also aimed to tap into the degree to which 
the drug is subjectively reinforcing, in these two populations.
A secondary aim of this thesis was to contribute to evaluating the ketamine model of 
psychosis and especially the suggestion that chronic administration of the drug 
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produces symptoms more similar to schizophrenia than following an acute dose. Data 
obtained from the planned work above would contribute to this evaluation but, more 
specifically, I aimed to investigate processes hypothesised to underlie symptoms in 
schizophrenia, such as self-monitoring and gating impairments. It was hoped that this 
might also clarify whether glutamatergic abnormalities contributed to any of these 
deficits. This work in turn would expand the intended characterisation of the chronic 
and acute cognitive effects of ketamine.
The work presented in thesis will attempt to address the above broad aims with a series 
of experiments: specific aims and hypotheses are reported in each experimental chapter. 
A total of three acute administration of ketamine studies were conducted in this thesis. 
As such data on the same participants are reported in different chapters: Chapter 2 
reports data collected in the same study as that in Chapter 6; the acute ketamine data 
for the Go/No-go task reported in Chapter 7 was collected in the same study as the 
acute ketamine semantic priming data reported in Chapter 4. Order of test 
administration is given in Appendix 1.
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Chapter 2: Ketamine and Memory Systems
A c u t e  e f f e c ts  o f  k e t a m i n e  o n  m e m o r y  s y s te m s  a n d  p s y c h o t i c  s y m p t o m s  
in  h e a l t h y  v o l u n t e e r s
“One problem I  find  with Ketamine is that the experience is difficult to bring back and 
reintegrate with routine reality. Memory o f  the experience is even difficult. Within 
hours after coming back, 99% o f the experience is inaccessible to my current conscious 
mind. The Ketamine experience is so bizarre and otherworldly that a normal mind can't 
even conceive o f  experiencing in this manner. It feels as though some part o f the mind 
protectively closes o ff access to the dimensions experienced on Ketamine..
D.M.Tumer, The Essential Psychededlic Guide, 1994
2.1 Overview
N-methyl-d-aspartate (NMDA) receptor antagonists have been demonstrated to induce 
schizophrenia-like symptoms and cognitive impairment in humans. The NMDA 
receptor has been strongly implicated in memory, but research to date on the effects of 
NMDA-antagonists has examined only some aspects of human memory functions. This 
study used a double-blind, placebo-controlled, independent groups design with 54 
healthy volunteers to examine the effects of infusions of two doses (0.4, 0.8 mg kg-1) of 
the NMDA antagonist ketamine upon the five human memory systems (Tulving, 1985), 
aspects of executive functioning and schizophrenia-like and dissociative symptoms. 
Ketamine produced a dose dependent impairment to episodic and working memory and 
a slowing of semantic processing. Ketamine also impaired recognition memory and 
procedural learning. Attention, perceptual priming and executive functioning were not 
affected following the drug. In addition, ketamine induced schizophrenia-like and 
dissociative symptoms which were not correlated with the cognitive measures. These 
data suggest that, in humans, ketamine produces a selective pattern of impairments to 
working, episodic and procedural memory but not to perceptual priming, attention and 
aspects of executive functioning.
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2.2 Introduction
The five memory systems proposed by Tulving (1985; Tulving & Schacter, 1994) were 
outlined in the previous chapter (Section 1.9.2). Previous research has addressed the 
effect of NMDA antagonism, via administration of ketamine, on some of these human 
memory systems. Whilst several studies have found ketamine induced impairments in 
verbal memory (e.g. Krystal et al., 1994; Harbome et al., 1996; Malhotra et al., 7996), 
only one study has investigated the effect of NMDA-receptor antagonism on the 
episodic memory system (Hetem et al., 2000; subsequent to writing, Honey et al., 
submitted). Both ‘remember’ and ‘know’ responses were reduced following a single 
dose of ketamine when compared to placebo. The authors argue that this indicates an 
impairment of episodic memory. A reduction in ‘remember’ responses supports this 
assertion but the reduction in ‘know’ responses may reflect semantic impairments. 
However, the lack of ‘lures’ in this study complicates interpretation of the findings. The 
effect of ketamine on the semantic memory system has been investigated in tasks in 
which participants are required to generate category members (semantic fluency) or 
words beginning with a specified letter (phonemic fluency). Conflicting results have 
been obtained from ketamine studies with fluency tasks of both impaired (Adler et al., 
1998) and preserved (Ghoneim et al., 1985) category fluency, and similar findings of an 
impairment to verbal fluency in some (Adler et al., 1998; Krystal et al., 1998c) but not 
all (Krystal et al., 1999a) studies. Findings concerning ketamine’s effects on working 
memory are also conflicting. Impairments have been found on the N-back task (Adler 
et al., 1998) but not on a spatial working memory task (Newcomer et al., 1999). In 
addition, two studies have found preserved backwards digit span (Ghoneim et al., 1985; 
Harris et al., 1975) but one study has found impaired forwards digit span (Harris et al., 
1975). Newcomer & Krystal (2001) in their review of memory research with NMDA- 
antagonists, noted that ketamine’s effects on memory and learning appear to be 
preferential to their effects on other cognitive functions and may be dose dependent. 
However, the effects of ketamine on the other two memory systems, procedural 
learning and perceptual representation have not previously been investigated.
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Although several studies have investigated the acute cognitive effects of ketamine on 
memory, they have been confined to single doses or, where more doses have been used, 
crossover designs have complicated interpretation of results due to the tachyphylaxis 
(or rapidly developing tolerance) that occurs following ketamine administration. 
Further, previous research has not examined the effect of this drug on the full range of 
human memory functions.
Therefore, the present study aimed to thoroughly characterize the dose-response impact 
of ketamine administration on the different memory systems. It was hypothesized that 
ketamine administration would impair episodic and working memory, replicating and 
extending previous findings. By using a more specific semantic memory task, this study 
hoped to clarify the effect of ketamine on this memory system. No prediction could be 
made as to the effects of ketamine on procedural learning or perceptual priming as 
these have not previously been investigated. The subjective effects that ketamine was 
expected to induce were increases in dissociative and schizotypal symptomatology.
2.3 Methods
2.3.1 Participants and Design
Participants were recruited through an advertisement and were paid for their 
participation. The study was carried out in accordance with the Declaration of Helsinki 
and was approved by the institutional ethics committee (the UCL/UCLH Committee on 
the Ethics of Human Research). All participants gave written, witnessed, informed 
consent. Inclusion criteria were that participants were between 18 and 35 years old and 
native English speakers. Participants were then selected for participation by a screening 
interview to exclude individuals with a propensity towards psychiatric disorders, and 
any substance misuse or general health problems.
Volunteers were screened by semi-structured interview (conducted by CM), 
questionnaire and physical examination to exclude those with i) psychotic illness in a
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first-degree relative; ii) current or past psychiatric problems [> 18 on the Beck 
Depression Inventory, (Beck, 1978) and >54 on the Speilberger Trait Anxiety Inventory 
(Spielberger, 1983) were used to screen current psychopathology in addition to DSM 
IV diagnostic criteria for psychotic illnesses iv) any significant history of substance 
misuse, including prior ketamine use; v) a positive result in a urinalysis screening for 
drugs of abuse; vi) hypertension; vii) outside normal levels (>25) on the Body Mass 
Index viii) a known allergy to ketamine; ix) those currently taking any prescribed 
medication (excluding oral contraceptives) x) any general physical health problems. At 
the screening interview, the premorbid IQ of each participant was also assessed by the 
‘Spot the Word’ test (Baddeley et al., 1993), an estimate of verbal intelligence based on 
lexical decision; trait dissociation was assessed by the Dissociative Experiences Scale 
(DES -  (Bernstein & Putnam, 1986).
Sixty-nine volunteers responded to the advertisement and eleven were excluded for 
failing to meet inclusion criteria (history of mental illness - 2, family history of mental 
illness - 3, prior substance misuse -  3, currently on medication - 3). 58 healthy 
volunteers took part in this study. Of these, four participants dropped out: two had 
adverse reactions to cannulation, one had an adverse reaction to 0.8mg kg'1 ketamine 
and did not wish to continue with the experiment, and one participant was excluded due 
to failing a urine screen upon the follow-up testing day. In total 54 participants 
completed the study (mean age 22.53±3.52 years). A mixed model, independent group 
design was used in which male and female participants were randomly allocated to 
treatment with either 0.8mg kg _1 ketamine hydrochloride, 0.4 mg kg 1 ketamine 
hydrochloride or placebo. Groups were balanced for gender; with 9 females and 9 
males in each group. Double-blind procedures were used throughout. Test versions 
were counterbalanced across participants and design.
71
2.3.2 Drug Administration
Participants received either ketamine (0.4 mg kg -1 or 0.8 mg kg ]) or saline placebo 
(0.9% NaCl) intravenously for 80 minutes. Pilot work demonstrated that tasks were 
sensitive to these doses of ketamine. A bolus dose was not used to minimise adverse 
effects. Low doses were chosen to ensure participants would understand the 
instructions to the tasks. This dosing regimen produces a dose of 0.005mg/kg/min or 
0.01 mg/kg/min ketamine in the low and high dose groups which is comparable to those 
used in previous studies (e.g. Krystal et al., 1994; Adler et al., 1998). Using local 
anesthesia, a 16 gauge intravenous cannula was inserted in the non-dominant forearm 
and after 5 minutes the ketamine infusion began via a Graseby intravenous infusion 
pump. A loading dose was used in order to minimize adverse effects. A urine sample 
was taken before the infusion began and a peripheral venous blood sample was taken 
65 minutes after commencing the infusion. Plasma was obtained immediately from 
blood samples by centrifugation and samples were stored at -80°C. Ketamine levels 
were measured using gas chromatography (ABS Laboratories, National Poisons Unit, 
London).
2.3.3 Procedure
Testing occurred at either 9am or 1 pm and the time of testing was broadly matched 
across groups. Participants arrived at the hospital after completing an overnight fast for 
morning testing, or a minimum of six hours fasting for afternoon testing. Participants 
were assessed on the pre-drug battery for 35 minutes. They were then allowed to rest 
for 15 minutes and then were cannulated. Approximately 5 minutes after cannulation, 
the anesthetist began the infusion. Participants were tested on a battery of tests similar 
to the pre-drug battery beginning 20 minutes after the start of infusion. Throughout the 
80 minute infusion the participant’s pulse, blood pressure and electrocardiagram were 
monitored. After infusion participants were provided with light refreshments and were 
then assessed 30 minutes later and then at hourly intervals by the medical staff as to 
their ‘street readiness’. A follow-up battery was given 3 days after the acute dose, 
findings of which are reported elsewhere (Chapter 6).
72
2.3.4 Assessments
Tests were selected to assess the range of human memory functions, dissociative and 
psychotogenic symptoms and mood effects. Tests were administered in the following 
order: subjective drowsiness, speed of comprehension, serial reaction time task, 
trailmaking, word-stem completion and cued recall, N-back working memory task, 
source memory, CADDS SSQ, subjective drowsiness.
Cognitive Tasks
Speed o f  Comprehension (Baddeley et al., 1992) : One of the factors tapped by this 
task is semantic memory. Participants were presented with 200 sentences some of 
which made sense (e.g. ‘Sharks are good swimmers’) and some o f which do not (e.g. 
‘Wives are made in factories’). They were given two minutes to mark which sentences 
made sense and which ones did not. The task was scored in number of sentences 
completed and number of errors.
Source Memory Task (Wilding and Rugg, 1996): This task was chosen as an index of 
episodic memory, i.e. awareness of when and where a stimulus was encoded. Stimuli 
consisted of 240 low frequency words. The words were divided randomly into six study 
lists of 40 words. In each study list half the words were spoken in a female voice and 
half in a male voice (allocation was randomly determined). At study words were 
presented to participants aurally, played on a tape recorder. During the study phase 
participants listened to each word, repeated it aloud and then, depending upon the 
gender of the voice it was presented in, rated the word as either ‘pleasant/ unpleasant’ 
or ‘abstract/ concrete’. After completing the list, there was a delay of six minutes, filled 
with another task, and then participants were presented with a test list. Test lists were 
created by combining the study list with another study list that had not been presented. 
Test words were presented visually on a computer monitor. Participants were instructed 
to say aloud whether each word was one that they had heard before and if so, whether it 
had been presented in a male or female voice. Participants gave their responses
73
verbally. Word recognition responses were recorded as hits, false alarms, misses and 
correct rejections. Source errors were also recorded. Preliminary analysis showed no 
group differences across the two encoding conditions so data were collapsed.
Word stem completion and cued recall (Bishop & Curran, 1995): This task was chosen 
as an index of perceptual priming and free recall, using a ‘Levels of Processing’ (LOP) 
encoding task (to distinguish between the perceptual representation system, which 
should not be affected by LOP, and the episodic memory system which should be 
affected by LOP). Stimuli were 96 words. In the study phase the participants were 
required to read aloud 64 words presented on the computer screen each for 4000ms 
with a 1500ms interval. For each block of 32 words the participants were given 
encoding instructions. For the semantic encoding condition participants were instructed 
to say whether the word presented depicted something living or non-living. For the 
physical encoding condition participants were instructed to say how many vowels were 
in each of the words. Encoding condition was counterbalanced across treatment groups. 
In the test phase, the word-stem completion task was given before the cued recall. In 
the word stem completion task participants were presented with 64 word stems (16 
previously semantically encoded, 16 previously physically encoded, 32 unseen) and 
asked to complete them with the first word that ‘popped into their head’ excluding 
proper nouns. Afterwards participants were asked if they noticed anything about the 
words that they had completed the word-stems with. The cued recall task then followed. 
Participants were given a sheet of 32 word-stems (16 semantically encoded, 16 
physically encoded) and were told that they had previously been shown all of the words 
that completed the word-stems. Participants were then asked to complete the stems with 
words they remembered being shown on the computer screen. Scores were recorded in 
terms of completion rates across the two encoding conditions and errors in the cued 
recall task and non-completed stems in the word-stem completion.
N-back working memory task (Braver et al., 1997): The task used a sequential letter 
paradigm and manipulated working memory load incrementally. The ‘0-back’
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condition was taken as an index of attention and the ‘1-back’ and ‘2-back’ conditions as 
tapping working memory. Stimuli were sequences of lower case consonants presented 
centrally for 1200ms with a 500ms inter-stimulus interval. Stimuli were organized in a 
pseudorandom sequence with targets occurring on 33% of the trials. Blocks were of 
112 seconds (66 stimuli) each participant experienced one block in each condition at 
each time point (total 9 blocks). Participants were presented stimuli on a VDU and 
responded to stimuli with their dominant hand, pressing a ‘yes’ button for targets and a 
‘no’ button for non-targets. In the ‘0-back’ condition participants were required to 
respond ‘yes’ if they saw a target letter (e.g. M). In the 1-back condition participants 
responded ‘yes’ to a letter if it was the same as the letter before it, in the 2-back 
condition if a letter was the same as two before it. RT’s and responses were recorded 
for each trial using Visual Basic software.
Trailmaking (Reitan, 1958): This task consisted of two parts, the first tapping 
psychomotor speed and the second executive functioning. In Part A of the task 
participants were required to connect 25 circles in ascending order as rapidly and 
accurately as possible. Part B again contains circles but with both numbers and letters 
in ascending order. Participants are again required to connect the circles as rapidly as 
possible this time alternating between the two different sequences (1 to A, A to 2, 2 to 
B, B to 3 etc.). A difference score was computed by taking time to complete on Part A 
away from time on Part B to give a measure of executive functioning controlling for 
simple psychomotor speed. Errors were also recorded.
Serial Reaction Time Task (SRT) (Shanks & Perruchet, 2002): This task was used as an 
index of procedural learning using a repeating sequence. Participants were required to 
press a key as soon as they see a target appear in one of four boxes on the computer 
screen. Participants are told that the task is a simple reaction time experiment but 
actually the targets appear in boxes in a set sequence, for 85% of the trials. The task 
thus taps participants’ ability to learn this underlying sequence. After a practice block 
of 10 trials with no underlying sequence, participants were subjected to one of two 
sequences balanced across conditions, for three blocks of 100 trials (a total of 300
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trials). In each trial a target (a ‘X’) appeared in one of the boxes. On 85% of the trials in 
each block the ‘X’ would be a location corespondent to the sequence that the 
participant was being trained on (probable trial). However, on 15% of the trials in each 
block the ‘X’ would appear in a location erroneous to the underlying sequence 
(improbable trial). The order of occurrence of the improbable trials was randomly 
determined. A trial ended when the participant pressed the correct corresponding key 
whereupon the target moved to a new location. Reaction times were recorded with 
Visual Basic software, and scored in terms of latency of responding correctly for 
probable trials, latency of responding correctly for improbable trials, number of errors 
on probable trials, number of errors on improbable trials.
Subjective ratings
Schizotypal Symptomatology Questionnaire (Curran & Morgan, 2000): a 30 item 
questionnaire designed to assess state schizophrenic-like symptoms in normal 
populations.
Adapted Dissociative States Scale (from Bremner et al., 1998): a 19-item subjectively 
rated measure tapped state dissociative symptoms.
Mood Rating Scale (Bond & Lader, 1974) : a 16-item visual analogue scale (VAS) was 
used to investigate subjective drowsiness.
At the end of the main session, the effectiveness of blinding was also assessed by both 
participant and experimenter guessing whether they thought that a drug had been 
administered.
2.3.5 Statistical Analyses
All statistical analyses were performed using SPSS Version 9.0. Group differences 
were examined using one-way ANOVAs and, where data was non-parametric, the 
Kruskall-Wallis test. The recognition memory component of the source memory task 
and the N-back were analyzed using signal detection theory (Snodgrass & Corwin, 
1988). This method was selected as it allows a separation of the response bias
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component from discriminability and yields a measure of not only of the ability to 
recognise a word/number but also the bias in responding. Within 
psychopharmacological research response bias can be an issue, either in terms of 
disinhibition or over-inhibition. Thus it is important to separate response bias, where 
possible, from memory data. The recognition and N-back data were then, along with 
most other cognitive tasks and subjective effects, analysed using 3 x 2  repeated 
measures analyses of variance (RMANOVA) with time (pre-drug, post-drug) as the 
within-subject factor and drug condition (placebo, 0.4mg kg -1 ketamine, 0.8 mg kg-1 
ketamine) as the between subject factor. Where significant interactions were found 
orthogonal contrasts were conducted comparing 1) placebo with both drug groups and 
then 2) low dose and high dose ketamine. Dunnetf s t and simple effects were analyzed 
in RMANOVAS with more than two factors. Bonferroni corrections were used to 
control for multiple comparisons and correlations. Non-significant main effects and 
interactions are not reported.
2.4 Results
2.4.1 Trait Scores, Demographics and Drug dosage
There were no significant group differences in age. Participants were additionally 
matched in premorbid I.Q. (spot the word) test, depression, alcohol and tobacco use and 
trait dissociation. There were no differences in the milliliters (mis) infused for the three 
groups [F(2, 51) = 0.39 p=0.68] or between the weights of the groups [F(2,51) = 0.44 
p=0.65] (Table 1). In total the 0.8 mg kg -1 and 0.4 mg kg -1 groups received a mean of 
56.45± 9.19 mg and 26.74 ± 7.56 mg ketamine respectively over 80 min.
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Placebo, 
mean (s.d)
0.4 mg kg _1 
ketamine, 
mean (s.d)
0.8 mg kg " 
ketamine, 
mean (s.d)
Age 21.83 (3.15) 21.17(1.69) 24.17(4.53)
Spot the word test 
score
50.00 (3.20) 49.67 (3.65) 49.65 (3.87)
Alcohol use, 
units/week
14.22 (8.89) 11.83 (7.67) 13.61 (8.51)
Tobacco use, 
cigarettes /day
2.11 (4.43) 3.33 (4.85) 1.78 (4.77)
BDI score 3.0 (3.6) 4.3 (4.9) 3.5 (4.9)
STA score 34.6(10.8) 32.5 (8.79) 33.8 (9.7)
DES score 32.3 (32.39) 31.6 (30.3) 31.5 (35.5)
Weight, kg 71.29(13.92) 66.84(18.87) 70.56(11.49)
mis infused 31.2 (6.05) 29.8 (3.71) 30.9 (5.58)
Table 2.1: Demographics across treatment groups
2.4.2 Cognitive Tasks
2.4.2.1 Source Memory: For recognition memory data d', an index of discriminability, 
and C, a measure of bias, were calculated using signal detection theory. RMANOVA 
analysis of discrimination (d') revealed a significant drug x time interaction [F = (2, 51) 
= 8.74 p<0.001] and significant main effects of time [ F(l, 51) = 42.59 p<0.001] and 
drug [ F (2,51) = 3.84 p<0.05]. (See Figure 2.1a). Contrasts revealed significantly lower
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Figure 2.1a: Mean d' index for recognition memory at each assessment point by each 
treatment condition; 2.1b: Mean proportion of correct source memory judgements pre 
and post drug across each condition
recognition memory scores in the drug groups as compared to placebo [t(51) = 3.98 
pO.OOl].
Analysis of the criterion (C), found a significant time x drug interaction [ F (2, 51) = 
3.75 p<0.03] and a main effect of time [ F (1, 51) = 21.92 p<0.001]. Contrasts revealed 
a difference in bias between the high and 0.4 mg kg _1 ketamine groups, such that the
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low dose group was significantly less conservative than the higher dose group [ t(51)= - 
2.09 p<0.04]. The criterion only changed in the high dose group from 0.40 ± 0.22 pre­
drug to 0.78 ± 0.42 post-drug, indicating that they became more conservative, i.e. they 
were more likely to say that they had not heard a previously presented word. Data on 
the probability of a correct source judgement (Ht) given recognition (Hf) were 
analyzed (Ht/ Ht'). There was a significant interaction between time and drug [ F (2, 51) 
= 18.84 pO.001] and significant main effects of drug [F(2,51) = 11.72 p<0.001] and 
time [ F(l,51) = 44.30, pO.001]. Contrasts found significantly lower correct 
identification of the source of memories in the drug groups as compared to placebo 
[t(51) = 4.91 p<0.001] and in the 0.8 mg kg 1 group compared to the 0.4 mg kg 1 
ketamine group [ t(51) = 3.68 p=0.001].The clear dose response relationship can be 
seen in Figure lb. However even given the marked impairments of the high dose group 
compared to the low dose and placebo groups, it is noteworthy that the high dose 
ketamine group was still performing above the 0.5 chance level.
placebo low dose high dose
Pre-Drug
0-Back -0.37 (0.28) -0.31(0.22) -0.37 (0.25)
1-Back -0.49 (0.31) -0.44 (0.33) -0.42 (0.29)
2-Back -0.57 (0.20) -0.72 (0.27) -0.65 (0.21)
Item Recognition 0.52 (0.28) 0.39 (0.24) 0.40 (0.22)
Post Drug
0-Back 0.76 (0.29) 0.62 (0.22) 0.64 (0.25)
1-Back -0.40 (0.17) -0.52 (0.25) -0.64 (0.41)
2-Back 0.01 (0.25) -0.12(0.28) -0.34 (0.27)
Item Recognition 0.62 (0.19) 0.54 (0.36) 0.78 (0.42)
Table 2.2 : Mean criterion across groups for the N-back and recognition memory tasks
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2.4.2.2 Speed o f  Comprehension
There was a significant drug x time interaction [ F(2, 51) = 11.72 p<0.001] and main 
effect of time [F (1, 51) = 4.93 p<0.03] on the number of completed sentences. 
Contrasts revealed that the placebo group completed more sentences than the 0.8 mg kg 
_1 and 0.4 mg kg 1 ketamine group [t(51) = 4.03 p<0.001] and significantly more 
sentences completed in the low dose ketamine compared to the high dose group [t(51) = 
2.68 p =0.01]. There was no effect of drug on number of errors in the speed of 
comprehension task or any interaction (See Fig 2.2).
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□  0 . 4  m g / k g  
k e t a m i n e
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k e t a m i n e
Figure 2.2: Mean number of sentences completed pre and post infusion across each 
treatment condition for speed of comprehension
2.4.2.3 N-Back Working Memory Task
For the N-back working memory data d' and C were also calculated. Analysis of d' 
with a 3 x 2 x 3 ANOVA yielded a significant time x drug interaction [ F (2, 51) = 7.49 
p<0.01] and a significant time x working memory load interaction [F(2, 102) = 3.69 
p<0.03] in addition to main effects of working memory load [ F(l, 51)= 350.12 
pO.001], time [F(l, 52) = 10.18 p<0.01] and drug [F(2, 51) = 4.08 p<0.03]. Further 
analysis of this data demonstrated group differences post-drug on the 1-back [ F(2,53) = 
5.58, p<0.01] and 2-back tasks [ F(2, 53) = 6.32 p<0.01 ] only (See Fig 2.3).
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Figure 2.3: D prime N-back working memory scores across working memory load , 
assessment point and treatment condition
Contrasts indicated that these difference were attributable to lower scores in the drug
groups compared to placebo on both the ‘ 1 back’ [ t(51) = 3.71 p=0.001 ] and ‘2 back’ [
t(53) = 2.34 p<0.03] tasks and lower scores in the 0.8 mg kg -1 than the 0.4 mg kg -1
ketamine group again both on the 1-back [t(53) =2.25 p<0.03] and 2 back [t(53) = 2.71
p<0.01]. As can be seen from Figure 2.3 the high dose ketamine group was performing
at levels close to chance in the 2-back condition post-drug. The response criterion (C)
also was analysed (See Table 2.2). A working memory load x drug interaction was
found [ F(4, 102) = 6.00 p<0.001], and a working memory load x time interaction [ F(2,
102) =189.414 p<0.001] in addition to main effects of working memory load [F (2,
102) = 110.21 pO.001] and time [F(l, 51)= 373.41 p<0.001]. Differences between
groups were revealed post-drug on the 2-back section of the task[ F(2,53)= 7.61
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p<0.01]. The drug groups were less conservative overall than the placebo group [ 
t(53)=3.07 p<0.01] and the high dose group was less conservative than the low dose 
group [ t(53)= 2.45 p<0.02], (Group means, post drug were: placebo: 0.014 ± 0.25; 0.4 
mg kg -1 ketamine: -0.12 ± 0.28; 0.8 mg kg -1 ketamine: - 0.34± 0.27). Reaction times 
(RTs) were not found to differ between the groups at any of the time points. There was 
however a main effect of working memory load [F(l, 51) = 147.24 p<0.001]. Within 
subjects contrasts revealed RT’s to increase with increasing memory load [F(l, 43) = 
199.73 p<0.001] (See Appendix, Table A1 for mean RTs).
2.4.2.4 LOP Retrieval Intentionality (Table 2.3)
Word- stem completion: Participants completed more word stems with studied than 
unstudied words, i.e. priming occurred, with a main effect of study Condition [F(l, 53) 
= 50.47 p<0.001]. The ratio of targets to distractors completed was computed as an 
index of priming. RMANOVA of these scores for semantically encoded stems and 
physically encoded stems revealed no effects of drug or encoding condition on priming. 
Cued Recall: Unlike the word stem completion condition encoding condition (semantic 
versus physical) had a significant effect on stem cued recall [F(l, 51) = 19.53 p<0.001] 
with semantically encoded words being better recalled than physically encoded words. 
There was a trend for a main effect of Drug [ F(2, 51) = 2.83 p =0.068].
In the ‘awareness’ test at the end, n=4 subjects reported being aware of having seen the 
words before (placebo =2, low dose = 2).
2.4.2.5 Serial Reaction Time Task
The two sequences which participants were trained on were combined in the analysis. 
RTs are only used for trials on which participants did not make errors and RTs from the 
first two trials of each block were disregarded because it would be impossible for 
participants to predict the location of the next target. A 3x2x3 RMANOVA found a 
significant Block x Drug interaction [F (4,106) = 3.55 p<0.01 p = 0.009], significant 
main effects of probable/improbable [ F(l, 53) = 13.51 p<0.01] and drug [ F (2,53) = 
8.59 p<0.01]. Post hoc Dunnetf s t revealed the placebo group to be significantly faster 
than the 0.4 mg kg'1 ketamine group [p<0.02 ] and the 0.8 mg kg _1 group [p<0.001].
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Paired comparisons (with applied Bonferroni correction) revealed significant 
differences between in reaction time between Blocks 1 and 2 in the placebo group[ 
[t( 17) = 3.056, p<0.007] and in the high dose group between Blocks 2 and 3 [ t(17) = 
4.07, p<0.001]. As can been seen from Figure 2.4, these reflect an decrease in reaction 
time in the placebo group from Block 1 to Block 2 and an increase in reaction time in 
the high dose ketamine group from Block 2 to Block 3.
Treatment Targets Completed Distractors
Completed
Targets:
Distractors
Target
Recall
Placebo
Overall 12.44(2.77) 7.56 (2.47) 1.86: 1 (0.79) 8.56 (4.36)
Semantic 6.17(2.24) 5.06 (2.48)
Physical 6.28(1.82) 3.50 (2.44)
Low dose 
ketamine
Overall 9.94 (2.36) 6.22 (2.21) 1.94: 1 (1.37) 7.61 (4.5)
Semantic 4.44 (2.73) 4.50 (2.38)
Physical 5.50 (2.46) 3.11 (2.78)
High dose 
ketamine
Overall 10.27 (3.75) 7.56 (2.48) 1.63:1 (1.17) 5.33 (3.61)
Semantic 5.39 (2.83) 3.33 (2.30)
Physical 4.88 (2.11) 2.00(1.94)
Table 2.3: Group means and standard deviations for(left to right): targets completed, 
distractors completed, ratio of targets completed to distractors completed, targets 
recalled
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Figure 2.4: Mean R T s for the serial reaction time task across probable and improbable 
trials
Analysis of the mean number of errors per block yielded a significant effect of 
Condition [ F(l,53) = 6.12 p <0.02] and a significant main effect of Block [F (2,106) = 
4.38 p<0.02 ]. However multiple comparisons did not demonstrate any further 
differences.
2.4.2.6 Trailmaking
For time taken to complete part A there were no significant group differences although
there was a trend for a Time x Drug interaction [F(2, 51) = 2.65 p=0.08]. In part B there
was a significant Time x Drug interaction for time taken to complete the task [F(2, 51)
= 5.73 p<0.01]. Contrasts demonstrated were greater time taken to complete the task by
the two drug groups compared to placebo [t(51) = 2.50 p<0.02] and in the 0.8 mg kg 1
ketamine group compared to the 0.4 mg k g _1 ketamine group post drug [ t(51) = 2.81
p<0.01]. An overall score for trailmaking was computed by subtracting the scores from
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the first part of the test from scores on the second part of test. This was to remove any 
general motor impairment effects from the task and concentrate upon the executive 
functioning component. Overall no significant effects of treatment condition, 
assessment point or errors were observed. (See Table 2.4)
Placebo Low dose High dose
Pre drug
Trails A, time taken sec 35.69(17.25) 37.89(15.41) 34.65 (10.46)
Trails A, no. errors 0.11 (0.47) 0 0
Trails B, time taken sec 54.44(18.76) 53.12(15.47) 51.53(21.20)
Trails B, no. errors 0.83 (2.71) 0.22 (0.94) 0.67(1.78)
Post drug
Trails A, time taken sec 31.65(10.99) 38.11 (12.90) 43.50(17.00)
Trails A, no. errors 0 0 0
Trails B, time taken sec 50.15(15.46) 54.83(17.83) 71.12(26.62)
Trails B, no. errors 0.67 (2.06) 0.72(1.84) 4.11(6.98)
Table 2.4: Trailmaking data pre and post drug across treatment condition 
2.4.3 Subjective Effects
2.4.3.1 Schizotypal Symptomatology (See Table 2.5) Data for schizotypyal symptoms 
were not normally distributed so were transformed by a square root transformation. 
However this did not affect the results of the RMANOVA’s so untransformed statistics 
and means are reported. When the overall score for schizotypyal symptoms was 
computed, RMANOVA demonstrated a significant Drug x Time interaction [F(2, 51) = 
10.95 p<0.001] and a significant effect of Time [F(l, 51) = 23.26 p<0.001]. Contrasts 
showed that both the drug groups scored more highly than the placebo group [t(51)= -
4.63 p<0.001] but there were no differences between the 0.4 and 0.8 mg kg -1 ketamine 
groups.
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2.4.3.2 Adapted Dissociative States Scale (See Table 2.5) RMANOVA of the overall 
ADSS score showed a significant Drug x Time interaction [ F(2, 51) = 21.30 p<0.001] 
and significant main effects of Drug [F(2, 51) = 17.28 p<0.001] and Time [F(l ,51) =
85.63 p<0.001]. Ketamine induced clear, dose-related dissociative effects. These were 
confirmed by further analysis of the interaction which revealed significantly lower 
scores in the placebo group compared to the two drug groups post-drug [ t(51) = -5.88 
pO.001] and the 0.4 mg kg -1 ketamine group compared to the 0.8 mg kg -1 ketamine 
group post-drug [ t(51) = -2.85 p<0.01 p=0.003].
Placebo Low dose High dose
ADSS total score pre 1 (1.28) 1.06(1.66) 3.17(7.67)
ADSS total score post 2.33 (3.20) 15.28(11.23) 27.28(15.91)
SSQ total score pre 6.89(10.63) 4.78 (6.79) 6.89(10.39)
SSQ total score post 4.61 (4.49) 14.39 (14.56) 18.61 (9.99)
Table 2.5 Means(standard deviations) of scores across treatments for the Adapted 
Dissociative States Scale (ADSS) and Schizotypal Symptomatology Questionnaire 
(SSQ) pre and post drug
2.4.3.3 Subjective Drowsiness: A 3x4 RMANOVA of the visual analogue scale for 
‘drowsiness’ yielded a significant Drug x Time interaction [F(6, 153) = 7.90 p<0.001], 
a significant main effect of Drug [F(2, 51) = 9.22 p<0.001] and Time[F (3, 153) = 
67.93 p<0.001]. Contrasts revealed that the placebo group were less drowsy than the 
two drug groups 10 min post drug [t(51)=-5.30 p<0.001], and 80 min post drug [t(51) = 
-6.19 p<0.001].
2.4.4. Correlations
As an attempt to investigate the link between schizophrenic-like symptoms and 
cognitive impairments correlations were conducted on key measures that demonstrated
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impairments (source memory, speed of comprehension, N-back) in the high dose 
ketamine group. There were trends, after Bonferroni correction for a correlation 
between scores post drug on the SSQ and d' for recognition memory (r=0.493, 
p=0.038) and time to process sentences on the speed of comprehension task (r =0.479, 
p=0.045).
Guess on Treatment: The high dose ketamine group were all accurate in discriminating 
the drug from placebo, and 16 (89%) of the low dose participants could discriminate the 
ketamine from placebo. The experimenter guessed incorrectly as to the treatment 
condition (placebo/ low dose/ high dose) 20 times (high dose group 8/18 times, low 
dose group 8/18 times, placebo 4/18 times), thus the experimenter was accurate 63% of 
the time.
Gender Differences: No drug x gender interactions emerged on the source memory 
task, speed of comprehension and the schizotypal symptomatology questionnaire.
Plasma ketamine levels: At 65 minutes, mean plasma ketamine levels were 128.96 
(±36.96) ng/ml for the low dose group and 261.90 (±31.56) ng/ml for the high dose 
group.
Other Responses: Seven participants reported feeling nauseous (high dose -  2 males, 4 
females, low dose -1 male). Of these, one low-dose male participant vomited 5 minutes 
after the infusion had been stopped. However all participants, when asked, felt able to 
continue with the tasks. Many participants in the ketamine groups reported visual 
changes such as blurred vision or a sense that everything was moving or flickering. 
Despite this however all participants felt they were able to proceed with the tasks.
2.5 Discussion
The present study investigated the effects of two doses of ketamine, 0.4 mg kg -1 and 
0.8 mg kg -1, on memory systems, and dissociative and schizotypal symptoms. The
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main findings were that ketamine impaired working and episodic memory with 
increasing dose, disrupted procedural and semantic memory regardless of dose whilst 
leaving perceptual priming intact. Ketamine also induced schizophrenic and 
dissociative symptoms, replicating previous studies (Krystal et al., 1994; Malhotra et 
al., 1996; Newcomer et al., 1999; Adler et al., 1999; Hetem et al., 2000).
Ketamine dose-dependently increased both source and recognition memory errors. 
These findings replicate the impairment in recognition memory observed previously 
with ketamine (Ghoneim et al., 1985; Malhotra et al., 1996; Hetem et al., 2000) but 
extend these findings to demonstrate an episodic memory impairment. The only 
previous study to examine episodic memory following ketamine indicated a decrease in 
both recollection and familiarity (Hetem et al., 2000; subsequent to writing Honey et 
al., submitted). There clearly is a parallel between impairments to conscious awareness 
(‘remembering’) and the source memory impairments we observed. Our finding of 
source memory deficits indicates not only an impairment of ‘what’ is remembered but 
also ‘how, why and where’. This supports the notion that the NMDA-receptor is 
important in episodic memory in humans. Neuroimaging studies suggest that these 
deficits in source memory may be a function of hyperactivation of the prefrontal cortex 
and underactivation of the hippocampus and medial temporal lobe structures as these 
areas are associated with source memory (Wheeler et al., 1997) and this pattern of 
neural activity has been found following ketamine administration (Breier et al. 1997; 
Vollenweider et al., 1997).
Interestingly, the high dose ketamine group, whilst impaired, were still performing well 
above chance levels on the source memory task. Many previous studies have found 
recognition memory to be at chance following a similar dose of ketamine to that used in 
this study (e.g. Malhotra et al., 1996; Hetem et al., 2000). The elaborative encoding 
procedure used in this task, where source was associated with both gender of voice and 
subsequent semantic judgement, appeared to elevate source memory scores pre-drug to 
near-ceiling levels. This elaborative encoding, post-drug, may also have acted to 
partially compensate for ketamine-induced encoding impairments.
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Working memory was dose dependency impaired in the present study, accompanied by 
a preservation of sustained attention. This finding replicates the work of Adler et al.
(1998). Preserved attentional processes following ketamine administration eliminate the 
possibility that memory impairments are due to any general impairment in attentional 
functioning. It is also important to remember, when considering all the cognitive 
findings of the current study, that no one task taps a single memory system, for example 
impaired working memory observed here may also be partially responsible for the 
deficits on the episodic memory task.
Our findings provide the first demonstration that perceptual priming is preserved 
following ketamine administration. The levels of processing manipulation was 
successful and demonstrated a dissociation in performance on the implicit and explicit 
aspects of the task, satisfying Schacter’s (1989) ‘retrieval intentionality criterion’. 
Thus, on word-stem completion, levels of processing did not affect performance, but on 
cued recall they did, with semantically encoded words being better remembered than 
physically encoded words. There was a trend towards lower scores in the ketamine 
groups on the cued recall task in line with previous research demonstrating that cued 
recall is less sensitive to drug-induced impairment than free recall (Bishop & Curran, 
1995). Interestingly, levels of cued recall were lower than stem completion throughout 
but lowest in the high dose ketamine group where twice as many stems were completed 
with targets in the implicit compared to explicit task. This would accord with the 
suggestion that in situations where conscious awareness is impaired, it may serve to 
have inhibitory effects on explicit memory (Danion et al., 1999). Preserved perceptual 
priming is of interest as no previous study has examined the effects of ketamine on this 
form of memory. This implies that a specific pattern of memory deficits is induced by 
ketamine rather than a global impairment on all memory tasks. Further investigation of 
priming with tasks such as process dissociation, that taps awareness in addition to 
priming, may be useful in interpreting these findings further.
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It is interesting to note that even though both priming and procedural learning tap 
processes that do not involve conscious awareness, different findings were observed on 
these tasks. In patients with organic memory disorders, such as the amnesias, non- 
conscious forms of memory are generally preserved. The finding of impaired 
procedural learning in the presence of preserved priming observed in the current study, 
is reminiscent of the cognitive pattern observed in Parkinson’s Disease (Jackson et al., 
1995). However, evidence for a true impairment to procedural learning is unclear, as 
the reaction times of the ketamine subjects were significantly slower than those of 
placebo overall. Speed of responding may putatively affect learning, slower responses 
may mean that participants require longer to learn the sequence. Ketamine also reduced 
psychomotor speed on trailmaking in the present study but did not affect trailmaking 
scores once psychomotor slowing had been controlled for. This replicates the findings 
of Harbome et al. (1996) and indicates a preservation of some aspects of frontal 
functioning.
Retrieval from semantic memory was examined in the present study using the speed of 
comprehension task. There was a dose response relationship between the number of 
sentences verified on this task. This may suggest semantic memory impairments 
following ketamine administration. However participants did not make any more errors 
after ketamine. In light of the trailmaking results discussed above and those stemming 
from the SRT where reaction times and speed were significantly slower in the ketamine 
group, it is again possible that ketamine effects on this task are due to general 
psychomotor slowing attributable to the anaesthetic and sedative effects of the drug.
The current study replicated the findings of previous work in revealing an increase in 
the schizophrenic like and dissociative symptoms following ketamine. These findings 
confirmed that the psychotomimetic effects of ketamine are detectable on both clinician 
and self-rated scales, and that ketamine, in the doses administered in this study, induced 
a state resembling some of the symptoms of schizophrenia. There have been 
suggestions in the literature that, as NMDA-antagonists induce psychotic symptoms 
and the NMDA-receptor is involved in memory, the cognitive deficits observed in
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schizophrenia may be mediated by the NMDA-receptor (e.g. Newomer & Krystal , 
2001). Whilst cognitive impairment in schizophrenia still remains ill-defined, highly 
tentatively it appears that the profile of cognitive effects of ketamine appears somewhat 
similar to that observed in schizophrenia and organic psychosis (Perlstein et al., 2001) 
but differs in impairments to procedural learning and preserved executive functioning. 
Moreover there was some indication that schizophrenia like symptoms were related to 
semantic and recognition memory deficits, in contrast to previous work which has 
shown a relationship between working memory and schizophrenia-like symptoms 
(Adler et al., 1998). Further research using techniques such as pharmacological 
functional magnetic resonance imaging may shed light on the similarity between 
neuroanatomical substrates of NMDA-antagonist induced cognitive impairments and 
those observed in schizophrenia.
This study was subject to several limitations. Firstly, the cognitive testing began after 
20 minutes, when ketamine may not have reached a plasma level comparable to that of 
previous ketamine research. This could explain the lack of errors on the speed of 
comprehension task, as this task was administered first. Secondly, the continuous 
infusion style used meant that ketamine levels may have been rising throughout the 
study, which could result in impairments on certain tasks being an effect of increasing 
dose rather than ketamine specificity for certain memory systems. Studies using steady 
state or pseudo-steady state infusion styles have negated this problem (Hetem et al., 
2000; Newcomer et al., 1999). A consequence of rising blood ketamine levels may also 
have been that sedation was increasing which would have compounded the effects of 
ketamine on these tasks. However the data would seem to indicate that this is not the 
case. The tasks that were not affected by ketamine were towards the end of the battery, 
for example, implicit memory, when ketamine levels and drowsiness had increased. 
Furthermore, tasks at the beginning of the battery demonstrated ketamine-induced 
impairments (e.g. procedural learning). Thus it would appear that the selectivity of 
ketamine’s effects on certain memory systems are not as a result of a test order that 
meant that tasks towards the end of the battery were subject to a combination of higher 
drowsiness and ketamine blood levels. Another limitation common to studies of this
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kind, is that tasks may not be of comparable difficulty and whilst on tasks such as the 
N-back it is possible to manipulate levels of difficulty, on the other tasks this was not 
feasible. Despite this, these tasks have been shown to be differentially sensitive to the 
impact of pharmacological manipulations of memory systems.
The doses of ketamine used in this experiment are somewhat lower and involved a 
different infusion style (continuous rather than a bolus then maintenance infusion) than 
some used in previous studies (e.g. Krystal et al., 1994; Malhotra et al., 1996; 
Newcomer et al., 1999). Hence comparisons across these studies are limited. Despite 
this, however, the cognitive effects of ketamine observed in the current study were 
similar to those detailed in the aforementioned papers. As this study has demonstrated 
discernible ketamine effects at these doses, then future research may consider using 
lower doses, although by targeting a possibly lower steady state to further investigate 
memory systems and ketamine. There were no baseline differences between the groups 
which confirms that variation between the groups post-infusion is a result of drug 
effects and not individual differences. Previous studies have used crossover designs but 
as ketamine is associated with tachyphylaxis and potential residual cognitive effects 
were possible then the independent groups design was considered to be preferable.
In summary, the present study replicated previous data suggesting a ketamine-induced 
impairment of working memory and preservation of attention and executive function. 
This study extended findings of an impairment in episodic memory following ketamine 
by demonstrating an impairment in memory for source. Ketamine produced a slowing 
of semantic processing but no increases in errors. Further novel findings from this study 
were of preserved perceptual priming and impaired procedural learning induced by 
ketamine. This is a cognitive profile that differs from both schizophrenia and organic 
memory disorders.
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Chapter 3: Source memory in ketamine
users
C h r o n i c  e f f e c ts  o f  k e t a m i n e  a b u s e :  e v id e n c e  f o r  a  p e r s i s t i n g  
i m p a i r m e n t  o f  s o u r c e  m e m o r y  in  r e c r e a t i o n a l  u s e r s
“The existence o f forgetting has never been proved: We only know that some things 
don't come to mind when we want them.”
Friedrich Nietzsche
3.1 Overview
Ketamine is an NMDA-receptor antagonist that is increasingly being used as a 
recreational drug. Previous work has shown gross generalised verbal memory 
impairments persisting 3 days after ketamine use in chronic users, however episodic 
memory has not specifically investigated in this population. The work presented in this 
chapter set out determine whether ketamine, on the night of drug use and 3 days later, is 
associated with impaired episodic memory as assessed by a source memory task. 
Twenty ketamine users and 20 poly-drug controls were compared on a source memory 
task both on day 0 and day 3. Participants also completed questionnaires on both days 
indexing schizophrenic-like and dissociative symptoms. On day 0, ketamine abusers 
were impaired on source memory and item recognition and scored more highly on 
schizophrenic and dissociative symptoms compared to poly-drug controls. On day 3 
ketamine abusers only displayed source memory impairments and these positively 
correlated with the level of schizophrenic-like symptoms on day 0. No differences on 
day 3 in schizophrenic-like or dissociative symptoms were observed. Ketamine abusers 
exhibit a persisting deficit in source memory on day 3 but not item recognition. These 
findings suggest that repeated use of ketamine produces chronic impairments to 
episodic memory.
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3.2 Introduction
A good deal of research has examined the acute effects of ketamine in healthy 
volunteers. However, relatively little is known about the effects of long-term ketamine 
abuse. In rats, repeated doses of NMDA-antagonists have produced persisting deficits 
in working memory performance (Jentsch et al., 1997b) and response inhibition 
(Jentsch et al., 1997a). A possible mechanism for these deficits is the neurotoxicity that 
has been found in rats administered of NMDA-receptor antagonists chronically. 
Repeated high doses of NMDA-antagonists induce neuronal degeneration in the 
posterior cingulate/retrosplenial cortex and other corticolimbic areas including the 
hippocampus, amgydala, and parietal, temporal, piriform and entorhinal cortices 
(Ellison & Switzer, 1993; Horvath & Buzsaki, 1993; Corso et al., 1997; Ellison, 1994). 
These neurotoxicity studies, however, used other non-competitive NMDA-receptor 
antagonists, such as phencyclidine (PCP) and dizocilipine (MK-801) with higher 
affinity for the NMDA-receptor than ketamine, The degree of neurotoxicity has been 
demonstrated to be related to the relative affinity to the NMDA-receptor (Olney et al., 
1989) therefore neurotoxicity associated with repeated ketamine, whilst observable, is 
more subtle (Keilhoff et al., 2004a; 2004b).
There is some anecdotal evidence of persisting cognitive impairment in humans
following ketamine abuse (Jansen, 1990; Lilly, 1978), however, only two studies have
formally examined the cognitive effects of ketamine in recreational users of the drug.
Curran & Morgan (Curran & Morgan, 2000) examined volunteers who reported taking
ketamine with a population matched for poly-drug use, on the night of their ketamine
use (day 0) and three days later (day 3). Day 0 effects replicated previous laboratory
acute studies showing a broad range of cognitive impairments (e.g. Krystal et al. 1994)
but three days later, participants were still impaired on tasks tapping episodic and
semantic memory. A further study attempted to examine whether these day 3 effects
were chronic or residual by comparing frequent and infrequent users of ketamine using
a similar design (Curran & Monaghan, 2001). Episodic and semantic memory
impairments were observed on day 3, as in the previous study, in the frequent but not
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the infrequent ketamine users. These findings are suggestive of chronic effects of 
ketamine, as transient residual impairments would theoretically have been observed in 
both the groups.
The day 3 episodic memory impairments observed in those previous studies were 
tapped using a prose recall task. Although this task does examine memory for 
information learnt whilst on the drug, it cannot be regarded as a comprehensive 
episodic memory measure as performance on this task does not require explicit memory 
for the actual encoding context. Episodic memory can more appropriately be studied 
using source memory tasks. These require participants not only to recognise the 
information learnt i.e. ‘what’ was learnt, but also to recollect which source the 
information originally came from, in terms of everyday memory the ‘how, where and 
when’ component. For example, in daily life, impaired source memory is observed 
when one recognises a person’s face but is unable to recollect where or when one 
previously met the person. In the laboratory, such tasks typically require the participant 
to remember which colour a word was presented in or whether it was spoken in a male 
or female voice. This aspect of episodic memory has been shown to be selectively 
impaired in certain disorders, for example, schizophrenia (Keefe et al., 1999; 
Vinogradov et al., 1997) and normal ageing (Schacter et al., 1994; Schacter et al., 1991; 
Wilding & Rugg, 1996). Previous research has demonstrated that an acute dose of 
ketamine in healthy volunteers impairs both item recognition and source memory 
(Morgan et al., 2004a) however three days later there was no impairment to either 
source or item memory (Morgan & Curran, unpublished observation). No research to 
date has examined source and item memory in chronic ketamine abusers.
Therefore this study was designed to investigate the acute and chronic effects of
ketamine on episodic memory, using a source memory paradigm in ketamine abusers
and matched polydrug controls on the night of drug use and three days later. We used
the same source memory task in this study as we used in a study with healthy
volunteers (Chapter 2; Morgan et al., 2004a). This allowed comparison between the
acute effects of ketamine in healthy volunteers and chronic effects in abusers. Given
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that chronic verbal memory impairments have already been demonstrated in ketamine 
abusers, we hypothesised that if these were due to a generalised memory deficit, then 
an impairment in both item recognition and source memory would be observed. 
However, if a selective deficit in the ability to encode, store or access contextual 
information about an event was responsible, then only a source memory impairment 
would be observed. Schizophrenic-like symptoms have also been found 3 days after 
drug use in ketamine users (Curran & Morgan 2000). Given the high incidence of 
source memory impairments in schizophrenia, we intended to investigate the 
relationship between these source memory failures and observed schizophrenic-like 
symptoms in ketamine-users.
3.3 Methods
3.3.1 Participants and design
Forty participants completed the study, 24 male and 16 female, recruited using a 
snowball sampling technique (Solowij et al., 1992): 20 ketamine users (mean age: 23.1 
±3.2 years, 9 females) and 20 polydrug using controls (mean age 23.9 ±5.4 years, 7 
females). Participants were tested on two occasions: on day 0, where the ketamine 
group were under the influence of the drug, and again 3 days later. Test versions were 
counterbalanced across group and day. The study was approved by the institutional 
ethical committee. Subjects were not paid for participation.
3.3.2 Procedure
Participants were approached in a party setting on day 0 and asked if they were
interested in taking part in a study about drug users. If they agreed volunteers were
taken individually to a quiet area where they informed the experimenter whether or not
they had taken or intended to take ketamine that evening. They were then asked about
other drug use and were excluded if they had taken any drugs other than small amounts
of cannabis (< 1 “joint”) or more than 2 units of alcohol that evening (n=5). Participants
were also excluded if they currently only used cannabis or alcohol as it was necessary
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to match the two groups for drug use (n=2). Participants on ketamine were asked to 
estimate when they had taken the drug, and only participants who had recently taken 
ketamine (i.e. within 10 minutes) were included. In addition, it was necessary to 
exclude 3 participants who had taken ketamine but then became unresponsive, due to 
large ketamine doses. Participants then completed the assessments detailed below and 
arrangements were made to meet up 3 days later. The task battery lasted a total of 
approximately 30 minutes. Participants were asked to abstain from using alcohol and 
other recreational drugs between the two test sessions. The follow-up test session on 
day 3 was carried out in the participant’s home, in a room with minimal distraction. 
They then completed the same assessments as on day 0 along with a pre-morbid IQ 
measure and a detailed drug-use questionnaire. Participants had used similar amounts 
of alcohol and cannabis between day 0 and day 3 but 2 participants were excluded for 
ecstasy use between the two days. Participants provided written, informed consent on 
both days of testing, on day 0 after ketamine and again on day 3 when drug-free.
3.3.3 Assessments on day 0 and day 3
Source memory task (Wilding & Rugg, 1996): This task was chosen as an index of 
episodic memory. Stimuli consisted of 160 low frequency words. The words were 
divided randomly into 4 study lists of 40 words. Words were broadly matched across 
lists in terms of letters per word, imagery value and frequency. In each study list, half 
the words were spoken in a female voice and half in a male voice (allocation was 
randomly determined). Study words were presented to participants aurally, played on a 
tape recorder. During the study phase participants listened to each word, repeated it 
aloud and then, depending upon the gender of the voice it was presented in, rated the 
word as either pleasant/unpleasant or abstract/concrete. The gender of the voice and 
task associated with it was counterbalanced across conditions, as was the study list. 
After completing the list, there was a delay of six minutes, filled with another task, and 
then participants were presented with a test list of 80 words, 40 previously presented 
words and 40 words not seen at study. Test words were presented visually on a laptop 
screen. Participants were instructed to report whether the word presented was one that
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they had heard before and if so, whether it had been presented in a male or female 
voice. Participants gave their responses verbally. Word recognition responses were 
recorded as hits, false alarms, misses and correct rejections. Source errors were also 
recorded.
Spot the word test (Baddeley et al., 1993): Participants were required to choose the real 
word out of pairs of words/non-words. This task has been shown to give a measure of 
IQ that is correlated 0.69 with the National Adult Reading Test (NART: (Crawford et 
al., 2001).
3.3.4 Subjective Ratings
Schizotypal Symptomatology Questionnaire (SSQ: Curran & Morgan 2000):
This is a 30-item questionnaire designed to assess state schizophrenic-like 
symptomatology, a purported disposition to schizophrenia or psychosis proneness. A 
higher score indicates a higher level of schizophrenic-like symptomatology.
Adapted Dissociative States Scale (ADDS): An adapted version of Bremmer et al.’s 
(1998) Clinician Administered Dissociative States Scale was used (Curran & Morgan
2000). This scale was a 19-point scale designed to assess dissociative states, with 
higher scores indicating higher levels of dissociation.
Visual Analogue Scales: A 16-item visual analogue scale was used to investigate mood 
symptoms (Bond & Lader, 1974). The scale yields three main factors: alertness, 
contentedness and calmness. A 15 item visual analogue scale was used to assess the 
subjective side effects of ketamine (See Appendix -  A5). Items included were memory 
impairment, out of body experiences, visual distortion, sound distortion, altered time 
perception, dizziness, impaired concentration, depression, feelings of altered reality, 
impaired memory, nausea, bodily numbness, unsteadiness, lack of co-ordination and 
confusion. Ketamine subjects also rated their Miking’, ‘feeling’ and ‘wanting’ of the 
drug effects on day 0.
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3.3.5 Statistical Analysis
Data from day 0 to day 3 were analysed using repeated-measures analysis of variance 
(RMANOVA) with day (0 or 3) as the within-subjects factor and group (ketamine or 
control) as between-subjects factors. Drug use patterns were compared using Mann- 
Whitney U-tests as these data were not normally distributed. % 2 were used to analyse 
categorical data, such as educational level For the source memory task d prime {d' = 
[z(Ht’) -z(Fa’)]}, an index of discriminability, was calculated for the item recognition 
data, as was the criterion, C (C=[z(Htf) + z(Fa')]/ 2} an index of bias, using signal 
detection theory (Snodgrass & Corwin, 1988). Signal detection theory was used as it 
attempts to separate bias in responding, which is an important issue with drug users, 
from discriminability of stimuli. Correlations were performed between schizophrenic­
like symptoms on day 0 and day 3 and source memory errors using Pearson’s 
coefficient. Non-significant main effects and interactions are not reported.
3.4 Results
3.4.1 Demographics and Drug Use
The two groups did not differ significantly in age, education level (higher- control: 12, 
ketamine i l l ;  further - control:4, ketamine 7; School leavers at 16 - control:4, 
ketamine:2) or pre-morbid IQ as assessed by the ‘Spot the Word’ test (control - 51.75± 
3.86; ketamine -  51.40± 4.50). Groups were matched on lifetime prevalence of drug 
use (Table 3.1) and differed only on years of use for LSD/hallucinogens [F(l,38) = 3.64 
p < 0.01], mean days used per month for amphetamine [U= 107 p < 0.01] and mean 
days of use per month of LSD/hallucinogens [U= 94.5 p < 0.01]. All of the above 
differences were attributable to greater drug use in the ketamine group. Additionally, 2 
controls and 2 volunteers from the ketamine group reported having taken 
benzodiazepines, 1 control reported using y-hydroxybutyrate (GHB) and 2 participants 
from the ketamine group reported use of heroin but all had only tried these drugs once.
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35% of the ketamine group participants reported that they had been using ketamine for 
5 years, 30% for 4 years, 30% for 2 years and the remaining5 % for 3 years. The mean 
number of days per month the ketamine group used the drug was 13.05 (±9.05). The 
mean dose reported was 1.42g (±0.87). None of the control group reported ever taking 
ketamine.
Years of drug use Dose used per 
session/day*
Number of days used 
per month (30 days)
Control Ketamine Control Ketamine Control Ketamine
Alcohol 7.45
(5.09)
7.40
(2.52)
7.05
(3.87)
7.15
(3.59)
19.10
(8.38)
22.80
(6.37)
Cannabis 5.40
(4.66)
5.60
(3.28)
2.80
(1.91)
5.65
(5.02)
23.20
(11.59)
21.35
(11.45)
MDMA 3.55
(2.04)
4.25
(1.74)
2.80
(1.74)
3.40
(1.60)
2.85
(1.60)
3.60
(1.88)
Amphetamine 2.80
(3.21)
3.05
(2.67)
0.64
(0.96)
0.57
(0.41)
1.05
(1.54)
2.75
(2.31)
LSD/
Hallucinogens
1.20
(1.91)
2.93
(2.74)
0.80
(1.01)
1.48
(1.35)
0.60
(1.05)
2.40
(2.54)
Cocaine 2.75
(2.67)
2.15
(2.18)
1.01
(0.97)
0.63
(0.65)
2.35
(2.7)
2.55
(2.72)
*MDMA and LSD were reported per tablet, alcohol per unit, tobacco and cannabis per 
cigarette smoked and cocaine, amphetamines and ketamine per gram.
Table 3.1: Mean (s.d) for drug use in the ketamine and control group : dose, years of 
use and 30 day prevalence.
On day 0 all of the ketamine group and none of the control group reported ketamine 
use. Both groups had also used alcohol (<2 units) and cannabis (<0.28g/ 1 ‘joint’) on
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day 0. There were no group differences in alcohol or cannabis use on day 0. 
Participants did not report any drug use between day 0 and day 3.
3.4.2 Cognitive Tasks
3.4.2.1 Source Memory
A RMANOVA of d' data (discriminability) yielded a highly significant day x group 
interaction [F(ij38) = 9.38 p < 0.004] and a main effect of group [F(i>38) = 8.40 p< 0.006]. 
Post-hoc simple effects analyses showed that the ketamine group had significantly 
lower means than the control group on day 0 [t(3g) = 3.55 p < 0.01], but there was no 
significant difference between the ketamine and control group on day 3 (Figure 3.1a).
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Figure 3.1a: d' values for recognition memory data across day 0 and 3 for ketamine 
users and poly-drug controls; Figure 3.1b: Proportion of correct source judgments 
across day o and day 3 for ketamine users and poly-drug controls
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An RMANOVA conducted on the criterion, C, data (response bias) showed a trend 
towards an interaction between day and group [F^g) = 3.24 p < 0.08], but no main 
effects of day or group. In terms of source memory, as seen in Figure 3.1b, the 
ketamine group were performing above chance (0.5) on both days. However, even 
though they improved on day 3, they were still significantly impaired compared to 
controls. RMANOVA of the proportion of correct source judgements given correct 
item recognition (Ht/Hf) revealed a significant day x group interaction [F(i,38) = 13.15 
p< 0.001] and a significant main effect of day [F^g) = 18.05 p< 0.001]. Post-hoc 
analyses found that the ketamine group produced more source errors both on day 0 [t(3g) 
= 5.96 p < 0.001) and on day 3[t<38>= 3.84 p < 0.001] (Figure 3.1b).
3.4.3 Subjective Ratings
3.4.3.1 Schizotypal symptomatology (Table 3.2): A RMANOVA conducted on the 
mean total scores for the control and ketamine group on the schizophrenic-like 
symptomatology scale revealed a significant day x group interaction [F(138) = 39.80 p< 
0.001]. There was also a highly significant day effect [F(i38) = 42.63 p< 0.001]. The 
ketamine group scored higher than the control group on day 0 as expected but there 
were no differences on day 3.
Day 0 Day 3
Control Ketamine Control Ketamine
Drowsiness (MRS) 36.93(15.18) 54.53 (6.76) 35.42 (14.65) 35.31 (15.42)
Discontentedness(MRS) 32.39(17.37) 34.61 (9.90) 31.25(17.65) 28.14(11.58)
Anxiety (MRS) 34.75 (18.02) 30.98(16.63) 35.48 (20.08) 27.88 (14.59)
SSQ score 13.5(10.64) 27.6 (12.94) 11.4 (8.40) 9.2 (7.46)
DSS score 5.7 (5.40) 21.5 (8.91) 5.0 (5.56) 1.6 (3.02)
Table 3.2: Mean (s.d) scores for subjective effects scales in ketamine ( n=20) and 
control (n=20) groups on day 0 and day 3 of testing
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3.4.3.2 Adapted Dissociative States Scale (Table 3.2): Total ADSS score also showed a 
significant group x day interaction [F(i,38) = 41.36 p< 0.001] and main effect of day 
[F(i,38) = 45.54 p< 0.001]. The ketamine group had similar scores to the control group 
on day 3, but much higher scores on day 0.
3.4.3.3 Visual Analogue scales
MRS: The Mood Rating Scale yields three factors, drowsiness, discontentedness and 
anxiety. RMANOVAs were carried out on each of the mood factors. The factor of 
drowsiness showed a significant group x day interaction (Fi ,38=9.12, p=0.004) and main 
effects of both day (Fi,38=12.49, p=0.001) and group (Fi,38=7.96, p=0.008). Table 3.2 
shows the mean sedation levels rated by each group on both days. A post hoc analysis 
revealed that ketamine users rated higher levels of sedation on day 0 (p<0.001), but 
there was no group difference on day 3. There were no differences between the groups 
on the other mood factors.
Subjective Effects Scale: The data from the Subjective Effects Scale are summarised in 
Table 3.3. Significant differences were found on each of the factors on day 0, except for 
depression and nausea. The ketamine group rated higher symptoms on the other 12 
scales on day 0. There were no group differences on day 3. (See also appendix 1 for p 
values). On day 0, ketamine users rated themselves as liking the drug [mean = 80.5 ± 
16.65]; wanting more of the drug [mean = 62.34 ± 24.32] and feeling the effects of the 
drug [mean = 50.6 ± 34.32]. Liking [ mean = 65.76 ± 28.24] and wanting the drug 
[79.34 ± 29.21] on day 3 did not differ significantly.
3.4.4 Correlations
Schizotypy scores on day 0 were significantly correlated with source memory errors on 
day 0 (r=0.702, p=0.001) and day 3 (r=0.535 p=0.015) but no correlation was found 
between schizotypy scores on day 3 and source memory errors.
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DAYO DAY 3
Control Ketamine Control Ketamine
Dizziness 6.70 (7.48) 41.00(25.25) 6.45 (7.28) 6.35(11.66)
Altered time 
perception
8.10(7.48) 37.40 (25.91) 7.95 (9.46) 7.85 (15.62)
Impaired
concentration
18.80(15.04) 52.45 (21.09) 14.75 (14.36) 10.35 (14.28)
Altered
reality
10.55 (13.32) 43.70 (31.60) 8.25(11.17) 9.15(15.10)
Depression 10.70(12.02) 19.45(17.90) 7.75 (7.72) 11.00(14.64)
Impaired
memory
11.25(16.60) 37.55 (22.92) 8.70(11.90) 9.50(15.66)
Nausea 7.65 (8.44) 19.65 (22.97) 8.85 (9.18) 7.35 (11.63)
Visual
distortion
8.80(10.50) 41.75 (26.96) 8.55 (9.32) 8.90(17.08)
Bodily
numbness
4.55 (4.94) 43.30 (28.02) 3.80 (3.94) 8.30 (14.80)
Unsteadiness 8.35 (10.59) 50.85 (22.93) 6.15(6.88) 9.25 (16.58)
Lack of 
coordination
10.15(13.60) 48.55 (29.56) 9.35(11.31) 8.65 (15.92)
Confusion 9.30 (9.82) 45.10(26.51) 12.25(18.72) 8.70 (20.44)
Distortion of 
sound
2.70 (4.17) 36.80 (23.53) 2.00 (3.32) 10.95(21.53)
Out-of-body
experience
2.55 (3.71) 25.60 (29.09) 3.70 (7.08) 7.85 (13.96)
Table 3.3: Means (s.d.) scores on the bodily symptoms ratings by the ketamine and 
control groups.
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3.5 Discussion
The two major findings of this study were that, on the night of drug use, both source 
and recognition memory were impaired in ketamine abusers, but 3 days after an acute 
dose of ketamine source memory was selectively impaired alongside intact item 
recognition. This extends previous findings of day 3 impairments to prose recall in 
ketamine abusers but indicates that this finding is not a generalised memory deficit but 
rather a specific detriment in recollecting contextual information associated with, and 
necessary for, episodic memory. By using exactly the same source memory task as has 
been used in the laboratory with healthy volunteers (Chapter 2), this allows for some 
degree of, albeit purely descriptive, comparison across the two populations. The 
chronic ketamine users exhibited a similar degree of impairment as observed in healthy 
volunteers given 0.8 mg/kg ketamine (over 80 mins) on day 0, but on day 3 the source 
memory impairment in ketamine abusers resembled that seen in healthy volunteers on 
day 0 following 0.4 mg/kg ketamine. The doses used by ketamine abusers in this study 
were considerably higher than the dose given in the laboratory (0.8 mg/kg ketamine) 
and yet memory impairments were similar on day 0. This may indicate some degree of 
tolerance to the effects of ketamine builds up over repeated drug use.
There are 3 possible explanations for these persisting source memory impairments in
ketamine abusers: residual effects, chronic effects and pre-existing differences in
abusers compared to controls. Residual acute ketamine effects seem unlikely both
because ketamine has a very short half-life (10-12 mins) with a terminal half life of 2-3
hours and because our laboratory study with healthy volunteers on the same source
memory task found no day 3 residual impairments to source or recognition memory
(Morgan & Curran, unpublished observation). Thus chronic effects of repeated
ketamine may be a more plausible interpretation, given previous findings of day 3
impairments in frequent, but not infrequent, users of ketamine (Curran & Monaghan
2001). The participants in the current study were using similar approximate doses to the
frequent users described by the latter authors. At the same time, whilst our
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interpretation of the findings leans towards chronic effects of ketamine, it is impossible 
to rule out the potential of pre-existing differences in ketamine abusers and non-abusers 
without the use of prospective studies. However, the two drug using groups were 
matched on pre-morbid IQ, educational level, use of other memory impairing drugs (i.e. 
alcohol and cannabis) and both groups had similar schizophrenic-like scores and item 
recognition memory on day three. Thus the finding in the ketamine group of a day 3 
source memory impairment seems likely to be attributable to chronic ketamine use.
Source memory impairments as observed in this study may potentially reflect 
neurotoxicity, as was found in rats following repeated doses of ketamine (Olney et al., 
1989). However, neurotoxicity in rats was detected in diverse regions including the 
medial temporal and diencephalic structures, the integrity of which is thought to be 
important for successful recognition memory (Squire, 1994) The apparently selective 
nature of the source memory impairment on day 3 is interesting in light of the 
widespread distribution of NMDA-receptors in the brain and their putative role in 
memory.
Source memory has been demonstrated in neuroimaging studies to engage preffontal
regions (Buckner & Koustall, 1998; Fletcher et al., 1997; Rugg et al., 1999) and to be
disproportionately poor in patients with damage to prefrontal regions (Shimamura &
Squire, 1987; Janowsky et al., 1989). Thus the selective source memory impairment
observed in this study may relate to findings in non-human primates and rats of
persisting deficits on tasks that seem to rely on frontal functions following repeated
NMDA-receptor antagonists (Jentsch et al., 1997b; Jentsch & Roth, 1999). It is possible
that a similar impairment to frontal functioning occurs in human long-term ketamine
abusers, especially in light of previous work demonstrating persistently impaired
fluency in this population, another task thought to have a considerable frontal
component (Curran & Morgan 2000; Curran & Monaghan 2001). The selective source
memory impairment observed here invokes comparisons with other populations, in
particular schizophrenia, where selective source memory impairments are also observed
(Keefe et al., 1999). Indeed there have been suggestions in the literature that repeated
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NMDA-receptor antagonist administration may provide a better model of schizophrenia 
than single dose (Jentsch & Roth 1999). The source memory impairment observed fits 
with this proposal but not the lack of day 3 schizophrenic-like symptomatology. 
However the possibility exists that chronic ketamine use represents a model of the 
chronic stages of schizophrenia where negative and cognitive symptoms dominate.
Acutely, schizophrenic-like and dissociative symptoms resembled those observed in the 
laboratory. No day 3 effects on these scales were observed. The finding of no day 3 
diffferences schizophrenic-like symptoms concurs with some (Curran & Monaghan
2001) but not all (Curran & Morgan 2000) previous work with abusers. Possible 
explanations for the discrepancies in the findings of these three studies may be that the 
participants were using higher doses of ketamine and for a longer period than those in 
the Curran & Morgan (2000) study but a similar dose to that used by frequent ketamine 
abusers in the Curran & Monaghan (2001) study where no schizophrenic-like 
symptomatology was observed. Thus it may be that these heavier ketamine abusers 
have developed psychological tolerance to the psychotomimetic after-effects of the 
drug. In addition individual differences in response to ketamine, which appear to be 
considerable even in healthy humans (Krystal et al. 1994), may account for these 
discrepancies and may possibly linked to genetic differences (Malhotra et al. 1996).
Interestingly, the source memory impairments observed on day 3 and especially on day 
0 were positively correlated with schizophrenic-like symptomatology on day 0 but not 
on day 3. This would seem to indicate that the degree to which the users experience the 
psychotomimetic effects of ketamine on day 0 is related to the degree to which they 
suffer persisting cognitive impairment. Subjective ratings of mood were not correlated 
with source memory, thus these cognitive impairments appear to be specifically related 
to the ability of ketamine to induce schizophrenic-like effects. These correlations may 
suggest that similar underlying processes are mediating the source memory 
impairments and schizophrenic-like symptoms observed in the current study in 
ketamine users. This could add weight to the chronic ketamine model of schizophrenia.
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This study was also subject to several limitations, common to virtually all studies of 
recreational drug users (Curran, 2000). Whilst both groups were well matched on 
demographics and attempts were made to match groups on all aspects of drug use there 
were still differences in monthly consumption of amphetamines and LSD. This 
highlights an issue common to all recreational drug research, that inevitably in a 
population of poly-drug users it is difficult to attribute effects to one particular drug, 
and it is possible that drugs are interacting to produce complex effects. Furthermore, 
due to the naturalistic testing environment, it was not feasible to obtain urine or blood 
samples to verify self-reports of drug use. Despite these issues, however, the main 
difference between the groups in terms of drug use was ketamine use. None of the 
control group reported ever using ketamine, whilst the ketamine group reported using 
the drug frequently and on average once every two days. In addition, neither chronic 
use of amphetamine nor LSD has been reported to affect source memory. In fact, 
chronic amphetamine use has been shown to impair recognition memory (Omstein et 
al., 2000), which was found to be preserved here. Moreover, the difference in days of 
use per month of these drugs between the groups was approximately one day. Further, 
the profile of subjective effects observed on day 0 in the present study (e.g. perceptual 
distortions, out of body experiences, bodily numbness) is largely unique to NMDA- 
antagonists and is in close accord with that observed in the laboratory, suggesting that 
the drug ingested by these drug users was indeed ketamine.
In summary, on day 0 under the influence of ketamine, chronic users displayed source 
and recognition memory impairments and schizophrenic-like, dissociative and 
subjective effects that resembled findings in the laboratory with healthy volunteers. 
However on day 3 the ketamine abusers exhibited no recognition memory impairment 
or schizophrenic-like or dissociative effects but did exhibit a selective impairment to 
memory for source. This may relate to preclinical work indicating that tasks tapping 
frontal function may be selectively impaired following chronic NMDA-receptor 
antagonists. Further work is required to examine the neuroanatomical substrates of 
these impairments and the effects of chronic ketamine on other frontal tasks such as
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response inhibition. These findings have worrying implications for the growing 
population of ketamine abusers.
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Chapter 4 : Semantic priming and ketamine
S e m a n t i c  p r i m i n g  a f t e r  k e t a m i n e  a c u t e l y  i n  h e a l t h y  v o l u n t e e r s  a n d  
f o l lo w in g  c h r o n i c  s e l f - a d m i n i s t r a t i o n  in  s u b s t a n c e  u s e r s
“The limits o f  my language are the limits o f  my mind. All I  know is what I  have words 
fo r”
Ludwig Wittgenstein
4.1 Overview
Ketamine is used acutely as a model of schizophrenia. It has been suggested chronic 
ketamine may also mimic aspects of this disorder, in particular impaired cognitive 
function. As semantic processing deficits are considered central to cognitive 
impairments in schizophrenia, this study aimed to characterize semantic impairments 
following both acute and chronic ketamine. We examined the acute effects of two 
doses of ketamine (Experiment 1) using a double-blind, placebo-controlled, 
independent groups design with 48 volunteers. Ketamine’s chronic effects (Experiment 
2) were explored in 16 ketamine users and 16 poly-drug controls. A semantic priming 
task with a frequency (high and low) and stimulus onset asynchrony (SOA: short- 
200ms, long-750ms) manipulation was used. In Experiment 1, acute ketamine 
produced inverse priming at the long SOA. In Experiment 2, ketamine users showed 
inverse priming for low-frequency words at the long SOA compared to poly-drug 
controls. The inverse priming effect at the long SOA induced by acute ketamine was 
indicative of controlled processing impairments. In ketamine users, there was also a 
suggestion of controlled processing impairments. Decreased priming for low-frequency 
words suggested that long-term ketamine abuse results in damage to the semantic store.
I l l
4.2 Introduction
In the cognitive domain, it has been widely demonstrated that a single dose of ketamine 
administered to healthy volunteers impairs working and episodic memory (Chapter 2; 
Krystal et al., 1994). However, its effects on the semantic memory system remain 
unclear. Most studies have tested the effects of ketamine on semantic memory using 
the category fluency task where impairments have been found in some (Abel et al., 
2003a; Adler et al., 1998) but not all (Ghoneim et al., 1985; Chapter 6) studies.
Nearly all research on the cognitive consequences of ketamine concerns the effects of a 
single dose. This is despite the suggestion that chronic ketamine may provide a better 
model of facets of schizophrenia (Jentsch & Roth, 1999; Phillips & Silverstein, 2003). 
Although, repeated doses of this anaesthetic cannot be given to healthy volunteers, for 
ethical reasons, a naturalistic population is available for studying the chronic effects of 
this drug. As ketamine is increasingly a substance of abuse among young people, users 
who repeatedly self-administer the drug can provide a window on the effects of its 
repeated use.
Two studies have assessed the effect of repeated ketamine use on category fluency. At 
the time of ketamine use, users were impaired in category fluency compared to controls 
(Curran & Morgan, 2000). These impairments were distinct from those observed in 
acute ketamine studies in that they not only reflected a reduction in the number of 
words generated but also represented increased errors (e.g. given the category fruit, one 
user produced ‘lemons, melons, Helen’s....). Whilst less pronounced, impaired fluency 
was still evident when the users were drug-free, 3 days after their ketamine use. A 
subsequent study also showed a similar pattern of impairment, with greater deficits in 
more frequent ketamine users (Curran & Monaghan, 2001).
Whilst the category fluency task used in the above ketamine studies does tap the
semantic memory system, it also requires sustained attention, working memory and
overt retrieval strategies, processes that are impaired by ketamine (e.g. Morgan et al.,
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2004a). Semantic memory deficits are considered to be central to cognitive impairment 
in schizophrenia by many researchers (Rossell et al., 2000). It is therefore important to 
determine the effects of ketamine on semantic memory using a task which loads on this 
system. Thus the focus of the present research is on semantic priming.
Semantic priming refers to the facilitation of responding to a word (e.g. table), when it 
is preceded by a semantically related word (e.g. chair) as compared with an unrelated 
word (e.g. sheep) (Neely, 1977; Meyer & Schvaneveldt, 1971; Fischler, 1977). 
Although semantic priming is more specific to the semantic memory system than other 
tasks, it still involves interactive processes. Initially, presentation of the word stimulus 
is thought to activate a node within the semantic memory network, subsequently 
activation from this node spreads to associated nodes, which facilitates processing of 
these words if they appear as targets. This process is thought to be automatic (Neely, 
2004), i.e. occurring without conscious awareness. Other mechanisms hypothesised to 
be involved later in the processing of a word include expectancy effects and semantic 
matching (Neely & Keefe, 1989). Expectancy is the pre-lexical mechanism whereby a 
set of potential targets is generated from the prime. It is thought that the processing of 
words outside the expectancy-generated set is inhibited, leading to increased reaction 
times (RTs) for unrelated words. Semantic matching refers to the matching post- 
lexically of the primes and targets for semantic similarity. The presence or absence of a 
semantic relationship provides information about the lexical status of a word (Chwilla 
et al., 1998). Both expectancy and semantic matching are thought to be controlled 
processes, requiring conscious effort. Fortunately, it is possible to manipulate semantic 
priming paradigms to investigate these two types of processing. As automatic 
processing occurs early in the processing of a stimulus, using a very short time between 
the presentation of a prime and a target (stimulus onset asynchrony: SOA < 250ms), 
allows investigation of automatic processes. Likewise, at longer SOA’s (<700ms) the 
action of more controlled processes can be explored.
Other parameters may also be manipulated in semantic priming tasks to yield valuable
insights into the nature of semantic memory impairments. In semantic dementia,
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patients who exhibit a progressive degradation of the semantic memory store ‘lose’ 
low-frequency words first (Warrington, 1975; Warrington & Cipolotti, 1996). 
However, certain aphasic patients have impaired access to semantic memory, and find 
low and high frequency words equally difficult to name (Warrington & Shallice, 1979). 
Thus, using high and low frequency words in a semantic priming paradigm could 
theoretically differentiate between impairments in access to, or storage of, semantic 
knowledge (Rossell et al., 2001). No previous research has examined semantic priming 
following either acute or chronic ketamine.
Therefore the aim of the current study was to examine semantic priming following 
acute ketamine administration in healthy volunteers (Experiment 1) and following 
repeated self-administration in recreational ketamine users (Experiment 2). Both short 
(250msec) and long SOA’s (750msec) were used to partially differentiate automatic 
and controlled processes in semantic memory. Previous work has indicated a relative 
preservation of automatic processing following a single dose of ketamine (Chapter 2) 
and in recreational ketamine users (Curran & Morgan, 2000). We were unsure of 
whether this would generalise to semantic processing but speculatively hypothesized 
disrupted priming at the long SOA only, indicative of controlled processing deficits, for 
both Experiments 1 and 2.
This study also used low and high frequency stimuli to differentiate access from 
storage impairments. For Experiment 1 we predicted that any semantic memory 
impairments observed in healthy volunteers following an acute dose of ketamine would 
be due to problems accessing information rather than storage loss, thus they should 
show equivalent priming for both high and low frequency words. Previous research has 
suggested that chronic ketamine use may eventually degrade the semantic store 
(Morgan et al., 2004c) thus in Experiment 2 we tentatively predicted a selective 
impairment of priming for low-frequency words but not high-frequency words.
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Experiment 1 -  Acute effects of ketamine on semantic priming in healthy 
volunteers
4.3 Methods and Materials
4.3.1 Design
An independent groups design was used in which male and female participants were 
randomly allocated to receive an infusion with one of two doses of ketamine or 
placebo. The three groups were balanced for gender with 8 females and 8 males in 
each. Double-blind procedures were used throughout.
4.3.2 Participants
Participants were recruited through an advertisement and were paid for their 
participation. The study was carried out in accordance with the Declaration of Helsinki 
and was approved by the UCL/UCLH ethics committee. All participants gave written, 
witnessed, informed consent on two occasions: at screening and then at the beginning 
of the testing session. Screening of participants followed the same procedures as used 
in a previous study (Morgan et al., 2004a). Participants underwent a semi-structured 
interview to investigate psychiatric history and drug use was verified by urinalysis. 
Inclusion criteria were that participants were between 18 and 35 years old and native 
English speakers. Exclusion criteria were current, past or a family history of psychiatric 
disorders; substance misuse; and general health problems. 48 participants completed the 
study [mean age placebo: 24.33±4.30; low-dose 23.75±3.79; high-dose 24.31±4.54], 1 
participant dropped out of the study during infusion of high-dose ketamine.
4.3.3 Drug Administration
A 16-gauge intravenous cannula was inserted in the non-dominant forearm. Ketamine 
infusion was via a Graseby intravenous infusion pump controlled by the Stanpump 
program (Schafer et al. 1990). The program uses a “BET” (bolus-elimination-transfer) 
infusion scheme that aims to achieve the target plasma concentration almost 
instantaneously by taking into account ketamine pharmacokinetics using a three
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compartment model (Domino et al., 1984). Participants received either ketamine (low- 
dose or high-dose) or placebo (0.9% NaCl solution). A peripheral venous blood sample 
was taken 50 minutes after commencing the infusion. The blood sample demonstrated 
that target concentrations (originally lOOng/ml, 200ng/ml) were exceeded (mean 
plasma concentrations: low-dose: 113.4±56.7ng/ml and high-dose: 236.7±65.3ng/ml).
4.3.4 Procedure
Testing began at either 9am or 1 pm and the time of testing was matched across groups. 
Participants arrived at the hospital after completing an overnight fast for morning 
testing, or a minimum of six hours fasting for afternoon testing. They were assessed on 
the pre-drug battery for 20 minutes, then allowed to rest for 15 minutes and then were 
cannulated. Approximately 5 minutes after cannulation, the anaesthetist began the 
infusion. Participants were tested on the main battery of tests, including semantic 
priming, beginning 15 minutes after the start of infusion. Throughout the 60-minute 
infusion each participant’s pulse, blood pressure and electrocardiagram were 
monitored. After infusion participants were provided with light refreshments and were 
assessed 30 minutes later and then at hourly intervals by the medical staff as to their 
‘street readiness’ and were discharged approximately 2 hours following infusion. 
Participants were given the telephone number of a clinical psychologist and an 
anaesthetist in case of adverse after effects; none were reported.
4.3.5 Assessments 
Semantic Priming
The stimuli were 360 concrete nouns and 120 pseudo-words. These were arranged in 
three conditions: related (e.g. bed-wardrobe: 60 word pairs), unrelated (e.g. bed- 
parsnip: 60 word pairs) and pseudo (e.g. bed-fips: 120 word pairs). Participants were 
presented with a prime word for 200ms, then, following an interval, were presented 
with the target word for 200ms (Figure 1). Participants could respond for 2000ms after 
the target was presented and between each trial (i.e. prime-target word pair) there was a 
blank screen for 2500ms. Half of the concrete nouns used were of a low frequency (1-
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30 words per million) and half were high frequency (>30 words per million). These 
were arranged in prime-target pairs of the same frequency. The task was run with two 
different SOAs (time between the onset of a prime and a target): short SOA (250ms) 
and long SOA (750ms). The order of the trials were randomised, with the constraint 
that any given trial type could not occur more than three times consecutively. All 
stimuli were presented in the centre of a computer screen using DMDX 
(http://www.u.arizona.edu/~iforster/dmdx/official.htm) software. Subjects were asked 
to indicate whether the target was real or a pseudo-word a two-button press. Subjects 
were told to respond as quickly and as accurately as they could. RTs and accuracy were 
recorded automatically. Two matched versions were used, which were counterbalanced 
across gender and drug treatment group.
Prime
SOA
Target
bookbam fish
coatshed smat
RELATED UNRELATED PSEUDO
Figure 4.1 Schematic of design of semantic priming task 
Subjective Effects
Participants completed the subjective effects questionnaires both pre drug (-lOmins) 
and post drug (+ 40mins).
Adapted Dissociative States Scale (ADSS): This questionnaire was the subjectively 
rated items of the Clinician Administered Dissociative States Scale (Bremner et al. 
1998) and assessed dissociation.
Schizotypal Symptomatology Questionnaire (SSQ: Curran & Morgan, 2000):
The 26-item self-rated questionnaire was employed to assess state schizotypal 
symptomatology.
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4.3.6 Statistical Analyses
Semantic priming was initially analysed with a 3x2x2x2 RMANOVA with one 
between-subjects factor: Drug (high-dose ketamine, low-dose ketamine and placebo) 
and three within subjects factors: Frequency (high and low), Relatedness (related, 
unrelated), and SOA (short and long) using either mean RTs or mean % error data. 
When significant interactions emerged the level of priming effect was computed 
(unrelated - related) and used in subsequent analysis. Subjects making more than 20% 
errors were excluded however none met these criteria so all were included. In addition, 
RTs more than 2.5 s.d’s from the overall mean for each subject were excluded, and RTs 
faster than 250msecs and slower than 1500msecs were discarded. A priori planned 
linear contrasts were conducted, to test for linear trends across placebo, low-dose and 
high-dose. Post-hoc Scheffe’s tests were conducted on the subjective effects data, the 
significance level was Bonferroni corrected to account for multiple comparisons (a  = 
0.0167). Non-significant main effects and interactions are not reported.
4.4 Results
4.4.1 Trait Scores, Demographics and Drug dosage
There were no significant group differences in age, premorbid I.Q. (spot the word), trait 
depression, trait anxiety, alcohol use, tobacco use, or trait dissociation (See Table 4.1).
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Placebo 100 ng/ml ketamine 200ng/ml ketamine
Age, years 24.33 (4.30) 23.75 (3.79) 24.31 (4.54)
Years in education 17.93(1.91) 17.06 (2.14) 17.80(2.11)
Spot the word, no. words 51.46(4.74) 51.83 (4.00) 50.53 (4.05)
BDI score 3.77 (5.39) 3.20 (3.80) 4.36 (5.35)
STAI score 13.46(11.89) 17.30 (8.90) 17.50 (8.99)
DES score 23.00(18.25) 20.30(15.96) 23.90(15.26)
Smokers, no. per group 5 8 7
Alcohol, units per week 12.20 (8.21) 14.44 (8.88) 16.07(14.06)
[Abbreviations - BDI : Beck Depression Inventory; STAI : Speilberger Trait Anxiety 
Inventory; DES: Dissociative Experiences Scale]
Table 4.1: Demographic and background variables across treatment condition in 
Experiment 1
4.4.2 Semantic Priming Data 
Reaction Time Data
Mean RTs for the 3 groups in each condition are shown in Table 2. There were two 3- 
way interactions: a Drug x Frequency x SOA interaction [F(2,45)= 8.05 p<0.001] and a 
Drug x Relatedness x SOA interaction [F(2>45) = 3.31 p<0.045]. There was a 2-way 
Relatedness x SOA interaction [F(2,45) = 24.09 p<0.001] and a main effect of 
Relatedness [ F(i, 45) = 4.82 p<0.033], with related pairs responded to faster (mean = 
685.16 ± 121.66) than unrelated pairs (mean = 701.80 ± 120.37) There was also a main 
effect of Frequency [F(i, 46) = 13.77 p<0.001], with faster reaction times for high- 
frequency (mean = 680.22 ± 121.73) than low-frequency (706.74 ± 116.05) words. 
There was also a trend for a main effect of Drug (p= 0.093; Group means - 200ng/ml 
ketamine: 748.37±118.28; lOOng/ml ketamine: 670.67±111.12; placebo:
666.26±114.54).
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RT Placebo lOOng/ml
ketamine
200ng/ml
ketamine
Polydrug
Controls
Ketamine
Users
Short
SOA
High
Related
646.7(115) 644.2 (132) 718(177) 659.4(126) 621.3 (89)
High
Unrelated
667.4(105) 673.1 (100) 735.8 (132) 683.7 (122) 660.0 (89)
Low
Related
644.6 (94) 652.4(109) 734.7(123) 660.7 (120) 642.6 (95)
Low
Unrelated
702.2(153) 685.4(113) 806.5 (153) 707.5 (131) 688.8 (91)
Long
SOA
High
Related
627.9(107) 668.6 (86) 759.7(158) 685.1 (115) 614.3 (79)
High
Unrelated
642.5 (120) 674.0 (93) 734.8(123) 678.7(114) 637.3 (77)
Low
Related
685.6(123) 697.5 (107) 761.7(118) 708.6 (139) 693.2 (92)
Low
Unrelated
713.3(138) 680.4 (93) 736.0(109) 745.8(136) 662.2(85)
Abbreviations RT= reaction time, SOA = stimulus onset asynchrony 
Table 4.2: Mean (SD) semantic priming RT’s (in msecs) across SOA, frequency and 
relatedness (with associated priming effects) across participants in both Experiment 1 
and Experiment 2
To explain the Drug x SOA x Relatedness interaction, we performed oneway ANOVAs 
using priming effects with the short SOA data; there were no group differences. There 
was a significant difference, however, at the long SOA [F(2?45) = 4.41 p=0.018]. As can 
be seen from Figure 4.2, this reflects a ketamine effect with greatest priming effect in 
the placebo group, and lowest in the high-dose ketamine group. This effect was
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confirmed by a significant linear trend across the 3 groups after the appropriate contrast 
[t(45)= 2.41, p<0.02].
To further investigate the above interaction the raw RTs for related targets and 
unrelated targets were analysed, we did not find a significant Drug x SOA interaction in 
either analysis.
Figure 4.2: Priming (unrelated RT -  related RT) scores across the 3 drug groups in 
Experiment 1 (placebo, lOOng/ml ketamine, 200ng/ml ketamine) and stimulus onset 
asynchrony (SOA: long and short).
Error data
Accuracy data for the 3 groups in each condition are shown in Table 3. There were no 
significant effects of Drug or group wise interactions showing that the groups are well 
matched in terms of accuracy
80 -
60
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a
1 20 □  Short SOA 
H  Long SOAT ■
-40 -
-60 J
placebo low dose 
ketamine
high dose 
ketamine
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RT Placebo lOOng/ml
ketamine
200ng/ml
ketamine
Polydrug
Controls
Ketamine
Users
Short
SOA
High
Related
0.96 (2.6) 3.59 (8.2) 2.15(3.7) 2.41(4.64) 1.93 (5.96)
Low
Related
4.68 (5.9) 5.09 (5.6) 3.20 (5.1) 6.01 (6.09) 5.44 (9.19)
High
Unrelated
3.37 (4.3) 6.77 (6.4) 2.23 (4.1) 2.15(4.20) 5.00 (6.66)
Low
Unrelated
5.13(7.1) 5.14(6.3) 6.41 (7.1) 6.88 (7.82) 6.21 (9.40)
Long
SOA
High
Related
2.78 (3.7) 2.45 (5.4) 2.45 (4.6) 1.85 (3.31) 4.13 (7.87)
High
Unrelated
1.38(2.5) 1.18(2.5) 1.34 (2.77) 0.44(1.78) 2.92 (8.42)
Low
Related
2.53 (4.2) 4.03 (6.1) 2.70 (5.55) 0.44(1.78) 2.92 (8.42)
Low
Unrelated
2.57 (4.3) 3.19(4.5) 2.23(4.11) 0.52 (2.08) 3.18
(10.52)
Abbreviations RT= reaction time, SOA = stimulus onset asynchrony
Table 4.3: Mean (SD) semantic priming error data (in number of errors) across SOA,
frequency and relatedness for Experiment 1 and Experiment 2.
4.4.3 Subjective Effects
4.4.3.1 SSQ
Schizotypal scores demonstrated a significant Drug x Time interaction [F(2, 45) = 4.03 
p<0.025]. Scheffe’s test on change scores pre/ post demonstrated significantly higher 
schizotypal symptomatology scores between high-dose and placebo (p<0.028) [means
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for change scores were (post - pre) : placebo —1.93±6.92; low-dose 1.67±6.95; high- 
dose 8.67±15.07].
4.4.3.2ADDS
Dissociation scores showed a significant Drug x Time interaction [F(2, 51) = 7.12 
p<0.002] and significant main effects of both Drug [F(2, 45) = 4.02 p<0.026] and Time 
[F(i 45) = 37.81 p<0.001] . Scheffe’s test on change scores (post -  pre) revealed 
significant higher dissociation scores in low-dose (p<0.01) and high-dose (p<0.006) 
ketamine group than placebo [mean change scores (post - pre) were placebo 1.07±3.30; 
low-dose 13.4± 11.04; high-dose 14.43±12.92)].
4.4.4 Correlations
There were no significant correlations between subjectively rated schizotypal or 
dissociative symptoms and priming effects.
Experiment 2 -  Semantic priming in recreational ketamine users
4.5 Methods and Materials
4.5.1 Participants and Design
32 participants completed the study: 17 males and 15 females. As ketamine users are a 
population of ‘poly-drug’ users; the comparison group were poly-drug controls 
matched for other psychotropic drug use except ketamine. The age range was 19-45 
years [polydrug controls: 21.50±3.20; ketamine group: 23.19±6.31]. Participants were 
recruited via volunteer databases, the internet and by snowball sampling (Solowij, Hall, 
and Lee, 1992). The ketamine group consisted of 16 participants who regularly took 
ketamine (a minimum of twice a month; 7 females). The control group consisted of 16 
ketamine naive participants who were broadly matched with ketamine users on 
recreational drug use apart from ketamine (8 females).
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4.5.2 Procedure
All participants who met the relevant drug criteria provided written, witnessed, 
informed consent. An identical battery to that employed in Experiment 1 was used. 
Additionally, a general drug history was taken from the participant, detailing their 
current and past drug use. Participants were asked to give a urine sample to test for 
recent drug use (cannabis, MDMA, cocaine, opiates, ketamine and benzodiazepines).
4.5.3 Statistical Analysis
Statistical analyses were similar to those used in Experiment 1, except correlations were 
conducted between drug use and priming effects with the a  levels raised to 0.01 to 
reduce type I errors.
4.6 Results
4.6.1 Demographics and Drug Use
There were no significant differences in age, gender or pre-morbid IQ [spot the word 
score- controls: 49.25±5.16; ketamine: 50.75±4.70]. Drug use data are presented in 
Table 4.4.There were no significant group differences in the use of cannabis, ecstasy or 
alcohol. The ketamine users had last used the drug a mean of 14.12±10.57 days ago, 
with a minimum last use of 3 days ago. Urine screens were all positive for cannabis but 
no other drugs of abuse. Other self-reported occasional drug use included cocaine (13 
ketamine / 9 controls), amphetamines (10 /2), benzodiazepines(2/l), LSD/ mushrooms 
(10/3), and amyl nitrate (4 / 0).
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Ketamine Polydrug
Controls
Ketamine Days Per Month 4.44 (2.5) 0.00 (0.00)
Years Used 2.02 (0.87) 0.00 (0.00)
Amount Used Per Session (grams) 0.8 (0.57) 0.00 (0.00)
Cannabis Days Per Month 9.31 (11.35) 11.00 (9.59)
Years Used 4.69 (3.96) 5.25 (3.87)
Amount Used Per Session (number of joints) 1.47(1.38) 1.88(1.10)
Ecstasy Days Per Month 3.18(3.47) 2.80 (4.78)
Years Used 3.94 (3.03) 3.36 (3.07)
Amount Used Per Session (tablets) 3.25 (2.29) 3.38 (4.66)
Alcohol Days Per Month 13.69 (18.00) 14.94 (8.50)
Years Used 8.88 (5.84) 6.38 (2.70)
Amount Used Per Session (units) 6.00 (4.41) 7.00 (4.24)
Table 4.4: Mean (s.d.) of ketamine, cannabis, ecstasy and alcohol used by participants 
in the ketamine and control groups in Experiment 2.
4.6.2 Semantic Priming Task 
Reaction Time Data
A 2x2x2x2 repeated measures ANOVA with Group (polydrug controls and ketamine), 
Frequency (high and low), SOAs (short and long), and Relatedness (related and 
unrelated pairs) was conducted using the reaction time data. These data are presented in 
Table 2. There was a 4-way Group x Relatedness x Frequency x SO A interaction 
[F(2,30) = 5.429, p = 0.027], a 3-way Group x Relatedness x Frequency interaction [F^o) 
= 4.745, p = 0.037], and a 2-way Relatedness x SOA interaction [F(i>30) = 8.17, p = 
0.008]. There was a main effect of Relatedness [F(i>30) = 30.99, p <0.001], whereby all 
participants were faster to respond to related (mean = 660.61 ± 97.64) than unrelated 
(mean = 682.97± 99.19) words, and a main effect of Frequency [F^o) = 30.99, p
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<0.001] where reaction times were quicker for high (654.92± 95.43) than low (688.67± 
100.92) frequency words. There were no main effects of SOA or Group.
Priming effects (unrelated -  related RT) were calculated and analysed. There was a 3- 
way interaction of Group x SOA x Frequency [ F(i; 30) = 5.43 p<0.027]; a 2-way Group 
x Frequency interaction [ F(i, 30) = 4.75 p<0.037] with greater priming effects in the 
ketamine group for high-frequency words compared to the poly-drug controls where the 
inverse pattern was evident (mean high-frequency - ketamine: 27.01±12.05, polydrug 
control: 9.09±12.42; low-frequency -  ketamine: 14.27±11.38, poly-drug controls: 
42.00±15.37); and a main effect of frequency [F(i>30) = 8.17 p<0.008]. The 3-way 
interaction is depicted in Figure 3. Post-hoc multiple comparisons (oneway ANOVAs) 
revealed significant differences between the groups only for low-frequency words at a 
long SOA [F(l,30) =6.711 p<0.015], where the ketamine group exhibited significantly 
less priming than the poly-drug controls.
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Figure 4.3: Priming (unrelated RT - related RT) scores across SOA and frequency in 
ketamine users and poly-drug controls in Experiment 2.
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Error Data
The error data is displayed in Table 4.3. There was no main effect of group or group- 
wise interactions, thus establishing accuracy was well-matched across the groups.
4.6.3 Subjective Ratings
There were no significant group differences on any of the subjective measures of 
schizotypal and dissociative symptoms. (See Table 4.5)
4.6.4 Correlations
There was a trend, after Bonferroni correction, for a significant correlation in the 
ketamine group between days per month of ketamine use and the high-frequency/short 
SOA priming effect (r=0.511, p=0.043).
Ketamine Polydrug Controls
ADSS 8.20(10.54) 6.81 (6.50)
PDI 35.13(4.75) 34.50 (4.75)
SSQ 16.87 (9.90) 15.1 (11.25)
MRS: Sedation 51.00(12.30) 49.78(10.48)
MRS: Discontentedness 36.04(16.41) 23.71 (26.24)
MRS: Anxiety 33.53 (14.20) 32.20(15/47)
Cognitive symptoms 45.50 (61.51) 55.38 (67.06)
Perceptual symptoms 44.69 (58.23) 47.43 (63.63)
Somatic symptoms 71.25 (50.53) 52.78 (59.44)
Table 4.5: Mean (SD) Subjective Effects in the ketamine and polydrug control groups. 
4.7 Discussion
The current study set out to examine semantic priming following both acute and 
chronic ketamine. In Experiment 1, acute ketamine produced dose-dependent ‘inverse 
priming’, i.e. a suggestion of faster RTs to unrelated than related words, at the long but 
not the short SOA. Ketamine also produced increases in subjectively rated
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schizophrenic and dissociative symptoms. In Experiment 2, the ketamine users also 
showed ‘inverse priming’ at the long SOA and not the short, but this time more 
specifically for low and not high frequency words. There were no other differences in 
priming between the groups. The groups did not differ in their drug use apart from 
ketamine and they were also well-matched on demographic variables and premorbid 
IQ. There was no evidence of any group differences in schizotypal, subjective or 
dissociative symptoms.
4.7.1 Acute ketamine
The key finding from Experiment 1 was that acute administration of ketamine produces 
a dose-dependent impairment of semantic priming at a long SOA. This was in 
accordance with our hypotheses and is, to our knowledge, the first study that has found 
a selective inverse priming effect at a long SOA with any group of subjects.
As discussed in the introduction three processes may be involved in semantic priming: 
automatic spreading of activation, expectancy and semantic matching. The only one of 
these processes to occur post-lexically is semantic matching i.e. matching primes and 
targets for semantic similarity. In terms of this data, ketamine may result in the 
semantic relationship between words being processed abnormally, resulting in slower 
RTs to related words than when semantic matching is intact. The disruption of 
controlled processing, i.e. semantic matching by ketamine is consistent with our 
original hypothesis. Previous research suggests that automatic processes are relatively 
preserved following acute administration of the drug (Chapter 2; Morgan et al., 2004a). 
Further work is necessary to tease apart the exact mechanisms involved in this 
impairment e.g. varying the strength of semantic association between word pairs to 
examine the role of semantic matching.
The reduction in priming observed here is somewhat similar to that seen in 
Alzheimer’s disease (Giffard et al., 2002) following extensive damage to the semantic 
network. It would appear the administration of ketamine, potentially via its action at the
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NMDA-receptor, acts as a massive insult to the semantic system. Ketamine may disrupt 
strategic semantic processing and this disruption is manifested as an inverse priming 
effect. The dose-related nature of the inverse priming effect at a long SOA, indicates a 
relationship between glutamatergic activity at the NMDA-receptor and the priming 
occurring at this time interval.
The N400 evoked related potential component is thought to reflect integration of 
stimulus meaning into an unfolding context (Kutas & Federmeier, 2000). This negative 
ERP component is normally attentuated in semantic priming paradigms but the 
attentuation of the N400 is reduced in cases of abnormal priming, e.g. with 
schizophrenics, whilst performing the task (Condray et al., 2003) and is also reduced 
after an acute dose of ketamine (Grunwald et al., 1999). This suggests that the 
ketamine-induced inverse priming observed in Experiment 1 may be the result of a 
deficit in online contextual processing of semantic information. NMDA-receptors have 
been proposed, via cognitive co-ordination, to play a role in contextual processing 
(Phillips and Silverstein, 2003). As semantic associations are probably dependent on 
contextual interactions (Kay et al., 1998) then disruption to NMDA-receptor activity 
could result in an inability to process contextual relationships between stimuli. One 
could speculate that a deficit in contextual processing would in turn lead to impaired 
semantic matching.
It is important to note that neither analysis of raw RTs for the unrelated and related 
words alone found an interaction of ketamine with SOA. Therefore it may be not only 
to decreased priming for related words but also facilitation of processing of unrelated 
words at the long SOA that are contributing to the interaction. Whilst the data from this 
study cannot speak to this issue, this topic is worthy of further investigation.
As predicted, an acute dose of ketamine did not differentially effect priming for high
and low frequency words. Based on the aphasia literature (Warrington, 1975), the lack
of frequency effects on semantic priming following acute ketamine suggest that the
inverse priming finding reported earlier is the result of problems accessing semantic
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knowledge and not problems with storage of semantic information, as one would expect 
following the acute administration of a drug.
The ketamine-induced impairment in semantic priming also suggests that the reduction 
in words generated on category fluency tasks observed in previous ketamine challenge 
studies are, in part, as a result of semantic memory deficits and not simply a by-product 
of impairments to other cognitive systems. These deficits may also contribute to 
ketamine-induced concreteness in proverb interpretation (e.g. Krystal et al., 1994). 
Given the lack of impairment at the short SOA, another potential explanation of these 
findings and the reduced number of words generated on the category fluency task could 
be an impairment in the efficiency of general semantic retrieval processes, which would 
be consistent with the lack of errors on this task. It may be that retrieval of one word 
serves to inhibit the retrieval of others. Studies using competition priming following an 
acute dose of ketamine may help to elucidate this point.
Limitations of Experiment 1 were that, despite the absence of a main effect of group 
overall, there were longer RTs in the group administered the higher dose of ketamine. 
These likely reflect the global sedative properties of this drug. Future studies might 
consider use of a sedative active placebo with minimal cognitive effects such as 
diphenhydramine. In Experiment 1 higher plasma levels of ketamine were achieved 
than targeted. However, variations in the plasma levels of ketamine achieved with this 
program have been found previously (e.g. Hetem et al., 2000) and may reflect 
inevitable individual differences in drug metabolism.
4.7.2 Chronic Ketamine
The main priming differences between ketamine users and poly-drug controls were of 
inverse priming selectively for low-frequency words at the long SOA. This probably 
reflects the combination of two processes. Firstly, inverse priming at the long SOA 
suggests an impairment in controlled processes as anticipated, and the probable reasons
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for this have been discussed above. This was similar, yet not as profound, as that 
observed in Experiment 1.
Secondly, the impairment of priming for low-frequency words may signify degradation 
of the semantic store, as has been shown in the neuropsychological literature 
(Warrington & Shallice, 1979). Frequency differences may only be evident at a long 
SOA as they are not as marked as those seen in patients with semantic dementia. This is 
also further indication that automatic processing is relatively preserved. However, it 
maybe that heavier ketamine users would also show inverse priming at the short SOA. 
The findings of inverse priming for low-frequency words at a long SOA therefore 
concur with our hypothesis that chronic ketamine causes a degradation of the semantic 
store and accord with the findings on fluency reported in Chapter 5.
A limitation of Experiment 2 was in that in order to isolate ketamine effects in a poly­
drug using population, it was necessary to compare ketamine users with poly-drug 
controls. The poly-drug control groups exhibited lower priming for high-frequency 
words at the long SOA than the placebo controls in Experiment 1. These differences in 
priming for high-frequency words at the long SOA may be a function of the poly-drug 
control group’s use of other drugs, including ecstasy and cannabis. Previous work has 
examined the effect of pharmacological manipulations on semantic priming, using 
dopaminergic (L-dopa -  Kishka et al., 1996; d-methampethamine -  Gouzoulis- 
Mayfrank et al., 1998) and serotonergic (Gouzoulis-Mayfrank et al., 1998b; Spitzer et 
al., 1996) manipulations but these studies have failed to find effects on direct priming 
as examined in this study. However these studies did find effects on an indirect priming 
task, where instead of using directly related semantic pairs (e.g. lemon-sour), mediated 
semantic pairs are presented (e.g. lemon - sweet) which do not display the mediator (i.e. 
sour). Future work could also examine the effect of ketamine on both direct and indirect 
priming, as indirect semantic priming has been found, in some studies, to be a better 
indicator of impaired performance in schizophrenia (Moritz et al., 2001). Another 
inevitable limitation of recreational drug user research is that it is impossible to rule out
pre-existing differences between the ketamine users and poly-drug controls without the
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use of prospective studies. Therefore it may not be ketamine per se, that is accounting 
for these findings but underlying variation which pre-disposes people to ketamine 
abuse. Recent research has demonstrated that healthy individuals with a family history 
of alcohol abuse have a blunted response to ketamine (Petrakis et al., 2004). We did not 
take family histories from drug users in this study or examine genetic data but these 
issues should be addressed in future research.
Our findings add to the existing literature that suggests that repeated ketamine use 
produces chronic effects on semantic memory. It extends our original findings of a 
deficit in category fluency when ketamine users were drug free (3 days after use of 
ketamine), to suggest a longer term deficit that could be reflect a degradation of the 
semantic store. It would be interesting to investigate whether this degradation is 
reversible. Recent work has suggested that category fluency impairments are reduced 
when users substantially reduce their ketamine use (Chapter 5) but this could be a result 
of subtle changes in executive function or attention.
The acute administration of ketamine produced schizophrenia-like and dissociative 
symptoms. Although ketamine users did not differ from the poly-drug control group on 
schizophrenia-like symptoms, both groups scored similarly to healthy volunteers 
following the highest dose of ketamine given in Experiment 1. However, as the scale 
used to examine schizophrenia-like symptoms was adapted from a schizotypal trait 
scale, these scores may reflect the elevated schizotypy scores noted in drug users 
(Morizot & Le Blanc, 2003).
The differences between priming following a single dose of ketamine in drug-naive
volunteers and repeated doses of ketamine in recreational users have worrying
implications for the growing population of ketamine users, in that they imply some
degradation of the semantic memory store. In this respect, compared to healthy
volunteers given acute dose of ketamine, ketamine users show a pattern of priming
more similar to that observed in schizophrenics, where a degradation of the store has
also been suggested (Rossell et al., 2000; 2004). However, it is not clear whether this
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semantic degeneration is progressive with the course of the illness as there has been 
little work examining priming in first episode, unmedicated patients or in longitudinal 
studies. Therefore it could be that acute ketamine may better model aspects of the more 
acute phases of schizophrenia.
Accuracy in both Experiment 1 and Experiment 2 was generally good, which is a 
reflection of the subtlety of the semantic impairments we have observed. In addition, 
ketamine users did not have longer RTs overall. This suggests that repeated ketamine 
use has an impact on semantic organisation independent of psychomotor speed which is 
an important dissociation that is not present in schizophrenia or following acute 
ketamine, further highlighting the importance of using chronic ketamine ‘modelling’ to 
disentangle specific cognitive processes at work in schizophrenia.
In summary, this study found reduced priming at the long SOA following both acute 
and ‘chronic’ ketamine. This is indicative of strategic processing deficits and may 
possibly be mediated by NMDA-R effects on cognitive co-ordination. There was also 
inverse-priming for low-frequency words at the long SOA in the ketamine users 
compared to poly-drug controls. These two findings potentially indicate a gradual 
degradation of the semantic store. In conclusion, acute and chronic ketamine have 
differential, and yet in both cases detrimental, effects on semantic priming.
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Chapter 5: Beyond the K-hole
A  3  y e a r  l o n g i t u d i n a l  i n v e s t i g a t io n  o f  t h e  c o g n i t iv e  a n d  s u b je c t iv e  
e f f e c t s  o f  k e t a m in e ,  in  r e c r e a t i o n a l  u s e r s  w h o  h a v e  s u b s t a n t i a l l y  
r e d u c e d  t h e i r  u s e  o f  t h e  d r u g
Question (CJAM): “What do you think are the negative long-term effects of ketamine 
use?”
Answer (Participant 10) “Well... that you end up locked inside your own head, beating 
your brain with a fish.”
5.1 Overview
Ketamine is a dissociative anaesthetic that is also a drug of abuse. Previous studies have 
demonstrated persisting episodic and semantic memory impairments in recreational 
ketamine users 3 days after taking ketamine. However, it was not known the degree to 
which these deficits might be reversible upon reduction or cessation of ketamine use. 
This study set out to follow-up a population of ketamine users tested 3 years previously 
and examine whether impairments observed 3 days after drug use are enduring or 
reversible. 18 ketamine users and 10 poly-drug controls from studies conducted 
between 3 and 4 years earlier were re-tested on the same battery of cognitive tasks and 
subjective measures. These tapped episodic, semantic and working memory and 
executive and attentional functioning. Subjective schizotypal, dissociative, mood and 
bodily symptoms were also examined and a drug use history recorded. Results: The 
ketamine users had reduced their frequency of use of ketamine by an average of 88.3%. 
Performance of ketamine users on tasks tapping semantic memory had improved and 
this improvement was correlated with their reduction in ketamine use. On tasks tapping 
episodic memory and attentional functioning, ketamine users still showed deficits 
compared to poly-drug controls. Higher levels of schizotypal symptoms and perceptual
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distortions were exhibited by the ketamine group although dissociative symptoms were 
similar to controls. These findings indicate that semantic memory impairments 
associated with recreational ketamine are reversible upon marked reduction of use, 
however impairments to episodic memory and possibly attentional functioning appear 
long-lasting. In addition, schizotypal symptoms and perceptual distortions may persist 
after cessation of ketamine use. Ketamine users, or potential users, should be aware of 
the enduring effects of this drug on aspects of memory and subjective experience.
135
5.2 Introduction
Ketamine is controlled under the Medicine’s Act (1984) in the U.K. and other European 
Countries, whereas it is a scheduled drug in the U.S.. Estimates of prevalence of 
ketamine use are scant, however, in a survey of club-goers in the U.K., 10% stated that 
they took ketamine on a regular basis (Mixmag, 2002). In the U.S., emergency room 
visits associated with ketamine use have risen 2 000% between 1995 and 2002 
(DAWN, 2003). Ketamine users report feelings of dissociation, hallucinations and out- 
of body experiences as the effects that draw them to use of the drug (Siegel, 1978). 
Indeed, the reinforcing effects of acute ketamine have recently been demonstrated in a 
controlled laboratory study of healthy volunteers. We (Chapter 6; Morgan et al., 2004b) 
found that non-drug abusers liked the effects of the drug and desired more of it, 
especially at low doses.
As discussed in Chapter 1, ketamine has long been acknowledged to be a
psychotomimetic drug (Domino, Chodoff, and Corssen, 1965) and as such has been
extensively investigated in the laboratory (Krystal et al., 1994; Chapter 2; 6; Morgan et
al 2004a; 2004b; Newcomer et al. 1999). The psychotomimetic properties of ketamine
have lead to the development of the NMDA-hypofimction model of schizophrenia
(Olney et al., 1999), which may have implications for psychopharmacological
treatments for this disorder. However, there have been some suggestions that the acute
effects of NMDA-antagonism may not be as appropriate a model of schizophrenia as
the chronic effects (Jentsch & Roth, 1999). This assertion has been supported largely by
animal work (Jenstch et al. 2000) but is also implied in the human phencyclidine (PCP)
literature. PCP is a non-competitive NMDA-antagonist similar to ketamine but with a
ten-fold greater affinity for this receptor (Rainey & Crowder, 1974). There was a high
incidence of PCP abuse, especially in the United States, in the 1970’s and 1980’s.
Anecdotally, there were many reports of protracted PCP psychosis following chronic
use lasting several days (Ellison, 1995). Whilst it is difficult to estimate the proportion
of PCP users who developed psychosis from clinical reports, one study examined 1 000
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patients presenting in emergency rooms with PCP intoxication. Twenty-five percent of 
this sample developed psychotic or catatonic reactions persisting for longer than the 
duration of acute drug effects (Allen & Young, 1978).
Despite the potential of chronic ketamine administration to induce a state resembling 
aspects of schizophrenia, there has been little research examining the consequences of 
its repeated use in the burgeoning population of users. Three studies have examined the 
effects of ketamine on the night of drug use and then 3 days later when drug free 
(Curran & Morgan, 2000; Curran & Monaghan, 2001; Chapter 3; Morgan et al., 
2004d). The effects on the night of drug use, in all 3 studies, were similar to those 
observed following an acute dose in the laboratory with healthy volunteers. But it was 
also found that, when compared to poly-drug using controls, three days after drug use 
ketamine users were still impaired on tasks tapping episodic and semantic memory 
(Curran & Morgan, 2000). In addition, they scored more highly on scale assessing 
schizotypal and dissociative symptoms. Using a ‘source’ memory task, in Chapter 3 we 
reported findings that replicate the day 3 episodic memory impairments. We also 
revealed these deficits to be selective, in that ketamine users could say whether they 
had seen a word previously (correct item recognition) but could not remember the 
context in which it had been presented (impaired source memory). This is a similar 
pattern of episodic memory impairment to that observed in schizophrenia (Danion, 
Rizzo, and Bruant, 1999) but intriguingly this is not observed following an acute dose 
of ketamine in the laboratory (Chapter 6). Curran & Monaghan (2001) compared 
frequent and infrequent ketamine users on day 3. They found greater impairments on 
episodic and semantic memory tasks in frequent ketamine users compared to infrequent 
users three days after taking the drug.
These day 3 effects can be interpreted in three ways (Curran & Morgan, 2000). Firstly,
it is possible that these were residual effects of ketamine use. However, this
interpretation is not sufficient to account for the data for several reasons. Firstly,
residual impairments would theoretically have been observed in both infrequent and
frequent users, however this was not the case. Secondly, subsequent research with
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healthy volunteers following an acute dose of ketamine has found no evidence of 
residual effects of ketamine 3 days following an acute dose (Chapter6; Morgan et al., 
2004a). Finally drugs acting on the glutamatergic NMDA-receptor affect fast excitatory 
synaptic potential change and the elimination half-life of ketamine is 2-3 hours 
(Goodman & Gilman, 2001), thus it is unlikely it would still be affecting behaviour 3 
days after use. The second explanation is that these are chronic effects, possibly related 
to neurotoxicity which is observed in animals following repeated doses of NMDA- 
receptor antagonists (e.g. Ellison, 1995) . The third explanation was that these are pre­
existing differences between ketamine users and non-users. Whilst it is difficult to rule 
out the possibility of pre-existing differences without prospective studies, the ketamine 
users were well matched with poly-drug controls on education, IQ and other 
demographic variables and were drawn from the same social group. The explanation of 
these day 3 deficits in terms of chronic effects thus appears most plausible. However, 
the central question remains as to the mechanism underlying these chronic effects of 
ketamine and whether it is possible to recover these functions upon cessation of 
ketamine use. In monkeys, self-administered PCP for up to 8 years did not produce any 
adverse physical reactions (Carroll, 1990). However in rats, studies that have 
administered single or highly spaced repeated doses of NMDA-receptor antagonists 
have found neurotoxicity that is localised mainly in cingulate and retrosplenial cortices 
(Olney et al. 1989; Olney et al. 1991). Also in rats, 5 days of continuous PCP treatment 
led to a different, more prolific pattern of neurodegeneration in a number of limbic 
system and limbic-related structures including the hippocampal and entorhinal cortices, 
the posterior cingulate cortex and olfactory regions (Ellison, 1995). Given most 
ketamine users are prone to bingeing and repeated dosing over an evening or a few 
consecutive days it is possible that the latter pattern of neurotoxicity is more relevant to 
their drug use.
No study has yet examined the effects of reduction of ketamine use on cognition and
memory in humans. One study did investigate the effects of reducing phencyclidine
(PCP) use in 15 PCP-users (Cosgrove & Newell, 1991) compared to 15 poly-drug
controls. This work reports an initial impairment in PCP users (compared to poly-drug
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controls) that reversed upon cessation or reduction of PCP use over 4 weeks. However, 
the findings of this study are difficult to interpret as little information is given on the 
degree of reduction in drug use and the potential relationship between this and recovery 
of cognitive function. Also, no data on the degree to which poly-drug users were 
matched with controls were presented. Further, the subjects were tested only over a 4- 
week period when they were taking other drugs concurrently. Finally, cognitively there 
were few significant differences at baseline or follow-up between poly-drug and PCP 
users, these only emerged when the data was collapsed into an ‘impairment ratio’ 
measure, which is of unknown validity. Thus, there is currently no existing research 
that adequately addresses the question of whether chronic effects of NMDA-receptor 
antagonists are reversible upon reduction or cessation of use of this drug.
Therefore the current study intended to investigate, using a longitudinal design, the 
impact of cessation or reduction of use of ketamine in a population of drug users tested 
between 3 and 4 years previously in two previous studies (Curran and Morgan et al., 
2000; Curran and Monaghan, 2001). The longitudinal design allows for examination of 
the extent to which changes in cognitive measures are due to changes in ketamine use. 
By comparing again to poly-drug controls, if cognitive impairments are chronic and yet 
reversible the performance in abstinent ketamine users should improve on episodic and 
semantic memory tasks to similar levels as poly-drug controls. However if impairments 
observed three days after drug use in the original studies were due to pre-existing 
differences or permanent chronic effects then performance should not differ from that 
on day 3 in the original study.
5.3 Method
5.3.1 Design
An independent group, longitudinal follow-up design was used. Data from day 3, when 
participants were drug free, were used for comparison with follow-up data and will 
hereafter be termed ‘baseline data’. Originally participants were recruited from night­
clubs and parties via snowball sampling (Solowij et al., 1992) and expressed an interest
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in taking part in future work. Attempts were made to contact these original participants. 
It was possible to contact 33 of the original 76. Thirty-one wished to take part in the 
follow-up study, which included 19 of the original ketamine users. However, one 
member of the original ketamine group had subsequently developed schizophrenia and 
2 of the poly-drug controls had started using ketamine. These volunteers were therefore 
excluded, leaving 18 participants from the original ketamine group and 10 from the 
original poly-drug control group.
5.3.2 Procedure
On the testing day participants were given a volunteer information sheet and then asked 
to give written, witnessed, informed consent. The participants gave details of their 
current drug use and answered some questions about their patterns of ketamine use (i.e. 
craving, periods of abstinence etc.). Premorbid IQ was assessed using the Spot the 
Word test (Baddeley et al., 1993) which requires participants to make lexical decisions 
between pairs of words and non-words. They were then assessed on a battery of 
cognitive tests.
5.3.3 Test Battery
The same battery of tests used as in the two previous studies was employed to compare 
data across time points. Tests were originally selected to assess memory functions, 
related cognitive functions, dissociative and psychotogenic symptoms. Test versions 
were initially counterbalanced across participants and design, and participants received 
different versions to those they received 3 or 4 years previously.
Semantic Memory
Speed of Comprehension (Baddeley et al., 1992) -  Participants were presented with 
200 sentences some of which were semantically correct (e.g. ‘Sharks are good 
swimmers’) and some of which were not ( e.g. ‘Wives are made in factories’). 
Participants were then instructed to go through the sentences for two minutes marking
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with a tick those which were semantically correct and, with a cross, those which were 
not. Scores were in number of correctly judged sentences and number of errors.
Semantic (Category) Fluency - Participants were provided with a super-ordinate 
category member (e.g. fruit) and asked to generate as many members of that category 
as possible in 90 seconds. The number of correct exemplars and number of repetition 
(i.e. perseverative errors: PE) and category (i.e. semantic errors: SE) errors were 
recorded.
Episodic Memory
Prose Recall -  Participants were played a taped passage of prose from the Rivermead 
Behavioural Memory Battery (Wilson et al., 1985) and were asked to recall it 
immediately afterwards and then after a delay, filled with other tasks, of approximately 
20 minutes. Recall was scored in terms of ‘idea units’ recalled, with one point for each 
exact synonym and half a point for incomplete recall or a close synonym (maximum 
score is 21).
Executive functioning
Digit Cancellation task -  Participants were asked to delete all the instances of the digit 
‘4’ from a sheet containing 400 random numbers. This task tapped focussed attention. 
Scores were time taken to complete the task and errors of commission/ omission.
Serial Sevens Task -  Participants were asked to sequentially subtract seven from a three 
figure number as many times as they can in a 90 second period. This task taps working 
memory. The number of correct subtractions and errors were recorded.
Phonological (Verbal) Fluency - Participants were given a single letter prompt (e.g. R) 
and required to generate as many words beginning with that letter in 90 seconds. This 
task was used a simple index of frontal functioning. Scores were number of correct 
exemplars and errors of repetition (i.e. perseverative) and alphabetical errors.
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Subjective Rating Scales
The following subjective rating scales were administered to participants: SSQ, ADDS, 
MRS, SES and are decribed in Chapter 2. Additionally we administered the Hospital 
Anxiety and Depression Scale (HADS) -A 14-tem questionnaire which was used to 
assess anxiety (HADS-A) and depression (HADS-D). Participants were asked to rate 
their mood “over the last week”.
5.3.4 Statistical Analysis
All statistical analyses were performed using SPSS Version 10.0. Repeated measures 
analyses of variance (RMANOVA) were conducted using time (3/4 years ago or 
current) as the within-subject variable and drug condition (ketamine user or polydrug 
control) as the between subject variable. When RMANOVA drug x time interactions 
were significant then post-hoc t-tests were conducted. For non-parametric data Mann- 
Whitney U was used and dichotomous data was analysed using % 2 analyses. 
Correlations were conducted using Pearson’s correlation coefficient for parametric and 
Spearman’s rank order correlation for non-parametric data. Correlations were only 
conducted on measures with significant group effects or interactions to minimise the 
chance of Type 1 errors. Correlations were conducted between ketamine, cannabis and 
alcohol use and performance on the cognitive measures and schizophrenic-like 
symptoms. Correlations were also only conducted with the ketamine group, to avoid 
replicating group differences. Non-signficant main effects and interactions are not 
reported.
5.4 Results
5.4.1 Demographics
There were 28 participants in total included in the study, 18 ketamine users (4 females) 
and 10 polydrug controls (6 females). There were no group differences in age or 
premorbid IQ as assessed with the Spot the Word test. There were no differences in 
anxiety as indexed by the HADS, between the ketamine users and poly-drug controls.
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However poly-drug controls scored less than ketamine users on the HADS depression 
scale (U=55.5, p<0.031). Data are given below in Table 5.1.
Age, years Spot the Word, 
no. correct
HADS-A HADS-D
Ketamine
Users
28.1 (0.81) 48.38 (3.46) 7.89 (4.96) 5.27 (4.32) *
Polydrug
Controls
26.5 (0.70) 50.12 (3.16) 6.63 (3.74) 2.00 (2.45)
* p<0.05
Table 5.1: Demographic variables and standard deviations across groups.
5.4.2 Drug Use (Table 5.2)
There were no differences in the proportion of each group that rated themselves as 
regular users of cannabis, alcohol, cocaine or ecstasy when examined with a % 2. In 
addition, there were no differences between the groups in the number of days per month 
they used these drugs. Dose data was not analysed due to difficulties in standardising 
participants estimates of drug use. There was a trend indicating the ketamine group had 
used cannabis for a longer number of years than controls (U= 46.5, p=0.052), this 
mirrored the non-significant age difference between the groups. There were no other 
differences in length of regular use of drugs.
Other current drug use reported by participants included amphetamines (4 ketamine 
users, 1 control), benzodiazepines (1 ketamine user, 1 control), LSD/psilocybin (2 
ketamine users, 1 control).
Ketamine users had decreased their frequency of ketamine use by an average of 88.3%, 
with 8 not having used the drug for over 6 months. The ketamine group used the drug a 
mean of 1.61 (3.19) days per month compared to a previous mean frequency of 6.45 
(8.13) days per month at baseline. Whilst the number of days the ketamine was used
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had decreased, the mean dose of ketamine used had increased from 0.31 (0.25) grams at 
baseline to 0.44 (0.97) grams at follow-up.
Ketamine Control
Percentage regular cannabis users 77.8% 80%
Days per month cannabis used 14.56 (2.91) 12.30(4.05)
Years since cannabis first used 9.94 (5.94) 8.37 (5.77)
Percentage regular alcohol users 94.4% 100%
Days per month alcohol used 16.67 (2.69) 13.70 (3.23)
Years since alcohol used 12.59(4.37) 12.53 (3.83)
Percentage regular MDMA users 72.2% 60%
Days per month MDMA used 1.36 (0.35) 1.10(0.41)
Year since MDMA first used 6.53 (3.74) 5.96 (3.64)
Percentage regular cocaine users 61.1% 50%
Days per month cocaine used 2.28 (0.94) 1.00 (0.44)
Years since first cocaine first used 3.35 (4.24) 2.89 (3.80)
Table 5.2: Drug use and standard deviations in ketamine and poly-drug control groups
5.4.3 Cognitive Tasks
5.4.3.1 Category generation (Figure 5.1)
A significant group x time interaction emerged on the number of category members 
generated ( F i^  = 5.19, p=0.032) and a main effect of time ( F i)26 = 7.50, p=0.011). 
Simple effects revealed that this was due to significantly lower numbers of category 
members generated by the ketamine users at original testing on day 3 (t lj27 =2.42 
p=0.023) but no difference between the groups 3 years later. There was a main effect 
of group ( F126 = 6.13, p=0.02) on the number of perseverative errors , indicating more
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Figure 5.1: Number of category exemplars generated in category fluency task in 
ketamine and poly-drug control users at baseline and follow-up.
PE were made by the ketamine group than controls at both time points (Table 5.4). 
Semantic errors were at floor levels in both groups at follow-up.
5.3.4.2 Speed o f Comprehension Task
A significant main effect of group was found on this task (F 1,26 = 8.73, p=0.007). The 
ketamine group completed fewer sentences on both test sessions than controls. But, as 
can be seen from Figure 5.2, the number of sentences judged correctly appears to 
increase in the ketamine group between day 3 and the 3 year follow-up testing point. 
Analysis of errors on the speed of comprehension task yielded a significant interaction 
(F 1,26 = 4.35, p=0.047). Simple effects analysis demonstrated that this was due to a 
significant difference between the groups on day 3 but not at follow-up. However, as 
can be seen from Table 5.3, errors were at floor at follow-up.
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Figure 5.2: Number of sentences correctly judged in the speed of comprehension task in 
ketamine and poly-drug control users at baseline and follow-up.
5.4.3.3 Prose Recall
Immediate prose recall scores showed a significant main effect of group (F iy26 = 4.36, 
p=0.047) reflecting better recall in the control group on both the original testing 
occasion and at follow-up (Figure 5.3a). Delayed prose recall reflected a similar pattern 
of results with a significant main effect of group (F 1^6 = 4.43, p=0.045). Again, from 
Figure 5.3b, a reduction in memory performance in the controls is visible, however the 
main effect reflects a tendency for the ketamine group to perform worse overall.
5.4.3.4 Digit Cancellation
There was a significant main effect of group on digit cancellation scores (F 1?26 = 7.09, 
p=0.013) but no interaction or main effect of time. This represents a poorer 
performance by the ketamine users over both time points [mean baseline 66.01 (14.12)
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Figure 5.3a: Immediate and 5.3b delayed prose recall scores across group and testing 
point, bars represent SEM.
secs, follow-up 65.32 (11.34) secs] compared to controls [mean baseline 54.60 (7.82) 
secs, follow-up 55.97 (8.74) secs]. There were no differences in the number of errors 
made (Table 5.3). Covarying digit cancellation time for errors did not affect the 
outcome of the analysis.
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Baseline Follow-up
Ketamine Control Ketamine Control
Category fluency, PE 1.94 (2.36) 0.5 (0.71) * 1.29 (2.29) 0.4 (0.68) *
Speed of
comprehension, errors
1.06(1.12) 0.2 (0.42) * 0.38 (0.46) 0.4 (0.52)
Digit cancellation, 
omission errors
1.06(1.10) 0.5 (0.53) 1.5(1.47) 1.1 (1.37)
Verbal fluency, PE 2.0(1.41) 1.0 (0.94) 1.06(1.76) 0.6 (0.84)
Serial Sevens, errors 3.78 (5.46) 2.2(3.19) 0.9(1.28) 1.5(1.94)
* p<0.05
Table 5.3: Error rates and standard deviations across all tasks at baseline and follow-up 
testing in ketamine users and controls, PE = perseverative errors
5.4.3.5 Serial Seven’s and Verbal fluency
There were no significant differences between controls and ketamine users at either 
time point on verbal fluency [baseline mean ketamine : 19.8 (6.23) words, controls: 
21.00 (5.94) words; follow-up ketamine 21 (5.62) words, controls 20.4 (4.01) words] or 
the serial seven’s task [baseline mean ketamine : 24.8 (8.16) subtractions, controls: 
20.78 (10.17) subtractions; follow-up ketamine 22 (9.33) subtractions, controls 23 
(7.97) subtractions] . There was a trend for a main effect of group on number of 
perseverative errors on the verbal fluency task (F i>26 = 3.30, p=0.081) and a main 
effect of time (F ^  = 3.17, p=0.087). This reflected poorer performance overall in the 
ketamine group, and poorer performance at follow-up than baseline in both groups.
5.4.4 Subjective Measures (Table 5.4)
5.4.4.1 Schizotypal Symptomatology Questionnaire
There was a significant main effect of group (F i;26 = 15.32, p=0.001) and of day (F ]>26 
= 59.25, p<0.001) but no interaction. The ketamine group still exhibited a greater
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degree of schizotypal symptomatology than the control group, however there was a 
decrease in schizotypal scores in both groups over the 3 or 4 years.
5.4.4.2 Adapted Dissociative States Scale
There was a significant main effect of time on the ADDS (F 126 = 5.93, p=0.022) which 
reflected a decrease in scores on the dissociative scale in both groups.
5.4.43 Mood Rating Scale
There were no group differences on any of the three factors of the mood rating scale 
(Drowsiness, Discontentedness and Anxiety) across the time points.
5.4.4.4 Subjective Effects Scale
The subjective effects can be divided into 3 factors : bodily, perceptual and mental 
state/cognitive. There were significant differences between the control group and 
ketamine users at follow-up on all three of these factors: perceptual distortions (U=34, 
p=0.007); bodily symptoms (U=21, p=0.001); and cognitive and mental state (U=39.5, 
p=0.014). These differences all reflected higher scores in the ketamine users than the 
controls.
5.4.5 Correlations
A highly significant correlation was found between change (Follow-up score -  
baseline score) in category fluency and both change in ketamine use (r = 0.712, 
p<0.002) and time since last ketamine use ( r= 0.723, p<0.002). To investigate whether 
impaired performance on the digit cancellation task might have resulted in significantly 
impaired performance on other tasks , correlations between digit cancellation at time 3 
and immediate and delayed recall were conducted. No significant correlations emerged.
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Baseline Follow-up
Ketamine Control Ketamine Controls
SSQ total 51.5(21.28) 24.8 (8.16)** 18.67(17.05) 4.0 (4.06) *
ADSS total 10.11(15.38) 5.44 (5.85) 3.24(4.53) 0.80 ( 1.54)
MRS-
Sedation
24.64(17.87) 38.55 (20.67) 37.07(17.18) 33.84(19.66)
MRS -  Dis­
contentedness
21.47(14.5) 37.92 (9.59) ** 34.3 (19.55) 31.48 (23.12)
MRS- Calm 24.54(13.87) 37.9 (9.59) * 36.61 (21.23) 39.85 (23.08)
BSS- somatic 12.12(12.61 9.62(16.58) 9.33(7.14) 1.14(1.25)**
BSS -  
perceptual
13.43 (9.20) 1.12(1.56) 8.4 (7.71) 1.18(1.45)**
BSS-
cognitive
16.13(20.08) 14.00 (20.08) 14.47 (14.89) 3.75 (3.95) *
* p<0.05, ** p< 0.01
Table 5.4: Subjective effects and standard deviations across groups at baseline and 
follow-up
5.5 Discussion
This study set out to investigate whether cognitive impairments observed 3 days after 
ketamine use in recreational drug users were reversible upon cessation or reduction of 
use of the drug. There were two main findings of this study. Firstly, ketamine users 
demonstrated a recovery of semantic memory function which was highly correlated 
with their reduction in use of the drug. Secondly, there was some evidence of a 
persisting impairment in episodic memory. Additionally, there was evidence of an 
attentional deficit after cessation or reduction of ketamine use. Decreases in 
dissociative and schizotypal symptomatology were found across both groups, however 
schizotypal symptomatology remained higher overall in the ketamine group compared 
to poly-drug controls.
150
The results of the current study suggest that upon reduction of ketamine use it is 
possible for ketamine users to recover some aspects of semantic memory function. The 
ketamine group showed a marked impairment of category fluency at baseline (day 3) 
compared to poly-drug controls. They generated fewer category exemplars when given 
a superordinate category name. In addition, they verified less sentences as semantically 
correct and made more errors of judgement on the speed of comprehension task. The 
two groups were well-matched on drug use, IQ and age, thus these differences appear 
to be attributable to ketamine use. Furthermore, deficits in performance on category 
fluency and speed of comprehension tasks were not found in healthy volunteers 3 days 
after a single dose of ketamine (Chapter 6; Morgan et al., 2004c). This suggests that 
these decrements in recreational users are not residual but chronic effects of ketamine.
But by follow-up testing 3 years later, aspects of semantic memory function had 
recovered. The number of exemplars generated on the category fluency task was no 
longer different from that of the poly-drug controls. On the speed of comprehension 
task, over both time points, the ketamine group judged less sentences correctly. 
However, ketamine users did improve on the number of sentences they judged correctly 
between day 3 and follow-up testing. The ketamine group also made a similar number 
of errors on the speed of comprehension task as the poly-drug controls at follow-up, 
which again suggests a recovery of semantic memory function. Three years after 
original testing, the ketamine group made more errors on the category fluency task, 
however as these were perseverative errors, they may be indicative of an executive 
functioning, rather than a semantic memory, deficit.
Amongst drugs of abuse, ketamine is unique in its capacity to impair semantic memory
(Curran & Weingartner, 2002). This effect appears to be more pronounced in ketamine
users than in healthy volunteers given a single dose of ketamine, where data on
semantic memory deficits are equivocal (Adler et al., 1998; Krystal et al., 1994;
Malhotra et al., 1996; Chapter 2; Morgan et al., 2004a). Semantic memory impairments
were further elucidated in Chapter 4, however we were unable to use this task in the
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current study as we were confined to the use of the measures from the original study. 
The semantic memory impairment associated with ketamine abuse is somewhat 
reminiscent of schizophrenia. Of the diverse cognitive deficits within the broad 
category we label “ schizophrenia”, category fluency has been suggested to be the most 
robust neuropsychological indicator (Arango et al., 1999). It is possible that the 
ketamine induced category fluency deficits are mediated in a similar way to those 
observed in schizophrenia, given the psychotomimetic properties of ketamine. The 
schizophrenia literature suggests that an impairment of category fluency could reflect 
one of two problems with semantic memory, either an impairment of access/ retrieval 
or a disorganisation of the semantic store (Allen et al., 1993). In this study, there were 
no baseline impairments in verbal fluency in ketamine users compared to poly-drug 
controls. If category fluency deficits reflect an impairment of access/retrieval from 
semantic memory then theoretically both verbal fluency and category fluency may have 
been equally impaired. The selective impairment to category fluency observed in the 
current study is therefore suggestive of a ketamine-induced disorganisation of the 
semantic store. This would appear to be, at least partially, reversible upon reduction of 
ketamine use. The latter assertion is supported by the high correlation between 
reduction in ketamine use and improvement in category fluency.
The number of sentences correctly judged on the speed of comprehension task 
improved in ketamine users but was still lower than that of controls. Unfortunately, as 
we used no measures of general reaction time it is not possible to tell the degree to 
which the lower number of sentences judged is reflective of general psychomotor 
slowing or semantic impairment. However, the reduction in number of errors observed 
made again suggests semantic memory improvement.
The neural substrates of this reversible impairment in semantic memory are unclear.
Animal studies with NMDA-antagonists have demonstrated diffuse neurotoxicity
throughout the brain following repeated doses of NMDA-antagonists. In rats,
neurotoxicty in the posterior cingulate cortex (retrosplenial cortex) was found to be
reversible 48 hours following an acute dose of an NMDA-antagonist (Olney et al.,
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1991). This area has been demonstrated to be important in semantic memory in humans 
(Nestor et al., 2002). However, it is difficult to extrapolate from this animal literature 
and to speculate as to what may be occurring neurologically to produce this 
improvement in functioning in ketamine users. Two neuroimaging studies of chronic 
PCP users compared to controls have suggested reduced glucose utilisation in 
preffontal areas (Hertzman et al., 2002; Wu et al., 1991). As intact performance on 
fluency tasks is dependent upon the integrity of the preffontal cortex, this may account 
for the initial impairments observed in ketamine users and recovery of pre-frontal 
function may underpin the reversal of deficits with markedly reduced ketamine use. 
Imaging studies would help to elucidate the neuroanatomical substrates of these 
impairments.
Episodic memory functioning in ketamine users did not appear to recover after 
reduction in use of the drug. At baseline, ketamine users recalled less of a passage of 
prose than poly-drug controls and at follow-up their performance level on prose recall 
was similar to baseline. This apparently persisting impairment was not correlated with 
the attention deficits observed on digit cancellation. As the groups were well matched 
on drug use, this deficit could be either attributable to pre-existing differences or 
ketamine use. The study reported in Chapter 3 demonstrated that ketamine users exhibit 
a selective impairment to source, and not recognition memory (Morgan et al., 2004b). It 
is not possible to tell from the present data if the persisting impairment in episodic 
memory observed here reflects a deficit in source memory, item memory or a 
generalised episodic memory impairment. Given the literature on source memory 
impairments in schizophrenia, it would be important to tease apart the nature of this 
episodic memory deficit.
This deficit may be related to ketamine induced neurotoxicity. A recent study that have
administered repeated doses of ketamine to rats for 5 consecutive days and then
examined neuronal functioning 3 weeks later, observed abnormal neurogenesis in the
hippocampus, an area important in human episodic memory (Bernstein et al., 2003). It
may be that similar abnormal neurogenesis occurs in humans who have repeatedly self-
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administered the drug, but further work is necessary to clarify this issue. Given the high 
densities of NMDA-receptors in areas important in memory in humans, it is feasible 
that repeated NMDA-antagonism could produce non-reversible impairments in episodic 
memory.
This group of ketamine users were slower at completing the attentional task both at 
baseline and follow-up. This was surprising as in the previous study, compared to poly­
drug controls, there had been no evidence of an attentional impairment in ketamine 
users (Curran & Morgan, 2000). The combined ketamine user group in this study used 
the drug more heavily than the ketamine group reported in the latter study. In addition, 
those participants from the study by Curran & Monaghan (2001) exhibited poorer 
attentional functioning at baseline than the ketamine users from the Curran & Morgan 
(2000) study. Thus heavy ketamine use appears to be associated with attentional 
impairments. This finding is intriguing as an acute dose of ketamine in the laboratory 
has been repeatedly associated with preserved attentional functioning (Krystal et al., 
1994; Malhotra et al., 1996; Adler et al., 1998; Newcomer et al., 1999; Chapter 2 
/Morgan et al., 2004a). However, there have been some suggestions of impaired 
vigilance following acute ketamine (Hetem et al., 2000; Krystal et al., 2000b). 
Ketamine users have reported attentional impairments to be a perceived long-term side 
effect of ketamine use (Siegel, 1978) and the findings of this study could be taken as 
evidence in support of these subjective reports. However, there was no difference in the 
number of errors made between the groups. Thus the slower digit cancellation time 
could again be indicative more general psychomotor slowing and not an attentional 
impairment, per se. Covarying for errors did not affect the outcome of the analysis so 
these findings would not appear to be attributable to a speed/accuracy trade off on the 
part of the controls.
Working memory and aspects of frontal functioning tapped by the serial seven’s and
verbal fluency tasks were preserved both on day 3 and at follow-up, compared to
controls. There was a trend for an increase in perseverative errors in the ketamine group
at both time points. This warrants further investigation, given the perseverative errors
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observed on the category fluency task. These errors could well reflect problems 
monitoring and holding ‘on-line’ exemplars that have been generated in fluency tasks. 
The serial seven’s task requires a lower level of maintenance in working memory than 
fluency tasks, but a higher level of manipulation. It could be that ketamine users have 
impaired maintenance, but intact manipulation of material in working memory.
Ketamine users exhibited higher levels of schizotypal symptoms and rated themselves 
more highly on visual analogue scales of perceptual distortions (e.g. visual, auditory, 
time perception and out of body experiences), cognitive impairments (e.g. impaired 
memory and concentration; confusion) and physical effects associated with ketamine 
(e.g. dizziness, bodily numbness, lack of co-ordination). Schizotypal symptoms had 
declined 3 years after initial testing but were still higher than controls. Schizotypal 
symptoms had also decreased in the poly-drug control group. This could be related to 
the documented reduction in schizotypy with increasing age (Morizot & Le Blanc, 
2003). It is not clear whether these elevated scores on schizotypal scales reflect pre- 
exisiting differences or chronic effects of ketamine use. No correlation was found 
between schizotypal symptoms and ketamine use. The scale used in this study was 
adapted to index state, rather than trait, schizotypy and reliably demonstrates change 
following acute ketamine. Nevertheless it remains possible that the scale was tapping 
into underlying schizotypal traits. Equally, however, the finding of increased 
schizotypal scores could be taken as evidence supporting the argument that chronic 
ketamine may be model some of the symptoms of schizophrenia. Whilst only anecdotal 
evidence, it is also interesting to note that one of the ketamine users from the sample of 
19 had developed schizophrenia. This has never been reported in longitudinal studies of 
other recreational drug using populations (e.g. ecstasy and cannabis users, (Zakzanis & 
Young, 2001).
Ketamine users also scored more highly than controls on visual analogue scales of
subjective effects including physical, perceptual and cognitive factors. They perceived
themselves amongst other symptoms to be more confused, have impaired memory and
concentration, rated themselves as more dizzy, and as experiencing a variety of
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perceptual phenomena including visual and auditory distortions. These could again be 
chronic effects of ketamine use and warrant further investigation. There were no 
differences in dissociation overall, but dissociative scores reduced in both groups across 
time. This may again be related to an increase in age and changes in lifestyle.
The longitudinal follow-up design used in this study was useful in allowing comparison 
across the groups over a 3-4 year time period. None of the volunteers had escalated use 
or even continued at the same level and all reported having little problems reducing 
their ketamine use, indicating a low potential for dependence on this drug. 
Unfortunately though, it was not possible to contact many of this population due to 
their transient lifestyles, as many were ‘squatters’ and ‘travellers’. Potentially, the 38 
members of the original ketamine group that could not be contacted may have 
continued ketamine use. In terms of experimental design, ideally a ‘continuing 
ketamine’ group would have been studied, as it is possible that other factors have 
caused the current sample to reduce their use. It is also impossible to rule out pre­
existing differences between ketamine users and non-ketamine using poly-drug controls 
without the use of prospective studies. But groups were well matched on other drug use 
and demographic variables. Moreover, the ketamine group’s scores on category 
fluency, at follow-up, were similar to those observed in the poly-drug using controls 
which does not suggest pre-existing differences in at least semantic memory 
functioning. Again, if a greater number than 2 participants in the poly-drug control 
group had started using ketamine, then examining the performance of a group of these 
type of drug users would have shed further light upon this issue. There were also 
differences between the groups on the HADS measure of depression at follow-up. 
Clinical levels of depression may impact on performance on attention and episodic 
memory tasks but there is no evidence to suggest that it would have affected semantic 
memory function (Zakzanis et al., 1998) and our ketamine users were not within a 
clinical range of depression. Nevertheless, the finding of increased depression is 
interesting, as ketamine has been reported to have prolonged antidepressant properties 
in depressed patients (Berman et al., 2000). Unfortunately, it was not possible to
compare across the two studies on this measure as Curran & Monaghan (2001) did not
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report the HADS, however participants in Curran & Morgan (2000) did not differ from 
controls on depression at baseline.
The present study also had several limitations in common with virtually all studies of 
recreational drug users (Curran, 2000). Retrospective estimates of drug use are 
inevitably inaccurate and it was not possible to investigate the participants’ reports 
objectively. It is also difficult to tease apart the effects of different drugs and their 
interactive effects on cognition in a population of poly-drug users. However, the high 
correlations with reported drug use and differing objective cognitive measures give 
some indication of which effects are attributable to which drug.
In summary, this study used a longitudinal, follow-up design to compare ketamine 
users and poly-drug controls scores from 3 days after taking the drug, with their 
performance 3 years later when all had ceased or reduced using the drug. Attentional 
impairments and schizotypal symptoms remained greater than those of poly-drug 
controls between 3 days and 3 years, however there was some decline in schizotypal 
symptoms in both groups across the two testing points. There was also evidence of an 
impairment in episodic memory that was still evident after 3 years. Semantic memory 
function was found to be impaired on the category fluency and speed of comprehension 
tests on day 3 but 3 years later category fluency performance and errors on the speed of 
comprehension task did not differ from controls. This indicates some recovery of 
semantic memory performance, but speed of comprehension was still slower. The 
improvement in category fluency correlated with the reduction in use of ketamine. 
These findings support the notion that repeated doses of ketamine may model aspects of 
schizophrenia. Whilst users may recover some cognitive function following cessation 
of ketamine use, ratings of subjective effects in ketamine users suggest that they may 
still experience some of the symptoms associated with the use of the drug up to 3 years 
afterward.
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Chapter 6: Special K?
K e t a m i n e  i m p a i r s  r e s p o n s e  i n h i b i t i o n  a n d  i s  p o s i t i v e l y  r e i n f o r c i n g  
i n  h e a l t h y  v o l u n t e e r s :  a  d o s e  r e s p o n s e  s t u d y
“A major concern fo r  the safe use o f  Ketamine is its very high potential for  
psychological addiction. A very large percentage o f  those who try Ketamine will 
consume it non-stop until their supply is exhausted. I ’ve seen this in jriends I ’ve 
known for many years who are regular psychedelic users and never had problems 
controlling their drug use...”
D M Turner (1994), The Essential Psychedelic Guide
6.1 Overview
The present study aimed to investigate the effects of ketamine on two processes 
related to drug abuse, response inhibition and reinforcement, and to examine 
whether an acute dose of ketamine produced residual cognitive effects in healthy 
volunteers. 54 healthy volunteers were given an 80 minute infusion of one of two 
doses (0.4, 0.8 mg kg-1) of ketamine or placebo. Subjects carried out a battery of 
tests at three time points: pre-infusion, during the infusion and 3 days later at 
follow-up. The battery consisted of tests of episodic and semantic memory, 
schizophrenic-like and dissociative symptoms, response inhibition and measures of 
subjective effects, including mood, bodily symptoms and enjoyment of and desire 
for the drug. Ketamine acutely impaired response inhibition and had related 
biphasic effects on the subjective reinforcing effects of the drug. Ketamine also 
acutely impaired episodic but not semantic memory and increased schizophrenic­
like and dissociative symptoms. No residual cognitive effects were observed 3 days 
following an acute dose. The reported increasing abuse of ketamine may be related 
to its capacity both to reinforce and to decrease response inhibition. The lack of 
residual effects in healthy volunteers on day 3 indicate that impairments found on 
day 3 in ketamine abusers suggests chronic effects in ketamine abusers. Although 
pre-existing differences cannot be ruled out, ketamine is a drug with high abuse 
potential and the consequences of its continued abuse may be severe.
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6.2 Introduction
Despite the increasing rate of ketamine abuse, little research has examined the 
effects of ketamine in relation to its reinforcing or dependence forming properties. 
Ketamine is self-administered in rats and non-human primates (Winger et al., 1989; 
Marquis et al., 1989) and in rats, produces conditioned place preference (Layer et 
al., 1993). Various processes are thought to underlie the maintenance of drug abuse. 
These include variations in dopaminergic transmission (Di Chiara, 1999) and more 
recently disruptions to other neurotransmitter systems have been implicated, 
including glutamate (Cornish et al., 1993). In humans, the role of cognitive 
processes in drug abuse and addiction, alongside neurotransmitter modulation, has 
been also emphasised (Giancola, 2000; Weingartner, 2000). Impaired executive 
functioning, that is the planning, initiation, and self-regulation of goal-directed 
behaviour, is related to increased drug use and likelihood of developing a substance 
use disorder (Giancola et al., 1996). Of the executive functions, it is inhibitory 
processes that are thought to be particularly important in models of drug abuse 
(Goldstein & Volkow, 2002). In relation to response inhibition, acute doses of 
ketamine have been demonstrated to disrupt performance on tasks in which 
defective inhibitory mechanisms are implicated, i.e. the Wisconsin Card Sorting 
Task (WCST) (Krystal et al., 1994; 1997; 2000). However, no research to date has 
directly examined processes of response inhibition following ketamine
Only two studies have examined the effects of ketamine in recreational users of the 
drug, these have been discussed previously in the thesis but as they are the basis of 
our rationale, they will also be reviewed here. A previous study set out to examine 
the acute and residual effects of ketamine in a population of abusers (Curran & 
Morgan, 2000). This compared volunteers who reported taking ketamine with a 
population matched for poly-drug use, on the night of their ketamine use (day 0) and 
three days later (day 3). Day 0 effects replicated previous laboratory acute studies 
showing a broad range of cognitive impairments (e.g. Krystal et al., 1994). 
Interestingly however, three days later, participants were still impaired on tasks 
tapping episodic and semantic memory, and had elevated levels of dissociation and
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schizotypal symptoms. The authors proposed three interpretations of this data. 
Firstly that regular use of ketamine over time may produce chronic effects. This 
may be related to animal studies suggesting that a single high dose or repeated doses 
of NMDA-antagonists may destroy neurons in the posterior cingulate and 
retrosplenial cortices and several other corticolimbic brain regions (Olney et al., 
1991). Secondly, that ketamine may produce more transient residual impairments on 
these tasks that, given the short-half life of ketamine, may possibly be attributable to 
the action of norketamine, a metabolite of ketamine with suggested 
psychotomimetic properties. Finally, that there are pre-existing differences between 
ketamine users and non-users that account for these day 3 effects.
In an attempt to clarify the former interpretation, a study compared both frequent 
and in-ffequent users of ketamine using a similar design, thus controlling for 
residual effects in both groups and reducing the possibility of pre-existing 
differences causing preference for ketamine use (Curran & Monaghan, 2001). 
Episodic and semantic memory impairments observed on day 3 in the previous 
study were found in frequent but not infrequent ketamine users. This does suggest 
chronic effects of ketamine, as more transient residual impairments would 
theoretically have been observed in both the groups. However, it is possible that had 
the infrequent user group been compared to poly-drug controls then residual 
impairments may have still been evident. Thus, it is not clear whether the findings 
reflect a residual effect, possibly attributable to higher dose, a chronic effect o f 
repeated ketamine use or a combination of the two. If the results of these studies do 
indeed represent a residual effect of ketamine, then impairments should be observed 
in healthy volunteers with no history of ketamine abuse. If  no residual effect of 
ketamine is found in healthy volunteers then we can infer that the residual 
impairments seen in previous studies were likely due to either chronic repeated use 
of this drug or to pre-existing differences between ketamine abusers and poly-drug 
controls. One previous study (Newcomer et al., 1999) examined residual 
schizophrenic symptoms in healthy volunteers 48 hours after an infusion and found 
no evidence o f residual effects. However, this study did not assess residual 
cognitive effects which have been shown by both Curran & Morgan (2000) and 
Curran & Monaghan (2001).
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Therefore the present study intended to investigate the acute and residual effects of 
a single dose of ketamine in healthy volunteers. Cognitive function was examined 
on measures which demonstrated residual impairments in recreational users. No 
previous study has examined the potential residual cognitive effects of ketamine in 
healthy volunteers, this would seem to be important, given evidence of residual 
effects in recreational users and suggestions of neurotoxicity in the animal research. 
In addition, as no research to date has investigated the effects of ketamine on 
measures related to drug abuse, this study set out to investigate the effects of 
ketamine on response inhibition and measures that tapped drug-related subjective 
effects, including the participant’s liking of and desire for the drug.
6.3 Method
6.3.1 Design, Procedure and Participants
This exactly followed the method reported in Chapter 2. Thus on the main test day 
the 54 participants were randomly allocated to receive either ketamine (0.4 mg kg -1 
or 0.8 mg kg ~l) or saline placebo (0.9% NaCl) intravenously for 80 minutes. This 
chapter reports further assessments on the main test day. Further all participants 
returned 4 days later for follow-up testing, lwhere they completed a similar battery 
of tests for residual effects and also gave a urine and peripheral venous blood 
sample.
6.3.2 Assessments
Tests were selected to assess response inhibition, semantic and episodic memory, 
dissociative and psychotogenic symptoms and subjective effects (including drug 
incentive salience). Additional tests were administered pre and post drug, the results 
of which have been reported in Chapter 2. Test versions were counterbalanced 
across participants and design.
Prose Recall sub-test of the Rivermead Behavioural Memory Test (Wilson et al., 
1985) - This task was used to test immediate and delayed prose recall. Participants 
were played a pre-recorded passage of prose similar to a news bulletin on a tape 
recorder. They were then asked to state verbally as much as they could recall i) 
immediately after presentation and then ii) after a short delay, filled with other
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tasks, of approximately 10 minutes. Participants were tested both pre and post drug 
on immediate and delayed recall. A third condition required participants to recall 
information learnt pre drug and information learnt post drug at the same time, after a 
long delay at the end of the infusion.. This was to assess whether ketamine impairs 
encoding (information learnt post drug should be more poorly remembered) or 
retrieval (both sets of information should be remembered equally as badly) in 
episodic memory. The passage of prose contained 21 ‘idea units’. Scoring was 
standard with each correctly remembered unit or exact synonym given one point, 
and half point scores were awarded for partial recall or partial synonyms.
Source Memory task -  See Chapter 2 for details (only follow-up data are presented 
here)
Fluency - Semantic and phonological tasks were chosen to tap executive 
functioning and retrieval from semantic memory. In Semantic Fluency, participants 
were provided with a super-ordinate category member (fruit, vegetables, musical 
instruments) and asked to generate as many members of that category as possible in 
90 seconds. Categories were matched for frequency of examples (Battig & 
Montague, 1969) In Phonological Fluency, participants were provided with a single 
letter prompt (R, M or B) and were required to generate as many words beginning 
with that letter in 90 seconds. Letters were matched for number of occurrences in 
the Oxford Mini-Dictionary (OUP, 1984). Number of category members and errors 
were recorded for both tasks.
The Hayling task (Burgess & Shallice, 1997) - This task was chosen to tap response 
initiation and response inhibition. In section one of the task, participants were read 
fifteen sentences each of which had the last word is missing (e.g. He posted a letter 
without a ...). The participant was asked to give a verbal response to complete the 
sentence, as quickly and sensibly as possible. In the second section of the test the 
participant is again presented with fifteen sentences but this time was asked to give 
a response that was completely incongruous with the sentence. The task yielded four 
measures, latency of response on section one (response initiation) and errors and 
latency to respond for the second section of the test (response suppression) along
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with an overall test score. As there was only one version, this task was only 
administered post drug.
6.3.3 Subjective ratings: The SSQ, ADDS and MRS described in Chapter 2 were 
again administered on day 4. In addition, the SES was given at each time point. This 
VAS was designed to test subjective side-effects of ketamine administration. The 
SES had fifteen items: memory impairment, out-of body experiences, visual 
distortion, sound distortion, altered time perception, dizziness, impaired 
concentration, depression, feeling o f altered reality, impaired memory, nausea or 
sickness, bodily numbness, unsteadiness, lack of co-ordination, confusion.
On the pre (as a control) and post-drug assessments, three additional items adapted 
from Kirk et al. (1998) were used to gauge the participant’s attitude towards the 
drug. Participants were required to rate whether they felt the effects of a drug 
(scale anchored between ‘Feel very strong effect of a drug’ and ‘Feel no effect of a 
drug’); whether they wanted more o f the drug ( scale anchored between ‘Want more 
of the drug’ and ‘ Want less of the drug’) and whether they liked the effects of the 
drug ( scale anchored between ‘Like effects of the drug a lot’ and ‘ Do not like the 
effects of the drug’).
6.3.4 Statistical Analysis
All statistical analyses were performed using SPSS Version 9.0. Group differences 
were examined using one-way ANOVAs and, where data was non-parametric, the 
Kruskall-Wallis test. For most cognitive tasks and subjective effects 3 x 3  repeated 
measures analyses of variance (RMANOVA) were conducted using time (pre-drug, 
post-drug, follow-up) as the within-subject variable and drug condition (placebo, 
0.4mg kg _1 ketamine , 0.8 mg kg-1 ketamine) as the between subject variable. 
Where significant interactions were found, orthogonal contrasts were conducted 
comparing 1) placebo with both drug groups and 2) low dose with high dose 
ketamine. Pearson’s correlations were conducted on selected data. Throughout, 
assumptions of normality were examined using Levene’s tests and Bonferroni 
corrections were applied, where appropriate, to control for multiple comparisons. 
Non-significant main effects and interactions are not reported.
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6.4 Results
6.4.1 Trait Scores, Demographics and Drug dosage
Participants were broadly matched for age. Groups were additionally matched on 
premorbid I.Q. (as gauged by the ‘spot the word’ test), depression, anxiety, trait 
dissociation, millilitres (mis) infused and weight (Table 6.1). In total the 0.8 mg kg 
1 group received a mean of 56.45± 9.19 mg ketamine over 80 min. The low dose 
group received 26.74 ± 7.56 mg ketamine over 80 mins (see Chapter 2 for further 
details).
Placebo, 
mean (s.d)
0.4 mg kg 
ketamine, 
mean (s.d)
0.8 mg kg 1 
ketamine, 
mean (s.d)
Age 21.83 (3.15) 21.17(1.69) 24.17(4.53)
Spot the word test score 50.00(3.20) 49.67 (3.65) 49.65(3.87)
BDI score 3(3.6) 4.3 (4.9) 3.5 (4.9)
STA score 34.6(10.8) 32.5 (8.79) 33.8 (9.7)
DES score 32.3 (32.39) 31.6 (30.3) 31.5 (35.5)
Weight, kg 71.29(13.92) 66.84(18.87) 70.56(11.49)
Mis infused 31.2 (6.05) 29.8 (3.71) 30.9 (5.58)
Table 6.1: Demographics across treatment groups
6.4.2 Cognitive Assessments
6.4.2.1 Prose Recall
A 3 x 2 x 2 RMANOVA of drug x test delay x time yielded a significant time x drug 
interaction [F (2, 51) = 6.98 p<0.05], a significant main effect of delay [F (2, 102) = 
88.22 p<0.001] and time [ F(l, 51) = 4.37 p<0.05]. Post-hoc analysis with 
Dunnett’s t demonstrated higher recall scores overall post-drug in the placebo group 
than the high dose ketamine group (p<0.005) but no difference in scores between 
the two drug groups or any pre-drug differences. Analysis o f the delay effect 
revealed significantly lower scores than immediate recall after a short delay across 
the groups and time points[ F(l,51) = 4.18 p<0.05 ] and significant differences 
between scores after a short delay and scores after a long delay i.e. at the end o f the 
infusion [ F(l,51) = 104.13 p<0.001]. These effects and interaction can be seen in
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the pre and post drug scores depicted in Figure 6.1. There were no differences in 
immediate and delayed prose recall scores at follow-up [group means immediate 
recall: Placebo:=10.92 ±2.73; low dose ketamine = 10.22±3.90; high dose ketamine 
= 9.13±3.51, group means delayed recall: Placebo = 10.47± 3.0; low dose 
ketamine = 9.72±3.603; high dose ketamine = 8.33±2.75]
6.4.2.2 Source Memory
A one-way ANOVA demonstrated no group differences on follow-up item 
recognition or source memory data.
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Figure 6.1: Prose recall scores pre and post drug across the three delay intervals and 
drug conditions
6.4.2.3 Fluency (Table 6. 2)
Phonemic Fluency
A RMANOVA showed a significant main effect of time on verbal fluency [F(2, 
102) = 4.80 p<0.05 p=0.01], attributable to significantly lower scores post-infusion 
compared to follow-up [F (1, 51) = 11.68 p<0.01 p=0.001] but no main effect of 
drug or interaction.
Semantic Fluency : A repeated measures ANOVA revealed a significant main effect 
of time on category fluency [F(2, 102) = 5.72 p<0.01 p= 0.004] with significantly 
lower scores overall post infusion compared to pre-infusion [F(l,53)= 5.52 p<0.05
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p=0.023 ] and follow-up [ F(l, 53) = 9.65 p<0.01 p=0.003] but no interaction or 
main effect of drug.
6.4.2.4 The Hayling Task
Scores for the Hayling were computed and analyses performed on four scores I) 
time to complete Hayling part 1 (logical completion); II) time to complete Hayling 
part 2 (illogical completion); III) number of errors on Hayling part 2 (inability to 
suppress logical responses where not required / response inhibition); and V) overall 
Hayling test score. A RMANOVA of task (Hayling 1 or Hayling 2) x drug, yielded 
a significant main effect of task [F(l,51) = 96.44 p<0.001], but no interaction or 
main drug effect. All groups took longer to complete the Hayling 2 sentences. 
Analysis of Hayling part 2 errors revealed significant differences between the 
groups [ F(2,53) = 10.30 p<0.001]. Contrasts found a difference between numbers 
of errors made in both ketamine groups and placebo [t(51) =2.67 p<0.02] which, as 
can be seen in Figure 2, was due to the 0.8 mg kg -1 ketamine group making more 
errors than the 0.4 mg kg -1 ketamine group [ t(51) = 3.67 p<0.01].
In addition analysis of the overall Hayling test score found a significant difference 
between the drug treatment groups [F(2, 53) = 5.65 p<0.01]. Contrasts were used to 
examine this data further and showed significantly lower scores in the 0.8 mg kg -1
Figure 6.2: Number of response inhibition errors made on the Hayling task across 
drug conditions
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ketamine group compared to the 0.4 mg kg -1 ketamine group[t(51) = 3.01 p<0.01] 
but no difference when both high and low drug groups were compared to placebo 
[means: placebo = 17.78 ± 2.10; low dose =17.94 ± 1.39; high dose = 15.67 ± 3.01].
6.4.3 Subjective Ejfects
6.4.3.1 Schizotypal Symptomatology
When the overall score for schizotypy was computed, RMANOVA demonstrated a 
significant drug x time interaction [F(4, 102) = 10.33 p<0.001] and a significant 
effect of time [F(2, 102) = 36.93 p<0.001]. Contrasts showed significant differences 
post drug, where the drug groups scored more highly than the placebo group [t(51)= 
3.19 p<0.001] but there was no difference between the low and 0.8 mg kg -1 
ketamine groups (Table 6.2).
6.4.3.2 Dissociative Symptomatology Scale
RMANOVA of the overall DSS score showed a significant drug x time interaction [ 
F(4, 102) = 21.33 p<0.001] and significant main effects of drug [F(2, 51) = 15.23 
p<0.001] and time [F(2,102) = 87.61 p<0.001]. Ketamine induced clear, dose- 
related dissociative effects. These were confirmed by further analysis of the 
interaction which revealed significantly lower scores in the placebo group compared 
to the two drug groups post-drug [ t(51) = -5.76 p<0.001] and in the 0.4 mg kg -1 
group compared to the 0.8 mg kg -1 ketamine group post-drug [ t(51) = -3.16 
p<0.01] (Table 6.2).
6.4.3.3 Visual Analogue Scales 
Mood Rating Scale
This scale yielded three factors: alertness/drowsiness, contentedness/
discontentedness and calmness/anxiety. Means for the mood rating scale are 
reported in Table 6.3. A 3x4 RMANOVA of the factor ‘ drowsiness’ yielded a 
significant drug x time interaction [F(6, 153) = 7.90 p<0.001] , a significant main 
effect of drug [F(2, 51) = 9.22 p<0.001] and time[F (3, 153) = 67.93 p<0.001]. 
Contrasts revealed that the placebo group were less drowsy than the two drug 
groups 10 min post drug [t(51)=-5.30 p<0.001], and 80 min post drug [t(51) = -6.19 
pO.001]. Analysis of the ‘discontentedness’ sub-factor yielded a significant drug x 
time interaction [F(6, 153) = 2.69 p<0.025] and significant effect of time [F(3, 153)
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= 5.56 p<0.01].Contrasts indicated that the 0.8 mg kg -1 ketamine group were 
significantly more discontented 80 min post drug than the 0.4 mg kg -1 ketamine 
group ( t(51)= -2.08 p<0.05]. There were no significant differences between any of 
the groups or assessment points on the ‘anxiety’ sub factor of the mood rating scale.
6.4.3.4 ‘Feel effects o f a drug? ’
There was a significant drug x time interaction for the VAS of ‘feel effects of a 
drug’ [ F(4,102) = 27.38 p<0.001] and significant main effects of both time [F(2, 
102) = 187.56 p<0.001] and drug [F(2, 51) = 55.68 pO.001]. Tests of simple effects 
showed significant group differences 10 min [ F(2, 53) = 33.55 p<0.001] and 80 
min post drug [ F(2, 53) = 50.71 p<0.001]. The 0.8 mg kg '* ketamine group felt 
stronger effects 10 min post drug than the 0.4 mg kg ~l ketamine group [ t(51) = - 
2.64 p<0.05 p=0.011] and both drug groups felt stronger drug effects than the 
placebo [t(51) = -7.75 p<0.001]. 80 min post drug there were no differences in two 
ketamine groups, but both groups felt much stronger effects than the placebo [ t(51) 
= -9.99 p<0.001]. In Figure 6.3 the differences between the placebo group and the 
two drug groups can be clearly seen as the change is from 0 to 80/90mm of the 100m 
m scale.
'Feel effects of a drug?'
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Figure 6.3: The subjective ‘feeling’ of drug effects on ketamine, across dose and 
time.
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Placebo 0.4 mg/kg ketamine 0.8 mg/kg ketamine
Pre Post Follow-
up
Pre Post Folow-
up
Pre Post Follow-
up
Phonological 14.56 14.38 15.89 15.11 15.33 16.39 15.33 13.72 16.17
fluency, N (4.19) (3.57) (3.92) (4.13) (2.45) (2.70) (4.60) (0.39) (2.94)
Phonological 0.33 0.33 0.28 0.11 0.33 0.5 0.28 0.61 0.39
fluency, errors (0.59) (0.49) (0.57) (0.32) (0.59) (0.86) (0.46) (0.85) (0.50)
Semantic 17.11 15.58 17.89 18.72 17.72 19.17 18.67 15.72 19.06
fluency, N (4.57) (3.92) (4.80) (4.32) (3.71) (3.85) (4.01) (4.23) (4.25)
Semantic 0.44 0.33 0.17 0.44 0.06 0.22 0.33 0.67 0.22
fluency, errors (0.62) (0.69) (0.38) (0.70) (0.24) (0.55) (0.49) (1.14) (0.55)
Schizotypal 6.89 4.61 3.17 4.78 14.39 3.94 6.89 18.61 3.94
symptoms (10.64) (4.49) (3.97) (6.80) (14.56) (6.35) (10.40) (9.99) (6.86)
Dissociative 1.00 2.33 0.28 1.06 15.28 0.72 1.06 27.27 3.17
states scale (1.28) (3.19) (0.58) (1.66) (11.23) (1.27) (3.07) (15.91) (7.67)
Table 6.2: Group means (s.d) for scores on fluency, schizotypal and dissociative scales across each assessment point
169
6.4.3.5 ‘Like effects o f the drug? '
For the rating ‘like effects of the drug’ there was a significant drug x time interaction 
[F(4, 102) = 6.60 p<0.001], and significant main effects of time [ F(2, 102) = 94.65 
p<0.001] and drug [ F(2,51) = 10.41 p<0.001]. Tests of simple effects showed 
significant differences between the groups at 10 min [ F(2,53)= 11.39 p<0.001] and 80 
min post drug [ F(2, 53) = 6.44 p<0.01]. At both time points the drug groups liked the 
‘effects of the drug’ more than the placebo group, 10 min [t(51) = -.469 p<0.001], 80 
min [t(51) = -3.07 p<0.01]. There was a trend for the 0.4 mg kg -1 ketamine group to 
like the effects of the drug more than the 0.8 mg kg -1 ketamine group at 80 min [ t(51) 
= 1.85 p=0.07]. These effects are clearly observable in Figure 6.4 where at 10 min the 
drug groups rated their liking of the drug similarly but at 80 min the high dose ketamine 
group’s ratings had decreased.
'Like the effects of the drug?'
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Figure 6.4: The subjective effects of ketamine on ratings of drug ‘liking’ across dose 
and time point.
6.4.3.6 ‘Want more o f  the drug? ’
The visual analogue scale ‘want more of the drug’ yielded a significant drug x time 
interaction [F(4, 102) = 4.92 p=0.001], a main effect of time [F(2, 102) = 63.47 
p<0.001] and drug [ F(2, 15) = 6.67 p<0.01]. Both drug groups had similar ‘wanting
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more’ ratings at 10 min, but at 80 min this desire had increased in the 0.4 mg kg -1 
group and decreased in the 0.8 mg kg 1 ketamine group. These effects can be observed 
in Figure 6.5 and were reflected in further analysis. Simple effects revealed drug 
differences 10 min post drug [ F(2, 53) = 7.08 p<0.01] and 80 min post drug [ F(2, 53)=
5.04 p<0.05]. At 10 min post drug both of the drug groups wanted more of the drug 
than the placebo group [t(51)= -3.72 p <0.001] . At 80 min post drug the two drug 
groups again wanted more of the drug than the placebo group [ t(51) = -2.23 p<0.03] 
but the 0.4 mg kg 1 ketamine group in turn wanted more of the drug than the 0.8 mg kg 
1 ketamine group [t(51) = 2.26 p<0.03].
'Want more of the drug?'
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Figure 6.5: The subjective effects of ketamine on ratings of wanting more of the drug 
across dose and time point.
Subjective Effects Scale (Table 6. 3)
The subjective effects scale yielded three main factors, ‘Perceptual disturbances’ 
(altered time perception, altered reality, visual distortions, distortion of sound and out 
of body experiences), ‘Somatic symptoms’ (dizziness, nausea /sickness, bodily 
numbness, unsteadiness, lack of co-ordination) and ‘Cognitive effects’ (impaired
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memory, confusion, impaired concentration, depression). A 4 x 3 RMANOVA of the 
perceptual distortions factor demonstrated a significant time x drug interaction 
[F(6,153) =23.11 p<0.001] and main effects of time[F(3,153) = 83.41 p<0.001] and 
drug [F(l,51) = 14.96 p<0.001]. Contrasts showed that these differences were due to 
higher scores in both drug groups than placebo during the infusion at both 10 mins 
[t(51)= 3.17 p<0.05] and 80 mins [t(51) = 7.85p<0.001] and higher scores in the high 
dose than low dose group 80 mins into the infusion [t(51) =3.51 p<0.001]. RMANOVA 
of the somatic symptoms factor yielded a significant time x drug interaction [F(6,153) = 
17.48, p<0.001] and significant main effects of time [F(3, 153) = 89.35 p<0.001] and 
drug [F(l,51) = 15.25, p<0.001].
Contrasts demonstrated higher scores in both drug groups than the placebo group both 
10 minutes [t(51)=4.81 p<0.001] and 80 minutes[t(51)=8.08 p<0.001] into the infusion. 
Analysis of the subjective ‘Cognitive effects’ again demonstrated a significant 
interaction time x drug [F(6,153) =18.90 pO.001], main effects of time 
[F(3,153)=l 12.65 p<0.001] and drug [F(l,51) = 11.97 p<0.001]. After calculating 
contrasts it was found that both drug groups had higher scores than the placebo group 
10 minutes [t(51)=3.58 p<0.01] and 80 minutes [t(51) = 8.69 p<0.001] into the infusion 
and that the high dose ketamine group had significantly higher scores after 80 minutes 
of infusion [t(51) =2.78 p<0.01].
6.4.4 Correlations
Given the suggestions that an interaction between the drug’s reinforcing effects and 
response inhibition may underlie the formation and maintenance of drug abuse, the 
relationship between these two variables was examined. In order to minimise the 
number of correlations conducted, correlations were only conducted between the 
Hayling errors of response inhibition and the ‘like effects of the drug’ and ‘want more 
of the drug’ visual analogue scales 80 mins post infusion. One significant correlation 
was found between the ‘want more of the drug’ visual analogue scale for the high and 
low dose ketamine groups and the Hayling response inhibition errors [r = -0.37
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Placebo 0.4 mg kg -1 ketamine 0.8 mg kg -1  ketamine
Pre 10 mins 80 Follow Pre 10 mins 80 mins Follow- Pre 10 mins 80 mins Follow-
mins -up up up
Drowsiness 28.48 31.29 37.04 23.20 35.13 53.54 62.49 25.62 30.10 59.25 71.95 25.96
(16.21) (18.68) (20.43) (19.54) (13.59) (16.20) (13.90) (17.61) (15.85) (13.95) (15.64) (14.65)
Anxiety 26.33 23.00 23.94 20.92 30.64 26.25 19.17 27.67 31.03 26.56 31.22 18.50
(16.59) (16.25) (17.78) (16.26) (13.92) (14.23) (15.44) (15.91) (13.19) (13.79) (21.28) (13.33)
Dis­ 23.8 23.32 26.83 22.34 29.56 26.22 27.20 25.57 25.54 29.12 38.36 20.86
contentedness (14.32) (15.80) (18.02) (16.33) (12.24) (13.33) (14.11) (14.64) (14.65) (14.70) (15.68) (11.53)
Perceptual 4.52 5.17 5.70 1.26 2.06 9.17 25.04 0.83 1.30 (2.88) 17.86 49.06 0.93
symptoms (8.57) (5.80) (8.76) (2.03) (3.06) (8.23) (18.04) (1.68) (17.60) (22.73) (1.35)
Cognitive 4.96 6.07 11.15 1.97 5.78 11.93 30.62 1.52 3.25 (4.12) 19.03 47.72 2.36
symptoms (7.74) (7.20) (12.98) (3.15) (6.86) (9.72) (16.68) (2.37) (13.99) (19.81) (3.26)
Somatic 4.87 8.43 7.9 1.17 2.98 20.78 38.5 1.02 2.50 (3.52) 33.49 55.5 3.61
symptoms (10.27) (9.82) (8.81) (1.17) (3.77) (15.91) (24.74) (1.88) (21.17) (27.65) (7.26)
Table 6.3: Mean (s.d) scores on the three factors of the mood rating scale, and bodily symptoms scale across treatment 
condition and assessment point
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p=0.025]. There was a trend towards a correlation between the ‘like more of the drug’ 
and the Hayling response inhbition errors [r=-0.32 p=0.057]. There were no 
correlations between SSQ and ADDS scores and the Hayling test.
6.5 Discussion
There are two main novel findings of the present study. Firstly, an acute dose of 
ketamine decreased response inhibition and was subjectively reinforcing in healthy 
volunteers. Secondly, there were no residual cognitive impairments or schizotypal/ 
dissociative effects three days after drug administration. This study also replicated 
previous findings in that ketamine acutely impaired prose recall and increased 
schizophrenia-like and dissociative symptoms (e.g. Krystal et al., 1994; Malhotra et al., 
1996; Harbome et al., 1996; Newcomer et al., 1999; Adler et al., 1998; Hetem et al., 
2000).
Response inhibition was found to be impaired in this study. As far as we are aware, this 
is the first study to directly examine the effect of ketamine on response inhibition in 
humans. Ketamine-induced impairments in response inhibition have been found 
previously on tasks such as the WCST (Krystal et al., 2000) that involve inhibitory 
processes but that also tap more complex mechanisms including procedural learning 
and working memory. It is important to note that no one task taps a single cognitive 
process, and hence the response inhibition deficits observed here may be related to 
working memory impairments induced by ketamine (e.g. Krystal et al., 1994; Chapter 
2). However as there were no group differences in responses on part I of this task, 
which placed a similar load on working memory as part II of the task, then deficits on 
part II may reflect a selective inhibition deficit.
This study is also the first to examine the reinforcing aspects of ketamine 
administration in humans. Subjective ratings of ‘high’ induced by ketamine have been 
previously examined (Krystal et al., 1994; Krystal et al., 1997), however these
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measures give no indication of the degree to which the drug is reinforcing. Ratings of 
desire for the drug and the degree to which drug effects were pleasant were increased in 
both drug groups but most highly in the low dose ketamine group. So even in non-drug 
abusing healthy humans, ketamine has dose dependent reinforcing effects. The high 
dose group, on the other hand, felt the effects of the drug most strongly as one would 
anticipate.
The findings of this study are consistent with the pre-clinical literature which suggests 
that NMDA antagonists disrupt response inhibition on tasks such as the 5-choice serial 
reaction time task where premature responding has been observed (e.g. Higgins et al., 
2003) and where ketamine has been found to be self-administered (e.g. Marquis et al., 
1989). These results also relate to the abuse literature where impaired response 
inhibition and salience attribution have been proposed to underlie drug addiction (I- 
RISA - Golstein & Volkow, 2002). Salience attribution refers to both the experience of 
strong positive reinforcement and attribution of primary salience to the drug. Whilst the 
subjective measures used in this study do not directly assess salience attribution, they 
reflect to some degree the extent to which the drug has become a reinforcing, positive 
stimulus (‘Like the drug...’) and the extent to which this reinforcement is salient 
(‘Want more of the drug...). Hence, the low correlation that was observed between the 
response inhibition measure and the participant’s subjective rating of their desire for 
more of the drug in this study may relate to the I-RISA model. This relationship 
suggests that these two processes may form part of a common circuit in drug abuse.
Ketamine’s effects on dopamine (DA) may have contributed to these findings, as DA 
modulation is common to drugs of abuse. Ketamine is known to have dopaminergic 
effects both directly through its low affinity action at dopamine reuptake sites and 
indirectly through NMDA-receptor modulation of dopaminergic systems (Irufine et al., 
1991; Javitt & Zukin, 1991; Smith et al., 1998). However, in animals, the effect of 
ketamine on dopamine is not correlated with its NMDA-antagonist-like discriminative 
properties (Snell et al., 1984). Also, the subjective ‘high’ induced by ketamine is also 
not affected by pre-treatment with a dopamine antagonist in humans (Krystal et al.,
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1997). The animal literature suggests that ketamine-mediated dopamine effects increase 
DA release in the prefrontal cortex (PFC) at low doses (Verma & Moghaddam, 1997) 
but interfere with the action of DA uptake sites at higher doses (Smith et al., 1981). 
The above differing mechanisms might potentially explain the biphasic drug effects 
observed in the current study as the lower dose being more reinforcing at 80 minutes 
than the higher dose. Recent preclinical evidence suggests that alterations in 
glutamatergic transmission are related to aspects of compulsive drug use, thus it is 
possible that ketamine-induced changes in glutamatergic transmission may also be 
responsible for the response inhibition deficits and associated drug incentive salience 
observed in this study. As other drugs, such as ethanol, with NMDA-receptor and 
glutamatergic action acutely disrupt response inhibition (Finn et al., 1999), a common 
mechanism may be involved in these deficits. In a previous study of recently detoxified 
alcoholics, ketamine failed to induce alcohol craving, however it did produce subjective 
ethanol-like effects (Krystal et al., 1998c). These ethanol-like effects were anecdotally 
noted by participants in the present study, particularly in the low dose group, many of 
whom likened the experience to being ‘quite drunk’. It is possible that this may have 
contributed to the low dose group’s desire for more of the drug and strong enjoyment of 
its effects. The high dose group reported stronger psychotomimetic effects, and thus the 
experience was less ethanol-like which may explain differing responses between the 
high and low dose ketamine groups on these scales. The above mechanisms may 
underlie the continued abuse of ketamine. Ketamine dependence has been reported 
anecdotally (Grinspoon & Bakalar, 1997; Siegel, 1978; Ahmed & Petchovsky, 1980; 
Hurt & Ritchie, 1994; Jansen, 1990; Kamaya & Krishna, 1987a), and is thought to be 
an increasing problem amongst abusers of this drug (Jansen, 2001). Further 
understanding of the relationship between this apparent disruption in inhibitory 
processes and increased drug incentive salience may benefit both models of drug 
addiction and understanding of the mechanisms of compulsive ketamine use.
The second major finding of this study was that there were no residual effects following 
an acute dose of ketamine in healthy volunteers on measures that demonstrated 
impairments in ketamine abusers. This extends the findings of Newcomer et al. (1999)
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who found no residual schizophrenic symptoms 48 hours after a ketamine infusion. The 
lack of residual cognitive effects observed in this study is interesting in light of research 
with recreational users where residual impairments on these cognitive tasks were found 
(Curran & Morgan, 2000; Curran & Monaghan, 2001). This would seem to indicate 
that residual effects in recreational users are not related to transient brain changes, as a 
result perhaps of residual levels of the metabolite norketamine, but indicative of chronic 
effects or pre-existing differences in abusers and non-abusers. If the impairments in 
recreational users are chronic effects, then they may possibly relate to lasting 
neurotoxicity, similar to that observed in animals (Olney et al., 1991). Pre-existing 
differences are difficult to rule out without prospective studies but the suggestion of 
chronic effects following repeated ketamine use has serious implications for the 
growing population of abusers. Chronic ketamine effects are also relevant to 
prescribing practice in some areas of medicine, such as chronic pain, where repeated 
doses of ketamine are often used (Hewitt, 2000). This lack of residual effects also 
offers ethical reassurance for future acute ketamine studies, in that prolonged effects 
following a single dose are not apparent, contrary to those observed in the PCP 
literature (Ellison, 1995).
Acutely ketamine also impaired prose recall, replicating the findings of previous studies 
( e.g.Harbome et al. 1996) and further establishing the role of the NMDA-receptor in 
episodic memory. Ketamine impaired memory for information learnt under the 
influence of the drug but not for information learnt prior to drug administration, hence 
supporting prior evidence suggesting ketamine’s effects on memory are as a result of 
encoding and not retrieval deficits (Malhotra et al., 1996; Hetem et al., 2000). Fluency, 
which taps frontal functioning was not affected by ketamine administration. This 
replicates the findings of some previous ketamine studies (Newcomer et al., 1999; 
Krystal et al., 2000; Abel et al., 2003) and yet differs from others (Adler et al., 1998; 
Krystal et al., 1994). It also differs from findings in populations of recreational users 
where category fluency has been found to be impaired with more errors made both 
acutely and residually (Curran & Morgan, 2000; Curran & Monaghan, 2001). The 
preserved fluency observed in the current study also indicates a selective sparing of
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some frontal functions, which suggests that response inhibition deficits were not as a 
result of a global impairment in executive functioning. Neuroimaging studies have 
found verbal fluency to be associated with activity in the left dorsolateral prefrontal 
cortex (Frith et al., 1991) whereas the orbitofrontal cortex and anterior cingulate have 
been implicated in response inhibition (Casey et al., 1997; Goldstein et al., 2001). 
Acute ketamine administration is associated with hyperfrontality and decreased 
activation in the anterior cingulate (Breier et al., 1997; Lahti et al., 1995a; Vollenweider 
et al., 1997). The behavioural data of the current study may indicate selective 
hyperactivation in some frontal regions. Ketamine acutely increased schizophrenic-like 
and dissociative symptoms, again replicating previous studies (e.g. Krystal et al., 1994). 
Visual analogue scales of mood and subjective effects reflected changes consistent with 
reports in the ketamine literature, such as increases in drowsiness and alterations in 
perceptual experiences. The subjective effects of perceived cognitive and perceptual 
disruptions were related to the dose of ketamine given, whereas somatic symptoms 
were not dose-dependent, and may be related to individual differences.
In summary, this study has replicated data from previous studies suggesting an episodic 
memory impairment, preservation of fluency and increase in schizotypal and 
dissociative symptoms. In addition, this study demonstrated no residual cognitive 
effects three days following administration of an acute dose, on measures that 
demonstrated residual effects in recreational users. Finally, related to recent preclinical 
findings (Higgins et al., 2003), an impairment in response inhibition was observed
acutely following ketamine and was found to be related to increases in subjective
ratings of desire for the drug. Further work is necessary to fully explore these
mechanisms as this may elucidate the role of response inhibition and salience
attribution in drug, and particularly, ketamine abuse.
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Chapter 7: Just say ‘No-go’ to drugs
R e s p o n s e  i n h ib i t i o n  f o l lo w in g  a c u te  k e t a m i n e  in  h e a l t h y  v o l u n t e e r s  
a n d  r e s p o n s e  i n h ib i t i o n  a n d  s a l i e n c e  a t t r i b u t i o n  in  r e c r e a t i o n a l  
k e t a m i n e  u s e r s
“Frequent use o f ketamine can lure one as an escape since a blissful and fantastic state 
o f fearless, disembodied consciousness is so easily available...”
D.M.Tumer (1994) The Essential Psychedelic Guide
7.1 Overview
In theories of drug abuse and dependence, two processes have been emphasised. The
first is an alteration in motivation whereby drug stimuli become more salient than other
‘natural’ reinforcers. The second is reduced ‘impulse control’ or inhibitory processes.
The study reported in this chapter had three main aims: 1) to further investigate
whether acute ketamine impairs response inhibition in healthy volunteers 2) to
investigate whether response inhibition is impaired in ketamine users and poly-drug
users compared to non-drug using controls 3) to investigate whether ketamine users
find ketamine stimuli more salient than ‘natural’ reinforcers. We examined the effects
of two doses of ketamine on response inhibition using a Go/No-go task in healthy
volunteers with a double-blind, placebo-controlled independent groups design
(Experiment 1). We tested ketamine users, poly-drug controls and non-drug users were
tested on the same Go/No-go task and additionally on a novel ‘Drug Go/No-go task’
(Experiment 2). The latter paradigm aimed to investigate salience attribution and
response inhibition within the same task. In Experiment 1, acute ketamine reduced the
number of hits on the Go/No-go task. In Experiment 2, on the night of drug use
ketamine both increased false alarms and decreased hits on the Go/No-go task. When
drug free, there were no differences in response inhibition between the three groups.
179
There was some evidence on the Drug Go/No-go that drug users, i.e. poly-drug controls 
and ketamine users, had reduced attentional bias to ‘natural’ incentive stimuli. The 
indication of reduced attentional bias to ‘natural’ incentive stimuli in recreational drug 
users is interesting and should be further investigated, however problems with the novel 
Drug Go/No-go task complicated interpretation of these data.
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7.2 Introduction
Ketamine dependence, as discussed in Chapter 1, has been reported in the popular press 
(Lilly, 1978; Sputz, 1989; Turner, 1994) and there have been a number of similar case 
reports in the medical literature (Ahmed & Petchovsky, 1980; Hurt & Ritchie, 1994b; 
Jansen, 1990; Lim, 2003; Moore & Bostwick, 1999; Pal et al., 2002; Soyka et al., 1993; 
Kamaya & Krishna, 1987b). In rats and non-human primates, ketamine is repeatedly 
self-administered (Marquis et al., 1989; Winger et al., 1989). Ketamine also produces 
conditioned place-preference in rats (Layer et al., 1993). An acute dose of this drug also 
increases ratings of subjective ‘high’ in healthy humans (Krystal et al., 1998b; Krystal 
et al., 1994). Further, healthy volunteers rated themselves as liking the effects of 
ketamine and wanting more of the drug after a single dose (Chapter 6; Morgan et al., 
2004b). It seems intriguing that these ‘schizophrenia-like’ effects can be perceived as 
pleasant and desirable even by non-drug users.
The desire to take a drug again and the degree to which its effects are perceived as 
pleasurable are thought to be governed by a complex interplay of several factors. 
Whilst more recently other neurotransmitter (NT) systems have been suggested to be 
involved (e.g. glutamatergic, Cornish et al., 1999) traditionally, the mesolimbic 
dopamine circuit is considered crucial in mediating the rewarding properties of drugs of 
abuse (Koob, 1992). Repeated stimulation of dopamine circuits is thought to lead to 
abnormal reward dependent learning (Di Chiara, 1999). Thus the drug user learns to 
strongly associate the drug of choice and cues connected to it, including people and 
places, with pleasure and reward.
It is thought that in drug users, this abnormal reward dependent learning leads to 
primary salience being attributed to the drug (Robinson & Berridge, 1993), at the 
expense of other available rewarding stimuli in the environment (Goldstein and 
Volkow, 2002). An example of how this is manifested in drug users’ lives is the version 
of the ‘cocktail party phenomenom’ (Moray, 1959) experienced by heavy drug users.
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Drug dependent individuals report that, even in a noisy environment, conversations that 
mention drugs capture their attention suddenly. The attention- grabbing properties of 
drug stimuli have been shown in a variety of drug using populations, for example in 
heroin addicts as a bias to drug- salient pictures in dot-probe tasks (Lubman et al., 
2000) and in alcohol dependent individuals with the Stroop task (Stetter et al., 1995). 
Wanting drugs over other available rewards in the environment is apparent from the 
manner in which drug users, and in particular drug dependent individuals, will rather 
take drugs than engage in more ‘naturally’ rewarding activities such as eating. Related 
to this, response to monetary rewards has been found to be reduced in abstinent 
smokers and restored after one cigarette (al-Adawi & Powell, 1997). However, as far 
as we are aware, no studies in the drug abuse field have addressed the issue of salience 
of drugs in direct comparison to other non-drug incentive stimuli.
Salience attribution is thought to be reliant on the frontal cortex interacting with limbic 
regions to determine the value of a reward and is particularly reliant on dopaminergic 
(Dayan & Balleine, 2002) and to a lesser extent glutamatergic (Reynolds & Berridge, 
2003) transmission. As ketamine stimulates both dopamine and glutamate release 
(Moghaddam et al., 1997), defective salience attribution processes may contribute to 
the maintenance of ketamine abuse.
Despite the clear role of ‘wanting’ and ‘liking’ the drug, users will continue to use a 
drug even when it ceases to be rewarding (Fischman et al., 1985), hence it has been 
postulated that the rewarding effects of drugs are necessary but not sufficient for the 
development of drug abuse (Goldstein & Volkow, 2002). Impairments in the cognitive 
domain are also thought to be key to the maintenance of substance misuse.
Frontal functioning is thought to be particularly impaired in drug users. It has been 
suggested that in compulsive drug use, prefrontal top-down processes are compromised 
and inhibitory control is reduced, leading to accentuated stimulus-driven behaviour. 
Substance abuse is thought to result in part from a breakdown in the control of self­
generated behaviour (Goldstein & Volkow, 2002). This renders users less able to
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prevent themselves seeking and then taking the drug. Research has found deficits in 
response inhibition in various drug using populations (Powell et al., 2002; Fillmore & 
Rush, 2002a) which supports this assertion. An acute dose of ketamine may also impair 
response inhibition in healthy volunteers (Chapter 6; Morgan et al., 2004d). It is 
therefore plausible that a breakdown in response inhibition could go some way to 
explaining the desire to repeatedly use ketamine. In support of this, frontal functioning 
as indexed by perseverative errors on a verbal fluency task was found to be impaired in 
frequent compared to infrequent ketamine users both on drug and when drug free 
(Curran & Monaghan, 2001). No research has addressed whether, amongst other frontal 
functions, response inhibition specifically is impaired in ketamine users.
These concepts of deficits that contribute to drug abuse have been brought together in 
the ‘Impaired Response Inhibition and Salience Attribution’ (I-RISA) model (Goldstein 
& Volkow, 2002). Whilst, it is accepted that many other processes are involved in 
deciding both the rewarding properties and maintenance of drug abuse (e.g. 
motivational, learning, affective) the latter authors propose that compulsive drug use is 
a result of “...overvaluing of drug reinforcers, undervaluing of alternative reinforcers 
and deficits in inhibitory control for drug responses...” (Goldstein & Volkow, 2002 pp. 
1642).
Given that impaired salience attribution and response inhibition are suggested in drug 
abuse, it seemed reasonable to speculate that ketamine users may show abnormal 
salience attribution to ketamine related-stimuli compared to other non-drug incentive 
stimuli. Specifically, ketamine users may also show particularly poor response 
inhibition to ketamine-related stimuli. We therefore developed a task to examine 
responses to drug related stimuli, compared to non-drug incentive stimuli (i.e. food, sex 
and money) and neutral stimuli (e.g. furniture). Importantly, we also designed the task 
to concurrently examine the ability to inhibit responses to these three different stimuli, 
thereby testing both components of the I-RISA model within the same task. This ‘drug 
Go/No-go task’ described below was employed in our fourth study of ketamine users.
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The aims of this study were three-fold. Firstly, we wished to investigate response 
inhibition following acute, acute on ‘chronic’ and ‘chronic’ ketamine. This was done in 
three ways, i) using a conventional Go/No-go task, in healthy volunteers following an 
acute dose of ketamine (Experiment 1) ii) using the same Go/No-go task in ketamine 
users both on the night of drug use (day 0) and then three days later (day 3) when drug 
free (Experiment 2) ii) using the novel Drug Go/No-go task on the 3rd day after drug 
use (Experiment 2). For the drug user studies, three groups of participants were 
compared: ketamine users, poly-drug controls and non-drug users. Drug using controls 
were used as an additional comparison group because ketamine users are a population 
of poly-drug users and thus to isolate the effects of ketamine it was important to 
compare not only to non-drug users, but to a group matched for drug use apart from 
ketamine. Based our previous findings of response inhibition impairments following an 
acute dose of ketamine in healthy volunteers on a complex response inhibition task 
(Morgan, 2004b; chapter 6) we predicted that acute ketamine would produce response 
inhibition impairments in Experiment 1. In Experiment 2 we predicted that, on day 0, 
ketamine users would demonstrate poorer response inhibition than poly-drug controls 
and non-drug users. Additionally we speculated that poly-drug users may also show 
reduced response inhibition compared to non-drug controls based on findings of greater 
impulsivity in poly-drug users (M.Morgan, 1998). On day 3, we predicted that 
response inhibition deficits would be reduced in ketamine users relative to day 0 but 
that both ketamine and poly-drug users would have impaired response inhibition 
compared to non-drug users (M. Morgan, 1998). We also tested response inhibition, by 
examining overall errors on the novel ‘Drug Go/No-go’ task.
The second aim was to examine salience attribution in drug users. We hypothesised 
that ketamine users should show an attentional bias towards ketamine-related stimuli. 
As our control groups both used alcohol and one used cannabis, we speculated that they 
may show more bias towards alcohol and cannabis than ketamine stimuli. We predicted 
that all participants would show a bias to incentive stimuli (food, sex, money related) 
compared to neutral, but based on the I-RISA model that the bias may be smaller in 
drug users compared to non-drug users. Our novel task was designed so that we could
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also test response inhibition to different types of stimuli in the same three groups of 
participants. We hypothesised that non-drug users would exhibit most false alarms and 
quickest reaction times to non-drug incentive stimuli, whereas the ketamine users 
should show most false alarms and quickest RTs to ketamine-related stimuli. We also 
aimed to use this study to pilot the novel Drug Go/No-go task to examine its feasibility 
and sensitivity to drug effects in a population of recreational drug users.
Experiment 1 -  Response inhibition following and acute dose of ketamine
7.3 Method
7.3.1 Design, Procedure, Particpants
These exactly followed those reported in Chapter 3. Thus 48 participants were 
randomly allocated to receive either ketamine (low-dose or high-dose) or placebo 
(0.9% NaCl solution). As part of the test battery administered, we also examined 
performance on the Go/No-go task before drug administration and during the infusion.
7.3.2 Go/No-go task:
This task tapped response inhibition and response reversal. The task consisted of three 
blocks: a practice block of 40 stimuli and two blocks of 100 stimuli (the task is depicted 
in Figure 7.1). Stimuli were 16 characters of the alphabet organised into two sets of 8. 
For the practice block participants were instructed to respond, by pressing a designated 
key on the computer keyboard as quickly as possible, to each letter on the screen. Each 
letter appeared for 800ms followed by an inter-stimulus interval (ISI) of 500ms. In the 
first test block (Phase 1) participants were instructed to respond by the same designated 
key press to all but two (e.g. L, C) of the eight letters. These two letters constituted the 
‘Nogo’ trials. The proportion of ‘Go’ stimuli was 75% and of ‘No-go’ stimuli was 
25%. Participants were then given a short break and then were presented with the 
second test block (Phase 2) and were then instructed not to respond to a different two 
(e.g. Q, N) of the eight letters . This required participants to respond to the two letters 
for which responses were required to be inhibited in the previous block (e.g. L, C), thus 
tapping response reversal. Scores were recorded in terms of false alarms (commission /
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response inhibition errors), hits (correct responses), misses on reversal trials and 
reaction times.
Practice Phase 1 Phase 2 (reversal)
Action: Respond to all letters Do not respond to L and C Do not respond to Q and N 
Figure 7.1: Schematic of the Go/No-go task
Subjective Ratings: the SSQ, ADDS, MRS were administered and results are reported 
in Chapter 3.
7.3.3 Statistical Analysis
Go/No-go data from day 0 were analysed using a repeated measures analysis of 
variance (RMANOVA) with Time (Pre-drug, Post drug) and Phase (1 - response 
inhibition or 2 - response inhibition & reversal) as the within subjects factors and 
Group (high dose ketamine, low dose ketamine or placebo) as the between subjects 
factor. Scheffe’s test was used to analyse significant interactions on the Go/No-go with 
the alpha level adjusted to 0.0167 to control for multiple comparisons. Non-significant 
main effects and interactions are not reported.
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7.4 Results
7.4.1 Go/No-go task
Analysis of the correct responses on the Go/No-go demonstrated a significant main 
effect of Time [F(l,45) = 20.83, p<0.001] and a Group by Time interaction [ F(2,45) = 
3.39, p=0.044]. Post-hoc tests demonstrated significantly lower hits post drug in the 
high dose group compared to the placebo (p =0.043) and low dose (p=0.026) -  See 
Figure 7.2.
For the false alarm data, there was a significant main effect of time [F(l,45) = 6.29, 
p=0.016] whereby more false alarms were made during the infusion than before.
There were no differences in the number of reversal omission errors pre and post drug 
in any of the groups.
For reaction times to hits, there was a main effect of Phase [F(l,45) =48.84, p<0.001] 
and a significant Phase x Time interaction [ F(l,45) = 6.80, p=0.013]. There was a 
significant decrease in reaction time for Phase 1 pre and post drug (p<0.001) but no 
difference in reaction time pre and post drug for Phase 2.
Reaction time to FAs, for those subjects that made false alarms on all sections of the 
task, yielded a similar main effect of Time [F(l,34) = 15.86, p<0.001] and a Phase x 
Time interaction [F(l,34) = 5.51, p=0.025]. There was a significant decrease in reaction 
time to false alarms on Phase 1 pre to post drug (p<0.012).
Mean hit, false alarm and reaction time data are presented in, the Appendix Table A3.
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Figure 7.2 : Number of hits on the Go/No-go task pre and post drug across treatment 
condition.
7.4.2 Subjective Effects : These are reported in Chapter 4.
Experiment 2 : Response inhibition and salience attribution in recreational 
ketamine users
7.6 Method
7.6.1 Participants and Design
Participants were recruited at dance music venues using a snowball sampling technique 
(Solowij et al., 1992). They were tested on two occasions: on day 0, when the ketamine 
group were under the influence of the drug and again 3 days later. Test versions were 
counterbalanced across group and day. The study was approved by the institutional 
ethics committee and was conducted in accordance with the Declaration of Helsinki.
- - - o- - - placebo
—  A —  - low dose
ketamine
— H—  high dose 
ketamine
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7.6.2 Procedure
Participants were approached in a party setting on day 0 by the experimenters and 
asked if they were interested in taking part in a study about drug users. If they agreed 
volunteers were taken individually to a quiet area where they were given full 
information about the study and informed the experimenter what, if any, drugs they had 
taken or intended to take that evening. They were excluded if they had taken any drugs 
other than 1) ketamine or 2) small amounts of cannabis (< 1 “joint”) or more than 2 
units of alcohol that evening. Participants on ketamine were asked to estimate when 
they had taken the drug, and only participants who had recently taken ketamine (i.e. 
within 10 minutes) were included. Participants then completed the assessments detailed 
below and arrangements were made to meet up 3 days later. The task battery lasted 
approximately 30 minutes. Participants were asked to abstain from using alcohol and 
other recreational drugs between the two test sessions. The follow-up test session on 
day 3 was carried out in the participant’s home or in a recreational centre, in a room 
with minimal distraction. They then completed the same assessments as on day 0 along 
with a pre-morbid IQ measure and a detailed drug-use questionnaire. Participants 
provided written, informed consent on both days of testing.
7.6.3 Assessments
Go/No-go : Details of this task are given above in Experiment 1. Participants were 
tested on Day 0 and Day 3.
Drug Go/No-go: Day 3
This novel task is designed to tap response inhibition and salience attribution. Stimuli 
were 54 words, 6 each from 3 separate categories: drug related words (ketamine, 
cannabis or alcohol-related), incentive words (food, sex and money related) and neutral 
words (furniture, fabric and building-related) (See Fig 7.3). Non-drug words were 
chosen from the MRC psycholinguistic database
(http://www.psv.uwa.edu.au/MRCDataBase/uwamrc.htm) and matched between 
categories for imageability. Words were selected from an original list of 135 (approx.
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15 per group). Drug words were rated by 5 ketamine users, 5 cannabis users and 5 
alcohol users (not included in this study and blind to its purpose) for representativeness 
of category and valence.
Drug words Incentive words Neutral words
Ketamine Sex Fabric
No-eo Go Go
Cannabis Money Buildings
Go No-eo Go
Alcohol Food Furniture
Go Go No-eo
Figure 7.3: The ‘Drug’ Go/no-go task.
The final words (See Appendix Table 4A) were selected on the basis of these ratings, 
i.e. the most representative of the category and the most positive valence. As 6 
unambiguous words could not be generated for the ketamine category, all groups of 
drug words contained three ambiguous and 3 non-ambiguous drug words. All stimuli 
were matched for word length, number of syllables and within category for frequency 
and ambiguity. Stimuli were presented in 9 blocks of 18, each block containing one set 
of words from each category. Each block contained 3 different sets of words to the 
block before, and words were pseudo-randomly presented within each block. Stimuli 
were presented in the centre of computer screen using DMDX software for 1000 msec 
with a 100 msec inter-stimulus interval (I.S.I). In each block participants were 
instructed not to respond to a particular category of words (e.g. ketamine-related words) 
but to respond to all other words (e.g. sex and fabric related words). Before the task 
participants were given a list containing all the words in each category to familiarise 
themselves with for 2 min. Then they were given a practice block containing different 
types of stimuli (all neutral) from those included in the task before moving on to the 
task itself. Performance measures were hits (number of targets correctly responded to),
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false alarms (number of commission errors) and reaction times. The task provided 3 
measures: i) overall performance irrespective of the nature of stimuli as a general 
measure of inhibitory control (false alarms); ii) an index of comparative salience of the 
different types of stimuli (e.g. incentive vs. drug - indexed by speed of response to the 
different stimuli); iii) a measure of response inhibition and salience attribution indexed 
by the number of false alarms to different types of stimuli.
Spot the word test (Baddeley et al., 1993): Participants were required to choose the real 
word out of pairs of words/non-words. This task has been shown to give a measure of 
IQ that is correlated 0.69 with the National Adult Reading Test (NART: (Crawford et 
al., 2001).
Subjective Ratings
Ratings used in previous studies (SSQ, ADDS, MRS, SES) were again employed on 
both day 0 and day 3. Two additional scales were administered on day 3:
Peter’s Delusions Inventory (Peters et al., 1999)
A 30-item questionnaire tapping delusional beliefs, in which participants also rated 
whether they held certain delusions with a yes/no response and then rated their distress, 
preoccupation and conviction regarding the delusion on a five point scale.
Barratt Impulsivity Scale (Patton et al., 1995)
A 30-ietm questionnaire was used to examine trait impulsivity. The scale has 3 factors: 
Attentional Impulsiveness, Motor Impulsiveness, and Nonplanning Impulsiveness.
7.6.4 Urine analysis
Participants were asked to give a urine sample to test for drug use (cannabis, MDMA, 
amphetamines cocaine, opiates, ketamine and benzodiazepines) on day 0 and day 3.
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7.6.5 Statistical Analyses
Go/No-go data from day 0 and day 3 were analysed using a repeated measures analysis 
of variance (RMANOVA) with Day (0 or 3) and Phase (1 - response inhibition or 2 - 
response inhibition & reversal) as the within subjects factor and Group (ketamine, poly­
drug or non-drug) as the between subjects factor. Scheffe’s test was used to analyse 
significant interactions on the Go/No-go with the alpha level adjusted to control for 
multiple comparisons.
Drug Go/No-go data was also analysed with a RMANOVA with Stimulus type (drug, 
incentive or neutral) as the within subjects factor and Group as the between subjects 
factor as above. Where significant interactions were obtained 2 planned orthogonal 
contrasts were conducted: I) ketamine vs poly-drug and non-drug controls II) drug 
users vs. non-drug users. If there were significant differences for the ‘drug’ stimuli a 
further RMANOVA was conducted with Drug stimulus type (ketamine, cannabis, 
alcohol) and the within subjects factor and Group (ketamine, poly-drug, non-drug) as 
the between subjects factor. The above contrasts were again conducted where 
significant interactions were found. There were no differences in responses to the 
different sets of words within the categories ‘neutral’ and ‘incentive’ so data were 
collapsed across the sets.
Subjective ratings on day 0 and 3 were also analysed with a RMANOVA (day, group). 
For demographic, trait questionnaire and drug use data one-way ANOVAs were 
conducted if the data were parametric and Kruskall-Wallis or Mann-Whitney U tests 
for non-parametric data dependent on the number of groups.
7.7 Results
7.7.1 Demographics and drug use
58 participants initially took part in the study, 5 dropped out before follow-up and 3 
were excluded (1 non-drug participant tested positive for cannabis and 2 of the 
ketamine group reported drug use between day 0 and day 3). 50 participants completed
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the study; 20 ketamine users (mean age 22.55 ±1.18 years, 8 females), 17 polydrug 
using controls (mean age 22.00 ± 1.70 years, 6 females) and 13 non-drug using controls 
(mean age 22.00 ± 0.01 years, 3 females). There were no significant differences in age, 
sex or premorbid IQ [Spot the word test score - ketamine: 48.10 ± 4.78; poly drug 
control: 50.24 ± 2.86; non-drug control: 46.3 ± 3.95]. The non-drug group did not 
report the current use of any recreational drugs except alcohol, where they were 
matched with the other groups [mean alcohol use non-drug -  14.3 (6.43) days per 
month; 7.51 (2.45) units per session; for 6.35 (2.56) years]. Six participants in the non­
drug group reported trying cannabis on a maximum of 3 occasions, but all had been 
abstinent for over a year. The ketamine and poly-drug control groups did not differ in 
lifetime prevalence of drug use (see Table 7.1) but differed in years of regular MDMA 
use (U= 90.50, p<0.014). Ketamine users had used ketamine for a mean of 2.70 ± 0.36 
days per month, using 0.46 ±0.10 grams per session and had taken the drug for 2.19 ± 
0.40 years.
All ketamine users who provided a urine sample (n=17) tested positive for ketamine on 
day 0. On day three, one of the ketamine group tested positive for ketamine but was not 
excluded as they claimed not to have taken ketamine for 3 days; 16 tested positive for 
THC. All of the control group who were tested (n=15) tested positive for THC on both 
days, but no other drugs. Of the non-drug group (n=13) none tested positive for any 
drugs of abuse.
7.7.2 Cognitive Assessments
7.7.2.1 Drug Go/No-go
Due to a recording error data for 2 participants in the ketamine group were lost 
therefore for this task: ketamine group (n=18), poly-drug control (n=17), non-drug 
(n=13).
There were no differences in the number of hits across groups or across the different 
stimuli on the Drug Go/no-go task. A RMANOVA of the reaction times for hits (to
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Drug, Neutral or Incentive words) yielded a significant Group x Stimulus type 
interaction [F (4,90) = 3.33 p=0.014]. Contrasts demonstrated faster RTs to incentive 
words in the non-drug group compared to the drug groups [t(45)=2.35 p=0.023] but no 
other differences. (Fig 7.4) Analysis of RTs to drug stimuli did not produce any 
significant group differences.
Drug Days/Month Amount/session Years taken
PD
control
N=17
Ketamine
users
N=20
PD
control
N=17
Ketamine
users
N=20
Control
users
N=17
Ketamine
users
N=20
Alcohol 17.53
(7.24)
17.85
(7.19)
9.12
(3.77)
9.00
(3.28)
6.18
(1.85)
6.65
(3.05)
Cannabis 10.12
(9.49)
14.40
(10.45)
2.34
(1.71)
2.53
(2.30)
6.00
(2.65)
6.03
(3.11)
Cocaine 1.06
(1.48)
1.05
(1.47)
0.45
(0.36)
0.29
(0.33)
2.82
(1.13)
2.90
(2.34)
Ecstasy 1.18
(1.38)
1.20
(0.77)
1.47
(1.12)
2.15
(0.81)
2.29
(1.65)
4.03*
(1.90)
Tobacco 13.59
(14.04)
17.80
(13.82)
5.06
(6.57)
4.60
(5.19)
2.18
(2.72)
3.45
(3.32)
Alcohol (no. units); cannabis (no. joints - 1 gram calculated to be approx. 6-8 joints);
ecstasy (no. tablets); tobacco (no. cigarettes) * p<0.01, PD = Poly-drug
Table 7.1: Means and standard deviations for drug use by experimental group and
control.
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Ketamine users Poly-drug controls Non-drug controls
No. Hits ketamine 11.67 (0.76) 11.29(1.69) 10.69(1.37)
No. Hits cannabis 11.02(1.21) 11.44 (0.66) 10.78(2.38)
No. Hits alcohol 11.17(1.29) 11.47 (0.54) 11.69(1.11)
No. Hits drug 33.86 (2.95) 34.20(1.77) 33.15(2.51)
No. Hits incentive 34.33 (4.64) 35.12(1.17) 33.31 (4.64)
No. Hits neutral 34.06(2.41) 35.12(1.9) 32.77 (4.71)
p<0.05
Table 7.2: Data for Hits on the Drug Go/ No-go task
Figure 7.4: Reaction time to targets across group and stimulus type. T-bars represent 
SEM.
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Figure 7.5: Number of false alarms, across group and stimulus type. T-bars represent 
standard error of the mean (SEM).
For number of false alarms (FAs) there was a Group x Stimulus Type interaction 
[F(4,90) = 3.96 p=0.042] and a significant main effect of Stimulus Type [F(2,90) = 
12.37, p= 0.004]. Planned contrasts indicated that non drug users made more false 
alarms than drug users for drug words [t(45) = 2.09 p=0.042] (Figure 7.5). Because of 
this group difference in FA’s separate analysis of the drug words was conducted, using 
the proportion of false alarms to each drug word. Contrasts indicated that non-drug and 
poly-drug users made more false alarms for ketamine stimuli than ketamine users [t(45) 
= 2.18 p=0.035] and that drug users make more false alarms for alcohol stimuli than 
non-drug users [t(45) =2.70 p=0.011] (Fig 7.6). There were no group differences in 
omission reversal errors.
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Figure 7.6: Proportion of false alarms (of total no. false alarms) for drug stimuli across 
group, T-bars represent SEM.
RT’s for false alarms were not analysed because few participants made false alarms on 
all 3 types of words [control n=4, poly-drug n= 9, ketamine n=12].
7.7.2.2 Go/No-go (Table 7.3)
Analysis of hit rates on the go/no-go task demonstrated a significant Group x Day 
interaction [F(2,49) = 6.77 p=0.03] and significant main effects of time [F(l,49) = 7.15 
p=0.011], and group [F(2,49) = 5.55 p=0.008]. A significant main effect of Phase 
[F(l,49) = 18.19 p<0.001] indicated all groups had fewer hits on the second (reversal) 
phase of the task. Exploring the Group x Day interaction with post-hoc Scheffes test, it 
was found that on day 0 there were significantly fewer hits in the ketamine group 
compared to the non-drug users and poly-drug controls at Phase 2 (both p< 0.01), and a 
trend for a difference on Phase 1 (p<0.029). On day 3 however, no there were no 
differences between the groups in either Phase.
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Ketamine users Poly drug users Non-drug users
Day 0 No. Hits Part 1 69.33 (7.38) 74.12(1.83) 72.80 (2.97)
No. Hits Part 2 65.53 (9.10) 72.70(1.76) 71 (2.74)
No. FA’s Part 1 8.73 (3.71) 5.59 (3.43) 4.2 (3.29)
No. FA’s Part 2 9.27 (2.96) 5.82 (3.00) 4.10(2.81)
Mean RT Hits Parti 412.17(35.7) 388.58 (41.27) 433.64 (78.17)
Mean RT Hits Part 2 420.85 (30.65) 425.77 (34.56) 467.82 (68.4)
Mean RT FA’s Part 1 335.18 (57.28) 346.70 (90.0) 345.94 (47.76)
Mean RT FA’s Part 2 359.66 (53.99) 380.59 (67.45) 393.31(73.43)
Day 3 No. Hits Part 1 74.13(1.12) 73.88(1.53) 72.70(1.76
No. Hits Part 2 72.81 (2.45) 72.80 (2.40) 71.8(1.81)
No. FA’s Part 1 6.46 (2.89) 5.255 (2.80) 4.4 (2.06)
No. FA’s Part 2 6.60 (2.92) 5.5 (2.94) 4.80 (2.97)
Mean RT Hits Parti 392.23 (42.75) 402.28 (46.6) 422.22 (39.96)
Mean RT Hits Part 2 422.92 (31.92) 418.43 (28.07) 457.31 (31.28)
Mean RT FA’s Part 1 339.90 (38.61) 329.87 (39.03) 362.33 (37.92)
Mean RT FA’s Part 2 394.41 (86.84) 379.26 (59.84) 450.72 (77.95)
Table 7.3: Go/No-go hits, false alarms (FA’s) and respective reaction times (RTs) 
across ketamine users, poly-drug users and non-drug users
Reaction time data for hits showed significant main effects of Phase [F(l,49) = 40.59, 
p<0.001] with slower RTs for Phase 2 than Phase 1 and Group [F(2,49) = 6.31 
p=0.004] Dunnetf s t demonstrated significantly faster RTs in the ketamine group 
compared to non-drug users (p=0.003) but no differences between the poly-drug 
controls and the ketamine users. There was also a trend for a Group x Day x Phase 
interaction [ F(2,49) = 2.72 p=0.078].
False alarm data showed a Group x Day interaction [F(2,49) = 4.23 p=0.022], a main 
effect of Day [F(l,49) p<0.049] and a highly significant main effect of Group [ F(2,44) 
= 7.47 p=0.002]. On day 0, post-hoc Scheffes tests demonstrated that false alarms rate
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in the ketamine users was higher than that of the non-drug users and poly-drug controls 
on both versions at the p<0.01 level; however there were no differences between the 
groups on day 3.
For the false alarm reaction time data there were no group differences, but there were 
main effects of Day [F (1, 44) = 16.05 p<0.001], with slower RTs on day 3 for all 
participants and Phase [F (1,44) = 48.76 p<0.001] with slower RTs to FA’s in all 
groups for Phase 2.
7.7.3 Subjective Effects (See Table 7.4)
7.7.3.1 Schizotypal Symptomatology Questionnaire: RMANOVA demonstrated a 
significant Group x Day interaction [F(2,47) = 28.57 p<0.001 ] and main effects of 
Day [F(l,47) = 37.47 p<0.001] and Group F[2,47] = 15.79 p<0.001]. Post-hoc analyses 
(Scheffe) showed that, there were higher levels of schizotypal symptoms in the 
ketamine group on day 0 than either control group (p<0.01) but no differences on day 3.
7.7.3.2 Adapted Dissociative Symptoms Scale: RMANOVA demonstrated a significant 
Group x Day interaction [F(2,47) = 28.03 p<0.001 ] and main effects of Day [F(l,47) = 
35.12 p<0.001] and Group F[2,47] = 39.71 p<0.001]. Post-hoc analyses (Scheffe) 
showed that, although the level of symptoms in the ketamine group decreased between 
day 0 and 3, there were greater levels of dissociative symptoms in the ketamine group 
on both day 0 and 3 than either control group (p<0.01).
7.7.3.3 Mood Rating Scale: There was a significant Day x Group interaction for the 
mood factor of sedation [F(2,47) = 8.056 p<0.007], as well as main effects of Day 
[F(l,47) =8.056 p<0.001] and Group [F(2,47) = 5.92 p<0.005]. Scores were higher in 
the ketamine group than the other two groups (p<0.01) on day 0.
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Ketamine
users
Poly-drug
controls
Non-drug
controls
DAYO SSQ 30.06(13.08) 9.75 (2.07) * 4.89(1.55)*
ADDS 42.6 (22.51) 4.94 (7.69) * 1.4(1.51)*
MRS-sedation 54.27(15.02) 26.40(16.57)* 29.11 (16.07)*
MRS-discontent 30.33 (13.65) 18.06 (9.25)* 24.86(13.48)*
MRS-anxiety 29.02 (16.04) 25.06(17.96)* 28.05(16.21)*
BSS- cognitive 41.48(18.02) 10.52(13.52) ** 12.36(12.49)**
BSS-perceptual 34.89 (14.47) 3.58 (5.97)** 4.98 (5.31)**
BSS-somatic 35.12 (15.52) 5.94 (9.63)** 3.18(3.43)**
DAY 3 SSQ 10.67 (7.98) 7.75 (5.26) 5.50 (4.50)
ADDS 4.22 (4.64) 0.94(1.48)* 0.7 (1.1)*
MRS-sedation 27.55(17.54) 24.18(16.19) 31.71 (22.81)
MRS-discontent 27.76(17.11) 24.10(16.58) 21.40(16.23)
MRS-anxiety 27.76(17.11) 24.10(16.57) 23.2(19.31)
BSS- cognitive 7.13(10.17) 6.52 (9.59) 9.23 (8.19)
BSS-perceptual 2.94 (5.09) 1.75 (3.53) 2.58 (3.42)
BSS-somatic 4.08 (6.05) 4.01 (4.91) 3.04(4.31)
PDI-Total 54.6 (34.51) 20.25 (24.14) * 13.2(18.51)*
BIS-10-Total 63.50 (8.15) 57.18(12.42) 42.08(10.51)**
BIS- 10- cognitive 20.16(3.20) 18.41 (4.51) 14.23 (5.05) **
BIS-10 -motor 23.29 (3.73) 21.18(5.05) 14.15(3.98)**
BIS-10- non-planning 19.94 (2.73) 17.59(4.37) 12.54(2.87)**
Table 7.4 : Subjective ratings in ketamine users, poly-drug users, non-drug users, *
p<0.01; **p<0.001
7.7.3.4 Bodily Symptoms Scale : There were higher levels of symptoms in the ketamine 
groups on all the three bodily symptoms factors on day 0 but no differences on day 3 
[Kruskall-Wallis: somatic = 19.30 p<0.001; perceptual= 24.60 p<0.001; cognitive= 
16.61 pcO.OOl].
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7.7.3.5 Peters delusion inventory (PDI): Analysis of the total score showed a significant 
difference between the three groups [ F(2,47) = 11.96 p<0.001] with scores being 
higher in the ketamine group than the other two groups.
Barratt Impulsivity Scale (BIS): There was a significant difference between the groups 
for the BIS total score [F (2, 47) = 16.18 p<0.001] this reflects greater scores in drug 
users than non-drug using controls [t(47) = 5.37 p<0.001].
7.8 Discussion
This study investigated response inhibition after an acute dose of ketamine in healthy 
volunteers and response inhibition and salience attribution in ketamine and poly-drug 
users and non-drug users. It piloted a novel task designed to examine these two 
processes. The main findings on day 3 were of an attentional bias to incentive stimuli in 
non-drug users but not in drug users. In addition, drug users made fewer errors to drug 
stimuli compared to non-users. Ketamine users made fewer errors to ketamine stimuli 
and non-illicit drug (alcohol) using controls made fewer false alarms to alcohol stimuli 
Apart from the above, there were no other differences in response inhibition in drug 
users compared to non-drug users on day 3. On day 0, there may have been evidence 
for response inhibition impairments in ketamine users but this is more likely a general 
performance decrement. Acute ketamine resulted in participants making fewer hits on 
the Go/No-go task in the high dose group.
7.8.1 Salience Attribution
Non-drug users demonstrated an attentional bias to incentive words i.e. food, sex and 
money, as shown by there faster response to these words than to other word categories, 
however there was no evidence of this bias in drug users. Whilst these are preliminary 
findings from a pilot study and hence must be viewed with caution, these results may 
reflect the ‘undervaluing’ of alternative reinforcers in drug users suggested by 
Goldstein and Volkow (2002). The attentional bias shown to non-drug incentive stimuli
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in this study has been shown before in a dot-probe task with food-related stimuli in 
hungry individuals (Mogg et al., 1998). As far as we are aware, however, this is the first 
study to directly compare responses to non-drug incentive and drug incentive stimuli in 
the same task. Again with the caveat that this was only a pilot study, it is possible that 
these findings may suggest a reduction in attentional bias to non-drug incentive stimuli 
in drug users compared to non-drug users. If further work confirms this lack of 
attentional bias to incentive words in drug users, then it is likely, as no ketamine 
specific effects emerged, that this effect was due to other drug use in this population, 
including MDMA and cocaine, and possibly interactive effects of using a combination 
of drugs. The reduction in salience of incentive or ‘naturally’ reinforcing stimuli could 
possibly be as a result of changes in the dopaminergic system as a result of drug abuse. 
It may be that even recreational drug users become used to the immediate pleasure 
associated with drug taking and thus become less interested in other rewarding 
activities, however this is purely speculative.
Contrary to our hypotheses, ketamine users did not show any attentional bias to 
ketamine stimuli and those who used no illict drugs did not show a bias to alcohol 
stimuli. This is also not consistent with the notion of Robinson & Berridge (2000) that 
drug stimuli can grab the attention of drug users. A possible reason may be related to 
the previous findings that alcohol users show attentional bias for alcohol related 
pictures but not words (Townshend & Duka, 2001). The latter authors suggest that 
words may represent more abstract alcohol-related representations as compared to 
pictures. However pictures were not used as visually ketamine is a white powder which 
is difficult to distinguish from other white powders used by this poly-drug group, such 
as cocaine and amphetamine. In addition, the use of written words instead of pictures in 
the current study may have been of lower ecological validity given this is not the format 
in which drug users normally encounter drug stimuli. Attentional bias to drug words 
has been shown in dot-probe tasks previously but only with drug dependent individuals 
(e.g. cocaine users .Franken et al., 2000). The participants in this study were 
recreational drug users and as such are likely to have a lesser attentional bias to drug 
stimuli than addicts. The findings of the current study, taken together with previous
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work could possibly suggest that en route to drug dependence, initially the salience of 
other rewarding stimuli decreases, and then gradually the salience of drug stimuli 
increases to exceed that of other environmental reinforcers. However, this is highly 
speculative and further work with individuals of differing levels of drug dependence is 
needed to clarify this. In addition, this task was more complex that the dot probe 
paradigm used previously to assess attentional bias. Possibly inhibiting a category of 
words concurrently to processing another may produce an interactive effect which 
masks attentional bias.
7.8.2 Response inhibition and impulsivity
Acutely, when administered to healthy volunteers, ketamine did not decrease response 
inhibition as predicted. The number of hits was reduced in the high dose ketamine 
group. This may represent either decreased vigilance or a form of ‘over-inhibition’. 
Decreased vigilance is unlikely as previous studies have demonstrated intact vigilance 
following an acute dose of ketamine on tasks such as the 0-Back (Chapter2; Adler et 
al., 1998). A more plausible explanation may be that participants were aware of an 
impairment in functioning and hence were ‘overinhibiting’ responses to compensate for 
this. The finding of intact response inhibition on this task of simple pre-potent 
responding indicate that previous findings of response inhibition impairments on the 
Hayling task (Chapter 6) do not reflect a general ketamine-induced response inhibition 
deficit. The Go/No-go taps the inhibition of a simple pre-potent motor response 
whereas the Hayling task requires the generation of a contextually irrelevant alternative 
for successful performance. It may be that deficits on the Hayling task relate to the 
semantic processing impairments described in Chapter 4. The impairment in controlled 
semantic processing reported in this could lead to an inability to adequately assess the 
contextual relevance of a semantic alternative. Thus the deficits reported in Chapter 6 
may reflect semantic abnormalities rather than a response inhibition impairment.
In Experiment 2, the investigation of acute on ‘chronic’ effects, the pattern was
different from that observed in healthy individuals in the laboratory following an acute
dose of ketamine. On day 0 the ketamine group made more false alarms but also less
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hits on the Go/No-go task than the non-drug and poly-drug groups. Due to the lower 
levels of hits on this task (i.e. response initiation) the finding must be interpreted with 
caution. It could be that the ketamine group are exhibiting a ketamine-induced response 
inhibition impairment. The reduced number of hits may represent overcompensation 
upon error detection. The ketamine users also had faster reaction times than non-drug 
users, which would not be expected given that ketamine is a sedative drug. Therefore 
the reduced number of hits could reflect a speed/accuracy trade off on the part of the 
ketamine users. The non-selective nature of the deficits makes these findings difficult to 
interpret and it is plausible that acute ketamine-induced impairments of working 
memory, attention and other cognitive systems may also impact on performance. The 
doses of ketamine reportedly taken by users on day 0 were much higher than those that 
have been administered in the laboratory. Given the established dose-response nature of 
ketamine-induced cognitive impairments it is possible that at a lower dose selective 
response inhibition impairments may have been evident, however the findings from 
Experiment 1 would seem to suggest this is not the case. There were no differences in 
response reversal both on and off drug between ketamine users, poly-drug controls and 
non-drug users. It may be that the reversal load of the task in the current study was not 
large enough to show differences between the groups.
On day 3 when the ketamine group were drug-free, there were no differences between 
the three groups in simple motor inhibition as indexed by the number of false alarms or 
reaction time to false alarms made on the Go/ No-go task. There were no differences in 
the number of hits or RT to hits which indicates that neither the ketamine nor the poly­
drug control groups had difficulties in initiating or inhibiting their responses on this 
task when drug-free. In addition, there was no main effect of group on the number of 
errors on the Drug Go/No-go task, again indicating no differences in response 
inhibition between drug users and non-drug users.
This is contrary to our hypotheses that impaired response inhibition may be associated 
with recreational drug users’, in particular ketamine users’, desire to take a drug 
repeatedly. Response inhibition deficits have been observed in drug dependent
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individuals who are currently drug free (e.g Fillmore & Rush, 2002b) with the same 
task as used in the current study. On the basis of self-ratings of impulsivity (e.g. 
McCann et al., 1994) and less widely validated measures (e.g. M.Morgan, 1998), the 
notion that recreational drug users demonstrate poorer response inhibition than non­
drug using controls has been largely accepted. Although this was a null finding, and 
hence we should be caution in out interpretation; the findings would suggest that 
response inhibition impairments are not evident in these recreational drug users. It may 
be that these are subtle effects requiring a larger sample size before they can be 
revealed, or that the particular task was not sensitive enough to detect differences. 
Preserved response inhibition has been found before with this task in recreational 
ecstasy users compared to cannabis controls (Fox et al., 2001) although this is the first 
study to examine response inhibition in recreational poly-drug compared to non-drug 
users. The ketamine group in this study was composed of relatively light users (2-3 
times a month) compared to previous studies where participants have taken ketamine 3- 
4 times per week (Curran and Monaghan, 2001). It would be interesting to investigate 
whether response inhibition deficits are present in people with more problematic drug 
use i.e. heavier ketamine users. Possibly the development of response inhibition deficits 
that are evident on this task may be one marker of the transition between recreational 
drug use and drug dependency.
There were differences between the non-drug and drug groups on day 3 on self-rated 
trait impulsivity. Both drug using groups rated themselves as more impulsive than their 
non-drug using counterparts, replicating other studies of impulsivity in drug users 
(M.Morgan, 1998). This is interesting given the lack of differences in response 
inhibition on day 3. However, it is likely that behavioural and subjective ratings assess 
different aspects of impulsivity.
7.8.3 Response Inhibition and Salience attribution
The findings from the Drug Go/No-go task are contrary to our hypotheses that ketamine 
users would make more false alarms to ketamine stimuli and non-drug users to non­
drug incentive stimuli. Ketamine users actually made the least false alarms to ketamine
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stimuli and the non-drug (alcohol) users made the least false alarms to alcohol stimuli. 
It is possible that an attentional bias towards a certain stimulus may in fact confer some 
kind of advantage in terms of response inhibition errors, making the subject more able 
to discern the drug-related stimuli from other less salient stimuli and hence more able to 
inhibit responses. However, this is not supported by the reaction time data that suggest 
that there is no attentional bias to drug stimuli in ketamine users or alcohol stimuli in 
alcohol users. Again it may be that due to the complexity of the task, an interaction of 
effects is occurring. Further work is necessary to tease apart the exact processes 
occurring. It may also be that as the drug users included in this study were not drug 
dependent, they are practised in exercising response inhibition for drug stimuli and the 
same may apply to the non-drug alcohol users. In addition, an inevitable pitfall of our 
design is that the ketamine groups were more familiar with the ‘drug’ words, so perhaps 
this is why they made less false alarms to these stimuli. Controlling for word frequency 
for these stimuli in these populations is clearly impossible as the ketamine users 
encounter ketamine words far more often. Thus perhaps these findings are the result of 
a word frequency confound. However, all groups should be equally familiar with the 
alcohol stimuli so this cannot account for the finding of better response inhibition in the 
non-drug groups to these stimuli. Finally, it may be that the inhibition of a simple 
preotent motor response may be highly different from the ‘real-world’ scenarios in 
which response inhibition deficits in drug users occur.
This is the first study to demonstrate higher levels of delusional thinking (PDI) amongst 
ketamine users compared to non-drug and poly-drug controls. Some previous studies 
with ketamine users have found elevated levels of schizotypal symptoms (Curran & 
Morgan, 2000; Chapter 5 / Morgan et al., 2004c) but ketamine users have not been 
assessed on delusional ideation previously. Further work is needed to clarify the exact 
nature of the pre-existing or persisting schizophrenia like effects associated with 
chronic ketamine use.
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7.8.4 Methodological considerations
As with all recreational drug user studies, there were several limitations inherent in 
testing the population in Experiment 2. Amongst studies of poly-drug users a strength 
of this research was the use of both urine tests and subjective reports to verify the drug 
use of participants, therefore we could verify that ketamine was taken on day 0 and 
subjective effects again served to confirm this. The drug histories taken from 
participants were not verified objectively as hair analysis was beyond the resources 
available for this study. All the poly-drug controls and all but one of the ketamine 
group tested positive for cannabis at follow-up. None of the participants reported 
smoking cannabis between day 0 and day 3. As cannabis is detectable in urine for up to 
21 days after acute use, its presence on day 3 in the urine of these poly-drug users is not 
surprising.
There were also some limitations associated with the non-drug using control group. 
Ideally the group would not have used any psychoactive substances. As it was 
impossible to find non-drug users from the same social demographic as the other 
groups who did not drink, it was necessary to include regular alcohol drinkers. 
Furthermore, 6 of the non-drug users had tried cannabis on a maximum of 3 occasions. 
All of these ‘non-drug users’ had abstained for over a year and none tested positive for 
cannabis. It may have been possible to find non-drinking controls who had never tried 
cannabis, however the authors felt it was more important to control for social 
background than to find a completely non-drug using group from a different setting.
In relation to the novel Drug Go/No-go task, one disadvantage (and yet also advantage)
was that it was relatively complex and theoretically aimed at tapping multiple processes
(response inhibition and salience attribution and their interaction). It is possible that
other processes than salience attribution and response inhibition were influencing
performance. However, the task is based on standard Go/No-go procedures used to test
response inhibition. It was not clear whether these words were acting as true incentives
or ‘motivational magnets’ (Berridge & Robinson, 2003) but concurrent skin
conductance recording might help to clarify this. As discussed above, another limitation
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is that ketamine users were inevitably more familiar with ketamine related words than 
non-drug users. To overcome this participants were shown the words beforehand. 
However this may in turn have created a working or episodic memory component to the 
task if participants tried to remember words in each category. Furthermore words were 
only repeated three times in the task which set constraints on the number of stimuli we 
were able to use. This was to try and ensure that words were being processed 
semantically and not perceptually, as may happen if words are repeatedly presented. 
However the low number of stimuli could have reduced the power of the task to detect 
effects. In retrospect we accept that the task may have been somewhat ambitious. It 
would have been better to use a simpler task, for example to examine salience 
attribution we could have used a dot probe that examines drug stimuli paired with 
incentive stimuli, perhaps with the use of pictures instead of words.
In summary, this study examined response inhibition, in healthy volunteers following 
an acute dose of ketamine and findings suggested an ‘over-inhibition’ of responding, 
contrary to hypotheses. The current study additionally investigated response inhibition 
and salience attribution in ketamine users compared to poly-drug users and non-drug 
using controls. We found no evidence of impaired response inhibition in ketamine users 
or recreational drug users in general compared to alcohol using controls. Our novel 
salience Go/No-go had some success in discerning both drug users from non-drug users 
and ketamine users from non-ketamine users. In terms of salience attribution, there 
were indications that the non-drug group were attributing primary salience to natural 
incentive stimuli (e.g. food) whereas the drug users did not. However, contrary to our 
expectations, the drug users did not demonstrate any attentional bias to drug stimuli and 
actually instead of being impaired, showed better response inhibition overall to drug 
stimuli. The ketamine users demonstrated improved response inhibition for ketamine 
words and the alcohol (i.e. non-illicit drug) users for alcohol words. This paradoxical 
effect may reflect a combination of attentional bias and /or compensatory mechanisms 
that maintain these users as recreational drug-using, rather than drug dependent, 
individuals.
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Chapter 8: Me-pulse inhibition
A  n o v e l  s e l f - m o n i to r in g  t a s k  p i lo t e d  in  h i g h  s c h iz o ty p y  s c o r e r s ,  
h e a l t h y  v o l u n t e e r s  f o l lo w in g  a n  a c u t e  d o s e  o f  k e t a m i n e  a n d  k e t a m i n e  
u s e r s
“I f  the doors o f perception were cleansed everything would 
appear to man as it is, infinite... ” William Blake
8.1 Overview
Previous work has demonstrated that the intensity of a perceived stimulus is lower for 
an identical stimulus when one generates it oneself compared to if it is externally 
generated. Externally produced sensory events are thought to be distinguished from 
internally generated stimuli on the basis of knowledge of one’s intentions and motor 
commands. Deficits in this form of self-monitoring have been proposed to underlie 
symptoms such as hallucinations and delusions in schizophrenia and there is some 
evidence to support this claim. This study set out to develop a novel paradigm -  ‘Me- 
pulse’ inhibition - to investigate self-monitoring in psychopharmacological studies 
based on the question ‘Can one startle oneself?’. Three populations were used to pilot 
the Me-pulse inhibition task: a) 10 high and 8 low scorers on the O-LIFE schizotypy 
scale (Experiment /); b) 8 healthy male volunteers administered either 200ng/ml target 
controlled infusion of ketamine and placebo in a within subjects design (Experiment 2); 
and c) 12 recreational ketamine users and 11 poly-drug controls (.Experiment 3). All 
received acoustic stimuli binaurally and the eyeblink component of the startle response 
was measured by recording EMG activity from the orbicularis oculi muscle. Three 
types of stimuli were administered. Participants either i) heard the startling stimulus 
alone ii) heard a prepulse (lead interval of 450msec) which preceded the startling 
stimulus (active attention prepulse inhibition - PPI) or iii) were given a signal to press 
a button to generate the startling stimulus themselves (Mepulse inhibition - MePI). In 
Experiment 1, there were no group differences in PPI but significantly lower MePI in
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high schizotypes. There were no differences between PPI following ketamine or 
placebo (Experiment 2) but there was a trend for lower MePI on ketamine. In 
Experiment 3, there was lower PPI in ketamine users than polydrug controls, but no 
differences in MePI. In high schizotypes and both groups of drug users there was 
evidence of facilitation of MePI i.e. higher than baseline startle. The Me-pulse 
inhibition paradigm was sensitive to differences between groups in 3 different 
populations. These differences may reflect deficits in self-monitoring that underpin 
some psychiatric symptoms induced by ketamine and observed in high scorers on 
schizotypy scales.
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8.2 Introduction
To avoid sensory overload, humans must select, screen, process and organise important 
information from the “ one great blooming, buzzing confusion” (James, 1890, pp.445) 
that is the world. It is important that our sensory systems discard or ‘gate out’ trivial 
stimuli so we may focus attention on the most important changes in our environment. 
However, in certain cases this screening process may go awry. In the popular media, 
psychedelic drugs, such as LSD, have long been viewed as disrupting the normal flow 
of information in and out of the senses (e.g. Huxley, 1954) and more recently 
schizophrenia has been explained in similar terms (Braff et al. 2001; Frith, 1992; Ford 
et al., 2001). Researchers have attempted to develop unifying theories to explain the 
symptoms of schizophrenia, some of which have suggested that failures in gating 
ingoing sensory information (i.e. ‘input’) lead to cognitive fragmentation, sensory 
overload and thought disorder (McGhie & Chapman, 1961; Braff, 1993). Others 
propose that disruption of the monitoring of outgoing information such as speech and 
other motor actions (i.e. ‘output’) deficits (e.g. Frith, 1992) underlie symptoms such as 
hallucinations and delusions of control. Ketamine is a psychedelic drug that can induce 
the schizophrenic symptoms described above (Krystal et al., 1994). It therefore seems 
possible that underlying the symptoms induced by ketamine there may also be deficits 
in monitoring the ‘input’ or ‘output’ of sensory information.
The origin of ‘input’ deficit theories of schizophrenia is the common complaint 
amongst schizophrenics that they are unable to prevent irrelevant thoughts and sensory 
stimuli from entering awareness. The ‘gating’ of incoming sensory information has 
been examined in schizophrenia using the prepulse inhibition (PPI) paradigm (for 
reviews see Braff et al., 2001; Geyer et al., 2001). As discussed in Chapter 1, PPI refers 
to the inhibition of the startle reflex associated with a sudden intense stimulus when it is 
preceded by a weak sensory stimulus (i.e. the prepulse). It has been suggested that PPI 
is protective, in that it occurs to ensure that the prepulse can be adequately processed 
without interference from subsequent events including the startling stimulus (Braff et 
al., 2001; Blumenthal, 1996). In this way it is thought that the ‘gating’ is functional to
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an organism as it helps to prevent sensory overload in a world where we are constantly 
bombarded with stimuli (Braff & Geyer, 1990). Schizophrenic patients in general 
exhibit reduced PPI independent of the modality of stimuli (e.g. (Kumari et al., 2000; 
Braff et al., 1978). Further, PPI is relatively unaffected by antipsychotic medications in 
either humans ( see Braff et al., 2001 for a review) or animals (see Geyer et al., 2001 
for a review).
Anecdotally, participants on ketamine like schizophrenics, report difficulties in 
stopping thoughts and sensory stimuli popping into their heads. Studies examining 
ketamine’s effects on PPI have produced equivocal results: enhanced PPI (Abel et al., 
2004; Duncan et al., 2001); reduced PPI (Umbricht et al., 2001) and no effect (van 
Berckel et al., 1998). However, the above studies were all passive attention paradigms 
that less robustly elicit PPI in schizophrenia than active attention paradigms (Dawson et 
al., 1993). Further all differed in the actual dose of ketamine and PPI paradigm used. It 
may also be that ‘input’ deficits do not account for the symptoms induced by ketamine.
Output theories suggest that an inability to distinguish between self generated and 
externally generated stimuli is involved in the positive symptoms of schizophrenia 
(Frith, 1992). It is often valuable to ‘gate out’, or at least reduce in intensity, stimuli 
which arise as a consequence of our own actions (Blakemore et al., 1999). Self- 
generated stimuli (e.g. one’s own voice) are evolutionarily generally of a lesser survival 
importance than externally generated events (e.g. the roar of a predator). Several 
theories postulate that externally produced sensory events are distinguished from 
internally generated stimuli on the basis of knowledge of our intentions and motor 
commands (Jeanerrod, 1988; Decety, 1996). It is thought that some form of central self­
monitoring system may anticipate the results of actions and therefore discern them from 
externally generated stimuli (Frith, 1992; Wolpert, 1997). Previous studies have indeed 
shown that the intensity of a perceived stimulus is lower for an identical stimulus when 
a subject generates it themselves compared to one that it is externally generated. One 
study looked at auditory evoked potentials (AEPs) recorded from the scalp and found 
that when an individual triggered a noise themselves, the resulting AEPs were of
212
shorter latency and decreased amplitude than when the noise was externally triggered 
(Schafer & Marcus, 1973). The authors termed this the ‘self-generation’ effect. In an 
elegant study, Blakemore and colleagues (1999) re-examined the phenomenon first 
noted by Weiskrantz et al. (1971) that people are unable to tickle themselves. In their 
study increasing the discrepancy between the predicted and actual consequences of self­
generated tactile stimuli increased their perceived ‘tickliness’. This suggests that the 
inability to tickle oneself occurs as a result of a prediction made by the motor system 
(or an ‘efference copy’). However, when Blakemore et al. (2000) compared ‘tickliness’ 
in patients with delusions of control and auditory hallucination with controls, the 
clinical sample rated self-produced sensations as similar to those generated by external 
agents. In addition, schizophrenic patients with hallucinations were more likely to 
attribute their own distorted voice to external sources than non-hallucinators or 
psychiatric controls(Johns et al., 2001) and were less able to identify their own, rotated 
drawings than healthy or non-psychotic psychiatric controls (Stirling et al., 1998). Thus 
there is some evidence support the theory that auditory hallucinations and passivity 
experiences are associated with a defect in monitoring ‘output’ or self-monitoring.
Anecdotally, many of the participants in the acute ketamine studies described in this 
thesis reported the sensation that they were not in control of their actions e.g. “... 
moving was like I was, like, a robot, like a puppet on strings...” (participant 8- 
Semantic priming study) which is reminiscent of delusions of control. As discussed 
above, this is thought to occur as a result of a failure to monitor one’s own actions i.e. 
output. So it seems possible that following acute ketamine administration a disruption 
to the self monitoring system occurs. However the existing self-monitoring tasks that 
have been used in schizophrenia such as tickling and drawing are inappropriate to test 
this because of the analgesic and motor effects of ketamine. Thus it was necessary to 
design a new task which we based upon the question, “Can one startle oneself?”
Whether one can startle oneself has not been previously examined. However (Schafer 
& Marcus, 1973; described above) showed that AEP responses to self-evoked auditory 
stimuli were attenuated compared to those generated by the experimenter. This
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reduction in AEP might suggest that there is a similar attenuation of responding due to 
an efference copy (i.e. a prediction of the sensory consequences of an action) produced 
in conjunction with a central monitoring system similar to that hypothesised to be 
involved in the suppression of ticklishness. Therefore we designed a new paradigm, 
based on an active attention version of pre-pulse inhibition, to include self-generated 
startling stimuli (‘me-pulses’) along with prepulses and startling stimuli. Thus in this 
task the startling stimulus will be one that is triggered by the participant in addition to 
the one that occurs following the prepulse. By examining responses to self-generated 
startle, we were also able to measure any reduction in response objectively by recording 
facial electromyographic (EMG) activity.
Whilst our aim was to examine ‘mepulse’ inhibition following acute ketamine, it was 
necessary to first pilot the paradigm to examine whether it was sensitive to 
schizophrenic-like differences. Whilst ideally we would have piloted the study with 
patients with schizophrenia, this was beyond the scope of the study. However it is not 
only schizophrenic patients who demonstrate delusional or hallucinatory thinking and 
experience perceptual aberrations such as those described above. Within the ‘normal’ 
population many individuals will experience something akin to a schizophrenic 
experience at some point in their lifetimes. For example, most people at some point will 
turn around because they think someone has said their name, only to find that there is 
no-one there. Some have argued that, rather than a discrete, diagnostic category, the 
concept of schizophrenia should be redefined as symptoms occurring on a continuum 
(Claridge, 1987; Chadwick et al., 2005). This notion of a continuum of schizophrenic 
symptoms has been termed schizotypy: at one end are individuals who experience full­
blown psychotic symptoms, whilst further along the continuum are healthy individuals 
who have personality traits that mark a proneness to psychosis e.g. believe in telepathy 
or magic. The concept of schizotypy has been shown to have validity in that healthy 
volunteers with high scores on schizotypy scales demonstrate poorer performance on 
tasks upon which schizophrenic patients themselves exhibit deficits (Peters et al., 1994; 
Claridge, 1994). In addition, individuals with high schizotypy scores are at a greater 
risk of developing a schizophrenic illness (Chapman & Chapman, 1987).
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Similarities between schizophrenia and schizotypy, have prompted a body of research 
that has utilised individuals assessed on schizotypy scales to investigate psychosis. The 
advantages of this line of research are that they circumvent several confounding 
variables common to research with schizophrenic patients i.e. long hospitalisations, 
medication, generalised performance deficits and varying levels of premorbid 
functioning. PPI has been examined in schizotypy before but with somewhat 
conflicting results of either no effect (Cadenhead & Braff, 1992; Lipp et al., 1994; 
Abel et al., 2004) or reduced PPI (Simons & Giardina, 1992; Cadenhead et al., 1993). 
The only research that has examined an active attention PPI paradigm as we intended to 
examine in this study found reduced PPI in individuals experiencing high levels of 
magical ideation compared to normals (Schnell et al., 1995).
Self-monitoring deficits as discussed, have been extensively investigated in 
schizophrenia but little research has examined their prevalence in psychosis prone 
individuals. Given that these individuals experience perceptual distortions and often 
have mildly delusional beliefs, according to Frith’s (1992) theory, they may exhibit 
some deficits in the monitoring of their own actions. Thus we decided to pilot our novel 
task in this population (Experiment 1). Following this we intended to examine self­
initiated startle following an acute dose of ketamine in healthy volunteers (Experiment
2) and finally we wished to examine the effect of chronic ketamine use in a population 
of substance users on performance on the same task (Experiment 3). Based on the 
findings of Schafer and Marcus (1973) it was hypothesised in Experiment 1 (pilot 
study) that individuals who are low in schizotypy will show a decrease in startle 
response to self-triggered stimuli, but individuals who are high in schizotypy will not 
show a decrease in amplitude of response. If high schizotypy individuals show a startle 
response to self- triggered stimuli which is just as great as that shown in response to 
randomly generated stimuli, then it can be said that they show the propensity to startle 
themselves. This would provide further support for the notion that schizophrenic-like 
symptoms derive from defective self-monitoring (output deficits). No previous research 
has addressed issues of self-monitoring with acute or chronic ketamine, so no specific
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predictions were made for experiments 2 & 3. However, given the anecdotal reports of 
altered monitoring experiences under the influence of acute ketamine, we speculated 
that the drug would induce a similar pattern to that found with high schizotypes.
An additional benefit to using this paradigm was that we were able to use an active 
attention PPI paradigm to look at perceptual gating deficits, as well as examining ‘me- 
pulse’ inhibition (hereafter MePI). Thus the study attempted to address existing 
controversies related to the idea that perceptual gating deficits only appear in 
schizophrenia patients versus the suggestion that in fact perceptual gating deficits 
appear in healthy volunteers who are high in schizotypy, and as such represent a trait 
marker for schizophrenic illness. More inhibition was found at 120 ms lead interval in 
an active attention paradigm in normals compared to individuals experiencing high 
levels of magical ideation (Schnell et al., 1995). Thus we predicted that in our study 
the high schizotypes may show impaired PPI. No previous study has examined active 
attention PPI following an acute dose of ketamine, or any form of PPI following 
chronic ketamine use. So whilst the paradigm was not designed specifically for 
examination of PPI, this was also possible.
Experiment 1: Mepulse and prepulse inhibition in high and low schizotypes: a 
pilot study
8.3 Method
8.3.1 Participants and Design
An independent group design was used to compare individuals who had high
schizotypy scores with individuals who had low schizotypy scores. Participants were
recruited through advertisments or via a database of volunteers for psychological
research. Inclusion criteria required participants to be aged between 18 and 30 years, to
have no serious mental illness or history of one, not taking any psychoactive
medication, have no hearing impairment or any history of head injury. After completing
an email version of the O-life questionnaire (Mason et al., 1995 described below), only
those whose total schizotypy (STA) score fell either below 10 points or above 24 points
were recruited (2 standard deviations away from the mean in a previous study, Beford
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et al., submitted). In addition, as the PPI response of women fluctuates over the 
menstrual cycle, female participants were required to participate in the experiment 
during the first four days of their period (see Swerlow et al., 1997).
8.3.2 Procedure
Participants gave written, witnessed informed consent on the day of testing, and then 
their demographic data were recorded.
8.3.3 Assessments
The O-life Questionnaire (Mason et al., 1995): This 159 item self-report questionnaire 
yields a total schizotypy score (STA) and scores on four dimensions of schizotypy (as 
identified by Claridge et al., 1996) as follows:
1) Unusual experiences - unusual perceptual events, hallucinatory experiences, and 
magical thinking.
2) Cognitive Disorganisation - difficulties in sustaining attention and concentration, as 
well as moodiness and social anxiety.
3) Introvertive Anhedonia - difficulties gaining enjoyment from social, or other sources, 
a lack of enjoyment of physical and emotional intimacy, and a preference for spending 
time alone. These items are thought to relate particularly to the ‘negative signs’ of 
schizophrenia.
4) Impulsive Nonconformity - asocial behaviours, impulsivity and non-conformity.
‘Me— pulse ' inhibition
Participants were seated in a comfortable chair. The area around each subject’s right 
eye was cleaned with an alcohol swab and then two miniature (4mm) Ag-AgCl 
electrodes were positioned over the orbicularis oculi muscle, approximately 5mm 
below the right eyelid, one directly below the pupil and one approximately 1 cm lateral 
to the first. The third (ground) was placed in the centre of the forehead. Eyeblinks were 
recorded as EMG activity using an EEG-8 bioamplifier (Psylab, UK) and digitised for 
later analysis. EMG activity was filtered with a 30 Hz high pass filter, a 500 Hz low
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pass filter and a 50 Hz hum-notch filter and recorded at 1KHZ for 250ms from the 
onset of the startle stimulus. Acoustic stimuli were calibrated with a sound level meter 
(Realistic) and consisted of 40ms bursts of 116db broadband noise with an 
instantaneous rise time over continuous background noise of 50db presented bi-aurally 
through headphones (Technics). The prepulses were 20ms duration noise bursts of 80db 
, i.e. 30db above background noise presented 430 msec before the pulse. Although not 
optimal for PPI, this lead interval was used because it was the mean time to respond 
with a button press to a green square in 20 volunteers. This was an attempt to make the 
delay between prepulse and pulse as similar as possible to the delay between ‘mepulse’ 
i.e. the cue prompting participant to initiate the pulse. The mepulse was a green square 
presented centrally on a VDU. After a five minute acclimatisation period with the 
background noise (50db) the first block of six 116db 40ms noise bursts was presented 
(pulse alone). These pulse alone trials were followed by the four blocks of 12 trials 
each: 4 pulse alone trials, 4 prepulse trials and 4 mepulse trials. The final block was 
identical to the first, consisting of six pulse alone noise bursts. The total session 
included 48 trials. Participants were seated throughout testing and asked to fixate upon 
the computer screen and press a button on a pad when they saw a green square on the 
screen. Responses that fell outside the physiological range for a reflex blink (20ms or 
beyond 90ms) were discarded. Responses were recorded as startle magnitudes, peak 
latencies and percentage MePI/PPI as differences in absolute pv units are correlated 
with baseline startle amplitude.
5min background 
50 db
Block 1:
6 x pulse alone
Block 6:
6 x pulse alone
Block 2-5 each: 
4xpulse alone 
4xprepulse+pulse 
4x ‘mepulse’+pulse
Figure 8.1: Schematic of the me-pulse task.
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8.3.4 Statistical A nalyses
Habituation and overall startle magnitude was examined by comparing startle responses 
on Block 1 with startle response on Block 6 in a RMANOVA with Group (High or Low 
schizotypy scorer) as a between subjects factor and Block (1 or 6) as a within subjects 
factor. Percentage Mepulse inhibition (MePI) was calculated with the data from trails 2- 
5, using following formula [100 * (total startle magnitude pulse trials -  total magnitude 
mepulse trials) / total startle magnitude pulse trials] and prepulse inhibition was 
calculated using the same formula but substituting prepulse data for mepulse. This was 
analysed as a 2 x 2 repeated measures, with Group (High or Low schizotypy) as a 
between subjects factor and Type of trial (Prepulse or Mepulse) as a within subjects 
factor. Given this was a new task and it was not clear how independent these processes 
were, separate Oneway ANOVAs were also run for the mepulse and prepulse data 
separately. Demographic data were analysed using t-tests, Chi-Squared analyses and 
where non-parametric, Mann-Whitney U tests. Correlations were conducted between 
schizotypy sub-factors and the percentage mepulse inhibition and prepulse inhibition. 
Non-significant main effects and interactions were not reported.
8.4 Results : Schizotypy groups
8.4.1 Demographics
10 participants had a total STA score of < 10 and formed the low schizotypy group (3 
males mean age: 24.10 ±7.92; 1 smoker; ) , 8 had a total STA score >24 and were 
entered in the high schizotypy group (3 males; mean age 27.5 ± 10.76 years; 2 
smokers). There were no differences in age or gender. Schizotypy data are given in 
Table 8.1 below.
8.4.2 Me-pulse task
8.4.2.1 Startle Magnitude and habituation (See Table 8.2)
2 x 2  RMANOVA demonstrated a significant main effect of Block [F(l,16)= 4.55 
p<0.05] which reflects a decrease in startle magnitude between Block 1 and Block 6
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(i.e. habituation occurred). The trend [F(l,16) = 3.47 p=0.082]for group difference 
reflects higher levels of startle in the low compared to the high schizotypes.
High schizotypy (n= 8) Low schizotypy 
(n=10)
Total STA score 27.25 (4.20) 6.40 (2.27)
Total score for unusual 
experiences
19.25(4.71) 2.89(2.15)
Total score for cognitive 
disorganisation
19.00 (5.07) 4.67 (4.33)
Total score for introvertive 
anhedonia
10.75 (4.37) 4.33 (5.77)
Total score for impulsivity 10.14(2.85) 5.78 (2.86)
Total score for SPQ 8.5 (5.08) 47.25 (14.02)
SPQ Cognitive factor 2.70(3.12) 14.63 (5.40)
SPQ Interpersonal factor 3.0(2.71) 20.25 (7.09)
SPQ Disorganised factor 2.80(1.75) 12.38(3.78)
Table 8.1: Mean (s.d.) scores in the high and low schizotypy groups on schizotypal 
symptoms.
High schizotypy n=8 Low schizotpy n=10
Block 1 startle magnitude, pv 15.21 (16.63) 45.81 (52.10)
Block 6 startle magnitude, pv 7.19(12.23) 22.47 (21.27)
Peak latency, msec 61 (31) 74 (61)
Table 8.2: Startle magnitude and peak latency in the high and low schizotypy groups
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8.4.2.2 Percentage Me-pulse/ Pre-pulse inhibition
Although a RMANOVA demonstrated no main effects or interactions, a oneway 
ANOVA showed a significant difference between the groups in mepulse inhibition 
[F(l,16)= 8.25 p=0.012], which is a result of an increase in startle response to self­
generated stimuli in the high schizotypy subjects compared to pulse alone, and a 
decrease in the low schizotypy subjects (See Fig 8.2). Mean reaction times to generate 
the mepulse did not differ significantly from the prepulse lead interval.
Figure 8.2: Percentage prepulse (%PPI) and mepulse (%MePI) inhibition across 
schizotypy groups.
□  Low schizotypy 
M High schizotypy40
|  20 -
■■  _
I
-60 -
-80 J
% PPI % MePI
There were no differences in the percentage of inhibition in the mepulse and prepulse 
conditions in the low schizotypes.
8.4.2.3 Peak latency
There were no group differences in peak latency.
8.4.3 Correlations
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There were significant negative correlations between percentage MePI and the 
schizotypy subscales of Cognitive disorganisation [r = -0.538, p=0.032] and 
Introvertive anhedonia [ r =-0.507 p=0.045].
Experiment 2 -  Effects of acute ketamine on mepulse and prepulse inhibition in 
healthy volunteers
8.5 Method
8.5.1 Participants and design
A crossover design was used to compare ketamine (200ng/ml) with placebo. Treatment 
order was balanced across subjects. The washout period between treatments was 2 -7 
days (mean 7.2 ± 3.65 days). 11 male participants were recruited into the study. They 
were screened using the procedures described in chapter 2, in addition to the criteria 
given in the previous experiment above. 2 participants with negligible baseline startle 
responses were excluded and 1 participant only completed one test day. Eight subjects 
completed both test days.
8.5.2 Drug administration
Participants attended test sessions in the morning having fasted from midnight the day 
before the study. Participants were cannulated in the non-dominant forearm and a 
computer controlled intravenous infusion began via a Graseby pump using the 
Stanpump program (Schafer et al., 1991) to maintain an estimated target plasma 
concentration of 200ng/ml. Drug administration was double blind, however the 
psychotomimetic and sedative effects of ketamine meant that treatment condition was 
apparent to the experimenter and subjects.
8.5.3 Assessments 
Mepulse task
The mepulse task used identical methods to those described in experiment 1.
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Subjective Effects
Five assessments used previously in this thesis were also administered: ADDS ; MRS; 
SSQ; Subjective Effects; Spot the Word.
8.5.4 Statistical Analyses
These were parallel to those described in Experiment 1, however instead of the between 
subjects factor of group, this study had the within subjects factor of Drug (placebo, 
ketamine). The sub-factors of the schizotypy state scale were correlated with 
perecentage MePI and percentage PPI.
8.6 Results: Acute ketamine
8.6.1 Demographics
The 8 participants in the current study had a mean age of 25.25 (3.19) years and had a 
spot the word score of 50 (3.82) and had spent 17 (1.77) years in education.
8.6.2 Mepulse task
8.6.2.1 Startle magnitude and habituation
An analysis of startle magnitude for blocks 1 and block 6 found a significant main 
effect of Block [ F(l,7) = 12.43 p=0.039] indicating habituation had occurred, however 
there were no main effects of group or interactions (Table 8.3).
8.6.2.2 Percentage prepulse inhibition and mepulse inhibition
A 2x2 RMANOVA with Drug and Trial type as within subjects factors found a trend 
for a main effect of group t(7) = 4.06 p=0.084. Further analysis demonstrated a trend 
for less mepulse inhibition on ketamine compared to placebo [ t(7) = 2.18, p = 0.066] 
(Fig 8.3)
Placebo Ketamine
Block 1 startle magnitude, pv 20.70(15.40) 18.49(13.47)
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Block 6 startle magnitude, pv 8.88 (6.50) 10.72 (8.30)
Table 8.3: Startle magnitude across placebo and ketamine treatment
8.6.2.3 Peak latency
There was no difference in peak latency across the test days.
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Figure 8.3: Percentage prepulse inhibition and mepulse inhibition across treatment day
8.6.3 Subjective effects
There was a trend for a main effect of day on schizotypal state scores [F(l,7) = 4.02, 
p=0.085]. There was a significant increase in dissociation on ketamine [Wilcoxon- 
Signed Ranks, Z = -2.54 p = 0.012]. There was a significant effect of Drug on 
drowsiness [F(l,7) = 10.09, p=0.016], again with greater drowsiness on ketamine. 
There was no effect of ketamine on discontentedness or anxiety. There was also a 
significant increase in somatic [F(l,7) = 15.81 p=0.007], cognitive [F(l,7) =10.80,
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p=0.013] and perceptual [F(l,7) = 7.94, p=0.026] symptoms on ketamine compared to 
placebo (Table 8.4).
Placebo Ketamine
ADSS 1.38 (2.77) 14.5 (7.58)
SSQ 6.0 (7.69) 12.75 (4.89)
MRS -  Drowsiness 34.73 (14.93) 55.72 (9.94)
MRS -  Discontentedness 28.48(13.39) 28.78(17.32)
MRS -Anxiety 14.07 (6.60) 10.38(7.24)
VAS -  Somatic 11.00(11.77) 39.94(13.71)
VAS -  Cognitive 8.69(10.24) 28.53(15.53)
VAS -  Perceptual 9.75(10.98) 29.45(17.62)
Table 8.4: Self-rated symptoms on placebo and ketamine.
Experiment 3: Mepulse and prepulse inhibition in ketamine users.
8.7 Method -  Ketamine users
8.7.1 Participants and Design
23 participants completed the study: 12 males and 11 females. As ketamine users are 
‘poly-drug’ users the comparison group were poly-drug controls matched for other 
psychotropic drug use except ketamine. The age range was 19-45 years [polydrug 
controls: 21.50 ± 3.20; ketamine group: 23.19 ± 6.31]. There were 4 females in the 
ketamine group and 7 females in the poly-drug control group. Participants were 
recruited via volunteer databases, the internet and by snowball sampling (Solowij, Hall, 
and Lee, 1992). The ketamine group consisted of 12 participants who regularly took 
ketamine (a minimum of twice a month). The control group consisted of 11 ketamine 
naive (polydrug) participants who were broadly matched with ketamine users on 
recreational drug use apart from ketamine.
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8.7.2 Procedure
All participants who met the relevant drug criteria provided written, witnessed, 
informed consent. An identical battery to that employed in Experiment 1 was used. 
Additionally, a general drug history was given by the participant, detailing their current 
and past drug use. Participants were asked to give a urine sample to test for recent drug 
use (cannabis, MDMA, cocaine, opiates, ketamine and benzodiazepines).
8.7.3 Assessments
Mepulse task: described above
Subjective Effects : SSQ, ADDS, PDI, SES ( alldescribed in Chapter 4)
8.7.4 Statistical Analyses
Statistical analyses were similar to those used in Experiment 1. Correlations were 
conducted between the state schizotypal and dissociative symptoms questionnaires and 
percentage PPI and percentage MePI.
8.8 Results: Ketamine Users
8.8.1 Demographics and Drug Use
There were no significant group differences in pre-morbid IQ [spot the word score- 
controls: 49.25 ± 5.16; ketamine: 50.75 ± 4.70], age or gender. There were no 
significant group differences in the use of cannabis, ecstasy or alcohol (See Table 8.5). 
The ketamine users had last used the drug a mean of 10.32 ± 9.45 days previously, with 
a minimum last use of 3 days earlier. Urine screens for both groups were all positive for 
cannabis but no other drugs of abuse. Other self-reported occasional drug use included 
cocaine (7 ketamine / 5 controls), amphetamines (5 / 2), valium (2/1), LSD/ mushrooms 
(6 / 2), and amyl nitrate (2 / 0).
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Ketamine
Users
Poly-drug
controls
Ketamine Days Per Month 4.17(2.51) 0.00 (0.00)
Years Used 1.80 (0.90) 0.00 (0.00)
Amount Used Per Session (grams) 0.68 (0.56) 0.00 (0.00)
Cannabis Days Per Month 10.25 (12.06) 10.45 (9.55)
Years Used 4.58 (3.82) 6.00 (4.22)
Amount Used Per Session (number of joints) 1.50(1.31) 1.91 (0.94)
Ecstasy Days Per Month 4.25 (3.89) 3.18(5.69)
Years Used 3.96 (3.25) 3.82 (3.34)
Amount Used Per Session (tablets) 3.83 (2.37) 3.82 (5.56)
Alcohol Days Per Month 11.83 (7.72) 17.72 (8.54)
Years Used 9.00 (6.59) 6.73 (2.97)
Amount Used Per Session (units) 5.67 (4.77) 6.64 (4.24)
Table 8.5: Patterns of drug use in the ketamine and poly-drug groups
8.8.2 Mepulse task
8.8.2.1 Startle Magnitude
2x2 RMANOVA demonstrated a significant main effect of block [F(l, 21) = 8.17 
p=0.009] but no main effect of group or interaction. The main effect of block reflected 
a decrease in both groups between Block 1 and Block 6 (i.e. habituation).
Ketamine users Poly-drug controls
Block 1 startle magnitude, pv 19.91 (18.79) 20.55 (22.22)
Block 6 startle magnitude, pv 9.17(8.55) 7.80 (9.61)
Table 8.6 - Startle magnitude across Blocks 1 and 6
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8.8.2.2 Percentage prepulse and mepulse inhibition
2 x 2  RMANOVA demonstrated a significant main effect of Trial Type [ F(l, 21) = 
5.79 p= 0.025] but no main effect of group or interaction. The main effect of Trial type 
reflected a lower percentage o f ‘me-pulse’ than ‘pre-pulse’ inhibition in both groups. In 
light of the schizotypy data, SSQ scores were entered as a covariate to the data which 
were reanalysed, however no differences emerged. A post-hoc comparison showed that 
poly-drug controls exhibited significantly more prepulse inhibition than ketamine users 
[F(l, 21) = 8.06 p=0.01]. There was a correlation between dissociative symptoms and 
percentage ‘me-pulse’ inhibition ( r = -0.453 p=0.03).
8.8.2.3 Peak latency
There were no effects of group on peak latency.
8.8.3 Subjective effects
There were no significant group differences in subjective effects (Table 8.7).
% PPI
□  poly drug controls 
EH ketamine users
% MePI
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Figure 8.4: Percentage PPI and MePI in ketamine users and poly-drug controls
Ketamine
Users
Polydrug Controls
ADSS 7.38 (10.38) 7.27 (6.46)
PDI 35.53 (3.62) 34.00 (4.46)
SSQ 16.13(10.01) 15.79(11.31)
Cognitive symptoms 68.18(50.54) 55.03 (60.81)
Perceptual symptoms 42.44 (57.14) 50.16(64.89)
Somatic symptoms 43.40 (60.01) 58.27 (68.37)
Table 8.7: Subjective effects across ketamine users and poly-drug controls 
8.9 Discussion
This study set out to examine self-monitoring following acute and chronic ketamine. It 
used a novel self-startle task that aimed to extend the existing prepulse inhibition 
paradigm. Experiment 1 piloted the task with high and low schizotypy subjects. Low 
schizotypy scorers showed inhibition of the startle response both following a prepulse 
and a self-generated pulse. High schizotypy scorers also showed prepulse inhibition and 
yet they exhibited facilitation (i.e. greater startle than for pulse alone) for the pulse 
following the mepulse. In Experiment 2, mepulse inhibition of the startle response was 
evident on placebo but an acute dose of ketamine tended to reduce this inhibition. There 
were no differences in prepulse inhibition on placebo or ketamine. In Experiment 3, 
both ketamine users and poly-drug users showed me-pulse facilitation, similar to that 
observed in the high schizotypes. The ketamine group showed significantly less 
prepulse inhibition than the poly-drug controls.
8.9.1 Schizotypy
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The key finding from the pilot study was of a difference in startle response to the ‘me­
pulse’. Whilst low schizotypes showed an inhibition of the startle response when they 
generated the startling stimulus themselves, the high schizotypes did not show such 
inhibition. In fact the high schizotypy group appeared to experience a facilitation of the 
startle response, i.e. their startle response was greater to self-generated pulses than to 
the unexpected pulse.
In relation to our aim of developing a new self-monitoring task, the results of this pilot 
study were encouraging. Supporting our initial predictions, there were differences on 
the me-pulse trials between high and low schizotypes but no differences on the pre­
pulse trials. The low schizotypes showed an inhibition of the startle response following 
a me-pulse whereas the high schizotypy group did not. The inhibition by the low 
schizotypes on mepulse trials may reflect similar processes as those hypothesised to 
occur in self-tickling (Blakemore et al., 1999). These are that an accurate prediction is 
made of the sensory consequences of a self -produced action (in this case pressing the 
button to generate a startling noise) and this prediction results in an attenuation in 
response, as the startling stimulus is identified as self-generated. In the high 
schizotypes, it may be that a defective self-monitoring system results in an 
inappropriate, or absent prediction of the consequences of an action, which in turn 
means that no attenuation of the startle response occurs. This would be in line with 
theories of deficits in monitoring the output of information in schizophrenia (Frith, 
1992) and is further supported to some degree by the correlations between decreasing 
mepulse inhibition and higher scores on some sub-types of schizotypal symptoms.
One problem for our new paradigm however, was that in low schizotypes the reduction 
in the startle response on me-pulse trials did not exceed the reduction observed on 
prepulse trials. Theoretically, as with tickling stimuli, a sensation that is self-produced 
would be subject to more inhibition than one which is simply predictable as it is subject 
to an efference copy (Frith et al., 2001). However, in this study there was no way of 
saying that the me-pulse was not just behaving as a pre-pulse in the low schizotypy 
group. It may be that as the startling stimulus was not generated by the subject
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themselves as would be a scream, for example, then the application of the efference 
copy explanation is not as appropriate here. In addition, in the tickling study, the 
participant made a movement and then the same shaped movement was made by a 
robot hand on their hand. In the current study the participant pressed a button which 
resulted in a loud noise, it could be that the cross-modal, second-order nature of the 
action and response reduced the degree of influence of self-monitoring. Furthermore, as 
prepulse inhibition is itself a special phenomenon in the manner in that it inhibits the 
startle response, perhaps it was not appropriate to use this as the predictable stimulus. 
In future it may be helpful to investigate the effect of varying the degree of discrepancy 
temporally between pressing the button and the startle response, as theoretically if the 
me-pulse is using an efference copy to reduce responses, then with greater discrepancy 
low schizotypes should show responses more similar to the high schizotypes.
Another finding that was contrary to our initial predictions (that startle inhibition would 
be reduced or abolished in the high schizotypy group by the mepulse) was that there 
was some facilitation of the startle response compared to the pulse alone. As these are 
pilot data from a novel task the findings should be viewed with caution. As far as we 
are aware, no previous study has examined the response to self-generated startling 
stimuli, thus there is no existing literature to suggest what the mechanism behind this 
facilitation in high schizotypes may be. A literature exists that describes prepulse 
facilitation, where responses to startling stimuli are enhanced at long stimulus durations 
(usually < 2000ms). This is thought to reflect a classic activating effect (Graham, 1975) 
where the prepulse causes the subject to orient to incoming information. Facilitation has 
been found to be greater for attended to than unattended to prepulses (Schnell et al., 
2000; Wynn et al., 2004; Hazlett et al., 1998) and simple attentional facilitation of the 
blink startle response has also been found previously in healthy volunteers even at short 
lead intervals (Neumann, 2004). Possibly these findings have some relevance here and 
suggest an interaction between attention and self-monitoring. As the green screen pre­
pulse requires an action to be generated, it may be that in the absence of an intact self­
monitoring system, the me-pulse simply causes greater attention to be allocated to the 
self-generated pulse than to the unexpected pulse that is passively attended to. This
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explanation is not completely satisfactory as the prepulse should cause the subject to 
orient towards the startling stimulus as well and thus cause a similar facilitation of the 
startle response, although perhaps to a lesser degree. Another explanation might be that 
due to an abnormal central self-monitoring system, the prediction made of the sensory 
consequences of the action is even more discrepant with the actual consequences than if 
no prediction were made, resulting in a greater startle response. However these 
explanations are purely speculative. Further investigation could vary the intensity or 
nature of the startling sound to investigate the ‘prediction’ hypothesis. Examining 
mepulse inhibition under conditions of divided attention could examine the influences 
of attentional processes.
Prepulse inhibition in the high schizotypes was not different from the low schizotypes. 
Although many passive attention studies have failed to find PPI deficits in schizotypy, 
our findings are contrary to those of Schnell et al. (1995) who used a similar active 
attention paradigm to the current study and found impaired prepulse inhibition in high 
schizotypes. However, the latter study used an interval of 120msec whereas our lead 
interval was 420 msec, which is towards the end of the temporal range that elicits PPI. 
PPI is not thought to be as robust at longer lead intervals than 120mesc (Braff et al.,
2001), so this could account for these findings. It has been suggested that PPI deficits 
observed in schizophrenia are related to attentional deficits associated with this disorder 
(Dawson et al., 1993). However, whilst we did not examine attention in this study, 
deficits have been found in high schizotypes (Braunstein-Bercovitz, 2000). PPI deficits 
are often not found in high schizotypy scorers (e.g. Abel et al., 2004) and were not 
found in this study. This may suggest something more complicated than simple 
attentional modulation of the startle response is occurring in individuals high in 
schizotypy. It may be that the PPI deficits observed in schizophrenia on similar 
paradigms are an artefact of medication or hospitalisation effects. Interestingly in a 
recent study using a passive attention paradigm in healthy volunteers, PPI at a very 
short lead interval (120msec) was increased with the use of monetary rewards (Hawk et 
al., 2004). This also implies a role for motivation in PPI which may also be a factor 
differing between schizophrenics and high schizotypy scorers.
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8.8.2 Acute ketamine
Experiment 2 generated two main findings: firstly ‘mepulse’ inhibition observed with 
placebo tended to be reduced after an acute dose of ketamine; secondly, there was no 
difference in PPI between ketamine and placebo on this active attention paradigm.
The mepulse inhibition observed on placebo in Experiment 2 was consistent with the 
findings in low schizotypes in Experiment 1, demonstrating that this paradigm produces 
robust inhibition for self-generated startle in healthy subjects. Again the MePI was no 
greater than PPI, inferring no extra level of inhibition for self-generated startle 
compared to predictable startle. The potential explanations of this finding have been 
discussed above.
Unlike the high schizotypes, there was no facilitation of the startle response following 
the mepulse in the ketamine group. This was in line with our original speculation, and 
may imply that the normal self-monitoring is disrupted by ketamine. In relation to the 
finding of facilitation in high schizotypes then, this may represent either a more 
superficial or possibly more profound impairment to the self-monitoring system. Only 
one dose of ketamine was used in experiment 2, however it would be interesting to see 
if facilitation occurs following higher and lower doses of the drug.
The absence of PPI deficits following an acute dose of ketamine is consistent with 
some previous studies (Van Berckel et al. 2001, Duncan et al 2000). It is however 
difficult to compare the findings from this study as other studies used different doses 
and have not used target-controlled infusions. In addition, the lead interval in this study 
was much longer than that used in previous work and further, an active attention 
paradigm was used. As acute ketamine does not impair focussed attention (Chapter 2; 
Morgan et al., 2004a) then perhaps it is not suprising that ketamine did not produce a
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deficit in active attention PPL Ketamine did not produce any changes in habituation, 
latency or startle unlike some (Abel et al., 2004) but not all other (Duncan et al., 2001; 
Van Berckel et al., 1998) studies.
The finding of preserved PPI also differs from the preclinical literature where 
impairments in PPI following NMDA -antagonists are consistently found (e.g. Geyer et 
al., 2001). However in animal studies doses of ketamine are often 10 times greater than 
those administered in human research. As discussed by Grunze et al. (1996) there is 
NMDA dependent modulation of inhibitory intrinsic circuits in the CA1 region of the 
hippocampus. The sensitivity of these circuits may result in either an increase or 
decrease in hippocampal output. Feedback loops engaging the striatum and the 
thalamus are thought to protect the cerebral cortex from sensory overload (Carlsson et 
al., 1999). Glutamatergic synapses within these feedback loops have been shown to be 
important in PPI in animals (Swerdlow et al., 2001). Carlsson et al. also suggested a 
role for glutamate as a ‘brake’ or ‘accelerator’ of monoaminergic systems resulting in 
increased or decreased flow of information to the cortex. A dose dependent 
investigation of the effects of ketamine on PPI would be helpful to clarify whether an 
inverted U-shaped relationship between ketamine adminstration and PPI exists.
8.8.3 Chronic ketamine
The main findings from Experiment 3, comparing ketamine users and poly-drug users, 
were of reduced PPI in the ketamine group compared to the poly-drug users and of a 
facilitated mepulse startle in both groups.
To our knowledge this is the first study that has examined active attention PPI in
ketamine users. The findings of reduced PPI are of relevance to the ketamine model of
schizophrenia, given that reduced PPI is consistently found in this disorder. Again, as
this paradigm used longer lead intervals than generally used in normal PPI these
findings must be interpreted with caution, although PPI deficits have been found in
schizophrenia patients at these lead intervals (Bolino et al., 1994). Our results are
contrary to those described in the animal literature. Repeated administration of
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ketamine has not been examined, although 14 days of treatment with PCP has been 
found to produce no long lasting changes in PPI in rats, despite evidence of significant 
neurotoxicity (Martinez et al., 1999). The relevance of findings from the animal studies 
is very limited by the active attention, instructed condition in which PPI occurred in this 
study. Animal paradigms are clearly uninstructed, passive attentional and as such are 
thought to rely on automatic processes. It has been suggested that the mechanisms 
regulating ‘attentional’ versus automatic (uninstructed’) PPI differ substantially (Braff 
et al., 2001). Primarily, ‘attentional’ PPI is mediated by attentional mechanisms 
although other mechanisms are clearly involved, as was demonstrated by the preserved 
PPI in high schizotypes despite reports of impaired attention. Indeed, attention deficits 
in ketamine users who had ceased or reduced their ketamine use substantially were 
found in Chapter 5 of this thesis but have not been found in other studies (Curran & 
Morgan, 2000; Curran & Monaghan, 2001). Therefore it is unclear whether the PPI 
deficits are related to attention impairments, motivational problems or actual deficits in 
gating of sensory information.
If the finding of impaired PPI does pertain to actual gating deficits, the notion of 
glutamate as a ‘brake’ or ‘accelerator’ as discussed above may be relevant. Whilst no 
research has examined the effect of repeated ketamine use on glutamate transmission in 
humans, in animals chronic PCP administration produces disrupted glutamatergic 
activity (Lindahl & Keifer, 2004). A decrease in glutamate could act as an ‘accelerator’ 
to monoaminergeric systems (via the inhibitory cortico-striatal-thalamic loop) thus 
increasing information flow to the cortex, which could result in decreased prepulse 
inhibition. In addition, when compared with the two other experiments reported in this 
chapter, elevated levels of PPI were shown in the poly-drug using controls in 
Experiment 3. Increased PPI has been found in MDMA users compared to cannabis 
users and non-drug users (Quednow et al., 2004). The poly-drug users in this study 
were recreational MDMA users which may explain their elevated PPI. The apparently 
reduced PPI in ketamine users might be a function of elevated levels of PPI in poly­
drug controls. However, ketamine users were matched with poly-drug controls on 
MDMA use, so theoretically should have experienced the same elevation in PPI. In
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addition, although statistical comparison cannot be made due to different conditions, 
inspection of the results suggests PPI in ketamine users was lower than that observed 
following placebo administration or in low schizotypes.
Both groups showed facilitation of their startle response for self-generated noises 
similar to that observed in the high schizotypes. The possible reasons for this have been 
discussed above. Again this may reflect a self-monitoring impairment. Self-monitoring 
has not been examined previously in drug users however behavioural inhibition has 
been extensively investigated. Whilst in chapter 7 we did not find response inhibition 
impairments in ketamine users and poly-drug users compared to non-drug users on a 
simple Go-No/Go task, response inhibition impairments have been found previously in 
recreational drug users (M.Morgan, 1998). Response inhibition may likely reflect self­
monitoring. An impaired ability to modulate and regulate one’s own behaviour has 
been suggested to be one of the key deficits in drug dependence (Goldstein & Volkow,
2002) and self-monitoring must play some role within this. Drug users, even of drugs 
that do not induce physical dependence, often report feeling compelled to use the drug 
and describe their drug use as almost beyond conscious control. This is somewhat 
reminiscent of delusions of control, however instead of misattributing the locus of 
control to external forces, drug users attribute it to the power of drug. It may be that 
there is also an abnormal prediction system at work in drug users that means they are 
less able to identify their actions as their own. Entirely speculatively, a deficit in 
predicting the actual sensory consequences of their actions in drug users might also be a 
factor in why, even when the effects of a drug become aversive, drug users continue to 
abuse them.
In addition, these two groups scored highly on baseline levels of schizotypy, so these 
deficits may be unrelated to drug use and reflect the higher levels of schizotypy, which 
have been noted in the past in drug users (Nunn et al., 2001). However covarying for 
schizotypal symptoms did not alter the outcome of the analysis. Unfortunately a 
comprehensive analysis of schizotypy using a measure such as the O-LIFE was not 
conducted, so the median split was only on the basis of the schizotypal
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symptomatology questionnaire. Correlations however demonstrated a relationship 
between dissociative symptoms and MePI deficits, indicating increasing dissociative 
symptoms with decreasing MePI. We could tentatively infer from this that dissociative 
sensations (e.g. feeling detached from their bodies) stem from a defect in self­
monitoring.
If the mepulse is taken as an indicator of self-monitoring then it appears that ketamine 
users have deficits both in monitoring sensory output and gating sensory input. This 
pattern is most like that observed in schizophrenia, although a more thorough 
exploration of the actual symptoms exhibited by these users is warranted.
8.8.4 Methodological considerations
All of the studies employed relatively small numbers of participants and require 
replicating with greater numbers. The studies seemed of sufficient power to detect 
differences however the possibility remains that with greater numbers further 
differences could emerge. In addition, the samples used are comparable with other PPI 
research (for a review see Braff et al., 2001). We did not control for smoking in the 
schizotypy group or the drug using groups and smoking has been shown to affect PPI 
(Della Casa et al., 1998). However when smoking was added as a covariate into the 
analyses it did not affect the results. Furthermore, in the schizotypy study there was a 
trend for a higher level of startle in the low schizotypy group. The mechanism behind 
this is not clear. However this could be problematic in that it is not clear whether startle 
magnitude affects PPI - and thus potentially MePI - although evidence suggests that 
they are not consistently related (Braff et al., 2001) as long as neither are at ceiling or 
floor levels.
The chronic ketamine study was subject to the same limitations of other recreational 
drug user studies which have been discussed in previous chapters. However a benefit of 
this study was the use of urine screens to verify that participants were not under the 
influence of drugs at the time of testing.
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Across all studies, there was some lack of consistency in the measures used to verify 
schizophrenic-like symptoms. As mentioned previously, use of the O-LIFE in all 
studies may have been helpful to correlate trait schizotypy with the current findings. In 
addition, as self-monitoring deficits are purported to relate specifically to positive 
symptoms, a thorough exploration of these in the acute and chronic ketamine studies 
would have been helpful to examine the relationship between these and self-monitoring 
deficits.
In relation to the task, further validation is required before we can say that the pattern 
obtained is due to self-monitoring deficits and not another mechanism. Ways this may 
be achieved were outlined above, including manipulating the delay and nature of the 
stimulus and dividing attention. Another way of shedding light on this would be by 
examining evoked related potentials (ERPs) to self and computer generated stimuli. A 
dampening of the N1 potential has been found previously when speaking in an ERP 
study (Ford et al., 2001) and a magnetoencephalographic (MEG) study (Curio et al., 
2000). To see if such a dampening occurs with self-generated startle might clarify 
whether the proposed self-monitoring mechanisms i.e. forward models are inducing an 
attenuation of the startle response or whether the attenuation observed in the low 
schizotypes and on placebo is in fact simply a result of the mepulse acting as a 
prepulse.
Despite the problems with the task it is clear that something unique is occurring in the 
high schizotypes and drug users to produce a greater response when the startling 
stimulus is generated themselves. The findings of these pilot studies suggest that the 
monitoring of actions i.e.’output’ may be impaired in high schizotypes, in drug users 
and following an acute dose of ketamine. For ketamine users, the PPI deficits suggest 
that repeated ketamine use may also affect the gating of incoming sensory information
i.e. ‘input’. The similarity between the pattern of effects observed on the mepulse in 
high schizotypes and drug users is interesting and may relate to recent theories that 
similar underlying processes are impaired in both schizophrenia and drug abuse 
(Chambers et al., 2001). Further understanding the suggested impairment in self-
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monitoring processes may aid in treatment for these disorders. In response to the 
question we originally posed “Can one startle oneself?”, it would appear that in healthy 
volunteers with no indication of psychosis proneness the answer is no. However healthy 
volunteers who experience high levels of schizophrenic-like symptoms can not only 
startle themselves but in fact startle themselves more than does an unexpected stimulus, 
as can poly-drug users and, to a much lesser extent, volunteers who have received a 
single dose of ketamine.
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Chapter 9: General Discussion
“Facts never speakfor themselves but are at the mercy o f  their in terpreters”
Franz Kafka
9.1 Overview
This thesis set out to examine some of the effects of acute administration and chronic 
self-administration of ketamine. Studies investigated the effects of ketamine on 
memory systems, including reward related processes, and the subjective effects of the 
drug, including dissociative and schizophrenic-like symptoms. The degree to which this 
thesis has further characterised the acute effects of ketamine will be summarised first in 
this final chapter. Then the clinical implications of the data presented in this work will 
be considered in light of two main research questions:
1. What are the consequences of ketamine abuse, its abuse potential and the factors 
that may underlie its continued use?
2. What are the implications of the findings of this thesis for the acute and chronic 
ketamine models of schizophrenia?
After the summary and the above questions have been considered, I will briefly discuss 
some of the general conceptual limitations constraining the work in this thesis and the 
methodological issues that arose. Finally I will reflect upon some of the potential 
implications of this work for future research.
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9.2 Acute Effects of Ketamine on Cognition
9.2.1 Episodic memory
The work of this thesis replicated the impairment in verbal memory observed in earlier 
studies (e.g. Krystal et al., 1994; Newcomer et al., 1999; Adler et al., 1998), extended 
these findings by examining the effects of an acute dose of ketamine on both recall and 
recognition and used levels of processing and source memory tasks to tease apart the 
relative effects on different components of episodic memory. The impairment observed 
on source memory was similar to that reported in a recent paper (Honey et al., 
submitted) and demonstrates the capacity of ketamine to impair information for 
contextual details at encoding along with more general mnemonic impairments. Whilst 
the binding of contextual details to memories is impaired by ketamine, as was evident 
by the source memory deficits, performance on this task was found even on high dose 
ketamine to be well above chance (unlike recognition memory in other previous studies 
e.g. Malhotra et al., 1997). This suggests that the elaborative encoding condition used 
in this task was beneficial to subjects following an acute dose of ketamine. Therefore it 
may also be that ketamine also blocks the umprompted initiation of mnemonic 
strategies that will later facilitate accurate performance on a source memory task, for 
example using a deeper level of processing at encoding.
Ketamine was found to impair recall of information learnt after drug administration but
not before. This supports the notion, which has been suggested by previous research
(Malhotra et al., 1996; Hetem et al., 2000; Honey et al., submitted), that ketamine
impairs encoding but not retrieval of information learnt on the drug. However, it is
possible that the behavioural tasks used in this thesis were not sensitive enough to
detect ketamine induced retrieval deficits. Despite the absence of behavioural effects on
retrieval processes observed in this work, recent neuroimaging research has
demonstrated a reduced left prefrontal activation when retrieving information encoded
prior to ketamine infusion (Honey et al., submitted). This is thought to represent an
inability to access the contextual details associated with a remembered stimulus. The
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use of compensatory strategies in retrieval therefore remains a possibility and should be 
further investigated. There have been previous suggestions that ketamine affects 
consolidation processes into long term memory (e.g. Krystal et al., 1994). However in 
this thesis, unlike the latter study, delayed recall was not affected disproportionately to 
immediate recall, and the pattern of performance mimicked that observed in healthy 
subjects, but simply at a lower level overall. In addition, when given soon after 
encoding, ketamine did not reduce the amount of information retrieved on drug as one 
might perhaps expect if consolidation was impaired.
The episodic memory data collected in this body of work confirm the role of the 
NMDA-R in the synaptic plasticity underpinning learning and memory in humans. 
Although the picture may be more complex than a simple blocking of LTP. 
Theoretically, generalising from activity at a cellular level, this disruption of episodic 
memory may more plausibly reflect the greater affinity of NMDA-R antagonists for 
blocking inhibitory rather than excitatory activity (Grunze et al., 1996). Administration 
of ketamine is thought to preferentially disrupt feedback inhibition on intemeurons 
(Grunze et al., 1996). This disinhibition produces a loss of adaptive functional 
modulation, or “tuning” of glutamatergic activity (Krystal et al., 1999) in the cortex. 
The inappropriate recruitment of neurons, temporally or spatially, causes a 
disproportionate magnitude of activation (Grunze et al., 2000; Lisman et al., 1998) and 
a resultant reduced capacity to terminate a response or process the next input. This may 
cause a loss of regionally specific functions for example “stimulus binding” in the 
hippocampus and working memory in PFC (Krystal et al., 1999), which may in turn 
produce these observed memory impairments.
9.2.2 Semantic Memory
Semantic memory was an important topic of investigation for this thesis as there have
been suggestions that ketamine is one of the few drugs to affect this memory system
(Curran & Weingartner, 2002) and there was no clear evidence with regards to the
existence of semantic memory deficits following ketamine administration. In our initial
study (Chapter 2), a smaller number of sentences were verified on ketamine in the
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speed of comprehension task which indicated some semantic processing impairment. 
However, verbal and category fluency were shown to be unaffected by ketamine 
(Chapter 6), in line with some previous studies (Newcomer et al., 1999; Krystal et al., 
1999). Due to the equivocal nature of these results a further study (Chapter 4) examined 
semantic processing more specifically using a semantic priming paradigm. Following 
an acute dose of ketamine, we found inverse priming at a long SOA but not at a short 
SOA. This was a highly novel finding, as inverse priming has only been found before in 
studies of emotional priming (Rossell & Nobre, 2004). The preservation of priming at a 
short SOA suggested that automatic spreading of activation in the semantic network is 
unimpaired. Controlled processing, on the other hand, may be disrupted as is evident 
from the inverse priming at a long SOA.
Based on the three processes proposed to be involved in semantic priming (see Chapter
4): automatic spreading of activation, expectancy and semantic matching, we 
interpreted this as a possible ketamine-induced impairment of semantic matching, a 
post-lexical process that matches targets and primes for semantic similarity. This may 
pertain to the notion of the NMDA-R involvement in contextual processing or 
‘cognitive co-ordination’ (Philips and Silverstein, 2003). However additionally, some 
of the ‘inverse priming’ observed was due to facilitation in processing of unrelated 
targets at a long SOA. Theoretically, this could reflect the dysregulation of inhibition 
that has been suggested by neural network models following NMDA-R antagonist 
administration (Grunze et al., 1996). Whilst it is accepted that it may be overly 
reductionist to presuppose that failure of inhibition at the cellular level mediates failure 
of inhibition at the cognitive level, there is evidence from neural network modelling to 
suggest that this may be the case (McCarley et al., 2005). A key element of both 
cognitive and biological networks is the ability to control excitation and maintain 
stability. In a semantic network, activation of a concept or representation is thought to 
produce various levels of excitatory buildup, which is reflected in competition between 
simultaneously activated representations (Nestor et al., 1998). The dysregulated 
network inhibition could, at this longer time period produce this facilitation of
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responding to normally distal concepts in a network, which may be behaviourally 
observed in facilitation of processing of unrelated words at a long SOA.
9.2.3 Working Memory, Attention and Executive functioning
Attention on the 0-back component of the N-back task was unimpaired by an acute 
dose of ketamine. This replicates the findings of other studies (e.g. Adler et al., 1998; 
Newcomer et al., 1999) and is clearly important as attention is involved in the 1-back 
and 2-back (as well as every cognitive task). Working memory was found to be 
impaired acutely by ketamine on both the 1 and 2 back section of the N-Back task. 
However, ketamine did not disproportionately affect the ability to hold on line the two 
previous letters, compared to one previous letter. This may indicate that maintenance in 
working memory is unaffected by ketamine but that updating of information is 
impaired and this supports other observed ketamine deficits in backwards digit span 
(e.g. Honey et al., 2003).
With regards to executive functioning, trailmaking was unaffected overall by acute 
ketamine administration, although there was some evidence of slower performance on 
part B of the task. Successful performance on the trailmaking task requires maintenance 
of a sequence in working memory (parts 1 and 2) and cognitive flexibility (part 2). As 
performance on part 1 of the task is intact then this may be further evidence that 
maintenance of information may be preserved after ketamine. The slowing on part 2, 
where participants are required to switch between two tasks, may indicate that cognitive 
flexibility is impaired by the drug.
Ketamine did not affect verbal fluency, which taps retrieval, selection and monitoring
processes. Response inhibition / suppression was assessed using the Hay ling task and
the Go/No-go task. On the Hayling task participants made more errors on Part B of the
task but not part A. This was indicative of disrupted response inhibition but not
response initiation. However, on a more simplistic measure of response inhibition, the
Go/No-go task, participants on an acute dose of ketamine made less correct responses
but showed no difference in the number of response inhibition errors suggested that
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inhibiting simple prepotent responding was intact following acute ketamine on the 
Go/No-go. The reduced number of hits may indicate that the ketamine group are ‘over­
inhibiting’ which may perhaps reflect a compensatory strategy to counteract their 
perceived impairment. Therefore a more parsimonious explanation of the findings of 
the Hayling task, rather than impaired response inhibition, may be that ketamine-related 
strategic or semantic impairment renders subjects unable to generate contextually 
irrelevant alternatives. Overall then from these executive functioning and working 
memory data, acute ketamine may have induced a deficit in cognitive flexibility but left 
selection and monitoring processes intact. A problem for the role of the proposed role 
of the NMDA-R theoretically in ‘cognitive co-ordination’ is the similarities shared 
between this notion conceptually and that of executive functioning, thus the relatively 
preserved executive functioning we observed following acute ketamine may provide 
evidence against this theory. However, the suggestion of this work is that deficits in 
executive functioning following acute ketamine administration stem from problems in 
the integration and manipulation of information, which, intuitively at least, would seem 
to be the most prototypical ‘co-ordinating’ function.
9.2.4 Perceptual priming and Procedural learning
Perceptual priming was preserved following a single dose of ketamine and procedural
learning was impaired, although this may have been complicated by slower reaction
times in the high dose ketamine group as previously discussed. This distinction is
interesting as in a variety of disorders (e.g. amnesia, schizophrenia) it is explicit
processes that are predominantly impaired and implicit processes that are preserved,
however following ketamine two implicit processes are differentially effected. It may
be that this procedural deficit is mediated by reduced DA-ergic transmission in the
basal ganglia, as is observed in Huntington’s disease. A further possibility may be that
as procedural learning required the encoding of contextual relations between a set of
stimuli, in order to learn the sequence appropriately, unlike priming which requires the
simple encoding of stimulus features, then it was this process that was impaired. It may
be that the distinction between contextual / non-contextual memory may be more
relevant to the findings of this thesis than the implicit/ explicit distinction. The latter
245
may also relate to the findings of other tasks such as the 0-back and the Go/No-go task, 
where performance was relatively unimpaired. Neither of these tasks required the 
encoding of contextual relationships between stimuli for correct performance. These 
findings contrast with those of previous work on tasks such as the AX-CPT task, where 
response inhibition / sustained attention errors following ketamine have been found but 
only on B-X trials (Umbricht et al., 2001; see Chapter 1) i.e. those that require the 
formation of a trace of transient contextual relations between stimuli. As the Go/No-go 
and 0-back tasks required responding or non-responding only to a specific stimulus, i.e. 
monitoring and not integration of information, this may explain why performance on 
these simple tasks was relatively preserved.
9.3 What are the consequences of ketamine abuse, its abuse potential and the 
factors that main underlie its continued use?
“7 can’t understand why anyone would want to take the stuff. It gives you nightmares 
doesn't it?” Consultant Psychiatrist in Addictions, quoted in Jansen, 2001.
Given the burgeoning population of ketamine users, two of the central questions of this 
thesis were i) what happens to people when they repeatedly use ketamine and ii) what is 
the abuse potential of the drug? Hence we conducted the first studies to investigate the 
impact of repeated ketamine self-administration in humans. Initially, by finding no 
memory or attentional impairments 3 days after an acute dose of ketamine in healthy 
volunteers (Chapter 6), we confirmed that any day 3 effects were likely to be chronic 
effects of the drug and not simply residual effects. We then concentrated on a 
characterisation of some of the cognitive effects of ketamine abuse and briefly 
attempted to examine some of the reward related processes involved in its maintenance.
9.3.1 Episodic Memory
Prose recall was found to be impaired in ketamine users 3 days after drug use (Chapter
5). In addition, item recognition and source memory were disrupted on the night of
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drug use, however 3 days later in ketamine users only source memory was found to be 
impaired, in the presence of intact item recognition. The day 3, or ‘chronic’ data may 
be explained using a familiarity versus recollection distinction (see Chapter 1). 
Ketamine use may have impaired recollection in the face of relatively preserved 
familiarity. This is in evident by the impaired prose recall and source discrimination 
observed, in the presence of relatively intact item recognition.
The episodic memory impairment observed on the night of drug use in ketamine users 
tested in phase one of the follow-up study reported in Chapter 5 was comparable to that 
observed following an acute dose of ketamine in healthy volunteers. However, given 
that doses reported by ketamine users were much higher than those administered in the 
acute studies, we may infer that these users have developed some degree of tolerance to 
the memory impairing effects of ketamine, and/or may have exhibited pre-existing 
differences in memory functioning. Tolerance to the memory impairing effects of 
ketamine might theoretically be related to NMDA-R upregulation, which has been 
observed in animal models following repeated NMDA-R antagonist administration 
(Arvanov & Wang, 1998).
9.3.2 Semantic Memory
The pattern of semantic memory impairments in ketamine users differs from those seen
following an acute dose of ketamine, in that overall they appear to be more profound.
On the speed of comprehension task ketamine users completed less sentences and made
more errors than poly-drug controls, which is indicative of gross semantic impairments,
as errors on this task are relatively difficult to elicit (Rossell et al., 2001). Ketamine
users also generated fewer exemplars in category but not verbal fluency. As discussed
in Chapter 5, the dissociation of performance on the above tasks may indicate impaired
storage of rather than access to semantic knowledge (Allen et al., 1993). This assertion
is also supported by work reported in Chapter 4, from the semantic priming study.
Semantic priming was again found to be reduced for the long SOA, indicating an
impairment in controlled semantic processes as discussed above. In addition however,
priming was lower for low frequency words. This suggests that some degradation of the
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semantic store may have occurred in this population. Alternatively, general semantic 
retrieval processes may be impaired following chronic ketamine use. This would be 
conistent with impaired category fluency and the preserved priming at a short SOA.
9.3.3 Working Memory, Attention and Executive Functioning
In chronic ketamine users, an impairment to attention was evident by slower 
performance on the digit cancellation task. The absence of errors on this task suggests 
that simple vigilance may be preserved in ketamine users but that monitoring of 
information was simply more effortful for these individuals. There was no correlation 
between attention and impaired performance on other tasks, such as prose recall, 
therefore attentional deficits were likely not underlying other cognitive impairments.
In the ketamine users, working memory was investigated using the serial seven’s task. 
Whilst in the original study upon which the follow-up longitudinal study (Chapter 5) 
was based, performance on the serial seven’s was impaired on the night of drug use (i.e. 
acute on chronic effect: Curran & Morgan, 2000), no impairment was evident 3 days 
after drug use. However, findings from this task may be influenced by baseline 
numeracy abilities (which may in turn be influenced by baseline working memory). 
Performance on the verbal fluency task was intact, however there was a trend for more 
perseverative errors in ketamine users. On the Go/No-go task when drug-free there 
were no differences between ketamine users and poly-drug controls (i.e. chronic 
effects), however on the night of drug use ketamine users made more false alarms and 
less hits. This evidence is inconclusive with regards to response inhibition; the false 
alarm increase could signal response inhibition deficits, however combined with less 
hits these data may indicate globally inaccurate performance. This contrasts with the 
animal literature where chronic NMDA-antagonism is associated with response 
inhibition and working memory deficits (see Jentsch & Roth, 1999 for a review).
It seems somewhat paradoxical that the changes following repeated antagonism of the
NMDA-R may result in a similar, if not slightly more selective, profile of effects on
cognitive functioning as acute antagonism. However neural network models suggest
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that theoretically both hypoglutamatergic states (reduced glutamatergic signal and 
associated excessive inhibition) and hyperglutamatergic states (heightened activation or 
inhibitory deficits) could produce similar cognitive disruptions (Lisman et al., 1998; 
Grossberg, 1984). In addition, abnormal hippocampal neurogenesis has been observed 
in rats following repeated ketamine, along with a reduced sensitivity of GABA-ergic 
intemeurons (Keilhoff et al., 2004) which again could theoretically produce disruptions 
in information processing similar to those described following acute ketamine. In 
addition, a reduction in DA transmission in the prefrontal cortex of monkeys has been 
observed following repeated NMDA-R antagonism. However the cognitive 
impairments observed following repeated ketamine self-administration in this thesis are 
less indicative of a DA-ergic mechanism, as in general DA-ergic impairments produce 
more wide ranging deficits on executive functioning and working memory tasks 
(Paulus et al., 2002) than were observed in our, admittedly limited, investigation.
9.3.4 Schizophrenia-like and dissociative symptoms.
There was some evidence of ketamine users having elevated levels of delusions and 
persisting subjective effects of ketamine, whilst drug free. Both ketamine users and 
poly-drug controls scored more highly on schizophrenic-like symptoms scales than 
placebo controls and in some studies scored in the range of healthy participants on 
ketamine. Of note in consideration of the persisting schizophrenia-like effects are the 
difference results obtained in studies throughout this thesis. In Chapters 5 and 7 
ketamine users showed evidence of some schizophrenic-like or dissociative symptoms 
when drug free, however in Chapters 3, 4 and 8, no such persisting effects were 
apparent. A wide variety of factors could theoretically account for these differences, 
most notably participants’ different degrees of ketamine use. However additionally, 
other factors such as age of first use, which were not explored in this thesis could also 
play a role in differential symptoms. There is a growing body of preclinical evidence 
that suggests that the age at which NMDA-R hypofunction is installed can lead to very 
different clinical and neuropathological representations (Olney & Farber, 1999; Olney 
et al., 1997; Farber et al., 1998; Newcomer et al., 2000).
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9.3.5 Reversibility o f impairments
Three years later, after reducing use of ketamine considerably, some semantic memory 
recovery was evident (Chapter 5). The semantic processing improvement was 
correlated with reduction in ketamine use. It is not yet clear what the mechanism of this 
reversible semantic impairment may be. It could be a compensatory psychological 
mechanism, that has been adopted to deal with the semantic impairments experienced 
by ketamine users or it could be reversible neurotoxicity similar to that observed in rats 
(Olneyetal., 1989).
However, persisting episodic and attentional impairments were still evident in ketamine 
users when compared to poly-drug controls after reducing their use of the drug nearly 
completely. This may relate to the irreversible cell death observed following repeated 
high doses of high affinity NMDA-R antagonists (Olmey et al., 1991). At this time the 
exact mechanism remains unclear. Regardless, these persistent memory and attentional 
impairments have worrying implications for ketamine abusers.
9.3.6 Abuse potential
The question of factors underlying and maintaining ketamine use is a more complex 
one and any inferences from this thesis should be viewed as purely speculative. As 
outlined in previous chapters, ketamine is self-administered in rats and non-human 
primates (Winger, Palmer, and Woods, 1989; Marquis, Webb, and Moreton, 1989) and 
in rats, produces conditioned place preference (Layer , Kaddis, and Wallace, 1993). 
However, the strong psychedelic effects of ketamine are such that approximately 65% 
of regular drug users who try it, do so only once (IDMU, 2005). However for a subset 
of users, such as those studied in this thesis, the rewarding effects are such that they 
wish to take the drug regularly and in some cases daily.
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In previous chapters we have considered the abuse capacity of ketamine in terms of the 
‘I-RISA’ model of drug abuse (Goldstein & Volkow, 2001) which has subsequently 
been updated (Volkow et al., 2003), but as discussed in Chapter 7, this theory may be 
more appropriate to drug dependent individuals. We found no clear evidence of 
response inhibition impairments following acute or chronic ketamine, and additionally 
none in a recreational drug using control group. Therefore to better answer our question 
as to why ketamine users wish to take the drug we have incorporated the findings of 
this thesis in a framework of reward proposed by Berridge and Robinsion (2003) and 
discuss the I-RISA briefly later. Berridge & Robinson argue that reward should be 
separated into its specific psychological components which they suggest to be: 1) 
learning 2) affect or emotion and 3) motivation. These component processes are 
thought to be interactive and within each level both implicit and explicit processes 
operate.
In terms of learning, ketamine impairs explicit learning processes, (as is evident from 
the episodic memory deficits observed in this thesis), whilst leaving some implicit 
processes intact. Perceptual priming and habituation were preserved following 
ketamine in healthy volunteers, two different processes that could contribute to 
continued drug use. Highly speculatively, habituation may be viewed as a form of low- 
level conditioning, which is know to be involved in developing stimulus-reward 
associations between a drug. Priming may allow the encoding of the basic stimulus 
features which become associated with reward. An apparent paradox for understanding 
the neurotransmitter basis of ketamine abuse, is that the NMDA-R is proposed to be 
involved in synaptic plasticity that allows learning of associations important to drug 
abuse (Thomas & Malenka, 2003) and competitive NMDA-R antagonists have been 
used in treatment of heroin and cocaine addiction (e.g. Krupitsky et al., 2001). 
However, subtle differences that occur following repeated ketamine administration, 
which yet remain to be elucidated, may eventually explain this seeming contradiction.
Affective modulation is also thought to be involved in the maintenance of drug abuse. 
In an acute study in this thesis, healthy volunteers rated themselves subjectively as
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‘liking’ the effects of ketamine at low doses however this liking became diminished at 
higher doses. This may relate to the proposed role of the NMDA-receptor in conveying 
an ‘intoxication signal’ in response to a large dose of ethanol (Krystal et al., 1999). In 
ketamine users however, at much higher reported doses of the drug, liking was greater 
than in the healthy volunteers. As these measures are based on subjective rating scales 
in different populations, it is not clear how comparable they are. However the increased 
subjective ‘liking’ of ketamine may imply either sensitisation to its pleasurable effects 
or pre-existing differences that blunt negative response to the drug. Sensitisation to the 
locomotor effects of NMDA-R is known to occur in animals (Xu & Domino, 1994; 
Phillips et al., 2001). Sensitisation may be linked with the implicit learning processes 
detailed above and may reflect of the activation of the mesolimbic DA pathways. 
However, in terms of ‘liking’, DA is thought to play less of a role than in salience and 
incentive processes detailed below (Berridge & Robinson, 2003).
Pre-existing differences in ketamine users that predispose them to use of the drug are 
another interesting possibility. Relevant to this, recent work has found that relatives of 
alcoholics have a blunted response to the dysphoric and yet heightened response to the 
euphoric effects of ketamine (Petrakis et al., 2004). This is certainly a candidate 
mechanism in differences in the liking responses reported in healthy volunteers and 
ketamine users. Altered baseline NMDA-R function could lead to the effects of the 
drug being perceived as more positive. Related to the liking ratings mentioned above, in 
the acute ketamine studies volunteers self rated contentedness was higher in the low 
dose ketamine group than the high dose group. However, ketamine users’ ratings of 
contentedness did not differ on drug when compared with drug free poly-drug control 
users. Thus ketamine users do not seem to be taking the drug for explicit pleasure, it 
may be that their rated ‘liking’ of the drug relates to implicit hedonic processes.
The third process proposed to be involved in drug mediated reward is motivation. 
Under this term, Berridge and Robinson include implicit incentive salience processes as 
well as conscious desire for a drug. Both of these processes were tested to some extent 
in this thesis. Incentive salience was examined to in the novel Drug Go/No-go task.
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Problems with this task have been discussed in Chapter 7. However, taking these into 
account, there was some suggestion from this study that ketamine users and poly-drug 
users may both have a reduced attentional bias for naturally reinforcing stimuli 
compared to non-drug users. If this is replicated, a DA-ergic mechanism is likely to be 
responsible as there were no ketamine specific differences. Hypereponsivity of the 
DAergic modulation of the nucleus accumbens has been demonstrated to be a 
consequence of long-term PCP exposure (Jenstch et al., 1998) and could contribute to 
the incentive salience processes which are a clear component of drug abuse.
Conscious desire for the drug was examined with subjective scales of ‘wanting’. 
Healthy volunteers on a low dose of ketamine wanted the drug more than those on a 
high dose, and both groups ‘wanted’ the drug more than placebo. In users, the wanting 
of the drug was greater than in healthy volunteers, which may again indicate 
sensitisation to its motivational properties. Again, however, caution should be exercised 
when making these comparisons across populations on a subjective effects scale.
Apart from the reward based processes discussed above, there are other factors that 
may play a role in maintaining ketamine abuse. The drug has a short duration of action, 
which has been demonstrated to be involved in the abuse potential of a drug (Feldman 
et al., 1996) and additionally in the bingeing behaviour that occurs on ketamine 
(Jansen, 2001). From a sociological perspective, the majority of ketamine users are 
young, white, middle-class males. For the studies included in this thesis, most of the 
participants were recruited from ‘squat parties’ or other underground dance venues. The 
sub-culture to which these users belong expresses dissatisfaction with conventional 
lifestyles. Anecdotally, from interviews with users, they report taking the drug because 
its effects are ‘interesting’, some users view it as an exploration of their own 
consciousness (Jansen, 2001). Thus even despite of perceived unpleasant effects people 
may continue using the drug as it as it relieves boredom, rather than providing any 
pleasurable effects per se. This may account for the dissociation between ‘liking the 
drug’ and conscious happiness ratings when on the drug.
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It is worth noting that in the longitudinal study reported in Chapter 5, participants had 
reduced their ketamine use by 88.3%, with nearly half having not used the drug for 6 
months. It would appear from this sample that the drug has a relatively low dependence 
forming potential. However, as noted in Chapter 5, it may be that participants who were 
heavier users and subject to greater downward social mobility were the participants we 
were not able to contact for follow-up.
9.4 What are the implications of the findings of this thesis for the ketamine model 
of psychosis?
Throughout the thesis reference has been made to the use of acute ketamine as a model 
of schizophrenia (e.g. Javitt & Zukin, 1997). In addition, I have cited studies that 
suggest that chronic administration of NMDA-antagonists may be a better model of 
aspects of schizophrenia, at least in animals (e.g. Jentsch & Roth, 1999). Following 
repeated ketamine administration in animals there are abnormalities in gene expression 
(Keilhoff et al., 2004) and changes in DA and Glu binding, possibly suggestive of 
schizophrenia-like changes (Bernstein et al., 2004). Although no attempt was made in 
this research to thoroughly test ketamine as a model by directly comparing its effects in 
healthy volunteers and ketamine users to schizophrenics on the same tasks, it does 
provide an opportunity to explore, to some extent, the degree to which chronic 
ketamine or acute ketamine in humans better ‘models’ the symptoms of schizophrenia.
One of the strengths of the acute ketamine model is its capacity to induce cognitive 
deficits which have been consistently associated with schizophrenia, unlike other 
pharmacological models. A problem for comparing ketamine’s effects with the 
cognitive deficits of schizophrenia is that, while effects in schizophrenia are relatively 
consistent across studies, the magnitude of impairment may vary, as would be expected 
from such a heterogenous disorder (Green et al., 2000). In addition, tasks have been 
categorised as referring to different cognitive functions in different studies (Jaeger et 
al., 2003). Hence it is often difficult to gauge which, if any, is the preferential
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impairment in schizophrenia. Further, cognitive deficits seem to be profound and wide- 
ranging and often confounded by medication effects and long hospitalisations. With 
these caveats in mind, the effects of ketamine will now be considered in light of 
evidence from patients with schizophrenia.
In terms of episodic memory impairments, acute ketamine induced both source and 
recognition memory impairments on a task that yielded only source memory 
impairments in drug-free ketamine users. The selective impairment of source memory 
is more congruent with the impairments reported in the schizophrenia literature (e.g. 
(Danion et a l . , 1999; Brebion et al., 2002) . From our exploration of semantic memory, 
there was an indication of a deficit in storage of semantic information in chronic 
ketamine users, whereas following acute ketamine healthy volunteers appeared to have 
problems in accessing semantic knowledge. The former is more consistent with 
schizophrenia (e.g. Danion et al., 1999). Both groups, however, displayed an inverse 
priming pattern that has not been observed in schizophrenia before. Hence it is unclear 
to what extent the pattern in either group reflects schizophrenia-like impairments.
The working memory impairment observed on the N-Back task in the acute ketamine 
group is reminiscent of that observed in schizophrenia on the same task. However on 
this task schizophrenics make disproportionately more errors on the 2-back part of the 
task (Perlstein et al., 2001), which were not observed following acute ketamine and are 
suggestive of a maintenance (rather than manipulation) problem. The ketamine users 
were not impaired on a potentially more taxing working memory task, although this 
comparison is complicated by the use of different tasks across the two studies. Neither 
group were impaired on response inhibition, which indicates intact monitoring 
processes in executive functioning. Response inhibition deficits have consistently been 
observed in schizophrenia (e.g. Leeson et al., 2005), although these have frequently 
been tapped with more complex measures such as the Hayling task, which did 
demonstrate effects of acute ketamine (high dose) in this thesis. The lack of impairment 
to perceptual priming in both groups is consistent with the schizophrenia literature. An 
impairment in focussed attention was observed in ketamine users, as tested by the digit
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cancellation task (although this also taps visual scanning and motor speed). No 
impairment on the 0-back was observed following acute ketamine. This is much less 
demanding however and impairments may have been evident on the digit cancellation 
test. In schizophrenia, impairments in attention have been observed, however not on the 
0-back task. Other studies have demonstrated ketamine induced impairments on more 
demanding attentional tasks such as the AX-CPT (Umbricht et al., 2000).
In reference to the original question of whether an acute dose of ketamine or chronic 
self-administration provides a better model of the cognitive deficits in schizophrenia, 
unsurprisingly, the current results do not yield a simple ‘yes’ or ‘no’. They suggest that 
in terms of semantic and episodic memory, cognitive deficits following repeated self­
administration of ketamine may be more similar to those observed in schizophrenia 
than those observed following the acute doses of the drug used here. However, for 
working memory and aspects of executive functioning, acute ketamine may produce a 
more similar pattern of impairment. In schizophrenia, working memory deficits are 
thought to be the cognitive function least affected by atypical antipsychotic treatment 
(Harvey et al., 2003) therefore in this respect acute ketamine may prove a more useful 
model for investigation of novel pharmacotherapies. However some researchers have 
argued that episodic and semantic memory impairments in schizophrenia are more 
profoundly affected (Tamlyn et al., 1992) and, of the range of cognitive impairments, 
are the best candidate for a differential deficit (e.g. (Saykin et al., 1991). On this basis, 
chronic ketamine self-administration may be a better model.
Although in this thesis analyses of schizophrenia-like symptoms were not the primary 
focus of our work, evidence from the SSQ and ADSS is useful in consideration of the 
adequacy of the ketamine model. In terms of symptoms, acute ketamine does reliably 
induce schizophrenic symptoms. Exercising caution while we do so, comparing across 
the studies the higher doses of ketamine used in the laboratory often induced 
schizophrenic symptoms numerically equivalent or lower to those reported in the 
chronic ketamine users when not on the drug. However, the finding of elevated 
schizophrenic symptoms in ketamine users is a less consistent one as in some cases
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similar symptoms were observed in the poly-drug control group which, as discussed 
previously, may reflect underlying trait schizotypy. By far the greatest schizophrenic­
like symptoms are reported by the ketamine users when under the influence of the drug 
and this probably reflects the higher doses used. Delusional symptoms were found to be 
greater in ketamine users than polydrug controls in one study (Chapter 6), but not 
others (Chapter 4, Chapter 8) although the users in the latter studies reported taking 
lower doses of ketamine which may account for this.
Perhaps, theoretically, the absence of consistent schizophrenia-like effects in drug-free 
ketamine users does not detract from their potential validity as a model of aspects of 
schizophrenia. If, as is increasingly suggested by the schizophrenia literature, chronic 
NMDA-R antagonism does occur endogenously in this disorder (see Krystal et al., 
2000 for a review), then repeated ketamine administration may mimic the functional 
and neurodegenerative consequences of such persistent antagonism. Although no work 
exists as yet to indicate whether NMDA-R upregulation occurs in ketamine users, it 
seems reasonable to conclude that this is the case from the animal literature (Keilhoff et 
al., 2004) and knowledge of the general effects of repeated drug administration 
(Feldman et al., 1997). There is also a literature to suggest this is the case in 
schizophrenia (e.g. Meador-Woodruff & Healy, 2000). Thus, whilst not mimicking the 
aetiology or acute phases of the disorder, the ketamine abusing population may depict 
later functional changes. Highly speculatively, the use of both chronic and acute models 
of schizophrenia may allow dissociation of the original glutamatergic-induced causes / 
symptoms and the subsequent consequences of chronic psychotic symptoms. Such 
dissociations were observed in this thesis. One example is the impaired PPI observed in 
ketamine users but not in volunteers following acute ketamine. If the latter conjecture is 
true this may suggest that PPI deficits are a result of neuroadaptive changes that occur 
as a result of repeated NMDA-R antagonism and not an initial cause of schizophrenic 
symptomatology. This idea is supported by the absence of a PPI deficit in psychosis 
prone subjects studied in Chapter 8 and the fact that PPI deficits in schizophrenia are 
seen only in chronic schizophrenics (Braff et al., 2001).
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In our consideration of the schizophrenic-like properties of ketamine, we wished to 
look at whether certain processes that theoretically underlie symptoms of schizophrenia 
are also impaired after ketamine. An influential theory of the origins of positive 
symptoms in schizophrenia was that of Frith (1992). This has been discussed previously 
in this thesis (see Chapter 9). We examined self-monitoring, which has been suggested 
to be disrupted in schizophrenia, in two ways; looking at self-monitoring of actions 
using the Mepulse inhibition task and monitoring of goals using the Go/no-go task. The 
results of this thesis did not suggest that a self-monitoring deficit similar to that 
proposed by Frith occurs following ketamine. There was some evidence that MePI was 
abolished following ketamine on our novel task. However, there was no clear indication 
of a deficit in inhibiting pre-potent responding, on acute ketamine or in ketamine users 
on the Go/No-go task. As the MePI paradigm was a novel one, and one not as yet 
validated with schizophrenia patients, it is difficult to make inferences from the 
findings on this task. In terms of schizotypy however, both ketamine users and poly­
drug controls were most similar to high schizotypes. This may have been confounded 
by higher trait schizotypy in drug users. For the high schizotypy group and both 
ketamine users and poly-drug controls there appeared to be some facilitation of startle 
when they generated the startling stimulus themselves. Hence Frith’s theory does not 
seem applicable to these data. Theoretically, the MePI findings may be explained by a 
more expansive notion, still compatible with that of Frith (1992), that suggests that in 
schizophrenia there are abnormalities in the representation of the egocentric-allocentric 
world. This theory suggests that in certain cases of schizophrenia, internal or familiar 
information becomes facilitated and novel or unfamiliar information tends to be ignored 
(Cohen & Servan-Schreiber, 1993). Purely speculatively, it may be that on the Mepulse 
task, the response to self-generated startling stimuli was enhanced as internal 
information is overaccentuated in drug users and psychosis prone subjects.
9.5 Conceptual Issues
Several conceptual issues limited the interpretation of findings from this thesis. These 
have been briefly addressed previously but will be summarised here.
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In terms of ‘modelling’ schizophrenia, the utility of any pharmacological probe is 
limited in several domains. The heterogeneity of the disorder and symptoms associated 
with it mean that it is unlikely that any single pharmacological agent will able to be 
adequately mimic every aspect of this complex disease. Furthermore when comparing 
across actual cognitive and behavioural symptoms elicited, the inconsistencies in the 
schizophrenia literature itself complicate analysis. In addition, post-mortem and 
neuroimaging data suggests that ‘schizophrenia’ involves a complex interplay between 
multiple neurotransmitter systems which in turn produces many neurodevelopmental 
and adaptive changes over time. It is highly unlikely that the acute, and to a lesser 
extent, chronic administration of a drug could adequately reproduce such a pattern of 
effects. Moreover abnormal brain morphology has been observed in schizophrenic 
patients which, particularly for the acute ketamine model, is unlikely to be elicited from 
a single dose of psychotomimetic drug. In addition, schizophrenia research has found 
regional selectivity of impairments which is unlikely to occur following administration 
of drug acting diffusely across the brain. Chronic ketamine may be more likely to 
model aspects of the disorder, given it may possibly produce some of the above 
structural and neuroadaptive changes. In future it may be more realistic and productive 
to focus on modelling specific symptoms rather than the ‘whole disorder’.
A further conceptual problem for relating the cognitve effects observed in this thesis to 
particular receptor (e.g. the NMDA-R) functioning is the diffuse action of the drug and 
its downstream effects on other neurotransmitter systems. I am aware that some of the 
generalisation from the cellular to the cognitive level in this discussion is goes beyond 
an acceptable inference from the available evidence. However, this discrepancy may in 
the future be remedied by the use of ever more specific imaging techniques to map 
cognitive effects onto brain, and eventually, cellular activity. Moreover, much of the 
speculation in this thesis concerning neurological changes (especially the chronic 
effects of ketamine) is based on the animal literature as there is no current work that 
relates to these mechanisms in humans.
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In terms of the cognitive tasks used, as reiterated throughout the thesis, most tap 
multiple memory and cognitive systems and hence cannot be viewed as diagnostic and 
independent indices any one ‘system’. Indeed, the use of a memory systems framework, 
whilst useful conceptually, may have obscured some of the common processes 
operating in these tasks and impaired by ketamine. Ever more careful dissection of the 
various cognitive components operating within each task will help to shed light on both 
the common and distinct elements affected by ketamine.
9.6 Methodological Reflections
“Regrets, I ’ve had a few... ” Frank Sinatra, My Way
Methodological limitations have been discussed throughout the thesis and only general 
points will be addressed here. Our investigation of the ‘chronic’ effects of ketamine in 
humans was necessarily through the use of a naturalistic sample of drug users. 
Problems associated with this are: i) ketamine users are poly-drug users ii) possible 
interactive effects of ketamine with other abused drugs; iii) pre-existing factors that 
predispose ketamine users to use the drug may mean there are baseline differences from 
controls regardless of drug use; iv) as a population they score more highly on trait 
schizotypy (Nunn et al., 2004). In hindsight, it would have been helpful to assess trait 
schizotypy, especially in ketamine, to use as a covariate in analysing schizophrenia-like 
effects.
The effects of ketamine, in particular the cognitive effects, are thought to be dependent 
on plasma levels (Newcomer & Krystal, 2001). As we used a continuous infusion 
paradigm in our first acute study, plasma levels may have been varying throughout the 
study which complicates interpretation of the findings. In the second study we sought to 
address this by using a target controlled infusion but this also yielded higher than 
expected ketamine levels. In addition, we took only one blood sample in these two 
studies which did not allow an accurate estimation of the plasma levels at the time of 
performing each cognitive task. In the pilot study of the MePI the lack of any plasma 
levels was a limitation. When relating the cognitive effects of ketamine to its
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pharmacological action at the NMDA-receptor along with inadequate knowledge of 
blood levels, a clear problem is the specificity of the drug for this receptor. Ketamine is 
normally prepared in a racemic mixture of two enantiomers S- and R-ketamine. S- 
ketamine has greater affinity for the NMDA-R and therefore would have been more 
appropriate for use in the studies contained in this thesis. However S-ketamine was 
difficult to obtain for human use in the U.K. at the time of the studies.
The first two acute ketamine studies were between-subjects designs. We used pre and 
post testing where possible but some tasks were available in only one version (e.g. the 
Hayling task). Repeated measures design, such as that used in Chapter 9, may be more 
appropriate in ketamine studies although tachyphylaxis and the interaction of the drug 
with practice effects on cognitive tasks complicate interpretation of findings in such 
designs. Practice or carry-over effects across testing sessions may also have been an 
issue in studies which used an ‘acute on chronic’ (on drug day 0; off drug day 3) 
design. However the lack of practice effects in the control groups meant that this was 
not a problem for the studies in this thesis.
In addition, the use of different measures in some of the chronic and acute ketamine 
studies limited the comparison across populations. Further, although our relatively 
crude mapping of schizophrenic symptoms using the SSQ reliably demonstrated 
changes in the two populations, this does not cover the full range of symptoms. In 
hindsight, the use of both clinical and observer rated, as well as subjective scales, could 
have been helpful.
9.7 Implications for future research
For the ketamine ‘model’ of psychosis, a direct comparison between acute and chronic 
ketamine and people with schizophrenia on processes such as self monitoring, 
executive functioning and inhibition would enhance its validity. We are currently 
collaborating to compare ketamine users directly with first-episode and chronic 
schizophrenic patients. Further, this thesis has highlighted the utility of comparing the
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‘chronic’ effects of ketamine directly with the acute effects. This approach would be 
enhanced by giving ketamine in an ‘acute on chronic’ laboratory setting, to users, poly­
drug controls and healthy volunteers where variables such as dose and test setting can 
be adequately controlled. To give ketamine to users who had reduced their use of the 
drug would also be interesting, to investigate issues of tolerance and reversibility of 
impairments, although there may be ethical issues to consider before adopting this 
approach.
Whilst behavioural studies can provide us with evidence of impairments and clues as to 
the processes underpinning them, data on the neuroanatomical substrates of these 
impairments would enhance our undertanding. With regards to ketamine abuse, despite 
evidence from animal studies of changes in receptor binding and neurotoxicity 
following repeated ketamine, metabolism in the rat brain is considerably different from 
that of humans and many of these animal studies used much higher doses than are taken 
by ketamine users or administered in ketamine studies. PET studies could demonstrate 
whether NMDA-receptor upregulation has occurred in ketamine users and could shed 
light on possible DA-ergic abnormalities. In addition, fMRI studies could demonstrate 
areas of activation on specific tasks following an acute dose of ketamine and in chronic 
users, as the possibility remains that apparently similar observed behavioural 
impairments reflect differing underlying neuroanatomical substrates and therefore 
processes. If activation patterns on acute and chronic ketamine were directly compared 
with data from patients with schizophrenia on similar tasks, any similarities would be 
stronger evidence of the construct, not only face, validity of the ketamine model of 
psychosis.
Directions for future research in relation to specific tasks in this thesis have been 
suggested in each chapter. In terms of cognition, areas of definite interest are a further 
characterisation of the effects of ketamine on memory systems and the neuroanatomical 
substrates of such impairments. Such an investigation has already begun in with 
working (Honey et al., 2004) and episodic memory (Honey et al., 2005). Of particular 
interest in terms of findings of this thesis, was the inverse priming observed in the
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semantic priming chapter which clearly warrants further investigation. We have a 
planned collaboration to investigate both the impact of semantic distance on semantic 
priming and the neuroanatomical substrates, by examining semantic priming during a 
ketamine infusion using phfMRI and comparing directly with data from the same task 
in schizophrenics and patients with bipolar disorder.
In this thesis we observed similarities between drug users and the psychosis prone 
subjects on our novel Me-pulse task. This may be consistent with the notion that similar 
processes may be impaired in drug abuse and schizophrenia ( e.g. Chambers et al., 
2001). Theoretically, this stems from the inadequacy of the ‘self-medication’ 
hypothesis of schizophrenia (see Goswami et al., 2004 for a review), as many 
schizophrenics report drug use that exacerbates, rather than alleviates their symptoms. 
Whilst it was beyond the scope of this thesis to address this point, the novel mepulse 
inhibition task demonstrated similarities between psychosis prone subjects and drug 
abusers generally. Our investigation of response inhibition suggested that such deficits 
in schizophrenia are not glutamatergically mediated. However, the impaired attentional 
bias to salient environmental reinforcers observed on the Drug Go/No-go task in drug 
users was somewhat reminiscent of the aberrant salience attribution that has been 
proposed in schizophrenics (Kapur, 2005). Convergent findings support the view that in 
schizophrenia frontal cortical activation deficits are related to a disruption in the 
processing of important environmental information. For example in schizophrenia, 
processing of novelty has been shown to be impaired on tasks such as the auditory 
oddball (e.g. van der Stelt et al., 2004). Acute ketamine has also been shown to impair 
the detection of novelty on such tasks (Krystal et al., 1998a). Further research would 
help elucidate the interaction between glutamate and dopamine in the assignment of 
salience to stimuli and may provide a key as to the neurobilogical underpinnings of the 
increased incidence of drug abuse in schizophrenia.
The longitudinal study reported in this thesis was based upon an opportunistic sample 
available 3 years after their initial assessment. It would thus be helpful to conduct a 
longitudinal study of ketamine users and track these participants. This work could also
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could examine genetic factors mediating response to ketamine. The Apo-lipoprotein s 
allele has been associated with decreased ketamine response in a previous study 
(Malhotra et al., 1997). Other candidate genes that have been suggested are: 
neuroreglin, BDNF, NAAG, and genes coding for NMDA-R transcription (Krystal, 
personal communication).
9.8 The Ph.D. hole ?
“Alice started to her feet fo r  it flashed across her mind that she had never before seen a 
rabbit with a waistcoat-pocket, or a watch to take out o f it, and burning with curiosity, 
she ran across the field after it, and fortunately it was just in time to see it pop down a 
large rabbit-hole under the hedge. In another moment down went Alice after it, never 
once considering how in the world she was to get out again. ..”
Lewis Carroll, Alice in Wonderland.
A ketamine user in Chapter 5 and one of the healthy volunteers from Chapter 2 both 
likened the ketamine experience to Alice’s Adventures in Wonderland. One feels 
oneself shrinking and growing, finding oneself in all sorts of curious predicaments and 
moving rapidly from one bizarre situation to the next. This invokes a further parallel 
between my own PhD and Wonderland. At times I have felt that I have been following 
a ‘white rabbit’, which has led me to investigate a broad range of topics. However, I 
eventually made it out of the rabbit hole, like Alice, with an (albeit slightly less 
exciting) story to tell.
Briefly my ‘journey’ consisted of first, for comparison with chronic effects, an 
investigation of the acute effects of ketamine on a broad spectrum of cognitive 
measures. I then focussed on semantic and episodic memory deficits elicited by acute 
ketamine. I repeated these investigations in ketamine users to allow for comparison 
between the two populations. I then investigated how enduring these memory 
impairments were in ketamine users. Given the high incidence of ketamine abuse and 
drug abuse in schizophrenia, I turned our characterisation of ketamine effects to those 
that may be theoretically involved in the development and the maintenance of drug
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abuse and lastly looked at processes that may underpin symptoms of schizophrenia. 
Overall, I have provided some of the first evidence of the chronic effects of ketamine in 
humans and of the ways in which these differ from acute effects. Whilst evidence 
concerning the effects of ketamine on abuse processes was somewhat inconclusive we 
have shown differences between drug users and non-drug users and similarities 
between drug users and psychosis prone individuals. I hope that work will continue to 
characterise the effects of ketamine both chronically and acutely and investigate 
neuroanatomical substrates of these effects. Synthesis of the three perspectives I have 
examined in this body of work (schizophrenia, drug abuse and cognition) was too broad 
an aim for this thesis but will hopefully occur in the future and these findings may in 
some way contribute to understanding the common processes within drug use in 
substance misusers and in people with schizophrenia.
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Appendix
Table A1: Reaction Times (RTs) for Hits and False Alarms (FAs) on the N-Back task.
Table A2: Significance levels for the subjective effects scale in Chapter 3.
Table A3: Reaction time (RT) data and totals for hits and false alarms (FAs) from 
Go/No-go task in the healthy volunteer ketamine challenge study reported in Chapter 7, 
Experiment 1.
Table A4: Words used in Salience Go/No-go task in Chapter 7 
Figure A5: Subjective Effects Scale for ketamine
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A1
Mean Std. Deviation
PRE DRUG
0-Back RT Hits placebo 430.16 46.23
low dose 429.28 48.54
high dose 445.39 73.82
0-Back RT FAs placebo 277.50 228.31
low dose 246.73 196.81
high dose 218.02 220.63
1-Back RT Hits placebo 523.45 101.61
low dose 560.71 92.26
high dose 559.20 120.20
1-Back RT FAs placebo 360.81 261.53
low dose 357.96 284.13
high dose 351.39 285.52
2-Back RT Hits placebo 708.69 97.53
low dose 746.31 106.10
high dose 707.27 97.25
2-Back RT FAs placebo 707.61 126.65
low dose 772.88 138.88
high dose 764.60 149.06
POST DRUG
0-Back RT Hits placebo 436.96 80.44
low dose 476.19 70.52
high dose 494.95 83.88
0-Back RT FAs placebo 114.11 179.12
low dose 191.49 202.70
high dose 191.98 217.23
1-Back RT Hits placebo 486.43 77.39
low dose 566.05 78.31
high dose 598.51 95.85
1-Back RT FAs placebo 385.51 280.47
low dose 474.09 316.74
high dose 481.99 283.75
2-Back RT Hits placebo 639.43 95.02
low dose 646.41 127.61
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high dose 682.35 90.76
2-Back RT FAs Placebo 688.61 150.78
low dose 671.61 148.92
high dose 675.83 115.50
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A2
DAYO DAY 3 DAY x 
DRUG DAY DRUGControl Ketamine Control Ketamine
Dizziness
6.70
(7.48)
41.00
(25.25)
6.45
(7.28)
6.35 (11.66)
*** *** ***
Altered time 
perception
8.10
(7.48)
37.40
(25.91)
7.95
(9.46)
7.85 (15.62)
*** *** **
Impaired
concentration
18.80
(15.04)
52.45
(21.09)
14.75
(14.36)
10.35
(14.28) *** *** **
Altered reality 10.55
(13.32)
43.70
(31.60)
8.25
(11.17)
9.15(15.10)
*** *** **
Depression
10.70
(12.02)
19.45
(17.90)
7.75
(7.72)
11.00
(14.64) NS ** NS
Impaired
memory
11.25
(16.60)
37.55
(22.92)
8.70
(11.90)
9.50(15.66)
*** *** **
Nausea
7.65
(8.44)
19.65
(22.97)
8.85
(9.18)
7.35(11.63)
** NS NS
Visual
distortion
8.80
(10.50)
41.75
(26.96)
8.55
(9.32)
8.90(17.08)
*** *** **
Bodily
numbness
4.55
(4.94)
43.30
(28.02)
3.80
(3.94)
8.30 (14.80)
*** *** ***
Unsteadiness
8.35
(10.59)
50.85
(22.93)
6.15
(6.88)
9.25 (16.58)
*** ♦♦♦ ***
Lack o f  
coordination
10.15
(13.60)
48.55
(29.56)
9.35
(11.31)
8.65 (15.92)
*** *** ***
Confusion
9.30
(9.82)
45.10
(26.51)
12.25
(18.72)
8.70 (20.44)
*** *** **
Distortion o f  
sound
2.70
(4.17)
36.80
(23.53)
2.00
(3.32)
10.95
(21.53) *** *** ***
Out-of-body
experience
2.55
(3.71)
25.60
(29.09)
3.70
(7.08)
7.85 (13.96)
NS ** ♦ ♦
***: p<0.001, **: p<0.01, NS: not significant.
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A3
Mean Std. Deviation
Pre -drug
Total hits Phase 1 placebo 74.625 1.024695
low dose 73.84615 1.863963
high dose 74.47059 1.007326
Total FAs Phase 1 placebo 4.25 2.620433
low dose 5.615385 3.594868
high dose 4.941176 4.249567
Mean RT Hits Phase 1 placebo 407.7836 57.68261
low dose 410.8465 67.0454
high dose 423.5361 71.32829
Mean RT FAs Phase 1 placebo 342.1996 63.62561
low dose 329.0447 52.77205
high dose 359.7868 82.23169
Total hits Phase 2 placebo 72.1875 2.197536
low dose 72.30769 1.93152
high dose 72.94118 1.886484
Total FAs Phase 2 placebo 3.5 2.898275
low dose 4.384615 4.628507
high dose 4.470588 3.590224
Total omission reversal 
errors Phase 2
placebo 0.4375 0.892095
low dose 0.076923 0.27735
high dose 0.294118 0.587868
Mean RT Hits Phase 2 placebo 457,5265 57.59075
low dose 450.4732 68.68204
high dose 460.5789 65.88883
Mean RT FAs Phase 2 placebo 432.7182 137.652
low dose 383.7473 71.25484
high dose 415.2438 113.6545
Post-drug
Total hits Phase 1 placebo 73.53333 4.155318
low dose 74.07692 1.705947
high dose 68.86667 8.943207
Total FAs Phase 1 placebo 5.266667 5.86109
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low dose 6.153846 3.954874
high dose 6.933333 5.020909
Mean RT Hits Phase 1 placebo 413.2632 45.14384
low dose 410.6803 48.04025
high dose 466.7899 125.5596
Mean RT FAs Phase 1 placebo 362.0588 53.99248
low dose 355.2992 62.39799
high dose 346.7932 99.67697
Total hits Phase 2 placebo 71.86667 4.103425
low dose 72.69231 3.400603
high dose 67 11.66803
Total FAs Phase 2 placebo 5.266667 5.404584
low dose 5.230769 3.745082
high dose 8.466667 5.527421
Total omission reversal 
errors Phase 2
placebo 3.066667 7.095941
low dose 0.923077 2.21591
high dose 2.533333 4.405624
Mean RT Hits Phase 2 placebo 443.886 65.69442
low dose 443.5303 70.4682
high dose 467.7857 110.6186
Mean RT FAs Phase 2 placebo 378.4821 69.50416
low dose 365.3784 80.62275
high dose 365.6 87.55485
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A4
Dl: KETAMINE D2: CANNABIS D3: ALCOHOL
Ketamine Cannabis Alcohol
K Marijuana Vodka
K-hole Hashish Lager
Snort Weed Drunk
Line Stoned Spirits
Gram Skunk Glass
11: FOOD 12: SEX 13: MONEY
Pizza Orgasm Cash
Ice-cream Erotic Money
Chocolate Lust Cheque
Cream cake Foreplay Millionaire
Strawberry Sensual Gold
Curry Sexual Riches
N l: FURNITURE N2: FABRIC N3: BUILDINGS
Cabinet Polyester Bam
Coffee table Cotton Apartment
Armchair Linen Office
Hat stand Nylon House
Footstool Corduroy Bungalow
Bookcase Tweed Shed
* Words in blue are ambiguous words related to the drug.
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A5
CONFIDENTIAL BODILY SYMPTOMS SCALE . Subject No Time.......
1. Please rate the way you tee! in terms of the dimensions given below 
Date........................ 2. Regard the line as representing the full range of each dimension
3. Rate your feelings as they are AT THE MOMENT
4. Marto clearly and perpendicularly across each line
No dizziness ____________________    Very severe dizziness
No altered time 
perception
No impaired 
concentration
No feelings of 
altered reality
No depression
No impaired 
memory
No nausea or 
sickness
No visual 
distortion
No bodily 
numbne^
J / '
No unsteadiness
No lack of 
co-ordination
No mental 
confusion
Nc distortion of 
sound
No ’out of body' 
experiences
Very severe altered time 
perception
Very severe impaired 
concentration
Very severe feelings of 
altered reality
Very severe 
depression
Very severe impairment 
of memory
Very severe nausea 
or sickness
Very severe visual 
distortion
Very severe bodily 
numbness
Very severe 
unsteadiness
Very severe lack of 
co-ordination
Very severe mental 
confusion
Very severe distortion 
of sound
Very severe 'out of body’ 
experiences
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